Document:

Exhibit 10.20 

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4)

and 230.406

 

OMB Approval 0990-0115

 

	 	1.THIS
    CONTRACT IS A RATED ORDER    	RATING	PAGE
    OF PAGES
	AWARD/CONTRACT	UNDER
    DPAS (15 CFR 350)                   ►	N/A.	 1 	     61
	2.
    CONTRACT (Proc. Inst. Ident.) NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQUEST/PROJECT NO.
	HHSO100201100013C	See
    Block 20C.	OS57601
	5. ISSUED BY	CODE	 	6. ADMINISTERED BY (If other than Item 6)	CODE	 
	Office
                                                                                                                          of Acquisitions
                                                                                                                          Management,
                                                                                                                          Contracts,
                                                                                                                          and
                                                                                                                          Grants
                                                                                                                          (AMCG)

        330 Independence
        Ave., S.W. Room G640

        Washington,
        D.C. 20201

         
	See
                                                                                       Block 5.

         

         

	7. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, state and ZIP Code)	8.
    DELIVERY 
	 

        Chimerix, Incorporated
	See
    Schedule.
	2505 Meridian Parkway, Suite 340	9/
    DISCOUNT FOR PROMPT PAYMENT
	Durham, NC 27713	N/A.
	 	 
	CAGE: 4WYN4	10.
    SUBMIT INVOICES	ITEM
	CODE
    DUNS No. 121785997	FACILITY
    CODE	ADDRESS
    SHOWN IN:	See Section G.
	11.
    SHIP TO/MARK FOR                      CODE	N/A	12.
                                                 PAYMENT WILL BE MADE BY
	CODE
	N/A
	 

        See Block 5.
	 	 

        See Block 5.

	13.
                                                                                     AUTHORITY FOR USING OTHER FULL AND OPEN COMPETITION:
                                                                                     N/A

        £ 10
        U.S.C. 2304(c)( )£ 41 U.S.C. 253(c)( )
	14.
                                                  ACCOUNTING AND APPROPRIATION DATA

        Appropriation
        Year: 2011; Object Class: 25329; CAN# 1992002 $24,819,527.00

         

	15A.
    ITEM NO.	15B.
    SUPPLIES/SERVICES	15C.
    UNIT PRICE 	15D.
    AMOUNT	15E.
    UNIT PRICE	15F.
    AMOUNT
	 

        See Section B.

         

         
	 	 	 

         
	 

         

         

	15G.
TOTAL AMOUNT OF CONTRACT    ►	$24,819,527.00
	16.
    TABLE OF CONTENTS
	(ü)
	SEC.
	DESCRIPTION	PAGE(S)
	(ü)
	SEC.
	DESCRIPTION
	PAGE(S)
	PART
                                                                                                                          I -
                                                                                                                          THE
                                                                                                                          SCHEDULE
	PART
    II - CONTRACT CLAUSES
	x	A
	SOLICITATION/CONTRACT
    FORM	1	x	I
	CONTRACT
                                                                                      CLAUSES
	54
	x	B
	SUPPLIES
    OR SERVICES AND PRICE/COST	3
	PART
    III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.
	x	C
	DESCRIPTION
    / SPECS / WORK STATEMENT	9
	x	J
	LIST
                                                                                                                          OF ATTACHMENTS
	60
	x	D
	PACKAGING
    AND MARKING	16
	 	PART
    IV - REPRESENTATIONS AND INSTRUCTIONS
	x	E
	INSPECTION
    AND ACCEPTANCE	16
	x	K
	REPRESENTATIONS,
                                                                                                                                    CERTIFICATIONS
                                                                                                                                    AND
                                                                                                                                    OTHER
                                                                                                                                    STATEMENTS
                                                                                                                                    OF
                                                                                                                                    OFFERORS
	61
     
	x	F
	DELIVERIES
    OR PERFORMANCE	17

	x	G
	CONTRACT
    ADMINISTRATION DATA	39
	 ̈	L
	INSTRS.,
                                                                                      CONDS., AND NOTICES TO OFFERORS
	 
	x	H
	SPECIAL
    CONTRACT REQUIREMENTS	44
	 ̈	M
	EVALUATION
                                                                                      FACTORS FOR AWARD
	 
	CONTRACTING
    OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE
	17.
    x CONTRACTOR’S NEGOTIATED AGREEMENT (Contractor is required to sign this
    document and return      1      copies to issuing office.) Contractor agrees to furnish and deliver all items or perform
    all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein.
    The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a)
    this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications,
    as are attached or incorporated by reference herein. (Attachments are listed herein.)	18.
    £  AWARD (Contractor is not required to sign this document.)
    Your offer on Solicitation Number  _________________________________, including the additions or changes made
    by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any
    continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government’s
    solicitation and your offer, and (b) this award/contract. No further contractual document is necessary.
	19A.
    NAME AND TITLE OF SIGNER (Type or print)	20A. NAME OF CONTRACTING OFFICER
	GEORGE
    R. PAINTER, PH.D., CSO AND CHAIRMAN	__ETHAN
                                                  J. MUELLER AMCG, ASPR, OS, DHHS

         

	19B.
    NAME OF CONTRACTOR	19C.
    DATE SIGNED	20B.
                                                                                                                       UNITED
                                                                                                                       STATES
                                                                                                                       OF AMERICA
	20C.
    DATE SIGNED
	_________/s/
                                                                                                                                                 George
                                                                                                                                                 R.
                                                                                                                                                 Painter__________

        (Signature
        of person authorized to sign)
	 

        2/15/11
	BY
                                                                                                                                                 _____/s/
                                                                                                                                                 Ethan
                                                                                                                                                 J.
                                                                                                                                                 Mueller
                                                                                                                                                 ___________

        (Signature
        of Contracting Officer)
	2/16/11
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	NSN 7540-01-152-8069 	26-107	STANDARD FORM 26 (REV.
    4-85)
	PREVIOUS EDITION UNUSABLE 	Computer Generated	Prescribed by GSAFAR (48 CFR) 53.214(a)

 

    	 

    	 

    

 

CONTRACT TABLE OF CONTENTS

 

	PART I –
    THE SCHEDULE	3
	SECTION
    B - SUPPLIES OR SERVICES AND PRICES/COSTS	3
	SECTION
    C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	9
	SECTION
    D - PACKAGING, MARKING AND SHIPPING	16
	SECTION
    E - INSPECTION AND ACCEPTANCE	16
	SECTION
    F - DELIVERIES OR PERFORMANCE	17
	SECTION
    G - CONTRACT ADMINISTRATION DATA	39
	SECTION
    H - SPECIAL CONTRACT REQUIREMENTS	44
	PART II – CONTRACT
    CLAUSES	54
	SECTION
    I - CONTRACT CLAUSES	54
	PART III - LIST OF DOCUMENTS,
    EXHIBITS AND OTHER ATTACHMENTS	60
	SECTION
    J - LIST OF ATTACHMENTS	60
	PART IV – REPRESENTATIONS
    AND INSTRUCTIONS	61
	SECTION
    K – REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	61

 

    	2

    	 

    

 

PART I – THE SCHEDULE

 

SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS

 

ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

 

This contract is for the development of CMX001 for
the Treatment of Smallpox. The Research and Development (R&D) effort for the antiviral will progress in specific stages that
cover the base performance segment and each of the four (4) option segments specified in this contract. Work performed during
the base segment and during each of the option segments is considered to constitute a non-severable discrete work segment that
is necessary for the R&D effort related to the antiviral. The Contractor must complete specific tasks required in each discrete
work segment before the Government will exercise any of the follow-on option segments. Exercise of the follow-on options is solely
at the discretion of the Government. The contractor’s success in completing the required tasks under each work segment must
be demonstrated through the Deliverables and Milestones specified under Article F.2. Those deliverables will support the GO/NO
GO Decision Gates specified therein. The GO/NO GO Decision Gates will constitute the basis for the Government’s decision,
at its sole discretion, to exercise any follow-on option segment.

 

Work under this contract will proceed for a maximum
of 5 years. The base and option segments under Contract Line Items (CLINs) 0001 through 0005 are event driven work segments rather
than time driven CLINs. The periods of performance listed under each of the CLINs under Article B.2 and B.3 below are estimated
time periods. Those individual time periods may be extended to complete the tasks required under each work segment. However, if
exercised, the completion of the final tasks required under CLIN 0005 and option segment 4 must be completed no later than 5 years
after initial award of this contract.

 

ARTICLE B.2. ESTIMATED COST AND FIXED FEE

 

		a.	The total estimated cost of the base performance
                                                                   segment is [...***...].

		b.	The total fixed fee for the base performance segment
                                                                   is $[...***...]. The fixed fee shall
                                                                   be paid as a percentage of costs incurred on any given month,
                                                                   subject to Allowable Cost and Payment and Fixed Fee Clauses.

		c.	The total amount of the base performance segment,
                                                                   CLIN 0001, represented by the sum of the total estimated
                                                                   cost plus fixed fee is $24,819,527.00.

		d.	It is estimated that the amount currently allotted will
                                                                   cover performance of the contract through 15 February
                                                                   2012.

 

	CLIN	 	 	 	Estimated
 Period of
 Performance	 	 	Supplies/Services	 	 	Total
 Estimated
 Cost	 	Fixed Fee	 	Total Estimated
 Cost Plus
 Fixed Fee	 
	0001	 	 	 	16 February 2011 through 15 February 2012	 	 	Research and development of CMX001 for the Treatment of Smallpox to include [...***...].		$	[...***...]	 	$	[...***...]	 	$	24,819,527.00	 

 

***Confidential Treatment Requested

 

    	3

    	 

    

 

	 	 	 	 	 	 	 	Reports and Other Data Deliverables.	 	 	 	 	 	 	 	 	 	 

 

ARTICLE B. 3. OPTION PRICES

 

		a.	Unless the government exercises its option pursuant to
                                                                   the option clause contained in ARTICLE I.3, the contract consists
                                                                   only of the Base Work segment specified in the Statement of
                                                                   Work as defined in SECTONS C and F, for the price set forth
                                                                   in ARTICLE B.2 of the contract.

		b.	Pursuant to FAR Clause 52.217-9 (Option to Extend the Term
                                                                   of the Contract), the Government may, by unilateral contract
                                                                   modification, require the Contractor to perform the Option
                                                                   Work Segments specified in the Statement of Work as defined
                                                                   in SECTIONS C and F of this contract. If the Government exercises
                                                                   the/these option(s), written notice must be given to the Contractor
                                                                   within 30 days after the Government has completed its analysis
                                                                   of the deliverables associated with the applicable GO/NO GO
                                                                   Decision gate; and the Government must give the Contractor
                                                                   a preliminary written notice of its intent to exercise the
                                                                   option at least 30 days before the contract expires. Specific
                                                                   information regarding the time frame for this notice is set
                                                                   forth in the OPTION CLAUSE Article in SECTION G of this contract.
                                                                   The estimated cost of the contract will be increased as set
                                                                   forth below:

 

OPTIONS

Option 1 (CLIN 0002)

Option 2 (CLIN 0003)

Option 3 (CLIN 0004)

Option 4 (CLIN 0005)

 

	CLIN	 	 	Estimated
 Period of
 Performance	 	 	Supplies/Services	 	 	Total
 Estimated
 Cost	 	Fixed Fee	 	Total
 Estimated
 Cost Plus
 Fixed Fee	 
	0002	 	 	 	16 February 2012 through 15 February 2013	 	 	 	[...***...]

[...***...]
	 	 	[...***...]	 	[...***...]	 	[...***...]	 
	0003	 	 	 	16 February 2013 through 15 February 2014	 	 	 	[...***...][...***...][...***...]	 	 	[...***...]	 	[...***...]	 	[...***...]	 
	0004	 	 	 	16 February 2014 through 15 February 2015	 	 	 	[...***...][...***...][...***...]	 	 	[...***...]	 	[...***...]	 	[...***...]	 

 

***Confidential Treatment Requested  

 

    	4

    	 

    
 

	0005	 	 	 	16 February 2015 through 15 February 2016	 	 	 	[...***...][...***...]	 	 	[...***...]	 	[...***...]	 	[...***...]	 

 

 

ARTICLE B. 4. PROVISIONS APPLICABLE TO DIRECT COSTS

 

		a.	Items Unallowable
                                                                               Unless Otherwise Provided

 

Notwithstanding the clauses, ALLOWABLE COST AND
PAYMENT and FIXED FEE, incorporated in this contract, unless authorized in writing by the Contracting Officer, the cost of the
following items or activities shall be unallowable as direct costs: 1) Acquisition, by purchase or lease, of any interest in real
property; 2) Special rearrangement or alteration of facilities; 3) Purchase or lease of any item of general purpose office
furniture or office equipment regardless of dollar value; and 4) Accountable Government Property.

 

		b.	Travel Costs

		1.	Travel

 

a.    Total expenditures for
travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance of this contract during
the base segment or any option segment(s) shall not exceed $[...***...] without the prior written approval of the
Contracting Officer. The Contractor shall notify the Contracting Officer in writing when travel has exceeded $[...***...]
within the base segment.

 

b.    Subject to the annual dollar
limitation specified under B.4.b.1.a. above, the Contactor shall invoice and be reimbursed for all travel costs in accordance
with Federal Acquisition Regulations (FAR) 31.2 – Contracts with Commercial Organizations, Subsection 31.205-46, Travel
Costs.

 

ARTICLE B.5. ADVANCE UNDERSTANDINGS

 

		a.	Man-in-Plant

 

With 7 days advance notice to the Contractor in writing
from the Contracting Officer, the Government may place a man-in-plant in the Contractor’s facility, who shall be subject
to the Contractor’s polices and procedures regarding security and facility access at all times while in the Contractor’s
facility.

 

		b.	Security Plan 

 

No Security Plan is required for this effort due to
an approved security waiver dated 12 November 2010.

 

***Confidential Treatment Requested

 

    	5

    	 

    

 

		c.	Subcontracts and Consultants

 

Award of any FFP subcontract or FFP consulting agreement
in excess of $100,000 or any cost reimbursement subcontract or consulting agreement shall not proceed without the prior written
consent of the Contracting Officer via a Contracting Officer Authorization (COA) Letter upon review of the supporting documentation
required by FAR Clause 52.244-2, Subcontracts. The Contracting Officer shall complete review of such documentation within eight
(8) business days and provide either an approval or request changes or additional information from the Contractor. Upon receipt
of the changes and additional information from the Contractor, the Contracting Officer will have eight (8) business days to review
the submitted information and respond. After receiving written consent of the subcontract by the Contracting Officer, a copy of
the signed, executed subcontract and consulting agreement shall be provided to the Contracting Officer.

 

		d.	Site Visits
                                                                                  and Inspections

 

At the discretion of the U.S. Government and independent
of activities conducted by the Contractor, within ten (10) business days notice to the Contractor via written notification from
the Contracting Officer, the U.S. Government reserves the right to conduct site visits and inspections on an as needed basis,
including collection of samples limited to 250 treatment courses of Final Drug Product and samples of key intermediates held at
the Contractor’s or Subcontractor’s site, provided that the Government’s collection of such samples shall not
frustrate the Contractor’s ability to perform under the contract, and provided further that such samples shall be used for
internal Government purposes only and not provided to any third party without the express written permission of Contractor.

 

		e.	Invoices
                                                                                  - Cost and Personnel Reporting, and Variances
                                                                                  from the Negotiated Budget

The Contractor agrees to provide a detailed breakdown
on invoices of the following cost categories:

		a.	Direct Labor - List individuals by name, title/position, hourly/annual
                                                             rate, level of effort, and amount claimed.

		b.	Fringe Benefits - Cite rate and amount

		c.	Overhead - Cite rate and amount

		d.	Materials & Supplies - Include detailed breakdown when total
                                                             amount is over $1,000.

		e.	Travel - Identify travelers, dates, destination, purpose of trip,
                                                             and amount. Cite COA, if appropriate. List separately domestic travel,
                                                             general scientific meeting travel, and foreign travel.

		f.	Consultant Fees - Identify individuals and amounts.

		g.	Subcontracts - Attach Subcontractor invoice(s).

		h.	Equipment - Cite authorization and amount.

		i.	Other Direct Costs - Include detailed breakdown when total amount
                                                             is over $1,000.

		j.	G&A - Cite rate and amount.

		k.	Total Cost

		l.	Fixed Fee

		m.	Total CPFF

 

Monthly Invoices must include the cumulative total
expenses to date, adjusted (as applicable) to show any amounts suspended by the Government.

 

    	6

    	 

    

 

		f.	Confidential
                                                                                  Treatment of Sensitive Information

 

The Contractor shall guarantee strict confidentiality of any
information/data of a sensitive nature that is provided to the Contractor by the Government during the performance of the contract.
The Government has determined that the information/data that the Contractor will be provided during the performance of the contract
is of a sensitive nature.

 

Disclosure of information/data that is sensitive in nature,
in whole or in part, by the Contractor can only be made after the Contractor receives prior written approval from the Contracting
Officer. Whenever the Contractor is uncertain with regard to the proper handling of information/data under the contract, the Contractor
shall obtain a written determination from the Contracting Officer. (See also HHSAR clause 352.224-70).

 

Notwithstanding the foregoing,
such information/data shall not be deemed of a sensitive nature with respect to the Contractor for purposes of this contract if
such information/data: (a) was already known to the Contractor; (b) was generally available or known, or was otherwise part of
the public domain, at the time of its disclosure to the Contractor; (c) became generally available or known, or otherwise became
part of the public domain, after its disclosure to, or, with respect to the information/data by, the Contractor through no fault
of the Contractor; (d) was disclosed to the Contractor, other than under an obligation of confidentiality or non-use, by a third
party who had no obligation to the Government that controls such information/data not to disclose such information/data to others;
or (e) was independently discovered or developed by the Contractor, as evidenced by its written records, without the use of information/data
belonging to the Government. 

 

Contractor may disclose information/data
of a sensitive nature provided by the Government to the extent that such disclosure is: (a) made in response to a valid order
of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental
or regulatory body of competent jurisdiction; provided, however, that the Contractor shall first have given notice
to the Government and give the Government a reasonable opportunity to quash such order and to obtain a protective order requiring
that the information/data of a sensitive nature that is the subject of such order be held in confidence by such court or agency
or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure
order is not quashed or a protective order is not obtained, the information/data disclosed in response to such court or governmental
order shall be limited to that information which is legally required to be disclosed in response to such court or governmental
order; (b) otherwise required by law, in the opinion of legal counsel to the Contractor as expressed in an opinion letter in form
and substance reasonably satisfactory to the Government, which shall be provided to the Government at least two (2) business days
prior to the Contractor’s disclosure of the information/data; or (c) made by the Contractor to the Regulatory Authorities
as required in connection with any filing, application or request for Regulatory Approval; provided, however, that
reasonable measures shall be taken to assure confidential treatment of such information/data.

 

		g.	RESERVED.

  

    	7

    	 

    

 

		h.	Sharing of
                                                                                  contract deliverables within United States Government
                                                                                  (USG)

 

In an effort to build a robust
medical countermeasure pipeline through increased collaboration, BARDA may share technical deliverables with USG entities responsible
for Medical Countermeasure Development.  In accordance with recommendations from the Public Health Emergency Medical Countermeasure
Enterprise Review, agreements established in the Integrated Portfolio’s Portfolio Advisory
Committee (PAC) Charter, Technology Transfer Agreements (TTA) between BARDA and the Defense Threat Reduction Agency and the National
Institute of Allergies and Infectious Diseases (NIAID), BARDA may share technical deliverables set forth in Article F.2 with colleagues
within the Integrated Portfolio.  This advance understanding does not authorize BARDA to share financial information outside
HHS. The Contractor is advised to review the terms of FAR Clause 52.227-14, Alternative II, regarding the Government’s rights
to deliverables submitted during performance as well as the Government’s rights to data contained within those deliverables.

 

		i.	Earned
                                                                                                                           Value
                                                                                                                           Management
                                                                                                                           System
                                                                                                                           (EVMS)
                                                                                                                           Implementation
                                                                                                                           Requirements

 

The Contractor and BARDA agree that the EVMS implementation
requirements that are contained in this contract are limited to the implementation requirements outlined by the 7 Principles of
Earned Value Management Tier 2 System Implementation Intent Guide contained in Attachment 9 of the contract. The total amount
of this contract reflects the use of the 7 Principles of EVMS Implementation. Any EVMS implementation requirements that are beyond
the intent of the 7 Principles of EVMS Implementation and/or exceed the negotiated cost to implement of $[...***...] shall not
proceed until the Contracting Officer sends a written request for a proposal to the Contractor and a bilateral modification is
issued to the contract for the purposes of incorporating the additional costs for the performance of these requirements into the
contract.

 

		j.	Recognition
                                                                                  of Dual Use Nature of CMX001

 

The Contractor and BARDA recognize and
acknowledge that CMX001 is being developed for several commercial indications (outside of the smallpox indication funded by BARDA
under this contract) using funds from financing sources independent of BARDA. As such, the development and commercialization of
CMX001 for such commercial indications shall not be impeded or in any way restricted by BARDA in the implementation of, or in
connection with, this contract. This includes an express acknowledgment by BARDA that the Contractor has no obligation to submit
for prior review or approval any information (including, but not limited to, clinical trial protocols, publications, and/or regulatory
submissions) regarding those activities funded 100% independently for commercial development efforts for CMX001. This excludes
activities directly funded in part/or in whole by BARDA. The Contractor agrees to work in good faith to provide BARDA with any
information related to the commercial development of CMX001 that the Contractor deems relevant, in its sole discretion, to the
development of the product for the smallpox indication.

 

		k.	Recognition
                                                                                  of Chimerix Control Over CMX001 Development
                                                                                  Program

 

In accordance with Articles C.2 and F.2 below, BARDA shall
have the opportunity to review and comment on certain Contractor documents, including study protocols, study reports, minutes
of meetings with the FDA, and other regulatory filings to FDA.  Wherever such review and comment is specifically required
by the terms of this contract, the Contractor shall provide BARDA with a minimum of eight (8) business days in which to review
and provide comments back to the Contractor provided, however, that at BARDA’s request, the Contractor shall provide
BARDA with such additional time for review and comment as Contractor deems practicable under the circumstances.  As the drug
sponsor, Contractor shall have sole discretion over the development of CMX001 and regarding how to respond to BARDA’s comments.
BARDA shall not require

 

***Confidential Treatment Requested

 

    	8

    	 

    

 

 Contractor to change a submission to FDA or other submission
that may impact the development of CMX001.  Except for study protocols, Contractor may make its submission to the FDA and/or
otherwise proceed with performance upon the expiration of the specified review period (if the Contractor has not received BARDA’s
comments), or upon issuance of the response to BARDA’s comments that is required by the terms of the contract.  For
study protocols, Contractor may make the submission and/or otherwise proceed with performance upon the expiration of the specified
review period (if the Contractor has not received BARDA’s comments), or upon issuance of the COA Letter. BARDA shall issue
COA Letters for study protocols within eight (8) business days of receipt of Contractor’s response to BARDA’s comments.

 

BARDA and the Contractor agree that wherever a contractual
deadline for review, comment and/or submission to BARDA is established within this contract, such deadline(s) may be impacted
by events currently unknown or unknowable that may trigger a need for the Contractor to respond to FDA without the ability to
provide the agreed upon advance notice to BARDA.  Contractor’s response to such events, should they occur, shall not
be deemed by BARDA to be a breach of this contract.

 

SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

 

ARTICLE C.1. STATEMENT OF WORK

 

Independently and not as an agent of the Government, the Contractor
shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the
Government as needed to perform the Statement of Work dated 10 February 2011 as set forth in SECTION J-List of Attachments, attached
hereto and made a part of the contract.

 

ARTICLE C.2. REPORTING REQUIREMENTS

 

Technical Reports

 

In addition to those reports required by the other terms of
this contract, the Contractor shall prepare and submit the following reports in the manner stated below and in accordance with
the DELIVERIES Article in SECTION F of this contract and in SECTION J-List of Attachments, attached hereto and made a part of
the contract. Such reports relate solely to the development activity funded under this contract.

 

A. Monthly Progress Report

 

This report shall include a description of the activities
during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists
of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist
of each calendar month.

 

The Contractor shall submit a Monthly Progress Report
on or before the 20th calendar day following the last day of each reporting period and shall include the following:

 

A cover page that includes the contract number and
title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail
address; and the date of submission; The progress report shall include a Table of Contents and Executive summary in accordance
with the DELIVERIES Article in SECTION F of this contract.

SECTION I-An introduction covering the purpose and
scope of the contract effort;

SECTION II-PROGRESS

SECTION II Part A: OVERALL PROGRESS-A description
of overall progress;

 

    	9

    	 

    

 

SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE
UPDATE-A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress
on administration and management issues (e.g. evaluating, and managing subcontractor performance, and personnel changes);

SECTION II Part C: TECHNICAL PROGRESS-For each activity
related to Gantt chart, document the results of work completed and cost incurred during the period covered in relation to proposed
progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description
shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions
resulting from analysis and scientific evaluation of data accumulated to date under the contract. The report shall include a description
of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have
occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of
data accumulated to date under the project;

SECTION II Part D; PROPOSED WORK-A summary of work
proposed related to Gantt chart for the next reporting period and preprints/reprints of papers and abstracts.

 

SECTION III Part A: Earned Value Management Reporting:
Contractor will provide a monthly Contract Performance Report (CPR) at an agreed upon reporting level (WBS level 3) using the
BARDA provided WBS and a Variance Analysis Report. EVMS shall be applied to all Cost Plus Fixed Fee CLINs as part of the Integrated
Master Project Plan following the Seven Principles of Earned Value Management. In accordance with FAR 52.215-2, Audit and Records-Negotiation,
BARDA may request, on a quarterly or ad hoc basis that the Contractor provide raw data. BARDA may request additional data at a
reporting level or at lower levels, as BARDA deems necessary so long as such requests do not impose requirements beyond what has
been specifically agreed to and funded by BARDA regarding EVMS implementation as provided in the Advance Understanding “Earned
Value Management System (EVMS) Implementation.”

 

A Monthly Progress Report will not be required in
the same month that the Quarterly or Annual Technical Progress Report is submitted.

 

B. Quarterly Progress Report

 

This report shall include a description of the activities
during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists
of the first full quarter of performance plus any fractional part of the initial quarter. Thereafter, the reporting period shall
consist of each calendar quarter.

 

The Contractor shall submit a Quarterly Progress
Report on or before the 20th calendar day following the last day of each reporting period and shall include the following:

A cover page that includes the contract number and
title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail
address; and the date of submission;

SECTION I-An introduction covering the purpose and
scope of the contract effort. The progress report shall include a Table of Contents and Executive summary in accordance with the
DELIVERIES Article in SECTION F of this contract.

SECTION II-PROGRESS

SECTION II Part A: OVERALL PROGRESS-A description
of overall progress;

SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE
UPDATE-A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress
on administration and management issues (e.g. evaluating, managing subcontractor performance and personnel changes);

 

    	10

    	 

    

 

SECTION II Part C: TECHNICAL PROGRESS-For each activity
related to Gantt chart, document the results of work completed and cost incurred during the period covered in relation to proposed
progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description
shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions
resulting from analysis and scientific evaluation of data accumulated to date under the contract. The report shall include a description
of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have
occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of
data accumulated to date under the project;

SECTION II Part D; PROPOSED WORK- A summary of work
proposed for the next reporting period; and preprints/reprints of papers, abstracts and a current/updated Gantt chart. A Quarterly
Progress Report will not be required in the same month that the Annual Progress Report is submitted.

SECTION III Part A: Earned Value Management Reporting:
Contractor will provide a quarterly Contract Performance Report (CPR) at an agreed upon reporting level (WBS level 3) using the
BARDA provided WBS and a Variance Analysis Report. EVMS shall be applied to all Cost Plus Fixed Fee CLINs as part of the Integrated
Master Project Plan following the Seven Principles of Earned Value Management. In accordance with FAR 52.215-2, Audit and Records-Negotiation,
BARDA may request, on a quarterly or ad hoc basis that the Contractor provide raw data. BARDA may request additional data at a
reporting level or at lower levels, as BARDA deems necessary so long as such requests do not impose requirements beyond what has
been specifically agreed to and funded by BARDA regarding EVMS implementation as provided in the Advance Understanding “Earned
Value Management System (EVMS) Implementation.”

 

C. Annual Progress Report

 

This report shall include a summation of the results
of the entire contract work for the period covered. An Annual Technical Progress Report will not be required for the period when
the Final Technical Progress Report is due. Monthly and Quarterly Progress Reports shall not be submitted in the same month when
an Annual Progress Report is due.

 

The first Annual Progress Report shall be due on
or before the 20th calendar day following the last day of the reporting period. Each Annual Progress Report shall include:

A Cover page that includes the contract number and
title; the type of report and period that it covers; the Contractor's name, address, telephone number, fax number, and email address;
and the date of submission; The progress report shall include a Table of Contents in accordance with the DELIVERIES Article in
SECTION F of this contract.

SECTION I: EXECUTIVE SUMMARY - A brief overview
of the work completed, and the major accomplishments achieved during the reporting period;

SECTION II: PROGRESS

SECTION II Part A: OVERALL PROGRESS-A description
of overall progress;

SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE
UPDATE-A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress
on administration and management issues (e.g. evaluating, and managing subcontractor performance; regulatory compliance audits,
and personnel changes);

SECTION II Part C: TECHNICAL PROGRESS - A detailed
description of the work performed structured to follow the activities and decision gates outlined at the Integrated Baseline Review
and as described in the Integrated Master Plan. The Report should include a description of any problems (technical or financial)
that occurred or were identified during the reporting period, and how these problems were resolved;

SECTION II Part D; PROPOSED WORK-A summary of work
proposed for the next year period to include an updated Gantt Chart.

 

    	11

    	 

    

 

SECTION III Part A: Earned Value Management Reporting:
Contractor will provide a quarterly Contract Performance Report (CPR) at an agreed upon (WBS level 3) reporting level using the
BARDA provided WBS and a Variance Analysis Report. EVMS shall be applied to all Cost Plus Fixed Fee CLINs as part of the Integrated
Master Project Plan following the Seven Principles of Earned Value Management. In accordance with FAR 52.215-2, Audit and Records-Negotiation,
BARDA may request, on a quarterly or ad hoc basis that the Contractor provide raw data. BARDA may request additional data at a
reporting level or at lower levels, as BARDA deems necessary so long as such requests do not impose requirements beyond what has
been specifically agreed to and funded by BARDA regarding EVMS implementation as provided in the Advance Understanding “Earned
Value Management System (EVMS) Implementation.”

 

Contractor also should include the following in
the Annual Progress Report:

 

		1.	Copies of manuscripts (published and unpublished), abstracts,
                                                                and any protocols or methods developed specifically under the
                                                                contract during the reporting period; and

 

		2.	A summary of any Subject Inventions per the requirements under
                                                                FAR Clause 52.227-11

 

		D.	Draft Final Technical Progress Report and Final Technical
Progress Report

 

These reports are to include a summation of the
work performed and results obtained for the entire contract period of performance. This report shall be in sufficient detail to
describe comprehensively the results achieved. The Draft Final Report and Final Report shall be submitted in accordance with the
DELIVERIES Article in SECTION F of the contract. An Annual Technical Progress Report will not be required for the period when
the Final Technical Progress Report is due. The Draft Final Technical Progress Report shall be submitted 75 calendar days before
the agreed completion date of the contract and the Final Technical Progress Report shall be submitted on or before the completion
date of the contract. The report shall conform to the following format:

 

		1.	Cover page to include the contract number, contract title, performance
                                                            period covered, Contractor's name and address, telephone number, fax
                                                            number, email address and submission date; The progress report shall
                                                            include a Table of Contents in accordance with the DELIVERIES Article
                                                            in SECTION F of this contract.

 

		2.	SECTION I: EXECUTIVE SUMMARY-Summarize the purpose and scope
                                                                of the contract effort including a summary of the major accomplishments
                                                                relative to the specific activities set forth in the Statement
                                                                of Work.

 

		3.	SECTION II: RESULTS-A detailed description of the work performed
                                                            related to the Gantt chart, the results obtained, and the impact of
                                                            the results on the scientific and/or public health community, including
                                                            a listing of all manuscripts (published and in preparation) and abstracts
                                                            presented during the entire period of performance, and a summary of
                                                            all inventions.

 

Draft Technical Progress Report: The Contractor
is required to submit the Draft Final Technical Progress Report to the Contracting Officer’s Technical Representative and
Contracting Officer. This draft report is due 75 calendar days before the completion date of the contract. The Contracting Officer’s
Technical Representative and Contracting Officer will review the Draft Final Technical Progress Report and provide the Contractor
with comments within 8 business days after receipt.

 

    	12

    	 

    

 

Final Technical Progress Report: The Contractor
will deliver the final version of the Final Technical Progress Report on or before the completion date of the contract. The final
version shall include or address the Contracting Officer’s Technical Representative comments and Contracting Officer comments
on the draft report. Final Technical Progress Report shall be submitted on or before the completion date of the contract.

 

		E.	Summary of Salient Results

The Contractor shall submit, with the Final Technical Progress Report, a summary (not to exceed 200 words) of salient results
achieved during the performance of the contract.

 

		F.	Other Technical Progress Reports

 

		1.	Draft Report for Clinical and
                                                                Non-Clinical Studies and Final Report for Clinical and Non-Clinical
                                                                Studies 

		·	The non-clinical
                                                                                                              and clinical trial
                                                                                                              reports shall follow
                                                                                                              the format of International
                                                                                                              Conference on Harmonization
                                                                                                              document ICH E3
                                                                                                              “Guidelines
                                                                                                              on Structure and
                                                                                                              Content of Clinical
                                                                                                              Study Reports”
                                                                                                              (http://www.pharmacontract.ch/support/su_ich_liste.htm).

		·	Draft
                                                                                                              Final Report for
                                                                                                              Clinical and Non-Clinical
                                                                                                              Studies funded by
                                                                                                              this contract will
                                                                                                              be submitted to
                                                                                                              the Contracting
                                                                                                              Officer’s
                                                                                                              Technical Representative
                                                                                                              and Contracting
                                                                                                              Officer (CO) for
                                                                                                              review and comment
                                                                                                              within 45 calendar
                                                                                                              days (draft) or
                                                                                                              75 calendar days
                                                                                                              (final) after completion
                                                                                                              of analysis of Pre-Clinical/Non
                                                                                                              Clinical/Clinical
                                                                                                              data and 8 business
                                                                                                              days prior to submission
                                                                                                              to FDA. Subcontractor
                                                                                                              prepared reports
                                                                                                              shall be submitted
                                                                                                              to the Contracting
                                                                                                              Officer’s
                                                                                                              Technical Representative
                                                                                                              and Contracting
                                                                                                              Officer (CO) for
                                                                                                              review and comment
                                                                                                              no later than 5
                                                                                                              business days after
                                                                                                              receipt by the prime
                                                                                                              contractor.

		·	The Contracting
                                                                                                              Officer shall provide
                                                                                                              written comments
                                                                                                              within 8 business
                                                                                                              days after the submission
                                                                                                              of the Draft Final
                                                                                                              Report for Clinical
                                                                                                              and Non-Clinical
                                                                                                              Studies.

		·	The
                                                                                                              comprehensive Final
                                                                                                              Report for Clinical
                                                                                                              and Non-Clinical
                                                                                                              Studies will be
                                                                                                              submitted to the
                                                                                                              Contracting Officer
                                                                                                              and the Contracting
                                                                                                              Officer’s
                                                                                                              Technical Representative
                                                                                                              within 30 calendar
                                                                                                              days after receiving
                                                                                                              comments on the
                                                                                                              Draft Final Report
                                                                                                              for Clinical and
                                                                                                              Non-Clinical Studies
                                                                                                              from the Contracting
                                                                                                              Officer.
                                                                                                              The final version
                                                                                                              shall include or
                                                                                                              address the Contracting
                                                                                                              Officer’s
                                                                                                              Technical Representative
                                                                                                              comments and Contracting
                                                                                                              Officer comments
                                                                                                              on the draft report.

		·	See section
                                                                                                              ARTICLE F.2. REPORTING
                                                                                                              REQUIREMENTS AND
                                                                                                              DELIVERABLES for
                                                                                                              additional clarification
                                                                                                              and deliverable
                                                                                                              requirements.

 

		G.	Audit Reports

 

Within three (3) business days of receipt of an FDA
Form 483 related to conformance to FDA regulations and guidance, including adherence to GLP, GMP, or GCP guidelines, as it relates
to performance under this contract where the results will adversely impact contract performance, the Contractor shall provide
the Contracting Officer’s Technical Representative and the Contracting Officer with copies of the form. Within fifteen (15)
business days of receipt of the form Contractor shall provide a plan for addressing areas of nonconformance to FDA regulations
and guidance for GLP, GMP or GCP guidelines as identified in the final audit report. See section ARTICLE F.2. REPORTING REQUIREMENTS
AND DELIVERABLES for additional clarification and deliverable requirements.

 

    	13

    	 

    

 

		H.	Clinical and Non-Clinical
                                                                       Protocols

 

BARDA has a responsibility to obtain documentation
concerning mechanisms and procedures that are in place to protect the safety of participants and animals in BARDA funded clinical
trials and non-clinical studies. Therefore the Contractor shall develop a protocol for each clinical trial and non-clinical study
funded under this contract and submit all such protocols and protocol amendments to the BARDA Contracting Officer’s Technical
Representative (COTR) for review by the Contracting Officer. Subject to Article B.5.k. above, the Contractor’s consideration
of the BARDA COTR comments shall be addressed in writing or by corrective action in the protocol prior to the issuance of a Contracting
Officer Authorization (COA) Letter authorizing the execution of the specific clinical trial or non-clinical study(ies).

 

Important information regarding performing human
subject research is available at http://www3.niaid.nih.gov/healthscience/clinicalstudies/. For additional information contractor
shall review the Attachment 11: Non-Clinical and Clinical Terms of Award set forth in SECTION J-List of Attachments and ARTICLE
F.2. REPORTING REQUIREMENTS AND DELIVERABLES.

 

Any updates to technical reports are to be addressed
in the Monthly, Quarterly and Annual Progress Reports. The Contractor shall advise the Contracting Officer’s Technical Representative
or designee in writing and via electronic communication in a timely manner of any issues potentially affecting contract performance.

 

		I.	Other Reports/Deliverables

 

The Contractor shall provide
all deliverables as outlined in the table under ARTICLE F.2. REPORTING REQUIREMENTS AND DELIVERABLES section of this document.

 

ARTICLE C.3. SUBJECT INVENTION REPORTING REQUIREMENT

 

All reports and documentation required by FAR Clause
52.227-11, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support
certification, shall be directed to the Extramural Inventions and Technology Resources Branch, OPERA, NIH, 6705 Rockledge Drive,
Room 2207, MSC 7987, Bethesda, Maryland 20892-7987 (Telephone: 301-435-1986). In addition, one copy of an annual utilization report,
and a copy of the final invention statement, shall be submitted to the Contracting Officer. The final invention statement (see
FAR 27.303(b)(2)(ii)) shall be submitted to the Contracting Officer on the expiration date of the contract. See also FAR clause
52.227-11 (Patent Rights-Ownership by the Contractor).

 

Reports and documentation submitted to the Contracting
Officer shall be sent to the following address:

 

    	14

    	 

    

 

Contracting Officer

Ethan J. Mueller

Office of Acquisitions Management, Contracts, and
Grants (AMCG)

330 Independence Avenue, S.W.

Room G640

Washington, D.C. 20201

Ethan.Mueller@hhs.gov

 

If no invention is disclosed or no activity has
occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to the
Contracting Officer at the address listed above.

 

To assist contractors in complying with invention
reporting requirements of the clause, "Interagency Edison," an electronic invention reporting system has been developed.
Use of Interagency Edison is encouraged as it streamlines the reporting process and greatly reduces paperwork. Access to the system
is through a secure interactive Web site to ensure that all information submitted is protected. Interagency Edison and information
relating to the capabilities of the system can be obtained from the Web ( http://www.iedison.gov ), or by contacting the
Extramural Inventions and Technology Resources Branch, OPERA, NIH.

 

ARTICLE C.4. PROJECT MEETING CONFERENCE CALLS
ONCE EVERY TWO WEEKS

			A conference call between the Contracting Officer’s Technical
                                                         Representative and the Contractor’s Program Manager shall occur
                                                         once every two weeks. During this call, the Program Manager will discuss
                                                         the activities during the reporting period, any problems that have arisen
                                                         and the activities planned for the ensuing reporting period. The first
                                                         reporting period consists of the first full month of performance plus
                                                         any fractional part of the initial month. Thereafter, the reporting period
                                                         shall consist of each calendar month. The Contractor’s Program
                                                         Manager may choose to include other key personnel on the conference call
                                                         to give detailed updates on specific projects or this may be requested
                                                         by the Contracting Officer’s Technical Representative.

 

ARTICLE C.5.  PROJECT MEETINGS  

The Contractor shall participate in Project Meetings
to coordinate the performance of the contract, as requested by the Contracting Officer’s Technical Representative. 
These meetings may include face-to-face meetings with BARDA/AMCG in Washington, D.C. and at work sites of the Contractor and its
subcontractors.  Such meetings may include, but are not limited to, meetings of the Contractor (and subcontractors invited
by the Contractor) to discuss study designs, site visits to the Contractor’s and subcontractor’s facilities, and meetings
with the Contractor and HHS officials to discuss the technical, regulatory, and ethical aspects of the program.  The Contractor
must provide data, reports, and presentations to groups of outside experts (subject to appropriate protections for Contractor
confidential or proprietary data) and USG personnel as required by the Contracting Officer’s Technical Representative in
order to facilitate review of contract activities. Subject to other provisions specified in this contract (See for example Article
F.2), the Contractor shall provide notice to

 

    	15

    	 

    

 

the COTR no later than 10 business days where practicable, prior to both formal and
informal meetings and communications with the Food and Drug Administration (FDA) related to the efforts funded by this contract
including anticipated telephone communications. In the event that the COTR or other authorized BARDA representative is unable
to participate in a meeting or telephone conference the Contractor shall provide the COTR with a written summary of all subjects
discussed no later than three (3) business days following the meeting or conference.

 

 

 

SECTION D – PACKAGING, MARKING AND SHIPPING

 

All deliverables required under this contract shall be packaged,
marked and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked with the contract
number and Contractor name. The Contractor shall guarantee that all required materials shall be delivered in immediate usable
and acceptable condition.

 

Report Deliverables

 

Unless otherwise specified by the Contracting Officer, delivery
of reports to be furnished to the Government under this contract (including invoices), shall be delivered to BARDA electronically
along with a concurrent email notification to the Contracting Officer, Contract Specialist, and COTR summarizing the electronic
delivery.

 

In addition, a physical hard copy, will be sent unless otherwise
specified by the Contracting Officer. Delivery of reports to be furnished to the Government under this contract (including invoices),
shall be addressed as follows:

 

Tyler Merkeley, M.S., MBA

Contracting Officer’s Technical Representative (COTR)

330 Independence Avenue, S.W.

Washington, D.C. 20201

202-260-0315 (Office)

Tyler.Merkeley@hhs.gov

 

Ethan J. Mueller, Contracting Officer (CO)

DHHS/OS/ASPR/AMCG

330 Independence Avenue, S.W.

Room G640

Washington, D.C. 20201

Ethan.Mueller@hhs.gov

 

SECTION E – INSPECTION AND ACCEPTANCE

 

		1.	The Contracting Officer (CO) or the duly authorized representative
                                                                  will perform inspection and acceptance of materials and services
                                                                  to be provided under this contract.

 

		2.	For the purpose of this SECTON, the designated Contracting
                                                                  Officer’s Technical Representative (COTR) is the authorized
                                                                  representative of the Contracting Officer. The COTR will assist
                                                                  in resolving technical issues that arise during performance.
                                                                  The COTR however is not authorized to change any contract terms
                                                                  or authorize any changes in the Statement of Work or modify
                                                                  or extend the period of performance, or authorize reimbursement
                                                                  of any costs incurred during performance.

 

    	16

    	 

    

 

		3.	Inspection and acceptance will be performed at:

 

Biomedical Advanced Research and Development Authority/Office
of Acquisition Management, Contracts, and Grants (AMCG)

Office of the Assistant Secretary for Preparedness
and Response

U.S. Department of Health and Human Services

330 Independence Avenue, S.W., Room G644

Washington, D.C. 20201

 

		4.	The contract incorporates the following clause by reference
                                                                  with the same force and effect as if it were given in full text.
                                                                  Upon request, the Contracting Officer will make its full text
                                                                  available.

 

FAR Clause 52.246-9, Inspection of Research and Development
(Short Form) (April 1984)

 

SECTION F – DELIVERIES OR PERFORMANCE

 

Deliveries and performance under these Contract
Line Item Numbers (CLINs) and Option CLINs shall be as follows:

 

ARTICLE F.1. ESTIMATED PERIOD OF PERFORMANCE

 

a. Under CLIN 0001, the estimated period of performance
for the base work segment of this contract shall be from 2/16/2011-2/15/2012. As discussed under Article B.1, this estimated period
of performance may be subject to adjustment. The period of performance for each of the Option work segments under CLINS 0002 through
0005 may also be subject to adjustment in order to complete the tasks required under each work segment.

 

	CLIN	 	Estimated Period of Performance	 	 	Supplies/Services	 
	0002	 	16 February 2012 through 15 February 2013	 	 	[...***...]

[...***...]

	 
	0003	 	16 February 2013 through 15 February 2014	 	 	[...***...]

[...***...]

	 
	0004	 	16 February 2014 through 15 February 2015	 	 	[...***...]

[...***...]

	 
	 	 	 	 	 	 	 	 	 

***Confidential Treatment Requested

 

    	17

    	 

    

 

	0005	 	16 February 2015 through 15 February 2016	 	 	[...***...]

[...***...]

	 
	 	 	 	 	 	 	 	 	 

ARTICLE F.2. DELIVERABLES

 

Successful performance of the final contract shall be deemed
to occur upon performance of the work set forth in the Statement of Work dated 10 February 2011 set forth in SECTION J-List of
Attachments of this contract and upon delivery and acceptance, as required by the Statement of Work, by the Contracting Officer,
or the duly authorized representative, of the following items in accordance with the stated delivery schedule:

 

The items specified below as described in the REPORTING REQUIREMENTS
Article in SECTION C of this contract and the Statement of Work dated 10 February 2011 set forth in SECTION J-List of Attachments
will be required to be delivered F.O.B. Destination as set forth in FAR 52.247-35, F.O.B. DESTINATION, WITHIN CONSIGNEE’S
PREMISES (APRIL 1984), and in accordance with and by the date(s) specified below and any specifications stated in SECTION D, PACKAGING,
MARKING AND SHIPPING, of this contract. All reports identified below relate solely to the development activity funded under this
contract:    

 

1. Other Contract Deliverables

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	1.	Project
    Meeting	Every two weeks

        or as amended by CO and COTR
	The Contractor shall participate in teleconferences
        every two weeks

        with BARDA to discuss the performance of the contract.
        The Contractor prepares a proposed agenda and shall record, maintain and provide draft-meeting minutes to the COTR for
        approval. The COTR will approve the draft version and distribute the final version to the Contract Officer (CO) and Contractor.
	·Contractor
        provides agenda 48hrs in advance of meeting to the COTR. COTR approves (with CO concurrence) and distributes agenda.

        ·Contractor
        provides meeting minutes within 2 business days of the meeting

        ·COTR
        reviews, comments and approves minutes
	1
    Electronic Copy to COTR and CO
	2.	Monthly,
    Quarterly and Annual Project Status Report/ Meeting	Monthly
    reports are due on the 20th of each month, except on months when Quarterly/Annual Technical Progress Reports are due	The
Monthly/Quarterly Project/Annual Status Report shall address the items listed below and cross-referenced to the Work Breakdown
Structure (WBS), Scope of Work (SOW), Integrated Master Schedule (IMS), Integrated Baseline
Review (IBR) report, Earned Value Management (EVM) Contract Performance Reports (CPR), and approval strategy.

1.An Executive Summary in MS PowerPoint (.ppt)
        format,
	Monthly Reports:

        ·Contractor
        provides Monthly Status Report deliverables on the 20th of each month. 

        ·COTR
and CO will review Monthly Reports with the Contractor and provide feedback

         

        Quarterly Meeting:

        ·
Contractor provides Quarterly Status Report
	1
    Electronic Copy 

to COTR and CO

 

***Confidential Treatment Requested

 

    	18

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	 	 	due	highlighting the progress, issues, and relevant activities in manufacturing, non-clinical, clinical, and regulatory.
        The Executive Summary should be limited to 2-3 pages and highlight critical issues for that reporting period. The Monthly,
        Quarterly, and Annual Technical Progress Report shall address each of the items below and be cross-referenced to the Critical
        Path, Integrated Master Schedule (IMS), EVM, WBS and the Risk Mitigation Matrix.

         

        2.Progress in meeting contract milestones - broken
        out by subtasks within each milestone, overall project assessment, problems encountered and recommended solutions. The
        reports shall detail the planned progress and actual progress during the period covered, explaining occurrences of any
        differences between the two, and the corrective steps.

        3.Provide EVM CPR (monthly) and Updated Risk Management
        Plan/Register (quarterly)

        4.The reports shall also include a three-month
        rolling forecast of key planned activities, referencing the WBS/IMS.

        5.A tracking log of progress on regulatory submissions
with the FDA submission number, description of submission, date of submission, status of submission, and next steps shall be updated
upon submission for all activities supported in part or whole with BARDA funding. 

6.	Estimated and Actual Expenses: This report shall also contain a narrative statement or in table form as to whether there is any significant discrepancy (greater than 10%) at this time between the % of work completed and the cumulative costs incurred to date. Monthly and Actual Expenses should be broken down to the appropriate WBS reporting level. This section of the report shall also contain estimates for the 
	five
business days prior to meeting. This report is an expanded version of the Monthly Status Report

        ·Contractor
        shall identify itinerary for the quarterly site visits 

        ·Contractor
        provides agenda to the COTR 48hrs in advance of meeting 

        ·COTR
        approves (with CO concurrence) and distributes agenda

        ·Contractor
        provides meeting minutes within 2 business days of the meeting

        ·COTR
        reviews, comments and approves minutes

         

        Annual Meeting:

        ·Contractor
provides Annual Project Status Report deliverables five business days prior to meeting. A draft report including .ppt slides should
be provided 5 business days prior to the meeting. The annual report should also include information from the annual meeting due
15 business days after the meeting.

        ·BARDA reserves the right to meet with the Contractor’s board of directors once a year to discuss
the contract at a time and place agreed upon by the parties. 

        · COTR approves (with CO concurrence) and distributes agenda

        · COTR approves (with CO concurrence) all meeting material

        · Contractor
provides 

         
	

 

    	19

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	 	 	 	subcontractors' expenses from the previous month if the subcontractor did not submit a bill in the previous month. Estimates
        shall be listed for each subcontractor. If the subcontractor(s) was not working or did not incur any costs in the previous
        month, then a statement to this effect should be included in this report for those respective subcontractors. This section
        should also include a summary of any cost savings identified by the Contractor. .

        7.Contractor shall identify the itinerary for the
        quarterly site visits (quarterly)
	 meeting
minutes within 2 business days of meeting

        ·COTR
        reviews, comments and approves minutes

        ·Contractor
        provides a FINAL annual report within 15 business days after the conclusion of the annual meeting. COTR (with CO concurrence)
        reviews, comments and approves FINAL Annual Report

        ·BARDA
        and Contractor shall participate in an in-process review
	 
	3.	Performance
    Measurement Baseline Review (PMBR)	Within
    90 days of contract award	
The PMBR Report shall
        address each of the items listed below and be cross-referenced to the WBS, SOW, IMS, Risk Management Plan and product
        approval strategy. 

        1.Contractor provides
        baseline proposal and PowerPoint brief

        2.Responsibility
        Assignment Matrix

        3.A description
        of the work scope through control account Work Authorization Documents (WADs) and/or WBS Dictionary down to the control
        account level

        4.Template for
        Work Packages

        5.Integrated Master
        Schedule (IMS) with the inclusion of agreed major milestones and control account plans (CAP) for all control accounts

        6.Baseline revision
        documentation and program logs (s) risk management plan.
	·Contractor
        provides baseline proposal, .ppt briefing, 10 business days prior to meeting

        ·Contractor
        provides agenda to the COTR 48hr in advance of meeting 

        ·COTR
        approves (with CO concurrence) and distributes agenda

        ·COTR
        approves (with CO concurrence) all meeting material

        ·Contractor
        provides minutes within 2 business days of the meeting

        ·COTR
        reviews and approves minutes 

        ·BARDA
        will review documentation and provide written comments and questions to Contractor

        ·Contractor
shall address its consideration of BARDA’s comments and resubmit PMBR Report within 10 business days
	1 Electronic Copy to COTR and CO

        

         

	4.	Risk
    	90 days 	The Contractor will provide
    a Risk	·Contractor shall provide 	1

 

    	20

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
		Management Plan	following contract award
        and updated quarterly

         
	Management Plan that outlines the impacts of each risk in relation to the cost, schedule and performance objectives.
    The Risk Management Plan will include risk mitigation strategies. Each risk mitigation strategy will capture how the corrective
    action will reduce impacts on cost, schedule and performance.	   a Risk Management Plan 90 days following contract award and update on
        the 20th of each Quarter in their Quarterly or Annual Project Status Reports 

        ·BARDA
        shall provide Contractor with a written list of concerns in response to Contractor’s submitted Risk Management Plan,
        and the Contractor must address in writing its consideration of all concerns raised by BARDA within 20 business days of
        Contractor’s receipt of this list of concerns.
	Electronic
Copy to COTR and CO
	5.	Integrated
    Master Schedule	The 20th of each month

         
	The
    Contractor will provide Integrated Master Schedule (IMS) with monthly status updates to reflect changes in schedule, performance,
    and critical path. Contractor will include BARDA Portfolio Management Milestones in their IMS and provide monthly updates
    within their IMS.	·The
        first draft IMS is due 30 days after contract award. The contractor and BARDA will establish an agreed upon IMS at the
        PMBR. 

        ·Thereafter
        the Contractor shall provide an Integrated Master Schedule on the 20th of each
        month in their Project Status Reports

        ·Integrated
        Master Schedule shall be in both PDF and Microsoft Project Form

        ·BARDA
        shall provide Contractor with a written list of concerns in response to Contractor’s submitted IMS, and the Contractor
        must address in writing its consideration of all concerns raised by BARDA within 10 business days of Contractor’s
        receipt of this list of concerns.
	1
    Electronic Copy (PDF and Microsoft Project Schedule (.mmp) format to COTR and CO
	6.	EVM / Contract Performance
    Report	The 20th day of the month after
        	Contractor will provide a monthly Contract Performance Report (CPR) Format 1 at WBS level 3 using the

	·Contractor
        shall provide a CPR and Variance Analysis Report on the
	Electronic
    Copy to COTR

 

    	21

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
			each calendar month

         
	BARDA provided WBS and a Variance Analysis Report (Format 5).

         

        A supplemental monthly Control Account Plan (CAP) report
        shall contain, at the work package level, time phased budget (budgeted cost of work scheduled (BCWS)), earned value (budgeted
        cost of work performed (BCWP)) and actual costs of work performed (ACWP) as captured in Contractor’s EVM systems.
        The contractor shall provide a rationale in the package of its use of % complete as EVMS methodology or identity if any
        other EVMS methodology is being used.
	20th day of the month after the end of each Month.
        ·Contractor
        shall discuss any anticipated cost savings or risks in its Variance Analysis Report. 

        ·Contractor
        shall provide a PDF of deliverables or in a format as directed by COTR.

        ·BARDA
        may request additional data at a reporting level or at lower levels, as BARDA deems
        necessary

        ·The
        Contractor must address in writing its consideration of all concerns raised by BARDA staff 
	 and CO
	7.	Incident Report	Within 24 or 48 hrs
    of activity or incident	The Contractor shall communicate to BARDA and document
        all critical programmatic concerns or risks within 48 hours. The Contractor shall communicate via email or telephone.

         

        In addition, the Contractor shall report to the government
        any activity or incident that is in violation of established security standards or indicates the loss or theft of government
        products within 24 hrs of loss or theft. The Contractor shall communicate via email, oral or written communication.
	·Email,
        Letter to CO Telephone (w/ written follow-up)

        ·Written
        communication with BARDA COTR and CO within 48 hrs of Contractor identifying a critical programmatic risk. Additional
        updates within 48 hrs of additional developments, additional information and/or understanding

        ·Contractor
        shall submit within 5 business days a Corrective Action Plan (if deemed necessary by Contractor)

        ·If
        corrective action is recommended, the Contractor must address in writing, within 5 business days, its consideration of
        concerns raised by BARDA

         
	1
    Electronic Copy COTR and CO 

 

    	22

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	8.	Deviation Request	TBD	Process
    for changing the IMS activities as baselined at the PMBR.	·Contractor
        shall submit a Deviation Request as soon as the Contractor has sufficient data to support the need for a significant change
        from the baselined IMS, mutually agreed upon at the PMBR (in excess of one (1) month) and/or PBMR costs (in excess of
        10%)

        ·The
        BARDA CO will review and provide a written response to the Deviation Request which may include rebaseline of the IMS and/or
        PBMR.

        ·Contractor
        shall address its consideration of BARDA’s comments within 10 business days. 
	1 Electronic Copy to COTR and CO

        

         

	9.	Draft and Final Technical
    Progress Report	Draft 75 calendar
    days before and Final shall be submitted on or before the completion date of the POP	A draft of Final Technical
        Progress Report containing a summation of the work performed and the results obtained
        for the entire contract period of performance. The draft report shall be duly marked as 'Draft'.

         

        The Final Technical
        Progress Report addressing Contractor’s consideration of the feedback received from
        BARDA and containing a summation of the work performed and the results obtained for the entire contract period of performance.
        This final report shall detail, document and summarize the results of the entire contract. This report shall be in sufficient
        detail to fully describe the progress achieved under all milestones. The final report shall be duly marked as 'Final'.
        
	·Contractor
        shall provide a draft Technical Progress Report 75 calendar days before the end of the POP and the Final Technical Progress
        Report shall be submitted on or before the completion date of the POP 

        ·COTR
        provides suggested edits and additional feedback, which Contractor will consider for incorporation into the Final Technical
        Progress Report 

        ·The
        Contractor shall submit one (1) copy of a comprehensive final report to the CO and one (1) copy (electronically on a CD)
        to the COTR
	1 Electronic Copy to COTR and CO

        

         

	10.	Product Transition
    Strategy	90 days prior to end
    of the	Contractor shall provide
        a 2-3 page summary document containing a Product Transition Strategy to 	·Contractor
shall provide a Product Transition Strategy to support
	1 Electronic
Copy to 

 

    	23

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
		
    	 (base/option) POP	support
transition of the product(s) prior to end of the base and/or option(s) POP. The Product Transition Strategy should provide a strategic
plan for further development and/or stockpiling of the product.

         

        The transition strategy shall provide options and/or
        a specific approach for the transition of MCM product for further development, procurement, approval by FDA and/or stockpile.
	transition
of the product(s) 90 days prior to end of the (base/option) POP as an addendum to that Quarter’s Quarterly Project Status
Report.
	COTR and CO

        

         

	11.	GO/NO GO Decision
    Gate Presentation	Event Driven Review
    following completion of a pre-defined stage of product development and prior to initiation of a new stage	Contractor
    shall provide a presentation following a prescribed template provided by BARDA prior to the Decision Gate Review	·Contractor
        shall provide an update to technical progress made towards completion of the GO/NO GO Decision
        Gate and provide the presentation, 10 business days prior to the Decision Gate Review

        ·Contractor
        shall submit written justification of progress towards satisfying GO/NO GO Decision
        Gate criteria

        ·After
        reviewing, the BARDA COTR and CO will provide a written response. 
	1 Electronic Copy to COTR and CO

        

         

         

	12.	Standard Operating
    Procedures	As requested by COTR
    and CO	Contractor
    shall provide Standard Operating Procedures (SOPs) relevant to the activities under this contract to BARDA for review,
    as they are completed and updated	·Contractor
    shall submit the Standard Operating Procedures (SOPs) in the form requested by the COTR
    and CO within 15 business days of request	1
    Electronic Copy to COTR and CO
	13.	Approval Strategy	Within 90 days of
    contract award and updated as part of the quarterly report (if strategy changes)	Contractor
    shall provide a 2-3 page summary of the approval strategy for all indications supported by this contract to include
    all clinical and non-clinical studies	·Contractor
        will submit proposed clinical and non-clinical strategy to support approval

        ·If
        corrective action is recommended by the BARDA COTR, the Contractor shall address in writing its consideration of concerns
        raised by BARDA 
	1
    Electronic Copy to COTR and CO
	14.	Study Protocol	At least 8 business
    	Contractor shall provide Pre-Clinical/Non-Clinical/ Clinical Trial

	· Contractor
        will submit proposed protocols to
	
1 Electronic 

 

    	24

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
			days for BARDA to review protocols prior to FDA submission and 30 days for study protocols that are not submitted to FDA	Protocols for studies funded under this contract to BARDA for review,
        prior to FDA submission
         

        (The CO and COTR reserves the right to request within
        the period of performance a non-proprietary Study Protocol for distribution within the United States Government(USG))
	·BARDA at least 8 business days prior to FDA submission or at least 30 days prior to
        study execution for study protocols that are not being submitted to the FDA 

        ·If
        corrective action is recommended , the Contractor must address in writing its consideration of all safety, regulatory,
        ethical, and conflict of interest concerns raised by BARDA 

        ·After
        receiving the required documentation the CO will provide a written Contract Officer Authorization (COA) Letter to the
        Contractor. This COA Letter provides authorization to the Contractor to execute the specific clinical or non-clinical
        study funded in part or in whole by BARDA

        ·If
        study protocols require submission to the FDA prior to execution, then FDA shall have final authority over Study Protocols
        and all amendments thereto.

        ·Final
        FDA submissions shall be submitted to BARDA concurrently or no later than 1 business day after its submission to CDER

         
	Copy to COTR and CO

        

         

	15.	Study Reports	Within 45 (draft)
    or 75 (final) calendar days after completion of analysis and 8 	Contractor shall provide
        Draft and Final Pre-Clinical/Non-Clinical Study Reports for studies funded under this contract to BARDA for review
        and edits within 45 (draft) or 75 (final) calendar days after completion of analysis of Pre-Clinical/Non-Clinical/ Clinical
        data and 15 business days	·Contractor shall provide Draft and Final Pre-Clinical/Non-Clinical Study Reports to BARDA within 45 (draft) or 75 (final) calendar days after completion of analyses
	
Electronic Copy to COTR and CO 

 

    	25

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
			business days prior to submission to FDA	prior
to submission to FDA

         

        (The CO and COTR reserves the right to request within
        the period of performance a non-proprietary Study Report for distribution within the USG)

         

        Contractor shall submit an interim study report to
        BARDA for any severable discrete work segments. If funding for a severable study is scheduled in two separate periods
        of performance than an interim study report is due on or before the completion date of the POP
	

        ·Contractor
        will submit proposed Pre-Clinical/Non-Clinical Study Report to BARDA for review
        and comment at least 8 business days prior to FDA Submission

        ·If
        corrective action is recommended , the Contractor must address in writing its consideration of all concerns raised by
        BARDA before FDA Submission

        ·Final
        FDA submissions shall be provided to BARDA concurrently or no later than 1 business day of its submission to CDER
	

        

	16.	Manufacturing Campaign
    Reports	Within 30 calendar
    days after receipt of batch records and 8 business days prior to submission to FDA	Contractor shall provide
        any Manufacturing Campaign Reports required by FDA to BARDA for review and comment prior to submission to FDA

         

        (The CO and COTR reserve the right to request within
        the period of performance a non-proprietary Manufacturing Campaign Reports for distribution within the USG)
	·Contractor
        will submit proposed Manufacturing Campaign Reports to BARDA at least 8 business
        days prior to FDA Submission.

        ·If
        corrective action is recommended , the Contractor must address in writing its consideration of all concerns raised by
        BARDA before FDA Submission

        ·Final
        FDA submissions shall be submitted to BARDA concurrently or no later than one (1) business day after its submission to
        CDER
	1
    Electronic Copy to COTR and CO
	17.	FDA Meeting Notification	Within 24 hours of
    scheduling meeting	The
    contractor shall forward the dates and times of any meeting with the FDA relating to work funded under this contract to BARDA
    and to the extent practicable arrange for appropriate BARDA staff to attend the FDA meetings. BARDA staff shall include up
    to a maximum of four people (PO, CO, and up to two (2) Subject Matter Experts (SME(s)).	·Contractor
    must notify BARDA of an upcoming meeting with the FDA relating to work funded under this contract within
    24 hours of scheduling the meeting, if practicable. To the extent practicable, Contractor will give	1
    Electronic Copy to COTR and CO

 

    	26

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	 	 	 	 	BARDA 10 business days
    notice prior to the scheduled meeting.	 
	18.	FDA Correspondence
    and Meeting Minutes	Within three (3) business
    days of receiving correspondence from the FDA	The
    contractor shall forward initial Contractor and CDER-issued draft minutes and final minutes of any meeting with the FDA relating
    to work funded under this contract to BARDA. All documents shall be duly marked as either 'Draft' or 'Final'.	·Contractor
    provides FDA correspondence and meeting minutes within three (3) business days of the
    meeting or correspondence
	1
Electronic Copy to COTR and CO

	19.	FDA Submissions	At least 15 business
    days where practicable, but no less than 8 business days prior to submission to FDA	The Contractor shall provide BARDA the opportunity
        to review and comment upon all draft regulatory filings and other material submissions and correspondence relating to
        work funded under this contract before submission to the FDA. Contractors shall provide BARDA with an electronic copy
        of the final FDA submission. All documents shall be duly marked as either 'Draft' or 'Final'.

         

         
	·Contractor
        will submit proposed FDA Meeting Briefing Packets to BARDA at least 15 business days where practicable, but no
        less than 8 business days prior to FDA submission
        

        ·If
        corrective action is recommended , the Contractor must address in writing its consideration of all concerns raised by
        BARDA staff before FDA submission

        ·Final
        FDA submissions shall be submitted to BARDA concurrently or no later than one (1) business day of its submission to CDER
	1
    Electronic Copy to COTR and CO 
	20.	FDA Audits	Within 10 business
    days of a scheduled audit or within 24 hours of an ad hoc site visits/audits if the FDA did not provide advanced notification	The
Contractor shall notify the COTR and CO within 24 hours of FDA's arrival to conduct site visits/audits by any regulatory agency.
In the event of an FDA inspection which occurs as a result of this contract and for this product, or for any other FDA inspection
that has the reasonable potential to impact the performance of this contract, the Contractor shall provide BARDA with an exact
copy (non-redacted of the FDA Form 483, Establishment Inspection Report (EIR). The contractor shall provide the COTR and CO copies
of the plan for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines as identified in the audit
report within 10 business days, status updates	·The
        Contractor shall notify the COTR and CO within 10 business days of a scheduled audit or within 24 hours of an ad hoc site
        visits/audits if the FDA did not provide advanced notification. Contractor must provide QA Audit Reports within 15 business
        days of the audit.

        ·The
        Contractor shall also provide copies of any FDA audit report received from subcontractors that occur as a result of this
        contract or for this product within three (3)

         
	1 Electronic Copy to COTR and CO

        

         

 

    	27

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	 	 	 	during the plan’s execution, and a copy of all final responses
    to the FDA. The Contractor shall also provide redacted copies of any FDA audit report received from subcontractors that occur
    as a result of this contract or for this product within three (3) business days of receiving correspondence from the FDA and/or
    third party. The Contractor shall make arrangements for a BARDA representative(s) to be present during the final debrief by
    the regulatory inspector.	business days of receiving such a report from the FDA and/or third party	 
	21.	QA Audit Reports	5 business days of
    report completion	The
    Contractor shall inform the COTR and CO in advance of upcoming audits/site visits of subcontractors
    funded under this contract as part of the regularly scheduled communications, including goals and agenda. BARDA reserves
    the right to observe the audit. Upon completion of the audit/site visit the Contractor shall provide a report capturing the
    findings, results and next steps in proceeding with the subcontractor. If action is requested of the subcontractor, details
    addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report,
    must be provided to BARDA. The Contractor shall provide responses from the subcontractors to address these concerns and plans
    for corrective action execution.	·The
        Contractor shall inform the COTR and CO 10 days in advance of upcoming audits/site visits of subcontractors 

        ·The
        Contractor shall notify the COTR and CO within 5 business days of report completion
	1 Electronic Copy to COTR and CO

        

         

	22.	BARDA Audit	Ad Hoc	The
    contractor shall accommodate periodic or ad hoc site visits by BARDA. If BARDA or the
    Contractor identifies any material issues during an audit, the Contractor shall capture the issues, identify potential solutions,
    and provide a report to BARDA. 	·If
        BARDA or the Contractor identifies any material issues during an audit, the Contractor shall capture the issues, identify
        potential solutions, and provide a report to BARDA within 10 business days.

        ·The
        COTR and CO will review the deliverable and provide a response to the Contractor.

        ·If
        corrective action is recommended and

         
	1
    Electronic Copy to COTR and CO

 

    	28

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
	 	 	 	 	undertaken, then Contractor will provide a final report to BARDA upon completion.	 
	23.	Technical Documents	Within 10 business
    days upon request by CO/COTR and 8 business days prior to submission to FDA	Contractor shall provide COTR and CO upon request with
        deliverables from the following contract funded activities: Process Development Reports, Assay Qualification Plan/Report,
        Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, SOPs, Master Production Records, Certificate
        of Analysis

         

        (The CO and COTR reserves the right to request within
        the period of performance a non-proprietary Technical Documents for distribution within the USG)
	·Contractor
        shall provide Technical documents within 10 business days upon request by CO/COTR 

        ·If
        additional time is required, Contractor shall request additional time from BARDA on a per deliverable basis

        ·If
        corrective action is recommended , the Contractor must address in writing its consideration of concerns raised by BARDA

        ·Contractor
        will submit proposed FDA Technical Documents to BARDA at least 5 business days
        prior to FDA submission 

        ·If
        corrective action is recommended, the Contractor must address in writing its consideration of all concerns raised by BARDA
        before FDA Submission
	For Final Documents:

         

        1 Electronic Copy to COTR and CO

        

         

         

	24.	Animal Model or Other
    Technology Transfer Package	Within 10 business
    days of request by CO/COTR	Contractor
    shall provide Animal Model or Other Technology Transfer Package relevant data	·Contractor
    shall provide Animal Model or other Technology Transfer Package within 10 business days of request by CO/COTR	1 Electronic Copy to COTR and CO

        

         

	25.	EVMS Raw Data	Within 20 business
    days after receipt of request by CO/COTR	 

        Contractor shall provide EVMS Raw Data for review by
        BARDA, if requested, in accordance with FAR 52.215-2, Audit and Records-Negotiation

         

         
	·Contractor
    shall provide Raw Data within 20 business days of request by CO/COTR	1 Electronic Copy to COTR and CO

        

         

	26.	Samples of Therapeutics	Within 20 business
    	Contractor
    shall provide samples of non-GMP candidate therapeutics 	·Contractor must submit samples of therapeutics 
	CO
    will provide 

 

    	29

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
			days of request by CO/COTR	and
GMP material manufactured with contract funding to include raw material, Bulk Drug Substance (BDS), Final Drug Product (FDP) and/or
labeled and packaged treatment courses. The request will state the type of material and the amount but it is not to exceed the
equivalent of 250 treatment courses or its individual manufacturing equivalent. The Contractor will be advised by the CO how samples
are to be packaged and where samples are to be shipped. It is acceptable to label material "Not for Clinical Use".
BARDA reserves the right to request samples throughout the period of performance.	within 20 business days of request by CO/COTR.

                                                                                ·The Contractor will be advised by the CO how samples are to be packaged and where samples are to be shipped. 
	details upon request
	27.	Publications	20 business days for
    manuscripts and 10 business days for abstracts	Any
    manuscript or scientific meeting abstract containing data generated under this contract must be submitted to BARDA for review
    prior to submission 	·Contractor
        must submit all manuscript or scientific meeting abstract to COTR and CO within 20 business days for manuscripts
        and 10 business days for abstracts

        ·Any
        Final submissions shall be submitted to BARDA concurrently or no later than one (1) business day of its submission
	1 Electronic Copy to COTR and CO

        

         

	28.	Press Releases	4 business days prior
    to release	The
    Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases	·The
        Contractor shall ensure that the CO has received and approved an advanced copy of any press release to this contract not
        less than 4 business days prior to the issuance of the press release

        ·Any
        final submissions shall be submitted to BARDA concurrently or no later than one (1) business day of its submission.
	1 Electronic Copy to COTR and CO

        

         

	29.	Contract financing
    Report	No later than the
    30th business day after the end of the 	The
    Financial Report shall be submitted by the Contractor in accordance with the instructions set forth in section G.4 of this
    contract. 	The
    Contractor shall provide the contract financing report no later than the 30th business day after the end of the reporting
    period in 	 

 

    	30

    	 

    

 

	#	Type of

    Deliverable	Frequency/

    time periods 	Description of Deliverable	Reporting Procedures	Quantity/

    Form
			reporting period		accordance with the instructions set forth in section G.4 of this contract. 	 

 

2. WBS Milestones/Deliverables
and Technical Deliverables 

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	1.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	2.	[...***...]	
        [...***...]

        [...***...]
	
        [...***...]

        [...***...]
	
        [...***...]

        [...***...]

        [...***...]
	
        [...***...]

        [...***...]

         
	
        [...***...]

        [...***...]

	3.	[...***...]	[...***...]	[...***...]	
        [...***...][...***...][...***...]

        [...***...][...***...]
	[...***...][...***...]	
        [...***...]

        [...***...]

 

****Confidential Treatment Requested

 

    	31

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	4.	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...][...***...]	
        [...***...]

        [...***...]

	5.	[...***...]	[...***...]	[...***...]	
        [...***...]

        [...***...]

        [...***...]
	
        [...***...]

        [...***...]
	
        [...***...]

        [...***...]

        [...***...]

	6.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	7.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	8.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	 

 

****Confidential Treatment Requested

 

    	32

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	 	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	9.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...]
	10.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	11.	[...***...]	[...***...]	[...***...]	[...***...]	
        [...***...]

        [...***...]

        [...***...]

        [...***...]
	
        [...***...]

        [...***...]

        [...***...]

 

****Confidential Treatment Requested

 

    	33

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	 	[...***...]	[...***...]	 	 	 	 
	12.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	13.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	14.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	15.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

****Confidential Treatment Requested

 

    	34

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	 	[...***...]	[...***...]	[...***...]	 	 	[...***...]
	16.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...] 
	17.	[...***...]	[...***...]	[...***...]	[...***...] 	[...***...]	[...***...] 
	18.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	19.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

****Confidential Treatment Requested

 

    	35

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	 	 	[...***...]	[...***...]	[...***...]	 	[...***...]
	20.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	21.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	
        [...***...]

        [...***...]

        [...***...]

	22.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	23.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	24.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

****Confidential Treatment Requested

 

    	36

    	 

    

 

	Contract Milestones and GO/NO GO Decision Gates
	Milestone	Milestone	GO/NO GO Decision Gates	 	 	 
	#	Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	25.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	26.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

Unless otherwise specified by the Contracting Officer, reports
to be furnished to the Government under this contract (including invoices), shall be delivered electronically along with a concurrent
email notification to the Contracting Officer, Contract Specialist, and COTR summarizing the electronic delivery.

 

In addition, unless otherwise specified by the Contracting
Officer, a physical hard copy of reports to be furnished to the Government under this contract (including invoices), shall be
sent and addressed as follows:

 

Contracting Officer’s and Contracting Specialist’s
address:

 

Ethan J. Mueller, Contracting Officer (CO)

DHHS/OS/ASPR/AMCG

330 Independence Avenue, S.W.

Room G640

Washington, D.C. 20201

Ethan.Mueller@hhs.gov

 

 

****Confidential Treatment Requested

    	37

    	 

    

 

Contracting Officer’s Technical Representative’s
address:

 

Tyler Merkeley, M.S., MBA

Contracting Officer’s Technical Representative (COTR)

330 Independence Avenue, S.W.

Washington, D.C. 20201

202-260-0315 (Office)

Tyler.Merkeley@hhs.gov

 

ARTICLE F.3. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2
(FEBRUARY 1998)

 

The contract incorporates the following clause(s) by reference,
with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text
available. Also, the full text of a clause may be accessed electronically at this address: http://www.acquisition.gov/comp/far/index.html

 

FEDERAL ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE:

 

52.242-15, Stop Work Order (August 1989) with Alternate I (April
1984).

 

    	38

    	 

    

 

SECTION G - CONTRACT ADMINISTRATION DATA

 

ARTICLE G.1. CONTRACTING OFFICER

 

The following Contracting Officer (CO)
will represent the Government for the purpose of this contract:

 

Ethan J. Mueller, Contracting Officer

DHHS/OS/ASPR/AMCG

330 Independence Avenue, S.W.

Room G640

Washington, D.C. 2020

E-mail: Ethan.Mueller@hhs.gov

 

		1)	The Contracting Officer is the only individual who can legally
                                                           commit the Government to the expenditure of public funds. No person
                                                           other than the Contracting Officer can make any changes to the terms,
                                                           conditions, general provisions, or other stipulations of this contract.

		2)	The Contracting Officer is the only person with the authority to
                                                           act as agent of the Government under this contract. Only the Contracting
                                                           Officer has authority to (1) direct or negotiate any changes in the
                                                           statement of work; (2) modify or extend the period of performance;
                                                           (3) change the delivery schedule; (4) authorize reimburse to the Contractor
                                                           of any costs incurred during the performance of this contract; (5)
                                                           otherwise change any terms and conditions of this contract.

		3)	No information other than that which may be contained in an authorized
                                                           modification to this contract, duly issued by the Contracting Officer,
                                                           which may be received from any person employed by the US Government,
                                                           other otherwise, shall be considered grounds for deviation from any
                                                           stipulation of this contract.

		4)	The Government may unilaterally change its COTR designation.

 

ARTICLE G.2. CONTRACTING OFFICER'S TECHNICAL REPRESENTATIVE
(COTR)

 

The following Contracting Officer's Technical Representative
(COTR) will represent the Government for the purpose of this contract:

 

Tyler Merkeley, M.S., MBA

Contracting Officer’s Technical Representative (COTR)

Biomedical Advanced Research and Development Authority (BARDA)

Office of the Assistant Secretary for Preparedness and Response

Department of Health and Human Services

202-260-0315 (Office)

Tyler.Merkeley@hhs.gov

 

Mailing Address:

330 Independence Avenue, SW

Washington, D.C. 20201

202-260-0315 (Office)

e-mail: Tyler.Merkeley@hhs.gov

 

    	39

    	 

    

 

Alternate PO/COTR:

Dr. Joseph Larsen

Alternate Contracting Officer’s Technical Representative
(COTR)

BARDA/ASPR/HHS

330 Independence Avenue, SW

Washington, D.C. 20201

202-260-0050(Office)

e-mail: Joseph.Larsen@hhs.gov

 

The COTR is responsible for: (1) monitoring the Contractor's
technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes
in requirements; (2) assisting the contracting Officer in interpreting the statement of work and any other technical performance
requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by
this contract; and (5) assisting in the resolution of technical problems encountered during performance.

 

ARTICLE G.3. KEY PERSONNEL

 

Pursuant to the Key Personnel clause incorporated in Section
I of this contract, the following individuals are considered to be essential to the work being performed hereunder:

 

	#	NAME	ORGANIZATION	TITLE
	1	[...***...]	Chimerix	[...***...]
	2	[...***...]	Chimerix	[...***...]
	3	[...***...]	Chimerix	[...***...]
	4	[...***...]	Chimerix	[...***...]
	5	[...***...]	Chimerix	[...***...]
	6	[...***...]	Chimerix	[...***...]
	7	[...***...]	Chimerix	[...***...]
	8	 	 	 
	9	 	 	 
	10	 	 	 
	11	 	 	 
	12	 	 	 
	13	 	 	 
	14	 	 	 
	15	 	 	 
	16	 	 	 

 

The key personnel specified in this contract
are considered to be essential to work performance. At least 30 business days prior to diverting any of the specified individuals
to other programs or contracts, including, where practicable, an instance when an individual must be replaced as a result of leaving
the employ of the Contractor, the Contractor shall notify the Contracting Officer and shall submit comprehensive justification
for the diversion or replacement request (including proposed substitutions for key personnel) to permit evaluation by the Government
of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without
the written consent of the Contracting Officer.

 

***Confidential Treatment Requested

 

    	40

    	 

    

 

ARTICLE G.4. CONTRACT FINANCIAL REPORT

 

a. Financial reports on the attached Financial Report
of Individual Project/Contract (see Attachments 2 and 3) shall be submitted by the Contractor in accordance with the instructions
for completing this form, which accompany the form, in an original and two copies, not later than the 30th business day after
the close of the reporting period. The line entries for subdivisions of work and elements of cost (expenditure categories) which
shall be reported within the total contract are discussed in paragraph e., below. Subsequent changes and/or additions in the line
entries shall be made in writing.

 

b. Unless otherwise stated in that part of the instructions
for completing this form, entitled " PREPARATION INSTRUCTIONS ," (see Attachment 4) all columns A through J, shall be
completed for each report submitted.

 

c. The first financial report shall cover the period
consisting of the first full three calendar months following the date of the contract, in addition to any fractional
part of the initial month. Thereafter, reports will be on a quarterly basis.

 

d. The Contracting Officer may require the Contractor
to submit detailed support for costs contained in one or more interim financial reports. This clause does not supersede the record
retention requirements in FAR Part 4.7.

 

e. The listing of expenditure categories to be reported
is incorporated within the Attachment entitled, "Financial Report of Individual Project/Contract," located in SECTION
J and made a part of this contract.

 

f. The Government may unilaterally revise the “Financial
Report of Individual Project/Contract” to reflect the allotment of additional funds.

 

ARTICLE G.5. INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL
REPORTING

 

		1)	The Contractor shall submit an electronic copy of contract monthly
                                                           invoices/financial reports to the address shown below:

 

DHHS/OS/ASPR/AMCG

Attn: Ethan J. Mueller, Contracting Officer

330 Independence Ave., S.W.

Room G640

Washington, D.C. 20201

 

		2)	Contractor invoices/financial reports shall conform to
the form, format, and content requirements of the instructions for Invoice/Financing requests and Contract Financial Reporting
made a part of the contract in Section J (See also Attachment 2) .

 

		3)	Monthly invoices must include the cumulative total expenses to
                                                           date, adjusted (as applicable) to show any amounts suspended by the
                                                           Government.

 

		4)	The Contractor agrees to immediately
                                                           notify the Contracting Officer in writing if there is an anticipated
                                                           overrun (any amount) or unexpended balance (greater than 10 percent)
                                                           of the estimated costs for the base segment or any option segment(s)
                                                           (See estimated costs under Articles B.2. and B.3., CLINs 0001 through
                                                           0005 to the contract) and the reasons for the variance. Also refer
                                                           to the requirements of the Limitation of Cost FAR 52.232-20 clause
                                                           in the contract.

 

    	41

    	 

    

 

		5)	All invoice submissions shall be in
                                                           accordance with FAR Clause 52.232-25 (c) in Section I of this contract.

 

ARTICLE G.6. REIMBURSEMENT OF COST

 

		1)	The Government shall reimburse the Contractor the cost determined
                                                           by the Contracting Officer to be allowable (hereinafter referred to
                                                           as allowable cost) in accordance with the clause entitled Allowable
                                                           Cost and Payment in Section I, Contract Clauses, and FAR Subpart 31.2.
                                                           Examples of allowable costs include, but are not limited to, the following:

 

		a)	All direct materials and supplies
                                                                that are used in the performing of the work provided for under
                                                                the contract, including those purchased for subcontracts and purchase
                                                                orders.

 

		b)	All direct labor, including supervisory,
                                                                that is properly chargeable directly to the contract, plus fringe
                                                                benefits.

 

		c)	All other items of cost budgeted
                                                                for and accepted in the negotiation of this basic contract or
                                                                modifications thereto.

 

		d)	Travel costs including per diem
                                                                or actual subsistence for personnel while in an actual travel
                                                                status in direct performance of the work and services required
                                                                under this contract subject to the following:

 

		(i)	Air travel shall be by the most direct
                                                             route using “air coach” or “air tourist”
                                                             (less than first class) unless it is clearly unreasonable or impractical
                                                             (e.g., not available for reasons other than avoidable delay in making
                                                             reservations, would require circuitous routing or entail additional
                                                             expense offsetting the savings on fare, or would not make necessary
                                                             connections).

 

		(ii)	Rail travel shall be by the most
                                                              direct route, first class with lower berth or nearest equivalent.

 

		(iii)	Costs incurred for lodging, meals,
                                                               and incidental expenses shall be considered reasonable and allowable
                                                               to the extent that they do not exceed on a daily basis the per
                                                               diem rates set forth in the Federal Travel Regulation (FTR).

 

		(iv)	Travel via privately owned automobile
                                                              shall be reimbursed at not more than the current General Services
                                                              Administration (GSA) FTR established mileage rate.

 

ARTICLE G.7. INDIRECT COST RATES

 

The following rates will be utilized for billing purposes during
the base period. Fringe benefits at [...***...]% and G&A at [...***...]%. The billing rates for each option period will be
based on the incurred cost submission for the previous calendar year, subject to Government audit adjustments. Final rate proposals must
be sent to the Contracting Officer, within 6 months subsequent to the fiscal year end. (See also FAR Clause 52.216-7 incorporated
herein)

 

****Confidential Treatment Requested

 

    	42

    	 

    

 

 

ARTICLE G.8. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

 

1. Contractor Performance Evaluations

 

Interim and final evaluations of Contractor performance
will be prepared on this contract in accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at the
time of completion of work. In addition to the final evaluation, an interim evaluation shall be submitted June 29, 2012.

 

Interim and final evaluations will be provided to
the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review
the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties,
the matter will be referred to an individual one level above the Contracting Officer whose decision will be final.

 

Copies of the evaluations, Contractor responses,
and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.

 

2. Electronic Access to Contractor Performance
Evaluations

 

Contractors that have Internet capability may access
evaluations through a secure Web site for review and comment by completing the registration form that can be obtained at the following
address:

 

http://oamp.od.nih.gov/OD/CPS/cps.asp

 

The registration process requires the Contractor
to identify an individual that will serve as a primary contact and who will be authorized access to the evaluation for review
and comment. In addition, the Contractor will be required to identify an alternate contact who will be responsible for notifying
the cognizant contracting official in the event the primary contact is unavailable to process the evaluation within the required
30-day time frame.

 

ARTICLE G.9. CONTRACT COMMUNICATIONS/CORRESPONDENCE (JULY
1999)

 

The Contractor shall identify all correspondence, reports,
and other data pertinent to this contract by imprinting the contract number from Page 1 of the contract.

 

    	43

    	 

    

 

ARTICLE G.10. GOVERNMENT PROPERTY

 

1. In addition to the requirements of the clause, GOVERNMENT
PROPERTY, incorporated in SECTION I of this contract, the Contractor shall comply with the provisions of HHS Publication, "Contractor's
Guide for Control of Government Property," which is incorporated into this contract by reference. This document can be accessed
at:

 

http://www.hhs.gov/oamp/policies/contractors_guide_for_control_of_gov_property.pdf
.. Among other issues, this publication provides a summary of the Contractor's responsibilities regarding purchasing
authorizations and inventory and reporting requirements under the contract.

 

2.
Notwithstanding the provisions outlined in the HHS Publication, "Contractor's Guide for Control of Government
Property," which is incorporated in this contract in paragraph 1. above, the Contractor shall use the form entitled, "Report
of Government Owned, Contractor Held Property" for submitting summary reports required under this contract, as directed by
the Contracting Officer or his/her designee. This form is included as an attachment in SECTION J of this contract.

 

3. Title will vest in the Government for equipment purchased
as a direct cost.

 

SECTION H - SPECIAL CONTRACT REQUIREMENTS

 

ARTICLE H.1. PROTECTION OF HUMAN SUBJECTS,
HHSAR 352.270-4 (January 2006)

 

			(a) The Contractor agrees that the rights and welfare of human subjects
                                                         involved in research under this contract shall be protected in accordance
                                                         with 45 CFR Part 46 and with the Contractor's current Assurance of Compliance
                                                         on file with the Office for Human Research Protections (OHRP), Department
                                                         of Health and Human Services. The Contractor further agrees to provide
                                                         certification at least annually that the Institutional Review Board has
                                                         reviewed and approved the procedures, which involve human subjects in
                                                         accordance with 45 CFR Part 46 and the Assurance of Compliance.

 

(b) The Contractor shall bear full responsibility
for the performance of all work and services involving the use of human subjects under this contract and shall ensure that work
is conducted in a proper manner and as safely as is feasible. The parties hereto agree that the Contractor retains the right to
control and direct the performance of all work under this contract. The Contractor shall not deem anything in this contract to
constitute the Contractor or any subcontractor, agent or employee of the Contractor, or any other person, organization, institution,
or group of any kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this
contract and will discharge its obligations, duties, and undertakings and the work pursuant thereto, whether requiring professional
judgment or otherwise, as an independent contractor without imputing liability on the part of the Government for the acts of the
Contractor or its employees.

 

    	44

    	 

    

 

(c) If at any time during the performance of this
contract, the Contracting Officer determines, in consultation with OHRP that the Contractor is not in compliance with any of the
requirements and/or standards stated in paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole
or in part, work and further payments under this contract until the Contractor corrects the noncompliance. The Contracting Officer
may communicate the notice of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective
action within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer
may, after consultation with OHRP, terminate this contract in whole or in part, and the Contractor's name may be removed from
the list of those contractors

with approved Human Subject Assurances.

 

ARTICLE H.2. HUMAN MATERIALS (ASSURANCE
OF OHRP COMPLIANCE)

 

The acquisition and supply of all human specimen
material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable
Federal, State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements,
monetary or otherwise, will be offered to any person to influence their donation of human material.

 

The Contractor shall provide written documentation
that all human materials obtained as a result of research involving human subjects conducted under this contract, by collaborating
sites, or by subcontractors identified under this contract, were obtained with prior approval by the Office for Human Research
Protections (OHRP) of an Assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction
applies to all collaborating sites without OHRP-approved Assurances, whether domestic or foreign, and compliance must be ensured
by the Contractor.

 

Provision by the Contractor to the Contracting Officer
of a properly completed "Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption",
Form OMB No. 0990-0263(formerly Optional Form 310), certifying IRB review and approval of the protocol from which the human materials
were obtained constitutes the written documentation required. The human subject certification can be met by submission of a self
designated form provided that it contains the information required by the "Protection of Human Subjects Assurance Identification/IRB
Certification/Declaration of Exemption", Form OMB No. 0990-0263(formerly Optional Form 310).

 

ARTICLE H.3. RESEARCH INVOLVING HUMAN FETAL
TISSUE

 

All research involving human fetal tissue shall
be conducted in accordance with the Public Health Service Act, 42 U.S.C. 289g-1 and 289g-2. Implementing regulations and guidance
for conducting research on human fetal tissue may be found at 45 CFR 46, Subpart B and http://grants1.nih.gov/grants/guide/notice-files/not93-235.html
 and any subsequent revisions to this NIH Guide to Grants and Contracts ("Guide") Notice.

 

The Contractor shall make available, for audit by
the Secretary, HHS, the physician statements and informed consents required by 42 USC 289g-1(b) and (c), or ensure HHS access
to those records, if maintained by an entity other than the Contractor.

 

ARTICLE H.4. NEEDLE EXCHANGE

 

The Contractor shall not use contract funds to
carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

 

ARTICLE H.5.

 

RESERVED.

 

    	45

    	 

    

  

ARTICLE H.6. CARE OF LIVE VERTEBRATE ANIMALS,
HHSAR 352.270-5 (October 2009)

 

(a) Before undertaking performance of any contract
involving animal-related activities where the species is regulated by USDA, the Contractor shall register with the Secretary of
Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CFR sections 2.25 through 2.28. The Contractor shall furnish
evidence of the registration to the Contracting Officer.

 

(b) The Contractor shall acquire vertebrate animals
used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR Sections 2.1-2.11, or from
a source that is exempt from licensing under those sections.

 

(c) The Contractor agrees that the care, use and
intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS)
Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for
the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the
United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR Subchapter A, Parts 1-4). In case of conflict between
standards, the more stringent standard shall govern.

 

(d) If at any time during performance
of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National
Institutes of

 

Health (NIH), that the Contractor is not in compliance
with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately
suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. Notice
of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action
within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in
consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor's name may be removed from the list
of those contractors with approved Assurances.

 

Note: The Contractor may request registration of
its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service
(APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office,
as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road,
Riverdale, Maryland 20737 (E-mail: ace@aphis.usda.gov; Web site: (http://www.aphis.usda.gov/animal_welfare).

 

ARTICLE H.7. ANIMAL WELFARE

 

All research involving live, vertebrate animals
shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. This policy
may be accessed at:

http://grants1.nih.gov/grants/olaw/references/phspol.htm

  

ARTICLE H.8. PROTECTION OF PERSONNEL WHO WORK
WITH NONHUMAN PRIMATES

 

All Contractor personnel who work with nonhuman
primates or enter rooms or areas containing nonhuman primates shall comply with the procedures set forth in NIH Policy

 

    	46

    	 

    

 

Manual 3044-2, entitled, "Protection of NIH Personnel
Who Work with Nonhuman Primates," located at the following URL:

http://www1.od.nih.gov/oma/manualchapters/intramural/3044-2/

 

ARTICLE H.9. PUBLICATION AND PUBLICITY

 

No information related to data obtained under this
contract shall be released or publicized without the prior written consent of the Contracting Officer Technical Representative.

 

In addition to the requirements set forth in HHSAR
Clause 352.227-70, Publications and Publicity incorporated by reference in SECTION I of this contract, the Contractor shall acknowledge
the support of the Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in
any media by including an acknowledgment substantially as follows:

"This project has been funded in whole or in part
with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness
and Response, Office of the Secretary, Department of Health and Human Services, under Contract No.                          
"

 

ARTICLE H.10. REPORTING MATTERS INVOLVING
FRAUD, WASTE AND ABUSE

 

Anyone who becomes aware of the existence or apparent
existence of fraud, waste and abuse in BARDA funded programs is encouraged to report such matters to the HHS Inspector General's
Office in writing or on the Inspector General's Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone
calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is:

 

Office of Inspector General

Department of Health and Human Services

TIPS HOTLINE

P.O. Box 23489

Washington, D.C. 20026

 

ARTICLE H.11. PROHIBITION ON CONTRACTOR
INVOLVEMENT WITH TERRORIST

 

ACTIVITIES

 

The Contractor acknowledges that U.S. Executive
Orders and Laws, including but not limited to E.O. 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources
and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the Contractor to ensure
compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.

 

ARTICLE H.12. CONFLICT OF INTEREST

 

The Contractor represents and warrants that, to
the best of the Contractor's knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational
conflict of interest, as defined in FAR Subpart 9.5, or that the Contractor has disclosed all such relevant information. 
Prior to commencement of any work, the Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge
and belief, no actual or potential conflict of interest exists or to identify to the Contracting Officer any actual or potential
conflict of interest the firm may have. In emergency situations, however, work may begin but notification shall be made within
five (5) working days.  The Contractor agrees that if an actual or potential organizational conflict of interest is identified
during performance, the

 

    	47

    	 

    

  

Contractor shall promptly make a full disclosure in writing to the Contracting
Officer. This disclosure shall include a description of actions, which the Contractor has taken or proposes to take, after consultation
with the Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest. The Contractor shall
continue performance until notified by the Contracting Officer of any contrary action to be taken.  Remedies include termination
of this contract for convenience, in whole or in part, if the Contracting Officer deems such termination necessary to avoid an
organizational conflict of interest. If the Contractor was aware of a potential organizational conflict of interest prior to award
or discovered an actual or potential conflict after award and did not disclose it or misrepresented relevant information to the
Contracting Officer, the Government may terminate the contract for default, debar the Contractor from Government contracting,
or pursue such other remedies as may be permitted by law or this contract.

 

ARTICLE H.13. EXERCISE OF OPTIONS

 

Unless the Government exercises its option pursuant
to the Option Clause set forth in Section I, Article I.3, the contract will consist only of CLIN 0001 of the Statement
of Work, Deliverables and Requirements as defined in Sections C, F and J of the contract. Pursuant to FAR Clause 52.217-9 (Option
to Extend the Term of the Contract) set forth in Section I of this contract, under Article I.3., the Government may, by unilateral
contract modification, require the Contractor to perform any of the additional CLINs listed in Section B, Article B.3., and
as also defined in Sections C, F and J of this contract. If the Government exercises an option, written notice must be given to
the Contractor within 30 days after the Government has completed its analysis of the deliverables associated with the applicable
GO/NO GO Decision gate; and the Government must give the Contractor a preliminary written notice of its intent to exercise
the option at least 30 days before the contract expires. The amount of the contract may then be increased as set forth in Section
B, Article B.3 provided that funds are available.

 

ARTICLE H.14. PROHIBITION ON THE USE OF APPROPRIATED
FUNDS FOR LOBBYING ACTIVITIES AND HHSAR 352.203-70 ANTI-LOBBYING (Jan 2006)

 

The Contractor is hereby notified of the restrictions
on the use of Department of Health and Human Service's funding for lobbying of Federal, State and Local legislative bodies.

 

Section 1352 of Title 10, United Stated Code (Public
Law 101-121, effective 12/23/89), among other things, prohibits a recipient (and their subcontractors) of a Federal contract,
grant, loan, or cooperative agreement from using appropriated funds (other than profits from a federal contract) to pay any person
for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee
of Congress, or an employee of a Member of Congress in connection with any of the following covered Federal actions; the awarding
of any Federal contract; the making of any Federal grant; the making of any Federal loan; the entering into of any cooperative
agreement; or the modification of any Federal contract, grant, loan, or cooperative agreement. For additional information of prohibitions
against lobbying activities, see FAR Subpart 3.8 and FAR Clause 52.203-12.

 

In addition, as set forth in HHSAR 352.203-70 “Anti-Lobbying”
(January 2006), the current Department of Health and Human Services Appropriations Act provides that no part of any appropriation
contained in this Act shall be used, other than for normal and recognized executive-legislative relationships, for publicity or
propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television,
or video presentation designed to support, or defeat legislation pending before the Congress, or any State or Local legislature
except in presentation to the Congress, or any State or Local legislative body itself.

 

    	48

    	 

    

 

The current Department of Health and Human Services
Appropriations Act also provides that no part of any appropriation contained in this Act shall be used to pay the salary or expenses
of any contract or grant recipient, or agent acting for such recipient, related to any activity designed to influence legislation
or appropriations pending before the Congress, or any State or Local legislature.

 

ARTICLE H.15. PRIVACY ACT APPLICABILITY (Apr 2000)

 

		1)	Notification is hereby given that the Contractor and its employees
                                                           are subject to criminal penalties for violation of the Privacy Act
                                                           to the same extent as employees of the Government. The Contractor shall
                                                           assure that each of its employees knows the prescribed rules of conduct
                                                           and that each is aware that he or she can be subjected to criminal
                                                           penalty for violation of the Act. A copy of 45 CFR Part 5b, Privacy
                                                           Act Regulations, may be obtained at http://www.gpoaccess.gov/cfr/index.html

 

		2)	The Project Officer is hereby designated as the official who is
                                                           responsible for monitoring contractor compliance with the Privacy Act.

 

		3)	The Contractor shall follow the Privacy Act guidance as contained
                                                           in the Privacy Act System of Records number 09-25-0200. This document
                                                           may be obtained at the following link: http://oma.od.nih.gov/ms/privacy/pa-files/0200.htm

 

ARTICLE H.16. LABORATORY LICENSE REQUIREMENTS (May 1998)

 

The Contractor shall comply with all applicable
requirements of Section 353 of the Public Health Service Act (Clinical Laboratory Improvement Act as amended). This requirement
shall also be included in any subcontract for services under the contract.

 

ARTICLE H.17. DISSEMINATION OF INFORMATION (May 1998)

 

No
information related to data obtained under this contract shall be released or publicized without the prior written consent of
the Contracting Officer.

 

ARTICLE H.18. IDENTIFICATION AND DISPOSITION OF DATA

 

The Contractor will be required to provide certain data generated
under this contract to the Department of Health and Human Services (DHHS). DHHS reserves the right to review any other data determined
by DHHS generated under this contract. The Contractor shall keep copies of all data required by the Food and Drug Administration
(FDA) relevant to this contract for the time specified by the FDA.

 

ARTICLE H.19. INFORMATION ON COMPLIANCE WITH ANIMAL CARE
REQUIREMENTS

 

Registration with the U. S. Dept. of Agriculture (USDA) is
required to use regulated species of animals for biomedical purposes. USDA is responsible for the enforcement of the Animal Welfare
Act (7 U.S.C. 2131 et. seq.), http://www.nal.usda.gov/awic/legislat/awa.htm.

 

The Public Health Service (PHS) Policy is administered by the
Office of Laboratory Animal Welfare (OLAW) http://grants2.nih.gov/grants/olaw/olaw.htm. An essential requirement of the
PHS Policy http://grants2.nih.gov/grants/olaw/references/phspol.htm is that every institution using live vertebrate animals
must obtain an approved assurance from OLAW before they can receive funding from any component of the U. S. Public Health Service.

 

    	49

    	 

    

 

The PHS Policy requires that Assured institutions base their
programs of animal care and use on the Guide for the Care and Use of Laboratory Animals
http://www.nap.edu/readingroom/books/labrats/ and that they comply with the regulations (9 CFR, Subchapter A) http://www.nal.usda.gov/awic/legislat/usdaleg1.htm
issued by the U.S. Department of Agriculture (USDA) under the Animal Welfare Act. The Guide may differ from USDA regulations
in some respects. Compliance with the USDA regulations is an absolute requirement of this Policy.

 

The Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC) http://www.aaalac.org is a professional organization that inspects and evaluates programs
of animal care for institutions at their request. Those that meet the high standards are given the accredited status. As of the
2002 revision of the PHS Policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC Accreditation is not
required to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool.
They also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published
by the Federated of Animal Science Societies http://www.fass.org.

 

ARTICLE H.20. REQUIREMENTS FOR ADEQUATE ASSURANCE OF PROTECTION
OF VERTEBRATE ANIMAL SUBJECTS

 

The PHS Policy on Humane Care and Use of Laboratory Animals
requires that applicant organizations proposing to use vertebrate animals file a written Animal Welfare Assurance with the Office
for Laboratory Animal Welfare (OLAW), establishing appropriate policies and procedures to ensure the humane care and use of live
vertebrate animals involved in research activities supported by the PHS. The PHS Policy stipulates that an applicant organization,
whether domestic or foreign, bears responsibility for the humane care and use of animals in PHS-supported research activities.
Also, the PHS policy defines “animal” as “any live, vertebrate animal used, or intended for use, in research,
research training, experimentation, biological testing or for related purposes”. This Policy implements and supplements
the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training, and
requires that institutions use the Guide for the Care and Use of Laboratory Animals as a basis for developing and implementing
an institutional animal care and use program. This Policy does not affect applicable State or local laws or regulations that impose
more stringent standards for the care and use of laboratory animals. All institutions are required to comply, as applicable, with
the Animal Welfare Act as amended (7 USC 2131 et. seq.) and other Federal statutes and regulations relating to animals. These
documents are available from the Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD 20892, (301)
496-7163. See http://grants.nih.gov/grants/olaw/olaw.htm.

 

No PHS supported work for research involving vertebrate animals
will be conducted by an organization, unless that organization is operating in accordance with an approved Animal Welfare Assurance
and provides verification that the Institutional Animal Care and Use Committee (IACUC) has reviewed and approved the proposed
activity in accordance with the PHS policy. Applications may be referred by the PHS back to the institution for further review
in the case of apparent or potential violations of the PHS Policy. No award to an individual will be made unless that individual
is affiliated with an assured organization that accepts responsibility for compliance with the PHS Policy. Foreign applicant organizations
applying for PHS awards for activities involving vertebrate animals are required to comply with PHS Policy or provide evidence
that acceptable standards for the humane care and use of animals will be met. Foreign applicant organizations are not required
to submit IACUC approval, but should provide information that is satisfactory to the Government to provide assurances for the
humane care of such animals.

 

 

ARTICLE H.21. APPROVAL OF REQUIRED ASSURANCE BY OLAW

 

    	50

    	 

    

  

Under governing regulations, federal funds which are administered
by the Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority (BARDA) shall
not be expended by the Contractor for research involving live vertebrate animals, nor shall live vertebrate animals be involved
in research activities by the Contractor under this award unless a satisfactory assurance of compliance with 7 U.S.C. 2316 and
9 CFR Sections 2.25-2.28 is submitted within 30 days of the date of this award and approved by the Office of Laboratory Animal
Welfare (OLAW). Each performance site (if any) must also assure compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 with
the following restriction: Only activities which do not directly involve live vertebrate animals (i.e. are clearly severable and
independent from those activities that do involve live vertebrate animals) may be conducted by the Contractor or individual performance
sites pending OLAW approval of their respective assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28. Additional
information regarding OLAW may be obtained via the Internet at http://grants2.nih.gov/grants/olaw/references/phspol.htm.

 

ARTICLE H.22. REGISTRATION WITH THE SELECT AGENT PROGRAM
FOR WORK INVOLVING THE POSSESSION, USE, AND/OR TRANSFER OF SELECT BIOLOGICAL AGENTS OR TOXINS

 

Work involving select biological agents or toxins shall not
be conducted under this contract until the Contractor and any affected subcontractor(s) are granted a certificate of registration
or are authorized to work with the applicable select agents.

 

For prime or subcontract awards to domestic institutions who
possess, use, and/or transfer Select Agents under this contract, the institution must complete registration with the Centers for
Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS) or the Animal and Plant Health Inspection
Services (APHIS), U.S. Department of Agriculture (USDA), as applicable, before performing work involving Select Agents, in accordance
with 42 CFR 73. No Government funds can be used for work involving Select Agents, as defined in 42 CFR 73, if the final registration
certificate is denied.

 

For prime or subcontract awards to foreign institutions who
possess, use, and/or transfer Select Agents under this contract, the institution must provide information satisfactory to the
Government that a process equivalent to that described in 42 CFR 73 (http://www.cdc.gov/od/sap/docs/42cfr73.pdf ) for U.S.
institutions is in place and will be administered on behalf of all Select Agent work sponsored by these funds before using these
funds for any work directly involving the Select Agents. The Contractor must provide information addressing the following key
elements appropriate for the foreign institution: safety, security, training, procedures for ensuring that only approved/appropriate
individuals have access to the Select Agents, and any applicable laws, regulations and policies equivalent to 42 CFR 73.
The Government will assess the policies and procedures for comparability to the U.S. requirements described in 42 CFR Part
73. When requested by the contracting officer, the Contractor shall provide key information delineating any laws, regulations,
policies, and procedures applicable to the foreign institution for the safe and secure possession, use, and transfer of Select
Agents. This includes summaries of safety, security, and training plans, and applicable laws, regulations, and policies. For the
purpose of security risk assessments, the Contractor must provide the names of all individuals at the foreign institution who
will have access to the Select Agents and procedures for ensuring that only approved and appropriate individuals have access to
Select Agents under the contract.

 

Listings of HHS select agents and toxins, biologic agents and
toxins, and overlap agents or toxins as well as information about the registration process, can be obtained on the Select Agent
Program Web site at http://www.cdc.gov/od/sap/.

 

    	51

    	 

    

 

ARTICLE H.23. EPA ENERGY STAR REQUIREMENTS

 

In compliance with Executive Order 12845 (requiring Agencies
to purchase energy efficient computer equipment) all microcomputers, including personal computers, monitors, and printers that
are purchased using Government funds in performance of a contract shall be equipped with or meet the energy efficient low-power
standby feature as defined by the EPA Energy Star program unless the equipment always meets EPA Energy Star efficiency levels.
The microcomputer, as configured with all components, must be Energy Star compliant.

 

This low-power feature must already be activated when the computer
equipment is delivered to the agency and be of equivalent functionality of similar power managed models. If the equipment will
be used on a local area network, the vendor must provide equipment that is fully compatible with the network environment. In addition,
the equipment will run commercial off-the-shelf software both before and after recovery from its energy conservation mode.

 

ARTICLE H.24. MANUFACTURING STANDARDS

 

The Good Manufacturing Practice Regulations (GMP)(21 CFR Parts
210-211) and regulations pertaining to small molecules will be the standard to be applied for manufacturing, processing, packaging,
storage and delivery of this product.

 

If at any time during the life of the contract, the Contractor
fails to comply with GMP in the manufacturing, processing, packaging, storage, stability and other testing of the manufactured
drug substance or product and delivery of this product and such failure results in a material adverse effect on the safety, purity
or potency of the product (a material failure) as identified by the FDA, the Contractor shall have thirty (30) calendar days from
the time such material failure is identified to cure such material failure. If, within the thirty (30) calendar day period, the
Contractor fails to take such an action to the satisfaction of the USG Project Officer, or fails to provide a remediation plan
that is acceptable to the COTR, then the contract may be terminated.

 

ARTICLE H.25. EXPORT CONTROL NOTIFICATION

 

Offerors are responsible for ensuring compliance with all export
control laws and regulations that maybe applicable to the export of and foreign access to their proposed technologies. Offerors
may consult with the Department of State with any questions regarding the International Traffic in Arms Regulation (ITAR) (22
CRF Parts 120-130) and /or the Department of Commerce regarding the Export Administration Regulations (15 CRF Parts 730-774).

 

ARTICLE H.26. INSTITUTIONAL RESPONSIBILITY REGARDING CONFLICTING
INTERESTS OF INVESTIGATORS

 

The Contractor shall comply with the requirements
of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure
that investigators (defined as the principal investigator and any other person who is responsible for the design, conduct, or
reporting of research funded under BARDA contracts) will not be biased by any conflicting financial interest.  For the purposes
of this part relating to financial interests, "Investigator" includes the Investigator's spouse and dependent children. 
45 CFR Part 94 is available at the following Web site:

http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr;sid=9f130b6d2d48bb73803ca91ce943be3a;rgn=div5;view=text;node=45%3A1.0.1.1.53;idno=45;cc=ecfr

 

    	52

    	 

    

 

As required by 45 CFR Part 94, the Contractor shall, at a minimum:

 

a. Maintain a written, enforceable policy on conflict of interest
that complies with 45 CFR Part 94 and inform each

investigator of the policy, the investigator's reporting responsibilities,
and the applicable regulations. The Contractor must take reasonable steps to ensure that investigators working as collaborators
or subcontractors comply with the regulations.

 

b. Designate an official(s) to solicit and review financial
disclosure statements from each investigator participating in BARDA-funded research. Based on established guidelines consistent
with the regulations, the designated official(s) must determine whether a conflict of interest exists, and if so, determine what
actions should be taken to manage, reduce, or eliminate such conflict. A conflict of interest exists when the designated official(s)
reasonably determines that a Significant Financial Interest could directly and significantly affect the design, conduct,
or reporting of the BARDA-funded research. The Contractor may require the management of other conflicting financial interests
in addition to those described in this paragraph, as it deems appropriate. Examples of conditions or restrictions that might be
imposed to manage actual or potential conflicts of interests are included in 45 CFR Part 94, under Management of Conflicting Interests.

 

c. Require all financial disclosures to be updated during the
period of the award, either on an annual basis or as new reportable Significant Financial Interests are obtained.

 

d. Maintain records, identifiable to each award, of all financial
disclosures and all actions taken by the Contractor with respect to each conflicting interest 3 years after final payment or,
where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract Records Retention.

 

e. Establish adequate enforcement mechanisms and provide for
sanctions where appropriate.

 

If a conflict of interest is identified, the Contractor
shall report to the Contracting Officer the existence of the conflicting interest found. This report shall be made and the conflicting
interest managed, reduced, or eliminated, at least on a temporary basis, within sixty (60) days of that identification.

 

If the failure of an investigator to comply with
the conflict of interest policy has biased the design, conduct, or reporting of the BARDA-funded research, the Contractor must
promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will take appropriate
action or refer the matter to the Contractor for further action which may include directions to the Contractor on how to maintain
appropriate objectivity in the funded research.

 

The Contracting Officer may at any time inquire into
the Contractor's procedures and actions regarding conflicts of interests in BARDA-funded research including a review of all records
pertinent to compliance with 45 CFR Part 94. The Contracting Officer may require submission of the records or review them on site.
On the basis of this review, the Contracting Officer may decide that a particular conflict of interest will bias the objectivity
of the BARDA-funded research to such an extent that further corrective action is needed or that the Contractor has not managed,
reduced, or eliminated the conflict of interest. The issuance of a Stop Work Order by the Contracting Officer may be necessary
until the matter is resolved.

 

If the Contracting Officer determines that BARDA-funded
clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been
designed, conducted, or reported by an investigator with a conflict of interest that was not disclosed or managed, the Contractor
must require disclosure of the conflict of interest in each public presentation of the results of the research.

 

    	53

    	 

    

 

ARTICLE H.27. REVIEW OF PRESS RELEASES

 

The contractor agrees to accurately and factually represent
the work conducted under the contract in all press releases. Misrepresenting contract results or releasing information that is
injurious to the integrity of BARDA may be construed as improper conduct. Press releases shall be considered to include the public
release of information to any medium, excluding peer-reviewed scientific publications. The contractor shall ensure that the COTR
has received an advance copy of any press release related to the contract not less than four (4) working days prior to the issuance
of the press release.

 

PART II - CONTRACT CLAUSES

 

SECTION I - CONTRACT CLAUSES

 

ARTICLE I.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE
(FEBRUARY 1998)

 

This contract incorporates the following clauses by reference,
with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full
text available. Also, the full text of a clause may be accessed electronically at these addresses: http://www.arnet.gov

 

General Clauses for Cost-Reimbursement Research and Development
Contract

 

		(1)	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

	FAR

        CLAUSE NO.
	 	DATE	 	TITLE
	 	 	 	 	 
	52.202-1	 	Jul 2004	 	Definitions
	 	 	 	 	 
	52.203-3	 	Apr 1984	 	Gratuities (Over $100,000)
	 	 	 	 	 
	52.203-5	 	Apr 1984	 	Covenant Against Contingent Fees (Over $100,000)
	 	 	 	 	 
	52.203-6	 	Sep 2006	 	Restrictions on Subcontractor Sales to the Government (Over $100,000)
	 	 	 	 	 
	52.203-7	 	Oct 2010	 	Anti-Kickback Procedures (Over $100,000)
	 	 	 	 	 
	52.203-8	 	Jan 1997	 	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over $100,000)
	 	 	 	 	 
	52.203-10	 	Jan 1997	 	Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000)
	 	 	 	 	 
	52.203-12	 	Oct 2010	 	Limitation on Payments to Influence Certain Federal Transactions (Over $100,000)
	 	 	 	 	 
	52.203-13	 	Apr 2010	 	Contractor Code of Business Ethics and Conduct
	 	 	 	 	 
	52.203-14	 	Dec 2007	 	Display of Hotline Poster
	 	 	 	 	 
	52.204-4	 	Aug 2000	 	Printed or Copied Double-Sided on Recycled Paper (Over $100,000)
	 	 	 	 	 
	52.204-7	 	Apr 2008	 	Central Contractor Registration
	 	 	 	 	 
	52.209-6	 	Sep 2006	 	Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for
    Debarment (Over $25,000)

 

    	54

    	 

    

 

	52.215-2	 	Oct 2010	 	Audit and Records - Negotiation (Over $100,000)
	 	 	 	 	 
	52.215-8	 	Oct 1997	 	Order of Precedence - Uniform Contract Format
	 	 	 	 	 
	52.215-10	 	Oct 2010	 	Price Reduction for Defective Certified Cost or Pricing Data
	 	 	 	 	 
	52.215-12	 	Oct 2010	 	Subcontractor Certified Cost or Pricing Data (Over $500,000)
	 	 	 	 	 
	52.215-14	 	Oct 2010	 	Integrity of Unit Prices (Over $100,000)
	 	 	 	 	 
	52.215-15	 	Oct 2010	 	Pension Adjustments and Asset Reversions
	 	 	 	 	 
	52.215-18	 	Jul 2005	 	Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions
	 	 	 	 	 
	52.215-19	 	Oct 1997	 	Notification of Ownership Changes
	 	 	 	 	 
	52.215-21	 	Oct 2010	 	Requirements for Certified Cost or Pricing Data or Information Other Than Certified Cost or Pricing Data – Modifications
	 	 	 	 	 
	52.216-7	 	Dec 2002	 	Allowable Cost and Payment (Note: the following language is included in this clause – "(3) The designated payment
    office will make interim payments for contract financing on the 30th day after the designated billing office receives
    a proper payment request...”
	 	 	 	 	 
	52.216-8	 	Mar 1997	 	Fixed Fee
	 	 	 	 	 
	52.219-8	 	Dec 2010	 	Utilization of Small Business Concerns (Over $100,000)
	 	 	 	 	 
	52.219-9	 	Oct 2010	 	Small Business Subcontracting Plan (Over $500,000)
	 	 	 	 	 
	52.219-16	 	Jan 1999	 	Liquidated Damages - Subcontracting Plan (Over $500,000)
	 	 	 	 	 
	52.222-3	 	Jun 2003	 	Convict Labor
	 	 	 	 	 
	52.222-19	 	Jul 2010	 	Child Labor – Cooperation with Authorities and Remedies
	 	 	 	 	 
	52.222-21	 	Feb 1999	 	Prohibition of Segregated Facilities
	 	 	 	 	 
	52.222-26	 	Mar 2007	 	Equal Opportunity
	 	 	 	 	 
	52.222-35	 	Sep 2010	 	Equal Opportunity for Veterans
	 	 	 	 	 
	52.222-36	 	Oct 2010	 	Affirmative Action for Workers with Disabilities
	 	 	 	 	 
	52.222-37	 	Sep 2010	 	Employment Reports on Veterans
	 	 	 	 	 
	52.222-50	 	Feb 2009	 	Combating Trafficking in Persons
	 	 	 	 	 
	52.222-54	 	Jan 2009	 	Employment Eligibility Verification
	 	 	 	 	 
	52.223-6	 	May 2001	 	Drug-Free Workplace
	 	 	 	 	 
	52.223-14	 	Aug 2003	 	Toxic Chemical Release Reporting (Over $100,000)
	 	 	 	 	 
	52.224-1	 	April 1984	 	Privacy Act Notification
	 	 	 	 	 
	52.224-2	 	April 1984	 	Privacy Act
	 	 	 	 	 
	52.225-1	 	Feb 2009	 	Buy American Act – Supplies

 

    	55

    	 

    

 

	52.225-13	 	Jun 2008	 	Restrictions on Certain Foreign Purchases
	 	 	 	 	 
	52.227-1	 	Dec 2007	 	Authorization and Consent, Alternate I (Apr 1984)
	 	 	 	 	 
	52.227-2	 	Dec 2007	 	Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000)
	 	 	 	 	 
	52.227-11	 	Dec 2007	 	Patent Rights - Ownership by the Contractor
	 	 	 	 	 
	52.227-14	 	Dec 2007	 	Rights in Data – General, Alternate II (Dec 2007)
	 	 	 	 	 
	52.229-8	 	Mar 1990	 	Taxes—Foreign Cost-Reimbursement Contracts
	 	 	 	 	 
	52.230-4	 	Jun 2010	 	Disclosure and Consistency of Cost Accounting Practices—Foreign Concerns
	 	 	 	 	 
	52.232-9	 	Apr 1984	 	Limitation on Withholding of Payments
	 	 	 	 	 
	52.232-17	 	Oct 2010	 	Interest (Over $100,000)
	 	 	 	 	 
	52.232-20	 	Apr 1984	 	Limitation of Cost
	 	 	 	 	 
	52.232-23	 	Jan 1986	 	Assignment of Claims
	 	 	 	 	 
	52.232-25	 	Oct 2008	 	Prompt Payment
	 	 	 	 	 
	52.232-33	 	Oct 2003	 	Payment by Electronic Funds Transfer—Central Contractor Registration
	 	 	 	 	 
	52.233-1	 	Jul 2002	 	Disputes
	 	 	 	 	 
	52.233-3	 	Aug 1996	 	Protest After Award, Alternate I (June 1985)
	 	 	 	 	 
	52.233-4	 	Oct 2004	 	Applicable Law for Breach of Contract Claim
	 	 	 	 	 
	52.242-1	 	Apr 1984	 	Notice of Intent to Disallow Costs
	 	 	 	 	 
	52.242-3	 	May 2001	 	Penalties for Unallowable Costs (Over $500,000)
	 	 	 	 	 
	52.242-4	 	Jan 1997	 	Certification of Final Indirect Costs
	 	 	 	 	 
	52.242-13	 	Jul 1995	 	Bankruptcy (Over $100,000)
	 	 	 	 	 
	52.242-15	 	Aug 1989	 	Stop Work Order. Alt I (Aug 1984)
	 	 	 	 	 
	52.243-2	 	Aug 1987	 	Changes - Cost Reimbursement, Alternate V (Apr 1984)
	 	 	 	 	 
	52.244-2	 	Oct 2010	 	Subcontracts
	 	 	 	 	 
	52.244-5	 	Dec 1996	 	Competition in Subcontracting (Over $100,000)
	 	 	 	 	 
	52.244-6	 	Oct 2010	 	Subcontracts for Commercial Items
	 	 	 	 	 
	52.245-1	 	Aug 2010	 	Government Property
	 	 	 	 	 
	52.245-9	 	Aug 2010	 	Use and Charges
	 	 	 	 	 
	52.246-23	 	Feb 1997	 	Limitation of Liability (Over $100,000)
	 	 	 	 	 
	52.249-6	 	May 2004	 	Termination (Cost-Reimbursement)
	 	 	 	 	 
	52-249-14	 	Apr 1984	 	Excusable Delays
	 	 	 	 	 
	52.253-1	 	Jan 1991	 	Computer Generated Forms

 

    	56

    	 

    

 

		(2)	DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION
                                                            (HHSAR) (48 CFR CHAPTER 3) CLAUSES:

 

	HHSAR

CLAUSE NO.	 	DATE	 	TITLE
	 	 	 	 	 
	352.202-1	 	Jan 2006	 	Definitions - with Alternate paragraph (h) (Jan 2001)
	 	 	 	 	 
	352.203-70	 	Jan 2006	 	Anti-Lobbying
	 	 	 	 	 
	352.216-70	 	Jan 2006	 	Additional Cost Principles
	 	 	 	 	 
	352.227-70	 	Jan 2006	 	Publications and Publicity
	 	 	 	 	 
	352.228-7	 	Dec 1991	 	Insurance - Liability to Third Persons
	 	 	 	 	 
	352.231-71	 	Jan. 2001	 	Pricing of adjustments.
	 	 	 	 	 
	352.233-71	 	Jan 2006	 	Litigation and Claims
	 	 	 	 	 
	352.234-3	 	Oct 2008	 	Full Earned Value Management System
	 	 	 	 	 
	352.242-70	 	Jan 2006	 	Key Personnel
	 	 	 	 	 
	352.242-73	 	Jan 2006	 	Withholding of Contract Payments
	 	 	 	 	 
	352.242-74	 	Apr 1984	 	Final Decisions on Audit Findings

 

ARTICLE I.2. ADDITIONAL CONTRACT CLAUSES

 

This contract incorporates the following clauses
by reference, with the same force and effect, as if they were given in full text.  Upon request, the Contracting Officer
will make their full text available.

 

a. FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1)
CLAUSES

 

		1.	FAR
                                                                                                                                       Clause
                                                                                                                                       52.215-17,
                                                                                                                                       Waiver
                                                                                                                                       of
                                                                                                                                       Facilities
                                                                                                                                       Capital
                                                                                                                                       Cost
                                                                                                                                       of
                                                                                                                                       Money
                                                                                                                                       (October
                                                                                                                                       1997).

 

		2.	FAR
                                                                                                                                       Clause
                                                                                                                                       52.219-25,
                                                                                                                                       Small
                                                                                                                                       Disadvantaged
                                                                                                                                       Business
                                                                                                                                       Participation
                                                                                                                                       Program—Disadvantaged
                                                                                                                                       Status
                                                                                                                                       and
                                                                                                                                       Reporting
                                                                                                                                       (April
                                                                                                                                       2008).

 

		3.	FAR
                                                                                                                                       Clause
                                                                                                                                       52.227-16,
                                                                                                                                       Additional
                                                                                                                                       Data
                                                                                                                                       Requirements
                                                                                                                                       (June
                                                                                                                                       1987).

 

b. DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION
(HHSAR) (48 CHAPTER 3) CLAUSES:

 

1. HHSAR Clause 352.223-70, Safety and Health (January
2006).

2. HHSAR Clause 352.224-70, Privacy Act (January
2006).

3. HHSAR Clause 352.201-70, Paperwork Reduction
Act (January 2006).

 

    	57

    	 

    

 

ARTICLE I.3. ADDITIONAL FAR CONTRACT CLAUSES
INCLUDED IN FULL TEXT

 

This contract incorporates the following clauses
in full text.

 

FEDERAL ACQUISITION REGULATION (FAR)(48 CFR CHAPTER
1)CLAUSES:

 

a.FAR Clause 52.217-9, Option to Extend the
Term of the Contract (Mar 2000)

 

(a)   The Government may extend the term of this contract by
written notice to the Contractor within 30 days after the Government has completed its analysis of the deliverables associated
with the applicable GO/NO GO Decision gate; provided that the Government gives the Contractor a preliminary written notice
of its intent to extend at least 30 days before the contract expires. The preliminary notice does not commit the Government to
an extension.

 

(b)   If the Government exercises this option, the extended contract
shall be considered to include this option clause.

 

(c)   The total duration of this contract, including the exercise
of any options under this clause, shall not exceed 5 years.

 

b.   FAR Clause 52.219-28, Post-Award Small Business
Program Representation (April 2009).

 

(a) Definitions . As used in this clause—

 

Long-term contract means
a contract of more than five years in duration, including options. However, the term does not include contracts that exceed five
years in duration because the period of performance has been extended for a cumulative period not to exceed six months under the
clause at 52.217-8, Option to Extend Services, or other appropriate authority.

Small business concern means a concern, including its affiliates, that is independently owned and operated, not dominant
in the field of operation in which it is bidding on Government contracts, and qualified as a small business under the criteria
in 13 CFR part 121 and the size standard in paragraph (c) of this clause.  Such a concern is "not dominant in its field
of operation" when it does not exercise a controlling or major influence on a national basis in a kind of business activity
in which a number of business concerns are primarily engaged.  In determining whether dominance exists, consideration shall
be given to all appropriate factors, including volume of business, number of employees, financial resources, competitive status
or position, ownership or control of materials, processes, patents, license agreements, facilities, sales territory, and nature
of business activity.

 

(b) If the Contractor represented that it was a small
business concern prior to award of this contract, the Contractor shall represent its size status according to paragraph (e) of
this clause or, if applicable, paragraph (g) of this clause, upon the occurrence of any of the following:

 

(1) Within 30 days after execution of a novation agreement
or within 30 days after modification of the contract to include this clause, if the novation agreement was executed prior to inclusion
of this clause in the contract.

 

(2) Within 30 days after a merger or acquisition that
does not require a novation or within 30 days after modification of the contract to include this clause, if the merger or acquisition
occurred prior to inclusion of this clause in the contract.

 

    	58

    	 

    

 

(3) For long-term contracts—

 

(i) Within 60 to 120 days prior to the end of the fifth
year of the contract; and

(ii) Within 60 to 120 days prior to the date specified in the contract for exercising any option thereafter.

 

(c) The Contractor shall represent its size status
in accordance with the size standard in effect at the time of this representation that corresponds to the North American Industry
Classification System (NAICS) code assigned to this contract. The small business size standard corresponding to this NAICS code
can be found at http://www.sba.gov/contractingopportunities/officials/size/index.html .

 

(d) The small business size standard for a Contractor
providing a product which it does not manufacture itself, for a contract other than a construction or service contract, is 500
employees.

(e) Except as provided in paragraph (g) of this clause,
the Contractor shall make the representation required by paragraph (b) of this clause by validating or updating all its representations
in the Online Representations and Certifications Application and its data in the Central Contractor Registration, as necessary,
to ensure that they reflect the Contractor's current status. The Contractor shall notify the contracting office in writing within
the timeframes specified in paragraph (b) of this clause that the data have been validated or updated, and provide the date of
the validation or update.

 

(f) If the Contractor represented that it was other
than a small business concern prior to award of this contract, the Contractor may, but is not required to, take the actions required
by paragraphs (e) or (g) of this clause.

 

(g) If the Contractor does not have representations
and certifications in ORCA, or does not have a representation in ORCA for the NAICS code applicable to this contract, the Contractor
is required to complete the following representation and submit it to the contracting office, along with the contract number and
the date on which the representation was completed:

 

[...***...].

 

[Contractor to sign and date and insert authorized
signer's name and title].

 

***Confidential Treatment Requested

 

    	59

    	 

    

 

PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

 

SECTION J - LIST OF ATTACHMENTS

 

The following documents are attached and incorporated
in this contract:

 

1. Statement of Work

 

Statement of Work, dated 10 February 2011.

 

2. Invoice/Financing Request Instructions and
Contract Financial Reporting Instructions for BARDA Cost-Reimbursement Type Contracts,

 

Invoice/Financing Request Instructions and Contract
Financial Reporting Instructions for BARDA Cost-Reimbursement Type Contracts, 5 pages.

 

3. Financial Report of Individual Project/Contract,
1 page

 

4. Instructions for Completing Financial Report
of Individual Project/Contract, 3 pages

 

5. Inclusion Enrollment Report

 

Inclusion Enrollment Report, 5/01 (Modified OAMP:
10/01), 1 page.

 

6. Research Patient Care Costs

 

Research Patient Care Costs, 1 page.

 

7. Report of Government Owned, Contractor Held
Property

 

Report of Government Owned, Contractor Held Property,
dated 12/2/09, 1 page. Located at: http://rcb.cancer.gov/rcb-internet/forms/Govt-Owned-Prop.pdf (Not Attached)

 

8. Earned Value Management (EVM) Requirements

 

9. 7 Principles of Earned Value Management Tier
2 System Implementation Intent Guide

 

10. Communication Management Plan

 

11. Non-Clinical and Clinical Terms of Award

 

    	60

    	 

    

 

PART IV - REPRESENTATIONS AND INSTRUCTIONS

 

SECTION K - REPRESENTATIONS, CERTIFICATIONS AND OTHER
STATEMENTS OF OFFERORS

 

The following documents are incorporated by reference in this
contract:

 

	1)	Annual Representations and Certifications completed at the Online Representations Applications (ORCA) website.
	 	 
	2)	Representations & Certifications dated 3 December 2010.
	 	 
	3)	Human Subjects Assurance Identification Number: 00010398.
	 	 
	4)	Animal Welfare Assurance Numbers:

  

	 	Battelle	A3034-01
	 	USAMRIID	A3473-01

 

    	61

    	 

    

 

Attachment 1 - Statement of Work.
dated 10 February 2011

 

    	 

    	 

    
  

BARDA
Broad Agency Announcement (BAA)

(CBRN-BAA-10-100-SOL-00012)

Advanced Research and Development of Chemical, Biological, Radiological, and

Nuclear Medical Countermeasures

DEVELOPMENT OF CMX-001 FOR THE TREATMENT OF SMALLPOX

Topical Area of Interest No. 3, Antimicrobial Drugs

Contractual Statement of Work

 

		1.	PREAMBLE

 

Independently and not as an agency of
the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material, equipment,
and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response to
the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00012.

 

In accordance with FAR 52.243-2, Changes-Cost
Reimbursement (Alt. V), the Government reserves the right to modify the milestones, progress, schedule, budget, or deliverables
to add or delete deliverables , process, or schedules if the need arises. Because of the nature of this research and development
(R&D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate
whether work should be redirected, removed, or whether schedule or budget adjustments should be made.

 

		1.0	Overall Objectives and Scope

 

The overall objective of this contract
is to advance the development of CMX-00l as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections and
dsDNA viruses. The scope of work for this contract includes preclinical, clinical and manufacturing development activities that
fall into the following areas: non-clinical efficacy studies; clinical activities; manufacturing activities; and all associated
regulatory, quality assurance, management, and administrative activities. The Research and Development (R&D) effort for the
antiviral will progress in specific stages that cover the base performance segment and four (4) option segments as specified in
this contract. The Contractor must complete specific tasks required in each of the five discrete work segments. The scope of work
has been broken into the following five phases which are discrete work segments:

 

		I.	       [...***...]

		II.	       [...***...]

		III.	       [...***...]

		IV.	       [...***...]

		V.	       [...***...]

 

***Confidential Treatment Requested

 

    	1

    	 

    

 

		2.	PHASE
                                                                                                                 I: [...***...]

 

Research and development of
CMX-001 for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...]. The contractor shall
carry out the following tasks and subtasks and in accordance with an agreed upon Integrated Master Schedule and Integrated Master
Plan (defined in 2.1.8 and 2.1.9 below) which shall further detail the conduct of the specific tasks and subtasks.

 

2.1Program Management

 

The Contractor shall provide for the following
as outlined below and in the contract deliverables list (Article F.2):

 

		2.1.1	The overall management, integration and coordination of
                                                                  all contract activities, including a technical and administrative
                                                                  infrastructure to ensure the efficient planning, initiation,
                                                                  implementation, and direction of all contract activities;

		2.1.2	A Principal Investigator (PI) responsible for project management,
                                                                  communication, tracking, monitoring and reporting on status
                                                                  and progress, and modification to the project requirements and
                                                                  timelines, including projects undertaken by subcontractors;
                                                                  The contract deliverables list (reference), identifies all contract
                                                                  deliverables and reporting requirements for this contract.

		2.1.3	Project Manager(s) with responsibility for monitoring and
                                                                  tracking day-to-day progress and timelines, coordinating communication
                                                                  and project activities; costs incurred; and program management;
                                                                  The contract deliverables list (reference), identifies all contract
                                                                  deliverables and reporting requirements for this contract.

		2.1.4	A BARDA Liaison with responsibility for effective communication
                                                                  with the Project Officer and Contracting Officer.

		2.1.5	Administrative and legal staff to provide development of
                                                                  compliant subcontracts, consulting, and other legal agreements,
                                                                  and ensure timely acquisition of all proprietary rights, including
                                                                  IP rights, and reporting all inventions made in the performance
                                                                  of the project.

		2.1.6	Administrative staff with responsibility for financial management
                                                                  and reporting on all activities conducted by the Contractor
                                                                  and any subcontractors.

  

***Confidential Treatment Requested

 

    	2

    	 

    

 

		2.1.7	Contract Review Meetings.

		2.1.7.1	The Contractor shall participate in regular meetings to
                                                                   coordinate and oversee the contract effort as directed by the
                                                                   Contracting and Project Officers. Such meetings may include,
                                                                   but are not limited to, meeting of the Contractors and subcontractors
                                                                   to discuss clinical manufacturing progress, product development,
                                                                   product assay development, scale up manufacturing development,
                                                                   clinical sample assays development, preclinical/clinical study
                                                                   designs and regulatory issues; meetings with individual contractors
                                                                   and other HHS officials to discuss the technical, regulatory,
                                                                   and ethical aspects of the program; and meeting with technical
                                                                   consultants to discuss technical data provided by the Contractor.

		2.1.7.2	The Contractor shall participate in teleconferences every
                                                                   two weeks between the Contractor and subcontractors and BARDA
                                                                   to review technical progress. Teleconferences or additional
                                                                   face-to-face meetings shall be more frequent at the request
                                                                   of BARDA.

		2.1.8	Integrated Master Schedule

		2.1.8.1	Within 30 calendar days of the effective date of the contract,
                                                                   the Contractor shall submit a first draft of an updated Integrated
                                                                   Master Schedule in a format agreed upon by BARDA to the Project
                                                                   Officer and the Contracting Officer for review and comment.
                                                                   The Integrated Master Schedule shall be incorporated into the
                                                                   contract, and will be used to monitor performance of the contract.
                                                                   Contractor shall include the key milestones and Go/No Go decision
                                                                   gates. The IMS for the period of performance will be mutually
                                                                   agreed upon at the PMBR

		2.1.9	Integrated Master Plan

		2.1.9.1	Work Breakdown Structure: The Contractor shall utilize
                                                                   a WBS template agreed upon by BARDA for reporting on the contact.
                                                                   The Contractor shall expand and delineate the Contract Work
                                                                   Breakdown Structure (CWBS) to a level agreed upon by BARDA
                                                                   as part of their Integrated Master Plan for contract reporting.
                                                                   The CWBS shall be discernable and consistent, BARDA may require
                                                                   Contractor to furnish WBS data at the work package level or
                                                                   at a lower level if there is significant complexity and risk
                                                                   associated with the task.

		2.1.9.2	GO/ NO-GO Decision Gates: The Integrated Master Plan outlines
                                                                   key milestones with “Go/No Go” decision criteria
                                                                   (entrance and exit criteria for each phase of the project).
                                                                   The project plan should include, but not be limited to milestones
                                                                   in manufacturing, non-clinical and clinical studies, and regulatory
                                                                   submissions.

		2.1.9.3	Earned Value Management System Plan: Subject to the requirements
                                                                   under 1-11-ISAR Clause 352.234-4, the Contractor shall use
                                                                   principles of Earned Value Management System (EVMS) in the
                                                                   management of this contract. The Seven Principles are:

		          I.	Plan all work scope for the program to completion.

 

    	3

    	 

    

 

		        II.	Break down the program work scope into finite pieces
that can be assigned to a responsible person or organization for control of technical, schedule, and cost objectives.

		       III.	Integrate program work scope, schedule, and cost objectives
into a performance measurement baseline plan against which accomplishments may be measured. Control Changes to the baseline.

		       IV.	Use actual cost incurred and recorded in accomplishing
the work performed.

		        V.	Objectively assess accomplishments at the work performance
level.

		       VI.	Analyze significant variances from the plan, forecast
impacts, and prepare an estimate at completion based on performance to date and work to be performed.

		      VII.	Use earned value information in the company’s management
processes.

 

Elements of EVMS shall be applied to all Cost Plus
Fixed Fee CLINs as part of the Integrated Master Project Plan, the Contractor shall submit a written summary of the management
procedures that it will establish, maintain and use to comply with EVMS requirements.

 

		2.1.10	Decision Gate Reporting: On completion of a stage of the
                                                                   product development, as defined in the agreed upon Integrated
                                                                   Master Schedule and Integrated Master Plan, the Contractor
                                                                   shall prepare and submit to the Project Officer and the Contracting
                                                                   Officer a Decision Gate Report that contains (i) sufficient
                                                                   detail, documentation and analysis to support successful completion
                                                                   of the stage according to the predetermined qualitative and
                                                                   quantitative criteria that were established for Go/No Go decision
                                                                   making; and (ii) a

                                                                   description of the next stage of product development to be
                                                                   initiated and a request for approval to proceed to the next
                                                                   stage of product development.

 

		2.1.11	Risk Management Plan: The Contractor shall develop a risk
                                                                   management plan within 90 days of contract award highlighting
                                                                   potential problems and/or issues that may arise during the
                                                                   life of the contract, their impact on cost, schedule and performance, and appropriate remediation plans. This plan
                                                                   should reference relevant RIBS elements where appropriate.
                                                                   Updates to this plan shall be included every three months (quarterly) in the monthly
                                                                   Project Status Report.

  

    	4

    	 

    
 

		2.1.12	Performance Measurement Baseline Review (PMBR): The Contractor
                                                                   shall submit a plan for a PMBR to occur within 90 days of contract
                                                                   award. At the PMBR, the Contractor and BARDA shall mutually
                                                                   agree upon the budget, schedule and technical plan baselines
                                                                   (Performance Measurement Baseline). These baselines shall be
                                                                   the basis for monitoring and reporting progress throughout
                                                                   the life of the contract. The PMBR is conducted to achieve
                                                                   confidence that the baselines accurately capture the entire
                                                                   technical scope of work, are consistent with contract schedule
                                                                   requirements, are reasonably and logically planned, and have
                                                                   adequate resources assigned. The goals of the PMBR are as FOLLOWS:

 

		          I.	Jointly assess areas such as the Contractor’s planning
for complete coverage of the SOW, logical scheduling of the work activities, adequate resources, and identification of inherent
risks

		        II.	Confirm the integrity of the Performance Measurement
Baseline (PMB)

		       III.	Foster the use of INM as a means of communication

		       IV.	Provide confidence in the validity of Contractor reporting

		        V.	Identify risks associated with the PMB

		       VI.	Present any revised PMBs for mutual agreement

		      VII.	Present an Integrated Master Schedule: The Contractor
shall deliver an initial program level Integrated Master Schedule (IMS) that rolls up all time-phased WBS elements down to the
activity level. This 1MS shall include the dependencies that exist between tasks. This IMS will be agreed to and finalized at
the PMBR. DI-MGMT-8 1 650 may be referenced as guidance in creation of the IMS (see

http://www.acq.osdanil/pm/).

		     VIII.	Present the Risk Management Plan

 

		2.1.13	Deviation Request: During the course of contract performance,
                                                                   in response to a need to change IMS activities as baselined
                                                                   at the PMBR, the Contractor shall submit a Deviation Report.
                                                                   This report shall request a change in the agreed-upon IMS and
                                                                   timelines. This report shall include: (i) discussion of the
                                                                   justification/rationale for the proposed change; (ii) options
                                                                   for addressing the needed changes from the agreed upon timelines,
                                                                   including a cost-benefit analysis of each option; and (iii)
                                                                   recommendations for the preferred option that includes a full
                                                                   analysis and discussion of the effect of the change on the
                                                                   entire product development program, timelines, and budget.

		2.1.14	Monthly and Annual Reports: The Contractor shall deliver
                                                                   Project Status Reports on a monthly basis. The reports shall
                                                                   address the items below cross referenced to the WBS, SOW, IMS,
                                                                   and EVM:

 

		          I.	Executive summary highlighting the progress, issues,
and relevant activities in manufacturing, non-clinical, clinical, and regulatory;

		         II.	Progress in meeting contract milestones, detailing the
planned progress and actual progress during the reporting period, explaining any differences between the two and corrective steps;

		        III.	Updated IMS;

		        IV.	Updated EVM;

 

    	5

    	 

    

		        V.	Updated Risk Management Plan (Every 3 months);

		       VI.	Three month rolling forecast of planned activities;

		      VII.	Progress of regulatory submissions;

		     VIII.	Estimated and actual expenses;

 

		2.1.15	Data Management: The Contractor shall develop and implement
                                                                   data management and quality control systems/procedures, including
                                                                   transmission, storage, confidentiality, and retrieval of all
                                                                   contract data;

		2.1.15.1	Provide for the statistical design and analysis of data
                                                                    resulting from the research;

		2.1.15.2	Provide raw data or specific analyses of data generated
                                                                    with contract funding to the Project Officer, upon request.

 

		2.2	Non-Clinical Toxicology

		2.2.1	N/A (no scope)

 

		2.3	Non-Clinical

	 	2.3.1	Develop and validate [...***...] to lower ...***...].
	 	 	 
	 	2.3.2	[...***...]: Conduct [...***...] studies including [...***...] studies, [...***...], and [...***...] studies in [...***...].
	 	 	 
	 	2.3.3	[...***...]

	 	2.3.3.1	Conduct [...***...] study in [...***...].
	 	 	 
	 	2.3.3.2	Conduct [...***...] studies including [...***...] studies, [...***...] studies including [...***...] for CMX-001 and [...***...] in [...***...].

	 	2.3.4	Use of [...***...] as a CMX-001 Surrogate in [...***...] Studies.

	 	2.3.4.1	Dose [...***...] with [...***...] to identify the concentration of the [...***...] in [...***...] associated with [...***...] of [...***...].

	 	2.3.5	Scaling of [...***...] to [...***...] by conducting studies with [...***...] to determine [...***...] in [...***...].
	 	 	 
	 	2.3.6	[...***...] determination of CMX00l, [...***...] and [...***...] in the [...***...].
	 	 	 
	 	2.3.7	Conduct [...***...] experiments to demonstrate [...***...] following effective [...***...] prior to [...***...].
	 	 	 
	 	2.3.8	Conduct studies to optimize [...***...] in [...***...].

 

		2.4	Clinical

		2.4.1	Measurement of [...***...] levels in [...***...] and correlate
                                                                  the [...***...] to studies conducted in [...***...].

		2.4.2	Conduct expanded access protocol ([...***...]).

 

***Confidential Treatment Requested

 

    	6

    	 

    

 

		2.5	Regulatory

		2.5.1	Engaging the FDA on a path to support the treatment of smallpox
                                                                  indication with CMX-001.

		2.5.2	Preparing materials for and requesting, scheduling and participating
                                                                  in all meetings with the FDA, including meetings to review EUA
                                                                  and/or all other data packages;

		2.5.3	Providing BARDA with (i) the initial draft minutes
                                                                  and final draft minutes of any formal meeting with the FDA;
                                                                  (ii) final minutes of any informal meeting with the FDA;

 

		2.6	CMC

		2.6.1	Chemical development and manufacture of one [...***...],
                                                                  to prepare for [...***...].

 

		3.	PHASE
                                                                                                                 II: [...***...]

 

Research and development of
CMX-001 for the treatment of smallpox to include the following activities: [...***...]. The contractor shall carry out the following
tasks and subtasks and in accordance with the agreed upon Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8
and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		3.1	Program Management (consistent with section 2.1)

		3.1.1	Program management scope in BASE year is consistent with
                                                                  program management scope in each option year.

 

		3.2	Non-toxicology

		3.2.1	N/A (no scope)

 

***Confidential Treatment Requested

 

    	7

    	 

    

 

		3.3	Non-Clinical

		3.3.1	Quantify [...***...] levels in [...***...] in [...***...].

		3.3.2	Determine [...***...] for CMX-001, [...***...], and [...***...]
                                                                  in [...***...].

		3.3.3	Scaling of [...***...] to [...***...] studies to determine
                                                                  scaling between [...***...] and [...***...] using [...***...]
                                                                  as well as comparisons of levels of [...***...] in the [...***...].

		3.3.4	[...***...] in the [...***...]. This study will determine
                                                                  the [...***...] in [...***...] and the concentration of [...***...]
                                                                  in [...***...] when [...***...] are treated with [...***...]
                                                                  at the effective dose and regimen.

		3.3.5	[...***...]- (Final Report from Sections 2.3.2.). The initial
                                                                  study ([...***...]) will compare different regimens of [...***...]
                                                                  administered after the [...***...]. The studies will include
                                                                  [...***...] and [...***...], as well as [...***...] including
                                                                  [...***...].

 

		3.4	Clinical

		3.4.1	Conduct [...***...] study in [...***...] will be conducted
                                                                  as part of the scope of work to determine whether CMX001 has
                                                                  a [...***...], as detected by [...***...].

		3.4.2	Analyze data and provide a Final Report for [...***...]
                                                                  evaluation of CMX001 in [...***...].

 

		3.5	Regulatory

		3.5.1	Engaging the FDA on a path to support the treatment of smallpox
                                                                  indication with CMX-001

		3.5.2	Preparing materials for and requesting, scheduling and participating
                                                                  in all meetings with the FDA, including meetings to review EUA
                                                                  and/or all other data packages;

		3.5.3	Providing BARDA with (i) the initial draft minutes and final
                                                                  draft minutes of any formal meeting with the FDA; (ii) final
                                                                  draft minutes of any informal meeting with the FDA;

 

***Confidential Treatment Requested

 

    	8

    	 

    

 

		3.6	CMC

		3.6.1	Validation of the [...***...] process: Validation of the
                                                                  process to demonstrate the [...***...] of a [...***...] of [...***...]
                                                                  will be performed.

		3.6.2	Validation of the [...***...] process to produce [...***...]:
                                                                  Validation of the process to demonstrate the [...***...] of
                                                                  a [...***...] of [...***...] will be performed.

 

		4.	PHASE
                                                                                                                 III: [...***...]

  

Research and development of CMX-001
for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...].

The contractor shall carry
out the following tasks and subtasks and in accordance with agreed upon Integrated Master Schedule and Integrated Master Plan
(defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		4.1	Program Management (Consistent with section 2.1)

		4.1.1	Program management scope in BASE year is consistent with
                                                                  program management scope in each option year.

 

		4.2	Non-toxicology

		4.2.1	N/A (no scope)

 

		4.3	Non-Clinical

		4.3.1	[...***...] studies: [...***...] will be conducted with
                                                                  the [...***...] of CMX001 identified in the [...***...] studies.
                                                                  [...***...] will be [...***...] to receive [...***...] beginning
                                                                  at the [...***...]. These studies will include [...***...] and
                                                                  [...***...] as well as [...***...] including [...***...] in
                                                                  [...***...]. The primary endpoint will be [...***...]

		4.3.2	[...***...] studies: This study will determine the [...***...]
                                                                  at the [...***...]. [...***...] and [...***...] at the [...***...].
                                                                  The primary endpoint will be [...***...]

		4.3.3	Initiate [...***...]: Conduct [...***...] studies for [...***...].
                                                                  This study will determine the [...***...] at doses selected
                                                                  based on [...***...]. [...***...] and [...***...].

 

***Confidential Treatment Requested

 

    	9

    	 

    

 

		4.4	Clinical

		4.4.1	Phases I [...***...] study, If acceptable to FDA, the [...***...]
                                                                  database will be supplemented by a study in [...***...]. The
                                                                  size of this study will be determined to ensure an adequate
                                                                  [...***...] database is available at the time of [...***...]

		4.4.2	[...***...] study. This study will [...***...] doses of
                                                                  CMX001 to [...***...] to determine if the [...***...] of CMX001
                                                                  are comparable to those observed for [...***...], and to determine
                                                                  if any dose adjustment is necessary in [...***...].

 

		4.5	Regulatory

		4.5.1	Generating all necessary data and preparing documentation
                                                                  for [...***...] submissions to regulatory agencies;

		4.5.2	Preparing materials for and requesting, scheduling and participating
                                                                  in all meetings with the FDA, including meetings to review [...***...],
                                                                  EUA and/or all other data packages;

		4.5.3	Providing BARDA with (i) the initial draft minutes
                                                                  and final draft minutes of any formal meeting with the FDA;
                                                                  (ii) final draft minutes of any informal meeting with the
                                                                  FDA;

		4.5.4	Filing of an [...***...]

 

		4.6	CMC

		4.6.1	Manufacture of [...***...] in sufficient quantities for
                                                                  use in non-clinical and late phase clinical studies. Develop
                                                                  [...***...].

 

		5.	PHASE
                                                                                                                 IV: [...***...]

 

Research and development of
CMX-001 for the treatment of smallpox to include the following activities: [...***...]. [...***...] studies and phase I [...***...]
study. The contractor shall carry out the following tasks and subtasks and in accordance with agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		5.1	Program Management (Consistent with section 2.1)

		5.1.1	Program management scope in BASE year is consistent with
                                                                  program management scope in each option year.

 

		5.2	Non-toxicology

		5.2.1	N/A (no scope)

 

***Confidential Treatment Requested

 

    	10

    	 

    

 

		5.3	Non-Clinical

		5.3.1	[...***...] studies. [...***...] will be randomized to receive
                                                                  [...***...] beginning at the [...***...]. These studies will
                                                                  include [...***...] and [...***...] as well as [...***...] including
                                                                  [...***...]. The primary endpoint will be [...***...]

		5.3.2	[...***...] Studies. This study will determine the [...***...]
                                                                  at the [...***...]. [...***...] and [...***...] at the [...***...].
                                                                  The primary endpoint will be [...***...]. If FDA requires a
                                                                  [...***...] in the [...***...] studies, the [...***...] study
                                                                  may not be needed.

		5.3.3	Conduct [...***...] Studies. This study will determine the
                                                                  [...***...] at the [...***...]. [...***...] and [...***...]
                                                                  at the [...***...].

 

		5.4	Clinical

		5.4.1	Phase 3 development including [...***...] study, [...***...]
                                                                  study, phases II [...***...] study. A [...***...] study will
                                                                  be conducted to compare the [...***...] of CMX001 in [...***...]
                                                                  to [...***...]. A [...***...] study will be conducted to compare
                                                                  the [...***...] of CMX001 when [...***...]. A [...***...] study
                                                                  will be conducted to [...***...] to support an NDA.

 

		5.5	Regulatory

		5.5.1	Generating all necessary data and preparing documentation
                                                                  for NDA submissions to regulatory agencies;

		5.5.2	Preparing materials for and requesting, scheduling and participating
                                                                  in all meetings with the FDA, including meetings to review IND,
                                                                  EUA and/or all other data packages;

		5.5.3	Providing BARDA with (i) the initial draft minutes
                                                                  and final draft minutes of any formal meeting with the FDA;
                                                                  (ii) final draft minutes of any informal meeting with the
                                                                  FDA;

 

		5.6	CMC

		5.6.1	[...***...]. [...***...] of the process to demonstrate the
                                                                  [...***...] of a [...***...] will be performed.

 

		6.	PHASE V: [...***...]

 

 

***Confidential Treatment Requested

 

    	11

    	 

    

  

Research and development of CMX-001
for the treatment of smallpox to include the following activities: [...***...]. The contractor shall carry out the following tasks
and subtasks and in accordance with an agreed upon Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and
2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		6.1	Program Management (Consistent with section 2.1)

		6.1.1	Program management scope in BASE year is consistent with
                                                                  program management scope in each option year.

 

		6.2	Non-toxicology

		6.2.1	N/A (no scope)

 

		6.3	Non-Clinical

		6.3.1	[...***...] Studies. This study replicates [...***...] if
                                                                  a [...***...] is necessary to achieve a [...***...] result.

 

		6.4	Clinical

		6.4.1	Compile [...***...]. A database of [...***...] data collected
                                                                  from all CMX001 clinical studies, irrespective of [...***...],
                                                                  will be populated and analyzed in order to support an [...***...]
                                                                  for smallpox.

 

		6.5	Regulatory

		6.5.1	Generating all necessary data and preparing documentation
                                                                  for NDA submissions to regulatory agencies;

		6.5.2	Submitting NDA documentation to the FDA in a timely manner,
                                                                  consistent with timelines set out in the contract and by the
                                                                  FDA.

		6.5.3	Preparing materials for and requesting, scheduling and participating
                                                                  in all meetings with the FDA, including meetings to review IND,
                                                                  EUA and/or all other data packages;

		6.5.4	Providing BARDA with (i) the initial draft minutes
                                                                  and final draft minutes of any formal meeting with the FDA;
                                                                  (ii) final draft minutes of any informal meeting with the
                                                                  FDA;

 

		6.6	CMC

		6.6.1	[...***...]. [...***...] of the process to demonstrate the
                                                                  [...***...] of a [...***...] will be performed.

 

		7.	Other
                                                                                                                 Items

 

		7.1	Facilities, Equipment and Other Resources. (Contract:
Section J)

The Contractor shall provide equipment; facilities
and other resources required for implementation of the SOW dated January 11, 2011 to comply with all Federal 

 

***Confidential Treatment Requested

 

    	12

    	 

    

 

and HHS regulations in:  

 

		7.1.1	The
[...***...] and use of [...***...];

		7.1.2	The
acquisition, handling, storage and shipment of [...***...], including
[...***...] required for working with the [...***...];

		7.1.3	The
[...***...] of [...***...]
under cGMP;

		7.1.3.1	The
design and conduct of [...***...]; and

		7.1.4	Design
and conduct of [...***...] under GCP.

 

***Confidential Treatment Requested

 

    	13

    	 

    

 

ATTACHMENT 2

 

INVOICE/FINANCING REQUEST AND CONTRACT
FINANCIAL REPORTING

INSTRUCTIONS FOR BARDA COST-REIMBURSEMENT TYPE CONTRACTS

 

Format: Payment requests shall be submitted on the Contractor’s
self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard
Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s self-generated
form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter
with the payment request.

 

Number of Copies: Payment requests shall be submitted
in the quantity specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

Frequency: Payment requests shall not be submitted more
frequently than once every two weeks in accordance with the Allowable Cost and Payment Clause incorporated into this contract.
Small business concerns may submit invoices/financing requests more frequently than every two weeks when authorized by the Contracting
Officer.

 

Cost Incurrence Period: Costs incurred must be within
the contract performance period or covered by precontract cost provisions.

 

Billing of Costs Incurred: If billed costs include (1)
costs of a prior billing period, but not previously billed, or (2) costs incurred during the contract period and claimed
after the contract period has expired, the Contractor shall site the amount(s) and month(s) in which it incurred such costs.

 

Contractor’s Fiscal Year: Payment requests shall
be prepared in such a manner that the Government can identify costs claimed with the Contractor’s fiscal year.

 

Currency: All BARDA contracts are expressed in United
States dollars. When the Government pays in a currency other than United States dollars, billings shall be expressed, and payment
by the Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations
may not be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract
may not exceed the United States dollars

authorized.

 

Costs Requiring Prior Approval: Costs requiring the
Contracting Officer’s approval, which are not set forth in an Advance Understanding in the contract, shall be identified
and reference the Contracting Officer’s Authorization (COA) Number. In addition, the Contractor shall show any cost set
forth in an Advance Understanding as a separate line item on the payment request.

 

Invoice/Financing Request Identification: Each payment
request shall be identified as either:

 

		(a)	Interim Invoice/Contract Financing Request: These are interim
                                                           payment requests submitted during the contract performance period.

 

		(b)	Completion Invoice: The completion invoice shall be submitted
                                                           promptly upon completion of the work, but no later than one year from
                                                           the contract completion date, or within 120 days after settlement of
                                                           the final indirect cost rates covering the year in which the contract
                                                           is physically complete (whichever date is later). The Contractor shall
                                                           submit the completion invoice when all costs have been assigned to
                                                           the contract and it completes all performance provisions.

 

		(c)	Final Invoice: A final invoice may be required after the
                                                           amounts owed have been settled between the Government and the Contractor
                                                           (e.g., resolution of all suspensions and audit exceptions).

 

Preparation and Itemization of the Invoice/Financing Request:
The Contractor shall furnish the information set forth in the instructions below. The instructions are keyed to the entries
on the Sample Invoice/Financing Request.

  

    	 

    	 

    

 

		(a)	Designated Billing Office Name and Address: Enter the designated
                                                           billing office name and address, as identified in the Invoice Submission
                                                           Instructions in Section G of the Contract Schedule.

 

		(b)	Contractor’s Name, Address, Point of Contact, VIN, and
                                                           DUNS or DUNS+4 Number: Show the Contractor’s name and address
                                                           exactly as they appear in the contract, along with the name, title,
                                                           phone number, and e-mail address of the person to notify in the event
                                                           of an improper invoice or, In the case of payment by method other than
                                                           Electronic Funds Transfer, to whom payment is to be sent. Provide the
                                                           Contractor’s Vendor Identification Number (VIN), and Data Universal
                                                           Numbering System (DUNS) number or DUNS+4. The DUNS number must identify
                                                           the Contractor’s name and address exactly as stated on the face
                                                           page of the contract. When an approved assignment has been made by
                                                           the Contractor, or a different payee has been designated, provide the
                                                           same information for the payee as is required for the Contractor (i.e.,
                                                           name, address, point of contact, VIN, and DUNS).

 

		(c)	Invoice/Financing Request Number: Insert the appropriate
                                                           serial number of the payment request.

 

		(d)	Date Invoice/Financing Request Prepared: Insert the date
                                                           the payment request is prepared.

 

		(e)	Contract Number and Order Number (if applicable): Insert
                                                           the contract number and order number (if applicable).

 

		(f)	Effective Date: Insert the effective date of the contract
                                                           or if billing under an order, the effective date of the order.

 

		(g)	Total Estimated Cost of Contract/Order: Insert the total
                                                           estimated cost of the contract, exclusive of fixed-fee. If billing
                                                           under an order, insert the total estimated cost of the order, exclusive
                                                           of fixed-fee. For incrementally funded contracts/orders, enter the
                                                           amount currently obligated and available for payment.

 

		(h)	Total Fixed-Fee: insert the total fixed-fee (where applicable).
                                                           For incrementally funded contracts/orders, enter the amount currently
                                                           obligated and available for payment.

 

		(i)	Two-Way/Three-Way Match: Identify whether payment is to
                                                           be made using a two-way or three-way match. To determine required payment
                                                           method, refer to the Invoice Submission Instructions in Section G of
                                                           the Contract Schedule.

 

		(j)	Office of Acquisitions: Insert the name of the Office of
                                                           Acquisitions, as identified in the Invoice Submission Instructions
                                                           in Section G of the Contract Schedule.

 

		(k)	Central Point of Distribution: Insert the Central Point
                                                           of Distribution, as identified in the Invoice Submission Instructions
                                                           in Section G of the Contract Schedule.

 

		(I)	Billing Period: Insert the beginning and ending dates (month,
                                                           day, and year) of the period in which costs were incurred and for which
                                                           reimbursement is claimed.

 

		(m)	Amount Billed - Current Period: Insert the amount claimed
                                                           for the current billing period by major cost element, including any
                                                           adjustments and fixed-fee. If the Contract Schedule contains separately
                                                           priced line items, identify the contract line item(s) on the payment
                                                           request and include a separate breakdown (by major cost element) for
                                                           each line item.

 

		(n)	Amount Billed - Cumulative: Insert the cumulative amounts
                                                           claimed by major cost element, including any adjustments and fixed-fee.
                                                           If the Contract Schedule contains separately priced line items, identify
                                                           the contract line item(s) on the payment request and include a separate
                                                           breakdown (by major cost element) for each line item.

 

		(o)	Direct Costs: Insert the major cost elements. For each element,
                                                           consider the application of the paragraph entitled “Costs Requiring
                                                           Prior Approval” on page 1 of these instructions.

 

    	 

    	 

    

 

		(1)	Direct Labor: Include salaries and wages paid
(or accrued) for direct performance of the contract.

 

For Level of Effort contracts only, the Contractor
shall provide the following information on a separate sheet of paper attached to the payment request:

 

- hours or percentage of effort and cost by labor category
(as specified in the Level of Effort Article in Section F of the contract) for the current billing period, and

 

- hours or percentage of effort and cost by labor category
from contract inception through the current billing period.  (NOTE: The Contracting Officer may require the Contractor
to provide additional breakdown for direct labor, such as position title, employee name, and salary or hourly rate.)

 

		(2)	Fringe Benefits: List any fringe benefits applicable
                                                                to direct labor and billed as a direct cost. Do not include in
                                                                this category fringe benefits that are included in indirect costs.

 

		(3)	Accountable Personal Property: Include permanent research
                                                                equipment and general purpose equipment having a unit acquisition
                                                                cost of $1,000 or more, with a life expectancy of more than two
                                                                years, and sensitive property regardless of cost (see the HHS
                                                                Contractor’s Guide for Control of Government Property).
                                                                Show permanent research equipment separate from general purpose
                                                                equipment.

 

On a separate sheet of paper attached to the payment
request, list each item for which reimbursement is requested. An asterisk (*) shall precede the item if the equipment is below
the $1,000 approval level. Include reference to the following (as applicable):

 

- item number for the specific piece of equipment listed
in the Property Schedule, and - COA number, if the equipment is not covered by the Property Schedule.

 

The Contracting Officer may require the Contractor
to provide further itemization of property having specific limitations set forth in the contract.

 

		(4)	Materials and Supplies: Include equipment with unit
                                                                costs of less than $1,000 or an expected service life of two years
                                                                or less, and consumable material and supplies regardless of amount.

 

		(5)	Premium Pay: List remuneration in excess of the basic
                                                                hourly rate.

 

		(6)	Consultant Fee: List fees paid to consultants. Identify
                                                                consultant by name or category as set forth in the contract or
                                                                COA, as well as the effort (i.e,, number of hours, days, etc.)
                                                                and rate billed.

 

		(7)	Travel: Include domestic and foreign travel. Foreign
                                                                travel is travel outside of Canada, the United States and its
                                                                territories and possessions. However, for an organization located
                                                                outside Canada, the United States and its territories and possessions,
                                                                foreign travel means travel outside that country. Foreign travel
                                                                must be billed separately from domestic travel.

 

		(8)	Subcontract Costs: List subcontractor(s) by name and
                                                                amount billed.

 

		(9)	Other: List all other direct costs in total unless
                                                                exceeding $1,000 in amount. If over $1,000, list cost elements
                                                                and dollar amounts separately. If the contract contains restrictions
                                                                on any cost element, that cost element must be listed separately.

 

		(p)	Cost of Money (COM): Cite the COM factor and base in effect
                                                           during the time the cost was incurred and for which reimbursement is
                                                           claimed.

 

		(q)	Indirect Costs: Identify the indirect cost base (IDC), indirect
                                                           cost rate, and amount billed for each indirect cost category.

 

		(r)	Fixed-Fee: Cite the formula or method of computation for
                                                           fixed-fee, if applicable. The fixed-fee must be claimed as provided
                                                           for by the contract.

 

		(s)	Total Amounts Claimed: Insert the total amounts claimed
                                                           for the current and cumulative periods.

 

    	 

    	 

    

 

		(t)	Adjustments: Include amounts conceded by the Contractor,
                                                           outstanding suspensions, and/or disapprovals subject to appeal.

 

		(u)	Grand Totals

 

		(v)	Certification of Salary Rate Limitation: If required by
                                                           the contract (see Invoice Submission Instructions in Section G of the
                                                           Contract Schedule), the Contractor shall include the following certification
                                                           at the bottom of the payment request:

                                                           

“I hereby certify that the
salaries billed in this payment request are in compliance with the Salary Rate Limitation Provisions in Section H of the contract.”

 

The Contracting Officer may require the Contractor to submit
detailed support for costs claimed on one or more interim payment requests.

 

FINANCIAL REPORTING INSTRUCTIONS:

 

These instructions are keyed to the Columns on the sample invoice/financing
request.

 

Column A - Expenditure Category: Enter the expenditure
categories required by the contract.

 

Column B - Cumulative Percentage of Effort/Hrs. - Negotiated:
Enter the percentage of effort or number of hours agreed to for each employee or labor category listed in Column A.

 

Column C - Cumulative Percentage of Effort/Hrs. - Actual:
Enter the percentage of effort or number of hours worked by each employee or labor category listed in Column A.

 

Column D - Amount Billed - Current: Enter amounts billed
during the current period.

 

Column E - Amount Billed - Cumulative: Enter the cumulative
amounts to date.

 

Column F - Cost at Completion: Enter data only when
the Contractor estimates that a particular expenditure category will vary from the amount negotiated. Realistic estimates are
essential.

 

Column G - Contract Amount: Enter the costs agreed to
for all expenditure categories listed in Column A.

 

Column H - Variance (Over or Under): Show the difference
between the estimated costs at completion (Column F) and negotiated costs (Column G) when entries have been made in Column F.
This column need not be filled in when Column F is blank. When a line item varies by plus or minus 10 percent, i.e., the percentage
arrived at by dividing Column F by Column G, an explanation of the variance should be submitted. In the case of an overrun (net
negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract.

 

Modifications: Any modification In the amount negotiated
for an item since the preceding report should be listed in the appropriate cost category.

 

Expenditures Not Negotiated: An expenditure for an item
for which no amount was negotiated (e.g., at the discretion of the Contractor in performance of its contract) should be listed
in the appropriate cost category and all columns filled in, except for G.  Column H will of course show a 100 percent
variance and will be explained along with those identified under H above.

 

    	 

    	 

    

 

SAMPLE INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORT

 

	
        (a)       Designated Billing Office
        Name and Address:

         

        DHHS/OS/ASPR/BARDA

        Attn: Contracting Officer

        330 Independence Ave., S.W.

        Room G644

        Washington, D.C. 20201

         

        (b)       Contractor’s Name,
        Address, Point of Contact, VIN, and DUNS or DUNS+4 Number:

         

        ABC CORPORATION

        100 Main Street

        Anywhere, USA Zip Code

         

        Name, Title, Phone Number, and E-mail Address of
        person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer,
        to whom payment is to be sent.

         

        VIN:

        DUNS or DUNS+4:

         
	
        (c)     Invoice/Financing Request No.:

         

        (d)     Date Invoice Prepared:

         

        (e)     Contract No, and Order No. (if applicable): __________

         

        (f)      Effective Date:

         

        (g)     Total Estimated Cost of Contract/Order:

         

        (h)     Total Fixed-Fee (if applicable):

         

        (i)       ̈Two-Way
Match: 

              ̈Three-way
Match:

         

        (j)      Office of Acquisitions:

         

        (k)     Central Point of Distribution:

	(i)  This invoice/financing request represents reimbursable costs for the period from _________ to 
	
        Expenditure Category*

        A
	Cumulative Percentage of

Effort/Hrs.	Amount Billed	Cost at Completion

F	Contract

Amount

G	Variance

H
	Negotiated

B	Actual

C	(m)

Current

D	(n)

Cumulative

E
	  (o)Direct Costs	 	 	 	 	 	 	 
	   (1)   Direct Labor	 	 	 	 	 	 	 
	   (2)   Fringe Benefits	 	 	 	 	 	 	 
	   (3)   Accountable Property	 	 	 	 	 	 	 
	   (4)   Materials & Supplies	 	 	 	 	 	 	 
	   (5)   Premium Pay	 	 	 	 	 	 	 
	   (6)   Consultant Fees	 	 	 	 	 	 	 
	   (7)   Travel	 	 	 	 	 	 	 
	   (8)   Subcontracts	 	 	 	 	 	 	 
	   (9)   Other	 	 	 	 	 	 	 
	  Total Direct Costs	 	 	 	 	 	 	 
	  (p)  Cost of Money	 	 	 	 	 	 	 
	  (q)  Indirect Costs	 	 	 	 	 	 	 
	  (r)  Fixed Fee	 	 	 	 	 	 	 
	  (s)  Total Amount Claimed	 	 	 	 	 	 	 
	  (t)  Adjustments	 	 	 	 	 	 	 
	  (u) Grand Totals	 	 	 	 	 	 	 
	
        I certify that all payments are for appropriate purposes and
        in accordance with the contract.

        ___________________________                            _____________________

(Name of Official)                                                     
(Title)

        ‘ Attach details as specified in the contract

 

    	 

    	 

    
 

ATTACHMENT 3

 

	FINANCIAL
        REPORT OF INDIVIDUAL

        PROJECT/CONTRACT

         

        Note:
        Complete this Form in Accordance with

        Accompanying Instructions.
	Project Task:

         

         
	Contract
    No.	Date
    of Report:	0990-0134

        0990-0131

	Reporting
    Period:	Contractor
    Name and Address:
	Expenditure
    Category	

                                                                                Percentage
                                                                                of
 Effort/Hours

                                                                                 
	Cumulative

    Incurred Cost

    at End of Prior

    Period	Incurred

    Cost-

    Current

    Period	Cumulative

    Cost to Date

    (D + E)	Estimated

    Cost to

    Complete	Estimated
    Cost at

    Completion

    (F + G)	Negotiated

    Contract

    Amount	Variance
    (Over

    or Under) (I -

    H)
	Negotiated	Actual
	A	B	C	D	E	F	G	H	I	J
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 

 

    	 

    	 

    
 

 

ATTACHMENT 4

INSTRUCTIONS FOR COMPLETING

“FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT”

 

GENERAL INFORMATION

 

Purpose. This Quarterly Financial Report is designed
to: (1) provide a management tool for use by be BARDA in monitoring the application of financial and personnel resources to the
BARDA contracts; (2) provide contractors with financial and personnel management data which is usable in their management processes;
(3) promptly indicate potential areas of contract underruns or overruns by making possible comparisons of actual performance and
projections with prior estimates on individual elements of cost and personnel; and (4) obtain contractor’s analyses of cause
and effect of significant variations between actual and prior estimates of financial and personnel performance.

 

REPORTING REQUIREMENTS

 

Scope. The specific cost and personnel elements to be
reported shall be established by mutual agreement prior to award. The Government may require the contractor to provide detailed
documentation to support any element(s) on one or more financial reports.

 

Number of Copies and Mailing Address. An original and
two (2) copies of the report(s) shall be sent to the contracting officer at the address shown on the face page of the contract,
no later than 30 working days after the end of the period reported. However, the contract may provide for one of the copies to
be sent directly to the Contracting Officer’s Technical Representative.

 

REPORTING STATISTICS

 

A modification which extends the period of performance of an
existing contract will not require reporting on a separate quarterly report, except where it is determined by the contracting officer
that separate reporting is necessary. Furthermore, when incrementally funded contracts are involved, each separate allotment is
not considered a separate contract entity (only a funding action). Therefore, the statistics under incrementally funded contracts
should be reported cumulatively from the inception of the contract through completion.

 

Definitions and Instructions for Completing the Quarterly
Report. For the purpose of establishing expenditure categories in Column A, the following definitions and instructions will
be utilized. Each contract will specify the categories to be reported.

 

		(1)	Key Personnel. Include key personnel regardless of annual salary rates. All such individuals should be listed by names
and job titles on a separate line including those whose salary is not directly charged to the contract but whose effort is directly
associated with the contract. The listing must be kept up to date.

 

		(2)	Personnel—Other. List as one amount unless otherwise required by the contract.

 

		(3)	Fringe Benefits. Include allowances and services provided by the contractor to employees as compensation in addition
to regular salaries and wages. If a fringe benefit rate(s) has been established, identify the base, rate, and amount billed for
each category. If a rate has not been established, the various fringe benefit costs may be required to be shown separately. Fringe
benefits which are included In the Indirect cost rate should not be shown here.

 

		(4)	Accountable Personal Property. Include nonexpendable personal property with an acquisition cost of $1,000 or more and
with an expected useful life of two or more years, and sensitive items regardless of cost. Form HHS 565, “Report of Accountable
Property,” must accompany the contractor’s public voucher (SF 1034/SF 1035) or this report if not previously submitted.
See “Contractor’s Guide for Control of Government Property.”

 

		(5)	Supplies. Include the cost of supplies and material and equipment charged directly to the contract, but excludes the
cost of nonexpendable equipment as defined in (4) above.

 

		(6)	Inpatient Care. Include costs associated with a subject while occupying a bed in a patient care setting. It normally
includes both routine and ancillary costs.

 

    	 

    	 

    

 

		(7)	Outpatient Care. Include costs associated with a subject while not occupying a bed. It normally includes ancillary costs
only.

 

		(8)	Travel. Include all direct costs of travel, including transportation, subsistence and miscellaneous expenses. Travel
for staff and consultants shall be shown separately. Identify foreign and domestic travel separately. If required by the contract,
the following information shall be submitted: (i) Name of traveler and purpose of trip; (ii) Place of departure, destination and
return, including time and dates; and (iii) Total cost of trip.

 

		(9)	Consultant Fee. Include fees paid to consultant(s). Identify each consultant with effort expended, billing rate, and
amount billed.

 

		(10)	Premium Pay. Include the amount of salaries and wages over and above the basic rate of pay.

 

		(11)	Subcontracts. List each subcontract by name and amount billed.

 

		(12)	Other Costs. Include any expenditure categories for which the Government does not require individual line item reporting.
It may include some of the above categories.

 

		(13)	Overhead/Indirect Costs. Identify the cost base, indirect cost rate, and amount billed for each indirect cost category.

 

		(14)	General and Administrative Expense. Cite the rate and the base. In the case of nonprofit organizations, this item will
usually be included in the indirect cost.

 

		(15)	Fee. Cite the fee earned, if any.

 

		(16)	Total Costs to the Government.

 

PREPARATION INSTRUCTIONS

 

These instructions are keyed to the Columns on the Quarterly
Report.

 

Column A—Expenditure Category. Enter the expenditure
categories required by the contract.

 

Column B—Percentage of Effort/Hours Negotiated.
Enter the percentage of effort or number of hours agreed to during contract negotiations for each labor category listed in Column
A.

 

Column C—Percentage of Effort/Hours-Actual. Enter
the cumulative percentage of effort or number of hours worked by each employee or group of employees listed in Column A.

 

Column D—Cumulative Incurred Cost at End of Prior Period.
Enter the cumulative incurred costs up to the end of the prior reporting period. This column will be blank at the time of the submission
of the initial report.

 

Column E—Incurred Cost-Current Period. Enter the
costs which were incurred during the current period. Column F—Cumulative Incurred Cost to Date. Enter the combined total
of Columns D and E.

 

Column G—Estimated Cost to Complete. Make entries
only when the contractor estimates that a particular expenditure category will vary from the amount negotiated. Realistic estimates
are essential.

 

Column H—Estimated Costs at Completion. Complete
only if an entry is made in Column G.

 

Column I—Negotiated Contract Amount. Enter in this
column the costs agreed to during contract negotiations for all expenditure categories listed in Column A.

    	 

    	 

    

 

Column J—Variance (Over or Under). Complete only
if an entry is made in Column H. When entries have been made in Column H, this column should show the difference between the estimated
costs at completion (Column H) and negotiated costs (Column I). When a line item varies by plus or minus 10 percent, i.e., the
percentage arrived at by dividing Column J by Column I, an explanation of the variance should be submitted. In the case of an overrun
(net negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract.

 

Modifications. List any modification in the amount negotiated
for an Item since the preceding report in the appropriate cost category.

 

Expenditures Not Negotiated. List any expenditure for
an item for which no amount was negotiated (e.g., at the discretion of the contractor in performance of its contract) in the appropriate
cost category and complete all columns except for 1. Column J will of course show a 100 percent variance and will be explained
along with those identified under J above.

 

    	 

    	 

    

 

Attachment 5

INCLUSION ENROLLMENT REPORT

 

This report format should NOT be used for
data collection from study participants

	Study Title:
	Total Enrollment:	Protocol Number:
	Contract Number:	 
	PART
    A. TOTAL ENROLLMENT REPORT: Number of Subjects Enrolled to Date (Cumulative) by Ethnicity and Race
	Ethnic Category	Sex/Gender
	Females	Males	Unknown or Not Reported	Total
	Hispanic or Latino	 	 	 	 
	Not Hispanic or Latino	 	 	 	 
	Unknown (Individuals not reporting ethnicity)	 	 	 	 
	Ethnic Category: Total of All Subjects*	 	 	 	 
	Racial Categories
	American Indian/Alaska Native	 	 	 	 
	Asian	 	 	 	 
	Native Hawaiian or Other Pacific Islander	 	 	 	 
	Black or African American	 	 	 	 
	White	 	 	 	 
	More than one race	 	 	 	 
	Unknown or not reported	 	 	 	 
	Racial Categories: Total of All Subjects*	 	 	 	 
	 
	PART B. HISPANIC ENROLLMENT REPORT: Number of Hispanics or Latinos Enrolled to Date (Cumulative)
	Racial
Categories	Females	Males	Unknown or Not Reported	Total
	American Indian/Alaska Native	 	 	 	 
	Asian	 	 	 	 
	Native Hawaiian or Other Pacific Islander	 	 	 	 
	Black or African American	 	 	 	 
	White	 	 	 	 
	More than one race	 	 	 	 
	Unknown or not reported	 	 	 	 
	Racial Categories: Total of Hispanics or Latinos**	 	 	 	 
	*These totals must agree

**These totals must agree	 	 	 	 
	 	 	 	 	 	 

 

    	 

    	 

    

 

ATTACHMENT 6

Research Patient Care Costs

 

(a) Research patient care costs are the costs of routine and
ancillary services provided to patients participating in research programs described in this contract.

 

(b) Research patient care costs shall be computed in a manner
consistent with the principles and procedures used by the Medicare Program for determining the part of Medicare reimbursement based
on reasonable costs. The Diagnostic Related Group (DRG) prospective reimbursement method used to determine the remaining portion of Medicare reimbursement shall not be used to determine research patient care costs.
Research patient care rates or amounts shall be established by the Secretary of HHS or his/her duly authorized representative.

 

(c) Prior to submitting an invoice for research patient care
costs under this contract, the contractor must make every reasonable effort to obtain third party payment, where third party payors (including Government agencies) are authorized or are under a legal obligation to
pay all or a portion of the charges incurred under this contract for research patient care.

 

(d) The contractor must maintain adequate procedures to identify
those research patients participating in this contract who are eligible for third party reimbursement.

 

(e) Only those charges not recoverable from third party payors
or patients and which are consistent with the terms and conditions of the contract are chargeable to this contract

 

    	 

    	 

    

 

Attachment 8 - Earned Value Management
(EVM) Requirements

 

The Contractor shall propose and provide a Performance Measurement
System that meets the Seven Principles of Earned Value Management. The Seven Principles are:

 

		1.	Plan all work scope for the program to completion of the contract.

 

		2.	Break down the program work scope into finite pieces that can be assigned to

a responsible person or organization for control of technical, schedule, and cost objectives.

 

		3.	Integrate program work scope, schedule, and cost objectives into a performance measurement baseline plan against which accomplishments
may be measured. Control changes to the baseline,

 

		4.	Use actual cost incurred and recorded in accomplishing the work performed.

 

		5.	Objectively assess accomplishments at the work performance level.

 

		6.	Analyze significant variances from the plan, forecast impacts, and prepare an estimate at completion based on performance to
date and work to be performed.

 

		7.	Use Performance Based information in the company’s management processes.

 

The Contractor shall develop a Work Breakdown Structure (WBS)
to an appropriate level and a WBS dictionary which lists and defines the WBS elements that also is inclusive of the applicable
EVM requirements.

 

Contractors required to provide Earned Value Management to their
project can obtain additional instruction from the 7 Principles of EVM Intent Guide.

 

The EVM requirements for this contract will be as follows:

 

Tier 2 — Contracts greater than $25m in total
value (includes base and options) and with a proposed product that has a Technology Readiness Level (TRL) of 6 or greater.

 

    	 

    	 

    

 

GLOSSARY OF TERMS

 

	Actual Cost of Work Performed (ACWP)	 	The costs actually applied and recorded in accomplishing the work performed within a specified period.
	 	 	 
	Baseline	 	(See Performance Measurement Baseline).
	 	 	 
	Budget at Completion (BAC)	 	The sum of all budgets (BCWS) allocated to the contract. Synonymous with the term Performance Measurement Baseline.
	 	 	 
	Budgeted Cost for Work Performed (BCWP)	 	The sum of the budgets for completed Work Packages and completed portions of open Work Packages, plus the appropriate portion of the budgets for level of effort and apportioned effort (Also see Earned Value).

 

    	 

    	 

    

 

	Control Account	 	A management control point at which actual costs can be accumulated and compared to budgeted cost for work performed. A control account is a natural control point for cost/schedule planning and control since it represents the work assigned to one responsible organizational element on one contract work breakdown structure (CWBS) element.
	 	 	 
	Control Account Manager	 	A member of a functional organization responsible for (CAM) task performance detailed in a Control Account and for managing the resources authorized to accomplish the tasks.
	 	 	 
	Control Account Plan

(CAP) Report	 	A CAP report is a timephased report which reflects all the work and effort to be performed in a control account. The CAP report will reflect the hours and dollars by element of cost (labor, subcontract, ODC, etc).

 

    	 

    	 

    

 

	Contract Performance Report (CPR)	 	The monthly report submitted to the customer showing the current, cumulative and at completion status, the performance measurement baseline, manpower 

loading, and a narrative explanation of significant program variances.
	 	 	 
	Contract Target Cost	 	The dollar value (excluding fee or profit) negotiated in the original contract plus the cumulative cost (excluding fee or profit) applicable to all definitizcd changes to the contract. It consists of the estimated

cost negotiated for a cost plus fixed fee contract and the definitized target cost for an incentive contract. The contract target cost does not include the value of authorized/un-negotiated work, and is thus equal to the contract budget base only when all authorized work has been negotiated/definitized.
	 	 	 
	Earned Value	 	See Budgeted Cost for Work Performed (BCWP)
	 	 	 
	Earned Value Management System (EVMS)	 	A project management system utilized for measuring project progress in an objective manner. Combines measurements of scope, schedule, and cost in a single integrated system.

 

    	 

    	 

    

 

	Estimate at Completion 

(EAC)	 	A value (expressed in dollars and/or hours) developed to represent a realistic appraisal of the final cost of tasks when accomplished. It’s the sum of direct & indirect costs to date plus the estimate of costs for all authorized Work remaining. The EAC = ACWP + the Estimate-to-Complete.
	 	 	 
	Estimate to Completion 

(ETC)	 	A value (expressed in dollar and/or hours) developed to represent a realistic appraisal of the cost of the work still required to be accomplished in completing a task.
	 	 	 
	Integrated Master Schedule (IMS)	 	The IMS expands the IMP to the work planning level. It defines the tasks, their durations, milestones, milestone dates which relate to the IMP completion criteria, and interdependencies required to complete the program. The IMP and IMS are used to track and execute the program.
	 	 	 
	Negotiated Contract Target Cost	 	The estimated cost negotiated in a Cost Plus Award 

Fee (CPAF), Cost Plus Fixed Fee (CPFF), Cost Plus Incentive Fee (CPIF) or Fixed Price Incentive Fee (BPIF) contract.

 

    	 

    	 

    

 

	Performance Measurement Baseline (PMB)	 	The time-phased budget plan against which contract performance is measured. It is formed by the budgets assigned to scheduled Control Accounts and the allocation of overhead costs. For future effort, not planned to the Control Account level, the performance measurement baseline also includes budgets assigned to higher level WBS elements, and undistributed budgets. It equals the total assigned budget less management reserve.
	 	 	 
	Risk Register	 	Is a tool commonly used in project planning and organizational risk assessments. It is °lien referred to as a Risk Log. It is used for identifying, analyzing and managing risks.
	 	 	 
	Variance Analysis Report (VAR)	 	The internal report completed by the Control Account Manager and submitted, through the Intermediate Manager, to the program manager for those Control Accounts which have variances in excess of established thresholds.

 

    	 

    	 

    

 

	Work Authorization Document (WAD)	 	A form used to formally authorize and budget work to the Control Account Manager. This document must include, as a minimum, the Control Account number, Statement of Work, scheduled start and finish dates, budget, and the identity of the CAM. It must be approved by Intermediate Manager, and be agreed to by the Control Account Manager.

 

    	 

    	 

    

 

 

Attachment 9 - Department of Health
& Human Services

HHS

Office of the Assistant Secretary for Preparedness and Readiness

ASPR

Biomedical Advanced Research and Development Authority

BARDA

 

7 Principles of Earned Value

Management

Tier 2

System implementation 

Intent Guide

 

01 November 2010

 

 

    	 

    	 

    

 

TABLE OF
CONTENTS

 

	OVERVIEW	1
	 	 
	EVM IMPLEMENTATION TIERS	3
	 	 
	SEVEN PRINCIPLES OF EVM	4
	 	 
	Principle I Plan all Work Scope	4
	 	 
	Principle 2: Break Work into Finite Pieces and Define Person/Organization Responsible for Work	4
	 	 
	Principle 3a: Integrate Scope, Schedule and Budget into a Performance Measurement Baseline	5
	 	 
	Principle 3b: Control Changes to the Baseline 	5
	 	 
	Principle 4: Use Actual Costs Incurred and Recorded in Accomplishing the Work Performed	6
	 	 
	Principle 5: Objectively Assess Accomplishments at the Work Performance Level	7
	 	 
	Principle 6a: Analyze Significant Variances From the Plan	8
	 	 
	Principle 6b: Prepare an Estimate at Completion Based on Performance to Date and Work to be Performed	9
	 	 
	Principle 7: Use EVMS Information in the Company’s Management Processes	9
	 	 
	APPENDIX: GLOSSARY OF TERMS	I0

 

    	 

    	 

    

 

		

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

OVERVIEW

 

Earned Value Management (EVM) is a program management
tool, technique, and discipline that facilitates systematic planning for and monitoring of, high value, complex projects. It
integrates a project’s scope of work with the related budget and schedule to permit detailed assessment of overall
performance during the life of the project.

 

Several government-wide guidance documents govern the
definition and use of EVM systems. Guidelines outlining the qualities and characteristics of an EVM system are set forth in
the American National Standards Institute/Electronic Industries Alliance (ANSI/EIA) Standard-748 (most current version).
More detailed and specific guidance and direction is contained in OMB Circular A-11, Preparation, Submission and Execution
fo the Budget, specifically in Part 7 of that Circular A-11, Planning, Budgeting, Acquisition, and Management of
Capital Assets, and its supplement, the Capital Programming Guide. Based on this collective OMB guidance, EVMS is
intended to be used on those pads of acquisitions that will involve developmental effort. This would include not only
those acquisitions designated by the agency as major systems but also those acquisitions that include significant
developmental, modification, or upgrade during the operational or steady-state phase of a program.

 

The FAR rule on EVMS became effective on July 5, 2006.
Its purpose is to implement EVMS policy in accordance with OMB Circular A-11. Because the new FAR coverage applies throughout
the executive branch and to agencies with disparate definitions of and processes and procedures for major systems
acquisitions, the FAR Council decided against a “one-size-fits all” approach and left several significant
aspects attic detailed implementation up to the discretion of each covered agency.

 

The FAR and Health and Human Services
Acquisition Regulations (HHSAR) language for EVMS will be utilized for all construction or Information Technology (IT)
projects. Since most of the acquisitions at the Biomedical Advanced Research and Development Agency (BARDA) are unique in
that most acquisitions are not Information Technology projects or construction projects, BARDA is developing EVM language
that incorporates the 7 Principles of Earned Value Management. These principles allow flexibility to an EVM system
structure but still meet the spirit of the ANSI/EIA Standard-748. It also incorporates discipline in implementation and
operations and also provides the same reporting data outlined by OMB.

 

The Seven Principles of Earned Value Management are as follows:

 

		1.	Plan all work scope to completion

 

		2.	Break down the program work scope into finite pieces that can be assigned to a responsible person or organization for control
of technical, schedule and cost objectives

 

		3.	Integrate program work scope, schedule, and cost objectives into a performance measurement baseline plan against which accomplishments
can be measured. Control changes to the baseline.

 

		4.	Use actual costs incurred and recorded in accomplishing the work performed.

 

    	1

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

		5.	Objectively assess accomplishments at the work performance level.

 

		6.	Analyze significant variances from the plan, forecast impacts, and prepare an estimate at completion based on performance to
date and work to be performed.

 

		7.	Use earned value information in the company’s management processes.

 

    	2

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 

 

EVM IMPLEMENTATION TIERS

 

BARDA will be implementing a tiered approach to EVM based on
the type of acquisition, size of the acquisition and the technical readiness level. There are three tiers and they are as follows:

 

TIER I

 

For all construction contracts and IT contracts the ANSI/EIA-748
Standard for Earned Value Management Systems will apply and all relevant FAR/HHSAR clauses pertaining to EVMS will be incorporated
in the contract. The National Defense Industrial Association (NDIA) Program Management Systems Committee (PMSC) ANSI/EIA-748 Standard
for Earned Value Management Systems Intent Guide should be used as guidance.

 

TIER 2

 

For countermeasure research and development contracts that
have a total acquisition costs greater than or equal to $25 million and have a Technical Readiness Level (TRL) of less than 7
will apply EVM principles for tracking cost, schedule and technical performance that comply with the 7 Principles of EVM
Implementation.

 

TIER 3

 

For countermeasure research and development contracts that are
greater than or equal to $10 million but less than $25 million and/or have a TRL of less than 7 will apply EVM principles for tracking
cost, schedule and technical performance that comply with the 7 Principles of EVM Implementation.

 

This Guide is an explanation of the intent of what is expected
for a Tier 2 or 3 system implementation of the 7 Principles of EVM.

 

    	3

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

SEVEN PRINCIPLES OF EVM

 

Principle 1: Plan all Work Scope

 

in a performance measurement system implementation the
Statement of Work (SOW) should reflect all work that is to be performed. In a 7 Principles implementation a Work Breakdown
Structure (WBS) shall be developed to include all elements of the SOW. The level of the WBS may not be as detailed as in a
Tier I implementation. It would be developed at a higher level, such as level three or four. It is beneficial and required to
develop a WBS dictionary that explains what work is going to be performed in each WBS. This will ensure that the
contractor has identified all work scope and left no major work undefined. It is recommended that the work packages
descriptions are clear and detailed so that there is an understanding of the work that is to be performed in the work
packages. For the 7 Principles implementation programs it would be acceptable for the WBS Dictionary be expanded to include
information that would normally be kept on a Work Authorization Document, such as charge numbers associated with the work,
period of performance, the manager who is responsible for the work, and budget associated with the WBS. The additional
“WAD info” would only be added to the lowest level (i.e. level 3 or 4) of the WBS. The roll up level WBS would
only include scope. By doing this documentation is limited to one document instead of two.

 

By developing a WBS and a WBS Dictionary/Work Authorization
Document the work scope has been defined but the documentation is greatly reduced and the costs associated with developing and
updating the documentation is reduced. The intent of the combination document is not to reduce the level of information provided
to the government but to reduce the amount of documents that need to be produced.

 

Principle 2: Break Work into Finite Pieces and Define Person/Organization
Responsible for Work

 

In a 7 Principles Tier 2 implementation it is recommended
that the work be broken into finite pieces in the schedule tool. It is recommended to plan the work by the lowest level WBS.
The lowest level WBS (level 3 or 4) should be the control account and the activities would act as the work packages. For Tier
2 programs that are of larger value (greater than $25M) the expectation is that the control account will be at least at level
4 and potentially level 5. Most of the normal functions accomplished when scheduling will be required on a 7 Principles Tier
2 implementation. These normal functions include, network scheduling, horizontal and vertical traceability, forecasting
schedule start and completion dates, and running critical path analysis. As part of vertical traceability it is expected
that all contract milestones will be listed on the schedule.

 

The schedule should include but is not limited to include the
following fields:

 

WBS number

Control Account number

Work package number

Task name

Duration

Baseline Start and Finish Dates

 

    	4

    	 

    

 

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 

 

Actual Start and Finish Dates

Forecast Start and Finish Dates

Predecessor/Successors

Activity Percent Complete

 

All the work scheduled at the lowest level WBS should be
identified by a single responsible manager. This manager, known as a Control Account Manager should be identified in the
schedule tool and/or in a cost tool. In a 7 Principles implementation, only individuals at the lowest level WBS need be
identified and there is no requirement for the costs to roll up by organization, although if it is not cost intensive or tool
restricted then developing the OBS is recommended. In many cases, BARDA will provide the top three levels of the WBS for the
contractor to use.

 

Principle 3a: Integrate Scope, Schedule and Budget into a
Performance Measurement Baseline

 

This principle integrates the work scope, the schedule and the
budget into a performance measurement baseline. Since we discussed work scope and schedule the focus of this principle is the incorporation
of the budget in a time-phased manner. The budget must be integrated with the scope of work and the schedule into a Performance
Measurement Baseline (PMB). An accepted way of incorporating the budget and integrating with the scope and schedule is to resource
load the Microsoft Project (or other scheduling tool) schedule. This is done by loading the individual people and their loaded rate
into the tool. This budget data will be input at the work package level with a rate that includes the indirect costs. The budget will have to have the capability to be rolled up to the control
account level and will need to be reported in a way that provides the responsible manager (Control Account Manager) with information
needed to manage the program. Resource loading of the schedule is not the only way to incorporate the budget. As long as the budget in the budget/EV tool is linked to the schedule activities and it is flexible to change when schedule baseline
dates change, then loading the budget in the Budget/EV tool is an acceptable way to integrate the cost and schedule baselines.

 

It is recommended that management reserve and undistributed
budget be utilized in the budgeting process. Undistributed budget is budget that has not yet been distributed to a control account
and it requires additional time to plan the work and distribute the budget to a control account. It is a temporary holding account
and budget should only stay in Undistributed Budget for one or two months. If the work scope is easily identified to all the control
accounts then the use of Undistributed Budget may not be necessary.

 

Management Reserve is budget that is set aside, normally by
the Program Manager, to be used to budget future but currently unknown tasks. It is associated with risk issues and is to be used
to mitigate risk. It is not part of the Performance Measurement Baseline and it should not be used for out of scope work and to cover overruns.

 

Principle 3b: Control Changes to the Baseline

 

A properly
controlled PMB is crucial to effective program management. The timely and accurate incorporation of contractual changes ensures
that the information generated from the execution of

 

    	5

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 the baseline plan provides an accurate picture of progress and facilitates
correct management actions and decisions. The accurate and timely incorporation of authorized and negotiated changes into the
PMB ensures that valid performance measurement information is generated for the new scope being executed. Near term new scope
effort should be planned and have budget in control accounts. Far term new scope effort that cannot be reasonably planned in the
near term can either be put in planning packages in the control account or left in Undistributed Budget if the control account
has not been identified. The timely and accurate incorporation of authorized and negotiated changes into the PMB ensures that
valid performance measurement information is generated for the new scope being executed. Budget revisions are made when work is
added to the contract and are traceable from authorized contract target costs to the control account budgets or from management
reserve. Management reserve may be used for future work when additional in-scope work has been identified.

 

Retroactive changes to the baseline may mask variance trends
and prevent the use of performance data to project estimates of cost and schedule at completion. Controlling retroactive adjustments,
which should only be made in the current period, if possible, is imperative because they could arbitrarily eliminate existing cost
and schedule variances.

 

The use of program budget logs should be used to track and log
all budget changes. The ability to track budget values for both the internal and external changes will help in the maintenance
of the performance measurement baseline from program start to completion. Contractor is expected to utilize baseline change documentation
facilitating the change. It should provide the rationale/justification, approval process, work scope additions or deletions, dollars,
changes to schedules, estimate at completion, etc. It should also include contractual change documents for external changes, such
as a contract modification, letter to proceed, not to exceed letter, change order, etc., that transmit and authorize the change
or addition to work, budget, and schedule. Other documents that should change if a change of scope has been authorized is: Statement
of Work, WBS (changes if applicable); WBS Dictionary (additions or deletions to scope); work authorization documents authorizing
new scope, schedule and budget; schedules.

 

Principle 4: Use Actual Costs Incurred and Recorded in Accomplishing
the Work Performed

 

Some of the new acquisitions at BARDA will be required to be
compliant with the Cost Accounting Standards. For 7 Principles implementation contractors must utilize a work order/job order/task
code charge number structure that uniquely identifies costs at the control account level. This will allow for accumulation and
summarization of costs to higher levels of the work breakdown structure. Actual costs are accumulated in the formal accounting
system in a manner consistent with the way the related work is planned and budgeted. Actual costs reported in the performance reports
agrees with the costs recorded in the accounting system or can be explained as timing differences. The contractor will have to
be able to incorporate and reconcile to the accounting system actual costs on their Contract Performance Reports (CPR) to the customer.

 

Depending on the amount of material and subcontractors on the
program, it is beneficial for management purposes, to include accruals, or estimated actuals, for these costs. Since material and
subcontractor invoices are not paid and recorded in the accounting system for up to several months after the work has been planned,
performance data will be skewed. Accruing or

 

    	6

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 

 estimating actual costs based on receipt (for material) and expended hours for subcontractors
will alleviate this issue. The use of accrual/estimated actuals should be reviewed on a case by case basis depending on the size
of program, the amount of material or subcontractor budget and costs. If the material and subcontract effort is minimal then the
time and effort needed to manage the accruals would outweigh the benefit of having the costs accrued since the performance data
would only be minimally affected.

 

If the subcontractor has a fixed price contract the prime contractor,
then the prime contractor must report actual costs in line with the work that is accomplished. The way this is accomplished is
to record the actual costs equal to the work that was performed on the CPR.

 

Principle 5: Objectively Assess Accomplishments at the Work
Performance Level

 

In order to meet this Principle, the scheduling of the scope
of work in work packages or activities need to incorporate measurable units or milestones in order to objectively assess accomplishments
or obtain what we call “earned value”. These units or milestones are given a value based on labor resources needed
to accomplish the work (which becomes the Budgeted Cost of Work Scheduled or BCWS). When they arc accomplished (known as Budgeted
Cost of Work Performed or BCWP) they receive the value associated with the budget which measures progress.

 

Schedule status to measure progress needs to be on at least
on a monthly basis although it is preferred on a bi-weekly basis. As part of the status process progress dates, such as actual
start/complete and forecast start/complete need to be updated.

 

Since Microsoft Project seems to be the schedule tool of choice
by most contractors, there are four types of earned value methodologies utilized by Microsoft Project of which two assess progress
by the completion of milestones and they are the 50/50 and 0/100 methodologies. In both cases, progress is reported for completion
milestones and in the 50/50 methodology fifty percent of the value of the work package/activity is credited for stalling the work.
The other two earned value methodologies are assessed percent complete (also know as Supervisor’s Estimate) and level of
effort (LOE). All four methodologies are legitimate earn value measurement techniques but the assessed percent complete based or
supervisor’s estimates are highly discouraged. The reason is that it is highly subjective and is not based on any quantifiable
criteria. BARDA will not accept these earned value methodologies unless approved as an exception on a case by ease basis. If percent
complete on work packages is used with objective measurable activities, the contractor must show distinct relationship between
the budget planned at the work package level and the value earned at the activity level. If this is done properly then the measurement
will be objective and the schedule variance will be clearly understood and easy to explain. If this is not done properly then schedule
activities are not aligned with the budget in the performance measurement baseline and schedule variances will not be easy to understand.
If the latter is the case, BARDA will not accept that as an acceptable earned value methodology.

 

There are built in weaknesses with the 0/100 and 50/50 methodologies
also. If the responsible manager is being asked to plan their work in monthly increments in order to utilize the 0/100 methodology
then they may be asked to break the work up in pieces that don’t make logical sense or represent the natural ending of the
work. Also the 50/50 methodology, which is usually used for a two month work package, will provide skewed monthly data if the
resources in the work

 

    	7

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 package are not loaded equally for each month. It will give
an artificial positive or negative schedule variance the first month and vice versa the next month.

 

Additional earned value methodologies, such as the weighted
milestone methodology and percent complete with milestone gates may be utilized. The weighted milestone method allows value to
be earned based on the resource value in each month, which eliminates artificial schedule variances.

 

For all discrete measurable work packages or control accounts,
there must be an activity in each month to measure. Gaps, in which there is nothing to measure in a month or months is not acceptable.

 

For subcontractors that have a fixed price contract with the
prime contractor, the expectation is that there will be no cost variance. The ACWP reported on the CPR will equal the BCWP earned,
regardless of the payment schedule with subcontractor.

 

Principle 6a: Analyze Significant Variances From the Plan

 

The purpose of this principle is to ensure that the earned value
data is analyzed by the contractor and reported to the customer. The 7 Principles programs should be able to calculate the cost
variance (BCWP minus Actual Cost of Work Performed (ACWP) and the schedule variance (BCWP minus BCWS) at least on a cumulative
basis. It is recommended that variances be calculated on a current month basis also. The EVM system should also provide both monthly
and cumulative Cost Performance Index (BCWP divided by ACWP) and Schedule Performance

Index (BCWP divided by the BCWS). This data should be provided at the control account level and at the roll up levels and it needs
to be in a format for Control Account Managers and program management to be able to utilize in managing the work.

 

It is also recommended that the To-Complete Performance Index
(TCPI) be included in the Control Account Manager performance report. The TCPI is a valuable index that calculates the cost performance
the control account needs to perform at in order to complete the work within the current reported EAC. When the TCPI is compared
against the cumulative CPI it gives a good indication whether or not the current EAC is reasonable. For example, if a cumulative
CPI is .85 and the TCPI calculates to equal 1.15 that is the performance factor that work would need to perform at in order to
meet the current EAC. If the cumulative CPI is .85 then it can be determined that the current EAC might not be reasonable. It allows
management and Project Controls the opportunity to question the Control Account Manager as to the validity of the current EAC.
As a rule in thumb if the deviation between the CPI and the TCPI is greater than .2 then the CAM should reassess the control account
EAC.

 

These reports, which should be provided monthly, should also
include the current Budget at Completion (BAC) and the current Estimate at Completion (BAC). In addition, it would be a plus if
the CAM could see a report with their time-phased spread of hours and dollars for their budget plan (BCWS), work accomplished (BCWP)
and actual costs (ACWP).

 

For all variances that exceed the contractual variance threshold
will include a description of what caused the variance, impact to the control account and the program, and a corrective action.

 

    	8

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

 

 

Principle 6b: Prepare an Estimate at Completion Based on
Performance to Date and Work to be Performed

 

Providing an updated EAC is a prime concern of the customer
and the contractor. Therefore a robust EAC process should be in place whether the program is ANSI compliant or not.

 

Based on the performance to date the Estimates at Completion
can be updated on a monthly basis by the Control Account Manager in the scheduling tool during the status process or in the cost/EVM
tool at the end of the month’s process prior to submittal of the EVM report. The EAC is an element of the performance
measurement system that needs to accurately reflect the contractor’s best estimate of what it will cost to complete the project.

 

Program management should be able to validate control account
manager’s EACs by looking at performance indices, such as the To-Complete Performance Index, as well as independent statistical
EACs.

 

Principle 7: Use EVMS Information in the Company’s
Management Processes

 

One of the key areas that concerns government Program Management
Offices (PMO) is the level of importance that contractor’s place on EVM as a management tool. During a site visit, such as
conducting an Integrated Baseline Review, the PMO gauges what the interest, knowledge, and most importantly, the usage of the performance
measurement data in managing the program. They want to know that the managers on the program, including the program manager, have received
some earned value training. The level of involvement and use of the EVM data to manage their schedule, cost and technical issues
is ascertained by questions. The PMO can also tell by how robust the EACs are and if the variance narratives are being written
with impacts to the program and corrective actions being monitored by the contractor. It is important that the contractor’s
management team, including the Program Manager, utilize the data from the performance measurement system as a management tool.
They should be knowledgeable and understand the data. They should know what is causing the variances and ensure that the variance
narratives are written properly and answer what the issues, impacts and corrective actions are. They should be able to demonstrate
that they use the information to assist them in the management decision process. They should hold their Control Account Managers
accountable to use the data and write clear proper variance analysis report (VAR). If the Control Account Manager does not write
a proper VAR then Project Controls needs to help instruct them how to do it. It is recommended that prior to the Earned Value report
be sent to the government that the Program Manager has a meeting with the Control Account Managers and Project Control and review
the data and ensure that the variance analysis is complete and that the Program Manager agrees with it. This review is also used
to ensure that the EACs arc acceptable to the Program Manager, who is ultimately responsible for the program EAC. This is an efficient
and quick way to make any adjustments to the earned value report since all the key personnel are in one room. If the data appears
to be unreliable then the PM needs to hold Project Controls accountable to ensure that they are using discipline in changing baselines,
assessing process properly, and capturing actual costs to ensure that the data that is reported is accurate.

 

    	9

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

APPENDIX: GLOSSARY OF TERMS

 

	Actual Cost of Work 

Performed (ACWP)	The costs actually applied and recorded in accomplishing the work performed within a specified period.
	 	 
	Actual Direct Cost	Those costs identified specifically with a contract, based upon the contractor’s cost identification and accumulation system as accepted by the cognizant DCAA representatives. (See Direct Costs).
	 	 
	Advance Agreement (AA)	An agreement between the contractor and the Contract Administration Office concerning the application of an approved earned value management system to contracts within the affected facility.
	 	 
	Authorized Work	That effort which has been authorized and is on contract, or that for which authorized contract costs have not been agreed to but for which written authorization has been received.
	 	 
	Baseline	(See Performance Measurement Baseline).
	 	 
	Budget at Completion (BAC)	The sum of all budgets (BCWS) allocated to the contract. Synonymous with the term Performance Measurement Baseline.
	 	 
	Budgeted Cost for Work Performed (BCWP)	The sum of the budgets for completed Work Packages and completed portions of open Work Packages, plus the appropriate portion of the budgets for level of effort and apportioned effort (Also see Earned Value).
	 	 
	Budgeted Cost for Work Scheduled (BCWP)	The sum of the budgets for completed Work Packages, planning packages, etc., scheduled to be accomplished (including in-process Work Packages), plus the amount of level of effort and apportioned effort scheduled to be accomplished within a given time period.

 

    	10

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Change Order (CO)	A formal authorization by the Procuring Contracting Officer for a change of scope to an existing contract 
	 	 
	Contract Modification	A written and binding authorization to proceed created after change proposal negotiations.
	 	 
	Contract Budget Base (CBB)	The negotiated contract cost plus the estimated cost of authorized unpriced work, where:
	 	 
	 	(1) Negotiated Contract Cost is that cost on which contractual agreement has been reached. For an incentive contract, it is the definitized contract target cost plus/minus the value of changes which have been priced and incorporated into the contract through contract change order or supplemental agreement. For fixed-fee contracts, it is the negotiated estimated cost. Changes to the estimated cost will consist only of the formal contract modifications or change orders or change in the contract statement of work, not for cost growth, and
	 	(2) Estimated cost of authorized, unpriced work is the estimated cost (excluding fee or profit) for that work for which written authorization has been received, but for which definitized contract prices have not been incorporated into the contract through supplemental agreement.
	 	 
	Control Account	A management control point at which actual costs can be accumulated and compared to budgeted cost for work performed. A control account is a natural control point for cost/schedule planning and control since it represents the work assigned to one responsible organizational element on one contract work breakdown structure (CWBS) element.
	 	 
	Control Account Manager (CAM)	A member of a functional organization responsible for task performance detailed in a Control Account and for managing the resources authorized to accomplish the tasks.

 

    	11

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Control Account Plan (CAP) Report	A CAP report is a timephased report which reflects all the work and effort to be performed in a control account. The CAP report will reflect the hours and dollars by element of cost (labor, subcontract, ODC, etc).
	 	 
	Contract Performance Report (CPR)	The monthly report submitted to the customer showing the current, cumulative and at completion status, the performance measurement baseline, manpower loading, and a narrative explanation of significant program variances.
	 	 
	Contract Target Cost	The dollar value (excluding fee or profit) negotiated in the original contract plus the cumulative cost (excluding fee or profit) applicable to all definitized changes to the contract. It consists of the estimated cost negotiated for a cost plus fixed fee contract and the definitized target cost for an incentive contract. The contract target cost does not include the value of authorized/un-negotiated work, and is thus equal to the contract budget base only when all authorized work has been negotiated/definitized.
	 	 
	Cost Performance Index (CPI)	An efficiency rating reflecting a project’s budget performance - either over or under. Measured as a ratio of the budgeted value of work accomplished versus the actual costs expended for a given project time period. The formula for CPI is BCWP/ACWP.
	 	 
	Discrete Effort	Program effort that has a measurable output, product or service.
	 	 
	Direct Costs	Those costs (labor, material, etc.) that can be reasonably and consistently related directly to service performed on a unit of work, and are charged directly to the contract, without distribution to an overhead unit.

 

    	12

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Earned Value	See Budgeted Cost for Work Performed (BCWP)
	 	 
	Earned Value Management System (EVMS)	A project management system utilized for measuring project progress in an objective manner. Combines measurements of scope, schedule, and cost in a single integrated system.
	 	 
	Estimate at Completion (EAC)	A value (expressed in dollars and/or hours) developed to represent a realistic appraisal of the final cost of tasks when accomplished. It’s the sum of direct & indirect costs to date plus the estimate of costs for all authorized Work remaining. The EAC ACWP ± the Estimate-to-Complete.
	 	 
	Estimate to Completion (ETC)	A value (expressed in dollar and/or hours) developed to represent a realistic appraisal of the cost of the work still required to be accomplished in completing a task.
	 	 
	Indirect Costs	Represents those costs, because they are incurred for common or joint objectives, are not readily subject to treatment as direct costs. (See overhead).
	 	 
	Integrated Baseline Review (IBR)	An Integrated Baseline Review (IBR) is a formal review led by the Government Program Manager and Technical Support Staff. An IBR is conducted jointly with the Government and their Contractor counterparts.
	 	 
	 	The purpose of an IBR is to: verify the technical content of the Performance Measurement Baseline (PMB); assess the accuracy of the related resources (budgets) and schedules; identify potential risks.
	 	 
	Integrated Master Plan (IMP)	The overall program plan including the work definition, technical approach, performance criteria, and completion criteria.

 

    	13

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Integrated Master Schedule (IMS)	The IMS expands the IMP to the work planning level. It defines the tasks, their durations, milestones, milestone dates which relate to the IMP completion criteria, and interdependencies required to complete the program. The IMP and 1MS are used to track and execute the program.
	 	 
	Integrated Product Team (IPT)	A grouping of project personnel along project objective lines rather than along organizational lines. Integrated Product Teams are work teams that represent a transition from a functional organization structure to a multi-functional project objective arrangement.
	 	 
	Internal Replanning	Replanning actions performed by the program for remaining effort within the recognized total allocated budget.
	 	 
	Level of Effort (LOE)	Work that does not result in a final product, e. g., liaison, coordination, follow-up, or other support activities, and which cannot be effectively associated with a definable end product process result. It is measured only in terms of resources actually consumed within a given time period.
	 	 
	Management Reserve (MR)	An amount of the total Contract Budget Base (CBB) withheld for management control purposes rather than designated for the accomplishment of a specific task or set of tasks. It is not a part of the Performance Measurement Baseline.
	 	 
	Negotiated Contract Target Cost	The estimated cost negotiated in a Cost Plus Award Fee (CPAF), Cost Plus Fixed Fee (CPFF), Cost Plus Incentive Fee (CPIF) or Fixed Price Incentive Fee (FPIF) contract.
	 	 
	Original Budget	The budget established at, or near, the time the contract was signed, based on the negotiated contract cost.

 

    	14

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Overhead	Indirect labor and material, supplies and services costs and other charges, which cannot be consistently identified with individual programs.
	 	 
	Other Direct Costs	A group of accounting elements which can be isolated to specific tasks, other than labor and material. Included in ODC are such items as travel, computer time, and services
	 	 
	Performance Measurement Baseline (PMB)	The time-phased budget plan against which contract performance is measured. It is formed by the budgets assigned to scheduled Control Accounts and the allocation of overhead costs. For future effort, not planned to the Control Account level, the performance measurement baseline also includes budgets assigned to higher level WBS elements, and undistributed budgets. It equals the total assigned budget less management reserve.
	 	 
	Performing Organization	A defined unit within the program organization structure, which applies the resources to performs the authorized scope of work.
	 	 
	Planning Package	A logical aggregation of far term work within a Control Account that can be identified and budgeted but not yet defined into Work Packages.
	 	 
	Reprogramming	Replanning of the effort remaining in the contract, resulting in a new budget allocation which exceeds the contract budget base. The resulting baseline is called an Over Target Baseline (OTB).
	 	 
	Responsible Organization	A defined unit within program’s organization structure that is assigned responsibility for accomplishing specific tasks.

 

    	15

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Risk Register	Is a tool commonly used in project planning and organizational risk assessments. It is often referred to as a Risk Log. It is used for identifying, analyzing and managing risks.
	 	 
	Schedule Performance Index (SPI)	An efficiency rating reflecting how quickly or slowly project work is progressing. Measured as a ratio of work accomplished versus work planned for a given period of time. The formula for SP1 is BCWP/BCWS.
	 	 
	Significant Variances	Those differences between planned and actual cost and schedule performance which require further review, analysis, or action. Appropriate thresholds are established as to the magnitude of variances which will require variance analysis.
	 	 
	Statistical Estimate at Completion	Is a single point estimate that can be quickly prepared and used to test the reasonableness of the current cost estimates and budget and to indicate when a comprehensive EAC should be prepared
	 	 
	To Complete Performance Index (TCPI)	An efficiency rating that provides a projection of the anticipated performance required to achieve the EAC. TCPI indicates the future required cost efficiency needed to achieve a target EAC (Estimate At Complete). Any significant difference between TCPI and the CPI needed to meet the EAC should be accounted for by management in their forecast of the final cost.
	 	 
	Total Allocated Budget (TAB)	The sum of all budgets allocated to the contract. Total allocated budget consists of the performance measurement baseline and all management reserve. The total allocated budget will reconcile directly to the Contract Budget Base (CBB). Any differences will be documented as to quantity and cause.

 

    	16

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Undistributed Budget (UB)	Budget applicable to contract effort which has not yet been identified to WBS elements at or below the lowest level of reporting to the Government.
	 	 
	Variance Analysis Report (VAR)	The internal report completed by the Control Account Manager and submitted, through the Intermediate Manager, to the program manager for those Control Accounts which have variances in excess of established thresholds.

 

    	17

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Variances	(See Significant Variances).
	 	 
	Work Authorization Document (WAD)	A form used to formally authorize and budget work to the Control Account Manager. This document must include, as a minimum, the Control Account number, Statement of Work, scheduled start and finish dates, budget, and the identity of the CAM. It must be approved by Intermediate Manager, and be agreed to by the Control Account Manager.
	 	 
	Work Breakdown Structure (WBS)	A product-oriented, family-tree composed of hardware, software, services, data and facilities which results from system engineering efforts. A work breakdown structure displays and defines the product(s) to be developed and/ or produced and relates the elements of work to be accomplished to each other and to the end product.
	 	 
	 	(1) Program WBS. The work breakdown structure that covers the acquisition of a specific defense material item and is related to contractual effort. A program work breakdown structure includes all applicable elements consisting of at least the first three levels of the work breakdown structure and extended by the program manager and /or contractor(s). A program work breakdown structure has uniform element terminology, definition, and placement in the family tree structure.
	 	 
	 	(2) Contract WBS (CWBS) The complete WBS for a contract, developed and used by a contractor within the guidelines of MIL-Handbook 881 (latest revision) or NASA WBS Handbook (insert reference) or other customer guidelines and according to the contract work statement. It includes the approved work breakdown structure for reporting purposes and its discretionary extension to the lower levels by the contractor, in accordance with MIL-Handbook 881 and the contract work statement. It includes all the elements for the products (hardware, software, data, or services) which are the responsibility of the contractor.

 

    	18

    	 

    

 

7 Principles of EVM Tier 2 System Implementation
Intent Guide

 

	Work Packages	Detailed short-span jobs, or material items, identified by the contractor for accomplishing work required to complete the contract. A Work Package has the following characteristics.
	 	 
	 	1.       It represents units of work at levels where work is performed.
	 	 
	 	2.        It is clearly distinguishable from all other work packages.
	 	 
	 	3.        It is assignable to a single organizational element.
	 	 
	 	4.        It has scheduled start and finish dates and, as applicable, interim milestones, all of which are representative of physical accomplishment.
	 	 
	 	5.        It has a budget or assigned value expressed in terms of dollars, man-hours or other measurable units.
	 	 
	 	6.        Its duration is limited to a relatively short span of time or it is subdivided by discrete value milestones to facilitate the objective measurement of work performed.
	 	 
	 	7.        It is integrated with detailed engineering, manufacturing, or other schedules.
	 	 
	Work Package Budgets	Resources which are formally assigned by the CAM to accomplish a Work Package, expressed in dollars and/or hours.

 

    	19

    	 

    
 

		

 

Attachment 10

 

Communication Management Plan

Biomedical Advanced Research and Development
Authority

(BARDA)

Broad Spectrum Antimicrobial Program

Chimerix Contract

Number HHSO100201100013C

330 Independence Ave. SW

Washington, DC 20201

 

    	 

    	 

    

 

BSA Communications Management Plan

 

Introduction:

 

The purpose of the Broad Spectrum Antimicrobial (BSA) communications
management plan is to define the communication requirements for the project and outline how BARDA and the Contractor will distribute
information. The communications management plan defines the following:

		o	Communication requirements based on roles,

		o	What information will be communicated,

		o	How the information will be communicated,

		o	When will information be distributed,

		o	Who does the communication,

		o	Who receives the communication,

 

This BSA communications management plan sets the communications
framework for this project. It will serve as a guide for communications throughout the period of performance and will be updated,
as communication needs change. This plan identifies and defines the roles of persons involved in the project. The BSA communications
management plan provides an in-depth guide on how the program plans to conduct meetings between stakeholders to ensure a successful
outcome. A project team directory is below to provide contact information for all stakeholders directly involved in the project.

 

Communications Management Approach

 

The BARDA Project Officer (PO) and Contracting Officer (CO)
and Contractor’s Program Manager will take a proactive role in ensuring effective communication between all parties on this
contract. The goal of all parties is to maintain a transparent communicative relationship that fosters the sharing of information
to relevant Stakeholders in a timely and efficient manor to facilitate the successful outcome of the programs mutual objectives,
the development of CMX-001 as a novel broad spectrum antibiotic for the therapeutic treatment of individuals exposed to biodefense
threat agents. This communication plan documents the communication requirements for all parties that will support the implementation
of this contract. The Communications Matrix will provide a guide for the communication process, including:

		o	What type of information Stakeholders will communicate,

		o	Who is responsible for communicating relevant information,

		o	When should stakeholders communicate program relevant information,

 

Roles

 

Project Sponsor: BSA Branch Chief

 

The project sponsor is responsible for overseeing the BSA contracts
and the champion of the project and has authorized the project by signing the project charter. This person is responsible for the
funding of the project and is ultimately responsible for its success. Since the Project Sponsor is at the executive level, communications
should be presented in summary format unless the Project Sponsor requests more detailed communications. Communication from the
Contractor to the Project Sponsor should flow through the BARDA

 

    	2

    	 

    

 

BSA Communications Management Plan

 

 

Contracting Officer or Project Officer through the appropriate
chain of command to the Project Sponsor, unless otherwise indicated by the Project Sponsor.

 

Contract Officer

 

The BARDA Contract Officer (CO) oversees the project at the
program level and is responsible for all contract related issues. The CO is the United State Government’s representative
that has the legal authority to bind BARDA to a contract with the Contractor. The CO will communicate directly with the Contractor
and shall be included on all communications between the Contractor and BARDA staff. At any time, if the Contractor shall have contractual
or programmatic concerns regarding the contract, scope of work, or any other issues, the Contractor should immediately address
all concerns directly to the CO.

 

Project Officer

 

The BARDA Project Officer (PO) [and/or Contracting Officer’s
Technical Representative (COTR)] oversees the project at the program level and is responsible for the technical implementation
of the BSA contract. The PO is responsible for managing the cost, schedule, and performance parameters for the contract. The PO
will be in regular communication with Contractor’s POC to ensure the contract is maintaining cost, schedule, and performance
objectives.

 

The PO manages day-to-day resources, provides project guidance,
monitors, and reports on the projects metrics as defined in the Project Management Plan. The PO is responsible for the execution
of the project and is the primary communicator for the project.

 

The PO is responsible for briefing the Project Sponsor and subsequent
leadership levels. The PO is the individual responsible for communicating program progress, program risk, and contract relevant
issues raised by the Product Coordination Team charter, stakeholders, and/or Contractor.

 

Program Manager

 

The BARDA Program Manager (PM) a contractor for BARDA will support
the Project Officer. The PM may communicate with the contractor on program management related issues on behalf of the BARDA PO.
The intent of the communication is to provide information and is not to be taken as a directive.

 

Key Stakeholders and the Product Coordination Team

 

The BARDA Branch Chief responsible for overseeing the BSA contract
signed a Product Coordination Team (PCT) Charter, identifying internal and external BARDA program members and stakeholders supporting
this contract. The BARDA BSA PCT will meet regularly to review the project. The PO will chair the PCT. Based on their technical
or program management expertise, each stakeholder and PCT member will play a key role. All BARDA and USG Team members will work
to communicate all activities through the PO.

 

    	3

    	 

    

 

BSA Communications Management Plan

 

Members of the PCT may at times work directly with other stakeholders
and/or the Contractor with consent of the CO and PO. In such situations, the CO, PO, and Contractor POC shall be included on all
communications. It is important to note that the intent of this communication is to provide information and is not to be taken
as a directive by the Contractor. If the recipient(s) believe(s) the information provided herein may be construed as a directive,
the recipient(s) should disregard that portion of the communication and contact the BARDA BSA Contracting Officer.

 

Contractor Liaison

 

The Contractor has identified a BARDA Liaison (BL) as a primary
POC and alternative POC (in the advent that the primary POC is unavailable) to communicate directly with the BARDA CO and PO. The
Contractor BL will work closely with the CO and BARDA PO to manage the implementation of this contract. This communication shall
be transparent and informative for all entities. Communication from the Contractor to BARDA should flow through the Contractor
BL to the CO and PO to ensure proper coordination within BARDA and the Contractor’s organization.

 

The Contractor’s BL is responsible for the implementation
of the scope of work agreed to under the contract. The Contractor’s BLprovide reports on the project’s metrics
as defined in the Project Management Plan. As the person responsible for the implementation of the project, the Contractor’s
BL is the primary communicator for the Contractor and responsible for distributing information according to the Communications
Management Plan.

 

Food and Drug Administration

 

The Food and Drug Administrations’, Center for Drug Evaluation
and Research (CDER) is the regulatory authority overseeing the development of the BSA Medical Countermeasure. CDER plays a critical
role in the success of this contract between BARDA and the Contractor. In an effort to provide open communication, the communications
management plan encourages the sharing of communications between the FDA, BARDA, and the Contractor. The communication management
plan does not prevent either BARDA or the Contractor from engaging CDER.

 

Project Team Directory

 

	Role	Name	Email	Phone
	Project Sponsor	[...***...]	[...***...]	[...***...]
	Contracting Officer	[...***...]	[...***...]	[...***...]
	Project Officer/PCT Chair	[...***...]	[...***...]	[...***...]
	Program Manager (Contractor)	[...***...]	[...***...]	[...***...]
	Contractor POC/BARDA Liaison	[...***...]	[...***...]	[...***...]
	Alternative Contractor	 	 	 

 

***Confidential Treatment Requested

 

    	4

    	 

    

 

BSA Communications Management Plan

 

Communication Deliverables and Procedures

 

The Contract Deliverables List (reference) outlines the communication
requirements and expectations for various types of meetings and program deliverables.

 

Guidelines for Meetings

 

Meeting Agenda

 

The Contractor will send the meeting agenda to the PO in advance
of the meeting as outlined in the Contract Deliverables List. The agenda will include ongoing action items, requested participants
and provide a brief agenda for the meeting. The BARDA PO will review and finalize the meeting agenda and distribute accordingly.

 

Meeting Minutes

 

The Contractor will draft meeting minutes and forward to the
PO within a specific amount of time as outlined in Contract Deliverables List. The meeting minutes will provide a synopsis of the
meeting, list of participants, highlight decisions made, reference supportive material and include the status of all open and closed
action items and a parking lot list. The BARDA PO will review and finalize meeting minutes.

 

Action Items

 

The meeting agenda and minutes will record action items. Action
items will include the action item, owner of the action item, and the anticipated date of completion. Meetings will start with
a review of the status of all action items from previous meetings and end with a review of all new action items resulting from
the meeting. The review of the new action items will include identifying the owner for each action item and setting a date for
completing the action item.

 

Meeting Chair - BARDA Project Officer

 

The meeting chair is responsible for distributing the meeting
agenda, facilitating the meeting and distributing the meeting minutes. As the meeting chair, the BARDA Project Officer will ensure
that the meeting starts and ends on time and that all presenters adhere to their allocated time frames. The Contractor will be
responsible for developing the initial agenda, drafting the minutes, capturing action items, and following up on meeting outcomes.

 

Note Taker: Contractor

 

The Contractor is the note taker responsible for documenting
the status of all meeting items, maintaining a parking lot item list and taking notes of anything else of importance during the
meeting. The note taker will give a copy of their minutes to the BARDA CO for final approval of meeting minutes.

 

    	5

    	 

    

 

BSA Communications Management Plan

 

Parking Lot

 

The parking lot is a tool used by the facilitator to record
and defer items which are not on the meeting agenda but that, merit further discussion later or through another forum.

A parking lot record should identify an owner for the item,
as this person will he responsible for ensuring follow-up. The Contractor will include a parking lot list in the meeting minutes.

 

    	6

    	 

    

 

Attachment 11

Non-Clinical Terms of Award

 

These Non-Clinical Terms of Award detail an agreement between
the Biomedical Advanced Research and Development Authority (BARDA) and the Awardee (i.e., the Contractor); they apply to all grants
and contracts that involve non-clinical research.

 

Draft protocols for each nonclinical study funded by BARDA will
be submitted to BARDA for review and comment. Contractor will address in writing its consideration of BARDA comments prior to submission
of protocols to the FDA for comment.

 

BARDA shall have rights to all protocols, data resulting from
execution of these protocols, and final reports, funded by BARDA under this contract, as defined in Rights in Data Clause
in FAR 52.227-14, Alternative II. BARDA reserves the right to request that the Awardee provide any contract deliverable in a non-proprietary
form, to ensure BARDA has the ability to review and distribute the deliverables, as BARDA deems necessary.

 

A.Safety and Monitoring Issues

 

PHS Policy on Humane Care and Use of Laboratory Animals

 

Before award and then with the annual progress report, the Awardee
must submit to BARDA a copy of the current Institutional Animal Care and Use Committees (IACUC) documentation of continuing review
and approval and the Office of Laboratory Animal Welfare (OLAW- National Institutes of Health) Federal Wide Assurance (FWA) number
for the institution or site.

 

If other institutions are involved in the research (e.g., a
multicenter trial or study), each institution’s IACUC must review and approve the protocol. They must also provide BARDA
initial documentation and documentation of continuing review and approval and FWA number.

 

The Awardee must ensure that the application as well as all
protocols are reviewed by the performing institution’s IACUC.

 

To help ensure the safety of animals used in BARDA funded studies,
the Awardee must provide BARDA copies of documents related to all major changes in the status of ongoing protocols for studies
funded by BARDA, including the following:

 

		o	All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid.

		o	All material changes in IACUC policies and procedures, identified by version number, date, and all required signatories (if
applicable)

		o	Termination or temporary suspension of the study(ies) for regulatory issues

		o	Termination or temporary suspension of the protocol.

		o	Any change that is made in the specific IACUC approval for the indicated study(ies).

		o	Any other problems or issues that could affect the scientific integrity of the study(ies), i.e. fraud, misrepresentation, misappropriation
of funds, etc.

 

Awardees must notify BARDA by email or fax of any of the above
changes within five business days from the time awardee becomes aware of such changes, followed by a letter signed by the institutional
business official, detailing notification of the change of status to the local IACUC and a copy of any responses from the IACUC.

 

    	 

    	 

    

 

If a non-clinical protocol has been reviewed by an institutional
biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Awardee must provide information about the initial
and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 

Non-Clinical Data and Safety Monitoring Requirements

 

BARDA strongly recommends continued safety monitoring for all
non-clinical studies of investigational drugs, devices, or biologics. FDA expects non-clinical studies to include safety in addition
to efficacy. Awardee should consider evaluation of clinical relevant safety markers in the pivotal and non-pivotal, non-clinical
studies.

 

BARDA will provide input to the Awardee decisions regarding
the type and extent of safety data accrual to be employed before the start of efficacy or safety studies.

 

The Awardee shall inform BARDA of any upcoming site visits and/or
audits of CRO facilities funded under this effort. BARDA reserves the right to accompany the awardee on site visits and/or audits
of CROs as BARDA deems necessary.

 

B.BARDA Review Process Before Non-Clinical Study Execution
Begins

 

BARDA is under the same policy-driven assurances as NIH in that
it has a responsibility to obtain documentation concerning mechanisms and procedures that are in place to protect the safety and
welfare of animals used in BARDA funded non-clinical trials. Therefore, before study execution, the Awardee must provide the following
(as applicable) for review by BARDA:

 

		o	IACUC approved (signed) non-clinical research protocol identified by version number, date, or both, including details of study
design, euthanasia criteria, proposed interventions, and exclusion criteria.

 

		o	Documentation of IACUC approval, including OLAW FWA number, IACUC registration number, and IACUC name.

 

		o	Awardee should reduce the number of animals required for a study using power of statistics

 

		o	Plans for the management of side effects, rules for interventions and euthanasia criteria

 

		o	Procedures for assessing and collecting safety data

 

		o	If a study is contracted through CRO(s), work orders and service agreements the Awardee shall assure that an integrated safety
documentation plan is in place for the study site, pharmacy service records on the dosing material to be used and excipients, and
laboratory services (including histopathology).

 

		o	Documentation that the Awardee or CRO and all staff responsible for the conduct of the research have received required training
in the protection and handling of animals

 

		o	Purchasing of animals and/or other supplies for non-clinical studies funded in part or in whole by BARDA requires written approval
by the Contracting Officer in accordance with the contract. The Awardee must have the ability to return/re-sell animals, at purchase
price, to distributor or a third party, in the event that the Contracting Officer Authorization is not granted.

 

		o	Provide justification for whether studies require good laboratory practice (GLP) conditions

 

		o	Provide justification for whether studies will be classified as non-pivotal or pivotal studies

 

Non-Clinical Studies not being submitted to the FDA prior
to execution:

 

Awardee will submit proposed protocols to BARDA at least 30
days prior to study execution for study protocols that are not being submitted to the FDA. BARDA staff comments will be forwarded
to the Awardee within 8 business days of receipt of the above information provided. The Awardee must address in writing its consideration
of all study design, safety, regulatory, ethical, and conflict of interest concerns raised by BARDA . After receiving the documentation,
the BARDA Contracting Officer will provide a written Contract Officer Authorization (COA) Letter to

 

    	 

    	 

    

 

the Awardee. This COA provides
authorization to the Awardee to execute the specific nonclinical study funded in part or in whole by BARDA.

 

Non-Clinical Studies that will be submitted to the FDA prior
to execution:

 

BARDA staff continents will be forwarded to the Awardee within
8 business days of receipt of the above information. The Awardee must address in writing its consideration of all study design,
safety, regulatory, ethical, and conflict of interest concerns raised by BARDA, However the FDA shall have final authority over
such protocols and protocol amendments. After receiving the documentation, the BARDA Contracting Officer will provide a Contracting
Officer Authorization (COA) Letter authorizing the execution of the study.

 

Final decisions regarding ongoing safety reporting requirements
for research not performed under an Investigational New Drug Application (IND) or investigational device exemption (IDE) must be
made by the Awardee in consultation with BARDA.

 

References

		o	Public Health Service Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/InvestigatorsNeed2Know.pdf)

		o	USDA Animal Welfare Act 

(http://awic.nal.usda.gov/nal_display/index.php?info_center=3&tax_level=3&tax_subject=182&top

ic_id=1118&Ievel3_d=6735&level4_id=0&level5_id=0&placement_default=0)

 

    	 

    	 

    

 

Clinical Terms of Award

 

These Clinical Terms of Award detail an agreement between the
Biomedical Advanced Research and Development Authority (BARDA) and the Awardee; they apply to all grants and contracts that involve
clinical research.

 

Draft protocols for each clinical study funded by BARDA will
be submitted to BARDA for review and comment. Contractor will address in writing its consideration of BARDA comments prior to submission
of protocols to the FDA for comment.

 

BARDA shall have rights to all protocols, data generated from
the execution of those protocols, and final reports, funded by BARDA under this contract, as defined in Rights in Data Clause in
FAR 52.227-14, Alternative II. BARDA reserves the right to request that the Awardee provide any contract deliverable in a non-proprietary
form, to ensure BARDA has the ability to review and distribute the deliverables, as BARDA deems necessary.

 

A.Safety and Monitoring Issues

 

Institutional Review Board (IRB) or independent Ethics Committee
(IEC) Approval

 

Before award and then with the annual progress report, the Awardee
must submit to BARDA a copy of the current IRB or IEC approved informed consent document, documentation of continuing review and
approval and the Office of Human Research Protections (OHRP) FWA number for the institution or site.

 

If other institutions are involved in the research (e.g., a
multicenter clinical trial or study), each institution’s IRB or IEC must review and approve the protocol. They must also
provide BARDA initial and annual documentation of continuing review and approval, including the current approved informed consent
document and FWA number.

 

The Awardee must ensure that the application as well as all
protocols are reviewed by their IRB or IEC.

 

To help ensure the safety of participants enrolled in BARDA
funded studies, the Awardee must provide BARDA copies of documents related to all major changes in the status of ongoing protocols
for studies funded by BARDA, including the following:

 

		o	All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid.

 

		o	All changes in informed consent documents, identified by version number, date, or both and dates it is valid.

 

		o	Termination or temporary suspension of patient accrual.

 

		o	Termination or temporary suspension of the protocol.

 

		o	Any change in IRB approval.

 

		o	Any other problems or issues that could affect the participants in the studies.

 

Awardees must notify BARDA through the Contracting Officer’s
Technical Representative (COTR) or Contracting Officer (CO) of any of the above changes within five working days by email or fax,
followed by a letter signed by the institutional business official, detailing notification of the change of status to the local
IRB and a copy of any responses from the IRB or IEC.

 

If a clinical protocol has been reviewed by an institutional
biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Awardee must provide information about the initial
and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 

    	 

    	 

    

 
 

 

Data and Safety Monitoring Requirements

 

BARDA strongly recommends independent safety monitoring for
clinical trials of investigational drugs, devices, or biologics; clinical trials of licensed products; and clinical research of
any type involving more than minimal risk to volunteers. Independent monitoring can take a variety of forms, Phase III clinical
trials must be reviewed by an independent data and safety monitoring board (DSMB); other trials may require DSMB oversight as well.
The Awardee shall inform BARDA of any upcoming site visits and/or audits of CRO facilities funded under this effort. BARDA reserves
the right to accompany the awardee on site visits and/or audits of CROs as BARDA deems necessary.

 

A risk is minimal where the probability and magnitude of harm
or discomfort anticipated in the proposed research are not greater than those ordinarily encountered in daily life or during the
performance of routine physical or psychological examinations or tests. For example, the risk of drawing a small amount of blood
from a healthy individual for research purposes is no greater than the risk of doing so as part of a routine physical examination
(45 CFR 46.102l).

 

Final decisions regarding the type of monitoring to be used
must be made by the Awardee before enrollment starts in consultation with BARDA. Discussions with the responsible BARDA COTR regarding
appropriate safety monitoring must occur before patient enrollment begins and may include discussions about the appointment of
one of the following.

 

		o	Independent Safety Monitor - a physician or other appropriate expert who is independent of the study and available in
real time to review and recommend appropriate action regarding adverse events and other safety issues.

 

		o	Independent Monitoring Committee (IMC) or Safety Monitoring Committee (SMC) - a small group of independent investigators
and biostatisticians who review data from a particular study.

 

		o	Data and Safety Monitoring Board - an independent committee charged with reviewing safety and trial progress and providing
advice with respect to study continuation, modification, and termination. All phase III clinical trials must be reviewed by a DSMB;
other trials may require DSMB oversight as well. Please refer to: NIAID Principles for Use of a Data and Safety Monitoring Board
(DSMB) For Oversight of Clinical Trials Policy.

 

When a monitor or monitoring board is organized, a description
of it, its charter or operating procedures (including a proposed meeting schedule and plan for review of adverse events), and roster
and curriculum vitae from all members must be submitted to BARDA before enrollment starts.

 

Additionally, the Awardee must submit written summaries of all
reviews conducted by the monitoring group to the BARDA within 30 days of reviews or meetings.

 

		B.	BARDA Protocol Review Process Before Patient Enrollment
Begins

 

BARDA has a responsibility to obtain documentation concerning
mechanisms and procedures that are in place to protect the safety of participants in BARDA-supported clinical trials. Therefore,
before patient accrual or participant enrollment, the Awardee must provide the following (as applicable) for review by BARDA.

 

		o	IRB or IEC approved clinical research protocol identified by version number, date, or both, including details of study design,
proposed interventions, patient eligibility, and exclusion criteria.

 

		o	Documentation of IRB or IEC approval, including OHRP FWA number, IRB or IEC registration number, and IRB or IEC name.

 

		o	IRB or IEC approved informed consent document, identified by version number, date, or both and date it is valid.

 

		o	Plans for the management of side effects.

 

		o	Procedures for assessing and reporting adverse events.

 

    	 

    	 

    

 

		o	Plans for data and safely monitoring (see A above) and monitoring of the clinical study site, pharmacy, and laboratory.

 

		o	Documentation that the Awardee and all study staff responsible for the design or conduct of the research have received Good
Clinical Practice (GCP) training in the protection of human subjects.

 

BARDA staff comments will be forwarded to the Awardee within
8 business days of receipt of the above information. The Awardee must address in writing its consideration of BARDA COTR comments.
However the FDA shall have final authority over such protocols and protocol amendments. After receiving the documentation, the
BARDA Contracting Officer will provide a Contracting Officer Authorization (COA) Letter authorizing the execution of the study.
This COA provides authorization to the awardee to execute the specific clinical study funded in part or in whole by BARDA.

 

		C.	Investigational New Drug or Investigational Device
Exemption Requirements

 

Consistent with federal regulations, clinical research projects
involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices
for a purpose other than that for which they were licensed) in humans under a research protocol must he performed under a Food
and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

 

Exceptions must be granted in writing by FDA. If the proposed
clinical trial will be performed under an IND or IDE, the Awardee must provide BARDA with the name and institution of the IND or
IDE sponsor, the date the IND or IDE was filed with FDA, the FDA IND or IDE number, any written comments from FDA, and the written
responses to those comments.

 

Unless FDA notifies Awardee otherwise, the Awardee must wait
30 calendar days from FDA receipt of an initial IND or IDE application before initiating a clinical trial.

 

The Awardee must notify BARDA if the FDA places a study on clinical
hold and provide BARDA any written comments from FDA, written responses to the comments, and documentation in writing that the
hold has been lifted.

 

The Awardee must not use grant or contract funds during a clinical
hold to fund clinical studies that are on hold.

 

Required Time-Sensitive Notification

 

Under an IND or IDE, the sponsor must provide FDA safely reports
of serious adverse events. Under these Clinical Terms of Award, the Awardee must submit copies to the responsible BARDA Project
Officer or the Contracting Officer’s technical representative (COTR) as follows:

 

		o	Expedited safety report of unexpected or life-threatening experience or death — A copy of any report of unexpected
or life-threatening experience or death associated with the use of an IND drug, which must be reported to FDA by telephone or fax
as soon as possible but no later than seven days after the IND sponsor’s receipt of the information, must be submitted to
the BARDA program officer or the contracting officer’s technical representative within 24 hours of FDA notification.

 

		o	Expedited safety reports of serious and unexpected adverse experiences — A copy of any report of unexpected and
serious adverse experience associated with use of an IND drug or any finding from tests in laboratory animals that suggests a significant
risk for human subjects, which must be reported in writing to FDA as soon as possible but no later than 15 days after the IND sponsor’s
receipt of the information, must be submitted to the BARDA Project Officer or the Contracting Officer’s Technical Representative
within 24 hours of FDA notification.

 

		o	IDE reports of unanticipated adverse device effect — A copy of any reports of unanticipated adverse device effect
submitted to FDA must be submitted to the BARDA Project Officer or the Contracting Officer’s Technical Representative within
24 hours of FDA notification.

 

    	 

    	 

    

 

		o	Expedited safety reports — should be sent to the BARDA Project Officer or the Contracting Officer’s Technical
Representative concurrently with the report to FDA.

 

		o	Other adverse events documented during the course of the trial should be included in the annual IND or IDE report and reported
to the BARDA annually.

 

In case of problems or issues, the BARDA Project Officer or
the Contracting Officer’s Technical Representative will contact the Awardee within 10 working days by email or fax.

 

		o	Safety reporting for research not performed under an IND or IDE

 

Final decisions regarding ongoing safety reporting requirements
for research not performed under an IND or IDE must be made by the Awardee in consultation with the BARDA Contracting Officer’s
Technical Representative.

 

    	 

    	 

    

  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	1

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0001	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
    MERIDIAN P	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	 

	E.
    IMPORTANT:         Contractor       x
    is not.          o is
    required to sign this document and return                  
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of
        this modification is to delete [...***...] to Article G.3. KEY PERSONNEL under contract number HHSO100201100013C.

        B.    This is a unilateral
        no cost modification. The total amount and all other terms and conditions of contract number HHSO100201100013C remain
        unchanged.

         

        Period of Performance:
        02/16/2011 to 02/15/2016

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME AND TITLE OF CONTRACTING OFFICER
    (Type or print)
	 	 
	 	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		 8/16/11
	 	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

 

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0002	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
    MERIDIAN P	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	 

	E.
    IMPORTANT:         Contractor       x
    is not.          o is
    required to sign this document and return                  
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The
purpose of this modification is to correct an administrative error in Modification 0001 under Contract Number HHSO100201100013C.
In Modification 0001 under Contract Number HHSO100201100013C under paragraph B, the incorrect Period of Performance was stated
as “Period of Performance: 2/16/2011 to 2/15/2016.” The statement “Period of Performance: 2/16/2011 to 2/15/2016.”
Under Modification 0001 under Contract Number HHSO100201100013C is hereby deleted. The correct Period of Performance for Contract
Number HHSO100201100013C under this Modification is 2/16/2011 to 2/15/2012.

         

        B.    This is a no cost modification. The total amount and all other terms and conditions of

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME AND TITLE OF CONTRACTING OFFICER
    (Type or print)
	 	 
	 	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		11/10/11

	 	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

    	 

    	 

    

 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE         OF
	 	HHSO100201100013C/0002	2	2

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	Contract number HHSO100201100013C remain unchanged.	 	 	 	 
	 	 	 	 	 	 
	 	Period of Performance: 02/16/2011 to 02/15/2012	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

    	 

    	 

    

 

 

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0003	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington,
        DC 20201

         

	8. NAME
                                                                   AND ADDRESS OF CONTRACTOR (No., street, county, State and
                                                                   ZIP Code)

	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
    MERIDIAN P	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral:
    Mutual Agreement of the Parties.
	 	 

	E.
IMPORTANT:         Contractor       £
is not.          S is required to sign this document and return         1         
copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The
        purpose of this modification is to incorporate the following changes into contract number HHSO100201100013C:

         

        1.    The
        period of performance for the base performance segment CLIN 0001 of contract number HHSO100201100013C is hereby changed
        from 16 February 2011 through 15 February 2012 to 16 February 2011 through 15 April 2012, at no additional cost to the
        Government.

         

        2.    The
        period of performance for the Option 1 performance segment CLIN 0002 of contract number HHSO100201100013C is hereby changed
        from 16 February 2012 through 15 February 2013

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME AND TITLE OF CONTRACTING OFFICER
    (Type or print)
	 	 
	KENNETH
                                                                                                                        I. MOCH,
                                                                                                                        CHIEF
                                                                                                                        EXECUTIVE
                                                                                                                        OFFICER

	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		11/30/11

	/s/
                                                                                                  Kenneth I. Moch

	11/30/11

	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

  

    	 

    	 

    

 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE       OF
	 	HHSO100201100013C/0003	2	2

 

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

 

	
        ITEM NO.

        (A)
	
        SUPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	to 16 April 2012 through 15 April 2013, at no additional cost to the Government. If exercised by a unilateral contract modification, the option exercise date for the Option 1 performance segment CLIN 0002 will be 16 April 2012.	 	 	 	 
	 	 	 	 	 	 
	 	B.      This is a no cost modification. The total amount and all other terms and conditions of contract number HHSO100201100013C remain unchanged.	 	 	 	 
	 	 	 	 	 	 
	 	Period of Performance: 02/16/2011 to 04/15/2012	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

 

    	 

    	 

    

  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROJECT NO. (if applicable)
	0004	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        DC 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W., Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No., street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
    MERIDIAN P	 	 
	2505 MERIDIAN PKWY, STE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	 

	E.
    IMPORTANT:         Contractor       x
    is not.          o is
    required to sign this document and return                  
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is to change the Contracting Officer’s Technical Representative
(COTR) under Contract number HHSO100201100013C:

         

        1.    All references throughout Contract Number HHSO100201100013C concerning the COTR, Tyler Merkeley and all
related information such as agency, address, telephone and email, etc. is hereby deleted and replaced with:

         

        

Claiborne O. Hughes

Contracting Officer’s Technical
Representative (COTR)

Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME AND TITLE OF CONTRACTING OFFICER
    (Type or print)
	 	 
	 	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		2/10/12

	 	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

  

    	 

    	 

    

  

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE         OF
	 	HHSO100201100013C/0004	2	2

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
        Biomedical Advanced Research and Development Authority
        (BARDA)

        Office of the Assistant Secretary for Preparedness
        and Response (ASPR)

        Department of Health and Human Services (HHS)

        375 E Street, SW

        Patriot Plaza 2

        Washington, D.C. 20024

        Telephone: 202-260-1790

        E-Mail: Claiborne.Hughes@hhs.gov

         

        2. The Alternate COTR will remain Dr. Joseph Larsen.

         

        B. This is a no cost modification. The total amount
        and al1 other terms and conditions of Contract Number HHSO100201100013C remain unchanged.

         

        Period of Performance: 02/16/2011 to 04/15/2012
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

 

    	 

    	 

    

  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0005	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt
of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral:
    Mutual Agreement of the Parties.
	 	 

	E.
IMPORTANT:         Contractor       £
is not.          S is required to sign this document and return          1        
copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.   The purpose of this modification is to incorporate the following changes into contract number HHSO100201100013C:

         

        1.    The period of performance for the base performance segment CLIN 0001 of contract number HHSO100201100013C
is hereby changed from 16 February 2011 through 15 April 2012 to 16 February 2011 through 15 June 2012, at no additional cost to
the Government.

         

        

2.    The period of performance
for the Option 1 performance segment CLIN 0002 of contract number HHSO100201100013C is hereby changed from 16 April 2012 through
15 April 2013 to 16

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF CONTRACTING
    OFFICER
	 	 
	KENNETH
                                                                                                                                            I.
                                                                                                                                            MOCH,
                                                                                                                                            PRESIDENT
                                                                                                                                            AND
                                                                                                                                            CEO

	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		 
	/s/
Kenneth I. Moch 

	2/24/12

	
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

    	 

    	 

    
 

 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE    OF      PAGES
	 	HHSO100201100013C/005	2	     2  

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
         June 2012 through 15 June 2013, at no additional
        cost to the Government. If exercised by a unilateral contract modification, the option exercise date for the Option 1 performance
        segment CLIN 0002 will be 16 June 2012.

         

        B. This is a no cost modification. The total amount
        and al1 other terms and conditions of contract number HHSO100201100013C remain unchanged.

         

        Period of Performance: 02/16/2011 to 06/15/2012
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)	 
	 	Sponsored by GSA	 
	 	FAR (48 CFR) 63.110	 
	 	 	
	 	 	 	 	 

  

    	 

    	 

    
  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0006	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        D.C. 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment. and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral:
    Mutual Agreement of the Parties.
	 	 

	E.
IMPORTANT:         Contractor      £ 
is not.          S is required to sign this document and return           1       
copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this
        modification is to incorporate  the following changes into contract number HHSO100201100013C.

         

        1.    The period of performance for the base performance segment CLIN 0001 of contract number HHSO100201100013C
is hereby changed from 16 February 2011 through 15 June 2012 to 16 February 2011 through 31 October 2012, at no additional cost
to the Government.

         

        2.    The
        period of performance for the Option 1 performance segment CLIN 0002 of contract number HHSO100201100013C is hereby changed
        from 16 June 2012 through 15 June 2013 to 1

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF CONTRACTING OFFICER

	 	 
	 KENNETH
    I. MOCH, PRESIDENT AND CEO	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		
	/s/
                                                                                                                                      Kenneth
                                                                                                                                      I.
                                                                                                                                      Moch

	 5/4/12	
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

 

    	 

    	 	

    
 

	CONTINUATION
SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE      OF     PAGES
	 	HHSO100201100013C/006	2	2

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
        November 2012 through 31 October 2013, at no additional
        cost to the Government. If exercised by a unilateral contract modification, the option exercise date for the Option 1 performance
        segment CLIN 0002 will be    1 November 2012.

         

        B. This is a no cost modification. The total amount
        and al1 other terms and conditions of contract number HHSO100201100013C remain unchanged.

         

        Period of Performance: 02/16/2011 to 10/31/2012
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

    	 

    	 

    
  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	1

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ. NO.	5.
    PROECT NO. (if applicable)
	0007	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        D.C. 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	 

	E.
    IMPORTANT:         Contractor       x
    is not.          o is
    required to sign this document and return                  
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of
        this modification is to delete [...***...] to Article G.3. KEY PERSONNEL under contract number HHSO100201100013C.

         

        B.    This is a unilateral
        no cost modification. The total amount and all other terms and conditions of contract number HHSO100201100013C remain
        unchanged.

         

        Period of Performance:
        02/16/2011 to 10/31/2012

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF CONTRACTING OFFICER
	 	 
	 	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		

	 	 	/s/
        Ethan J. Mueller
	5/21/12 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	17

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ. NO.	5.
    PROECT NO. (if applicable)
	0008	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        D.C. 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)             Net
                                     Increase:                   $4,638,693.00

        See Schedule

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 S	D.OTHER
    (Specify type of modification and authority)
	 	Bilateral: Mutual Agreement of the Parties.

	E.
    IMPORTANT:         Contractor        ̈
    is not.          x is
    required to sign this document and return          1        
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is to add the following efforts into the base segment of Contract Number
HHSO100201100013C and to replace the Principal Investigator:

         

        

1.    Conduct
the [...***...] in the [...***...].

 

2.    Complete
the [...***...].

 

3.    Complete
the [...***...] of the [...***...],

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF CONTRACTING OFFICER
	 	 
	 TIMOTHY W. TROST, CHIEF FINANCIAL OFFICER	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		

	 /s/ Timothy W. Trost	7/9/12

	
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

  

***Confidential Treatment Requested

 

    	 

    	 

    
 

	CONTINUATION SHEET	
        REFERENCE NO. OF DOCUMENT BEING
        CONTINUED

        HHSO100201100013C/008
	PAGEOFPAGES
	2	17

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
         

        4.
        Support ongoing [...***...].

         

        5. Technical Management/Regulatory/Quality Support.

         

        As a result, Attachment 1, Statement of Work dated
        10 February 2012, under PART III, LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS, SECTION J - LIST OF ATTACHMENTS is hereby
        deleted and replaced with the attached Statement of Work dated 19 June 2012.

         

        1. Under Article F.2. DELIVERABLES, the attached changes
        are hereby incorporated into 2. WBS Milestones/Deliverables and Technical Deliverables.

         

        2. The addition of these efforts to the base segment
        of Contract Number HHSO0100201100013C results in Contract Line Item Number (CLIN) 0001 being changed as follows:

         

        Total Estimated Cost: From[...***...] By [...***...
        ]To [...***...]

         

        Total Fixed Fee: From [...***...] By [...***...] To
        [...***...]

         

        Total Estimated Cost Plus Fixed Fee: From $24,819,527.00
        By $4,638,693.00 To $29,458,220.00

         

        3. This modification hereby results in an increase
        in the total amount of the contract from $24,819,527.00 by $4,638,693.00 to $29,458,220.00.

         

        4. Block 15G of the SF 26, the amount of $24,819,527.00
        shall be changed to $29,458,220.00. Also in Block 14 of the SF 26, the following CAN Number is added as follows:

         

        Appropriation Year: 2012; Object Class: 25329; CAN
        1992002 $4,638,693.00

         

        5. The period of performance for the base segment
        CLIN 0001 of Contract Number HHSO100201100013C is hereby changed from 16 February 2011 through 31 October 2012 to 16 February 2011
        through 31 March 2013.

         

        6. The period of performance for the Option 1 performance
        segment CLIN 0002 of Contract Number HHSO100201100013C of 1 November 2012 through 31 October 2013 will remain unchanged. This bilateral
        modification does not authorize the performance of any Option segments under the contract.

         

        7. Delete [...***...] to Article G.3. KEY PERSONNEL
        under contract Number HHSO100201100013C.

         

        B. All other terms and conditions of the contract
        remain unchanged.

        Delivery: 03/31/2013

        Delivery Location Code: OS-BARDA-SWITZER

        OS-BARDA-SWITZER

        330 Independence Ave, SW, Rm G644

        Continued ...
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

***Confidential Treatment Requested

    	 

    	 

    

 

	CONTINUATION
SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE       OF       PAGES
	 	HHSO100201100013C/008	3	17

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

		
        Washington DC 20201 US

         

        FOB: Destination

        Period of Performance: 02/16/2011 to 03/31/2013

         

        Change Item 1 to read as follows(amount shown is the
        obligated amount):

         

        

        
	 	 	 	
	1	Research and development of CMXOOl for the Treatment of Smallpox to include [...***...].

                                                                                 

                                                                                

Reports and Other Data Deliverables.

 

Obligated Amount: $4,638,693.00

 

Amount: $24,819,527.00

Accounting Info:

2011.1992002.25329 Appr. Yr. : 2011 CAN: 1992002 Object
Class: 25329

Funded: $0.00

 

Amount: $4,638,693.00

Accounting Info:

2012.1992002.25329 Appr. Yr. : 2012 CAN: 1992002 Object
Class: 25329

Funded: $4,638,693.00

                                                                                 
	 	 	 	4,638,693.00
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

***Confidential Treatment Requested

    	 

    	 

    

 

BARDA
Broad Agency Announcement (BAA)

(CBRN-BAA-10-100-SOL-00012)

Advanced Research and Development of Chemical,
Biological, Radiological, and

Nuclear Medical Countermeasures

DEVELOPMENT
OF CMX-001 FOR THE TREATMENT OF SMALLPOX 

Topical Area of Interest No. 3, Antimicrobial
Drugs

 

Contractual Statement of Work

 

1. PREAMBLE

 

Independently
and not as an agency of the Government, the Contractor shall be required to furnish all the
necessary services, qualified personnel, material, equipment, and facilities, not otherwise
provided by the Government, as needed to perform the Statement of Work submitted in response
to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-1 0-1 00-SOL-00012.

 

In accordance
with FAR 52.243-2, Changes-Cost Reimbursement (Alt. V), the Government reserves the right
to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables,
process, or schedules if the need arises. Because of the nature of this research and development
(R&D) contract and the complexities inherent in this and prior programs, at designated
milestones the Government will evaluate whether work should be redirected, removed, or whether
schedule or budget adjustments should be made.

 

1.0 Overall Objectives and Scope

 

The overall
objective of this contract is to advance the development of CMX-001 as a broad-spectrum therapeutic
antiviral for the treatment of smallpox infections and dsDNA viruses. The scope of work for
this contract includes preclinical, clinical and manufacturing development activities that
fall into the following areas: non-clinical efficacy studies; clinical activities; manufacturing
activities; and all associated regulatory, quality assurance, management, and administrative
activities. The Research and Development (R&D) effort for the antiviral will progress
in specific stages that cover the base performance segment and four (4) option segments as
specified in this contract. The Contractor must complete specific tasks required in each of
the five discrete work segments. The scope of work has been broken into the following five
phases which are discrete work segments:

 

	 	I.	 	[...***...]
	 	II.	 	[...***...]
	 	III.	 	[...***...]
	 	IV.	 	[...***...]
	 	V.	 	[...***...]

 

***Confidential Treatment Requested

    	1

    	 

    

 

		2	PHASE 1: [...***...]

 

Research
and development of CMX-001 for the treatment of smallpox and dsDNA viruses to include the
following activities: [...***...]. The contractor shall carry out the following tasks and subtasks and in
accordance with an agreed upon Integrated Master Schedule and Integrated Master Plan (defined
in 2.1.8 and 2.1.9 below) which shall further detail the conduct of the specific tasks and
subtasks.

 

		2.1	Program Management

 

The
Contractor shall provide for the following as outlined below and in the contract deliverables
list (Article F.2):

 

		2.1.1	The overall management, integration and coordination of all contract activities,
including a technical and administrative infrastructure to ensure the efficient planning,
initiation, implementation, and direction of all contract activities;

 

		2.1.2	A Principal Investigator (PI) responsible for project management, communication,
tracking, monitoring and reporting on status and progress, and modification to the project
requirements and timelines, including projects undertaken
by subcontractors; The contract deliverables list (reference), identifies all contract deliverables
and reporting requirements for this contract.

 

		2.1.3	Project Manager(s) with responsibility for monitoring and tracking day-to-day progress
and timelines, coordinating communication and project activities; costs incurred; and program
management; The contract deliverables list (reference), identifies all contract deliverables
and reporting requirements for this contract.

 

		2.1.4	A BARDA Liaison with responsibility for effective communication with the Project
Officer and Contracting Officer.

 

		2.1.5	Administrative and legal staff to provide development of compliant subcontracts,
consulting, and other legal agreements, and ensure timely acquisition of all proprietary rights,
including IP rights, and reporting all inventions made
in the performance of the project.

 

		2.1.6	Administrative staff with responsibility for financial management and reporting
on all activities conducted by the Contractor and any subcontractors.

 

***Confidential Treatment
Requested

    	2

    	 

    
 

 

		2.1.7	Contract Review Meetings.

		2.1.7.1	The Contractor shall participate in regular meetings to coordinate and oversee
the contract effort as directed by the Contracting and Project Officers. Such meetings may
include, but are not limited to, meeting of the Contractors and subcontractors to discuss
clinical manufacturing progress, product development, product assay development, scale up
manufacturing development, clinical sample assays development, preclinical/clinical
study designs and regulatory issues; meetings with individual contractors and other HHS officials
to discuss the technical, regulatory, and ethical aspects of the program; and meeting with
technical consultants to discuss technical data provided by the Contractor.

		2.1.7.2	The Contractor shall participate in teleconferences every two weeks between
the Contractor and subcontractors and BARDA to review technical progress. Teleconferences
or additional face-to-face meetings shall be more frequent at the request of BARDA.

		2.1.8	Integrated Master Schedule

		2.1.8.1	Within 30 calendar days of the effective date of the contract, the Contractor
shall submit a first draft of an updated Integrated Master Schedule in a format agreed upon
by BARDA to the Project Officer and the Contracting Officer for review and comment. The Integrated
Master Schedule shall be incorporated into the contract, and will be used to monitor
performance of the contract. Contractor shall include the key milestones and Go/No Go decision
gates. The IMS for the period of performance will be mutually agreed upon at the PMBR

		2.1.9	Integrated Master Plan

		2.1.9.1	Work Breakdown Structure: The Contractor shall utilize a WBS template
agreed upon by BARDA for reporting on the contact. The Contractor shall expand and delineate
the Contract Work Breakdown Structure (CWBS) to a level agreed upon by BARDA as part of their
Integrated Master Plan for contract reporting. The CWBS shall be discernable
and consistent. BARDA may require Contractor to furnish WBS data at the work package level
or at a lower level if there is significant complexity and risk associated with the task.

		2.1.9.2	GO/NO-GO Decision Gates: The Integrated Master Plan outlines key milestones with "Go/No Go" decision criteria (entrance
and exit criteria for each phase of the project). The project plan should include, but not

be limited to, milestones in manufacturing, non-clinical and clinical studies, and regulatory submissions.

		2.1.9.3	Earned Value Management System Plan: Subject to the requirements under
HHSAR Clause 352.234-4, the Contractor shall use principles of Earned Value Management System
(EVMS) in the management of this contract. The Seven Principles are:

		I.	Plan all work scope for the program to completion.

 

    	3

    	 

    

 

		II.	Break down the program
work scope into finite pieces that can be assigned to a responsible person or organization
for control of technical, schedule, and cost objectives.

		III.	Integrate program work
scope, schedule, and cost

objectives into a performance measurement baseline plan against
which accomplishments may be measured. Control Changes to the baseline.

		IV.	Use actual cost incurred
and recorded in accomplishing the work performed.

		V.	Objectively assess accomplishments
at the work

performance level.

		VI.	Analyze significant variances
from the plan, forecast impacts, and prepare an estimate at completion based on performance
to date and work to be performed.

		VII.	Use earned value information
in the company's management processes.

 

Elements of EVMS shall
be applied to all Cost Plus Fixed Fee CLINs as part of
the Integrated Master Project Plan, the Contractor shall submit a written summary of the management
procedures that it will establish, maintain and use to comply with EVMS requirements.

 

		2.1.10	Decision Gate Reporting: On completion of a stage of the product development,
as defined in the agreed upon Integrated Master Schedule and Integrated Master Plan, the Contractor
shall prepare and submit to the Project Officer and the Contracting Officer a Decision Gate
Report that contains (i) sufficient detail, documentation and analysis to support successful
completion of the stage according to the predetermined qualitative and quantitative
criteria that were established for Go/No Go decision making; and (ii) a description
of the next stage of product development to be initiated and a request for approval to proceed
to the next stage of product development.

 

		2.1.11	Risk Management Plan: The Contractor shall develop a risk management plan within
90 days of contract award highlighting potential problems and/or issues that may arise during
the life of the contract, their impact on cost, schedule and performance, and appropriate
remediation plans. This plan should reference relevant WBS elements where appropriate. Updates
to this plan shall be included every three months (quarterly) in the monthly Project Status
Report.

 

    	4

    	 

    
 

		2.1.12	Performance Measurement Baseline Review (PMBR): The Contractor shall submit
a plan for a PMBR to occur within 90 days of contract award. At the PMBR, the Contractor and
BARDA shall mutually agree upon the budget, schedule and technical plan baselines (Performance
Measurement Baseline). These baselines shall be the basis for monitoring and reporting progress
throughout the life of the contract. The PMBR is conducted to achieve confidence
that the baselines accurately capture the entire technical scope of work, are consistent with
contract schedule requirements, are reasonably and logically planned, and have adequate resources
assigned. The goals of the PMBR are as FOLLOWS:

 

		I.	Jointly assess areas such
as the Contractor's planning for complete coverage of the SOW, logical scheduling of the
work activities, adequate resources, and identification of inherent risks

		II.	Confirm the integrity of
the Performance Measurement Baseline (PMB)

		III.	Foster the use of EVM as
a means of communication

		IV.	Provide confidence in the
validity of Contractor reporting

		V.	Identify risks associated
with the PMB

		VI.	Present any revised PMBs
for mutual agreement

		VII.	Present an Integrated Master
Schedule: The Contractor shall deliver an initial program level Integrated Master Schedule
(IMS) that rolls up all time-phased WBS elements down to the activity level. This
IMS shall include the dependencies that exist between tasks.
This IMS will be agreed to and finalized at the PMBR. DI-MGMT-81650 may be referenced
as guidance in creation of the IMS (see http://www.acq.osd.mil/pml).

		VIII.	Present the Risk Management
Plan

 

		2.1.13	Deviation Request: During the course of contract performance, in response to a need to change IMS activities as baselined at
the PMBR, the Contractor shall submit a Deviation Report. This report shall request a change in the agreed-upon IMS and timelines.
This report shall include: (i) discussion of the justification/rationale for the proposed change; (ii) options for addressing the
needed changes from the agreed upon timelines, including a cost-benefit analysis of each option; and (iii) recommendations for
the preferred option that includes a full analysis and discussion of the effect of the change on the entire product development
program, timelines, and budget.
	 	 	 

		2.1.14	Monthly and Annual Reports: The Contractor shall deliver Project Status Reports on a monthly basis. The reports shall address
the items below cross referenced to the WBS, SOW, IMS, and EVM:

		I.	Executive summary highlighting the progress, issues,
and relevant activities in manufacturing, non-clinical, clinical, and regulatory;

		II.	Progress in meeting contract milestones, detailing the
planned progress and actual progress during the reporting period, explaining any differences between the two and corrective steps;

 

			

    	5

    	 

    

 

 

		III.	Updated IMS;

		IV.	Updated EVM;

		V.	Updated Risk Management Plan (Every 3 months);

		VI.	Three month rolling forecast of planned activities;

		VII.	Progress of regulatory submissions;

		VIII.	Estimated and actual expenses;

 

		2.1.15	Data Management: The Contractor shall develop and implement data management and quality control systems/procedures, including
transmission, storage, confidentiality, and retrieval of all contract data;

		2.1.15.1	Provide for the statistical design and analysis of data resulting from the research;

		2.1.15.2	Provide raw data or specific analyses of data generated with contract funding to the Project Officer, upon request.

 

		2.2	Non-Clinical Toxicology

		2.2.1	N/A (no scope)

 

		2.3	Non-Clinical

		2.3.1	Develop and validate [...***...] to lower [...***...].

		2.3.2	[...***...]: Conduct [...***...] studies including [...***...] studies, [...***...], and [...***...]
studies in [...***...].

		2.3.3	[...***...]

		2.3.3.1	Conduct [...***...] study in [...***...].

		2.3.3.2	Conduct [...***...] studies including [...***...] studies, [...***...] studies including [...***...]
for CMX-001 and [...***...] in [...***...].

		2.3.4	Use of [...***...] as a CMX-001 Surrogate in [...***...] Studies.

		2.3.4.1	Dose [...***...] with [...***...] to identify the concentration of the [...***...] in [...***...]
associated with [...***...] of [...***...].

		2.3.5	Scaling of [...***...] to [...***...] by conducting studies with [...***...] to determine [...***...]
in [...***...].

		2.3.6	[...***...] determination of CMX00l, [...***...] and [...***...] in the [...***...].

		2.3.7	Conduct [...***...] experiments to demonstrate
[...***...] following effective [...***...] prior to [...***...].

		2.3.8	Conduct studies to optimize [...***...] in [...***...].

		2.3.9	Conduct CMX-001 [...***...] study in [...***...] at a dose of CMX001 equivalent or less than [...***...]
with treatment beginning at the [...***...]

 

***Confidential Treatment Requested

    	6

    	 

    

 

		2.4	Clinical

		2.4.1	Measurement of [...***...] levels in [...***...] and correlate the [...***...] to studies conducted in
[...***...].

		2.4.2	Conduct expanded access protocol ([...***...]).

		2.4.3	Analyze data and provide a Final Report for [...***...] evaluation of CMX001 in patients ([...***...])

 

		2.5	Regulatory

		2.5.1	Engaging the FDA on a path to support the treatment of smallpox indication with CMX-001

		2.5.2	Preparing materials for and requesting, scheduling and participating in all meetings with the FDA, including meetings to review
EUA and/or all other data packages;

		2.5.3	Providing BARDA with (i) the initial draft minutes and final draft minutes of any formal meeting with the FDA; (ii) final minutes
of any informal meeting with the FDA;

		2.5.4	Obtain FDA concurrence on the feasibility of the proposed [...***...] with CMX001/[...***...]/[...***...]
in the [...***...] ([...***...]), including FDA feedback on [...***...] and review of data for the first [...***...]
enrolled in the [...***...] sub-study

		2.5.5	Develop and submit a revised [...***...] for CMX001 for Treatment of Smallpox, including [...***...] for FDA
review and comment, and revise the [...***...] as requested by FDA

 

		2.6	CMC

		2.6.1	Validation of the [...***...] process: Validation of the process to demonstrate the [...***...] of a [...***...]
of acceptable quality will be performed.

		2.6.2	Validation of the [...***...] process to produce [...***...]: Validation of the process to demonstrate the [...***...]
of a [...***...] of acceptable quality will be performed.

 

		3.	PHASE II: [...***...]

 

Research and development of
CMX-001 for the treatment of smallpox to include the following activities: [...***...]. The contractor shall carry out the
following tasks and subtasks and in accordance with the agreed upon Integrated Master Schedule and Integrated Master Plan (defined
in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

***Confidential Treatment
Requested

    	7

    	 

    

 

		3.1	Program Management (consistent with section 2.1)

		3.1.1	Program management scope in BASE year is consistent with program management scope in each option year.

 

		3.2	Non-toxicology

		3.2.1	N/A (no scope)

 

		3.3	Non-Clinical

		3.3.1	Quantify [...***...] levels in [...***...] in [...***...].

		3.3.2	Determine [...***...] for CMX-001, [...***...], and [...***...] in [...***...].

		3.3.3	Scaling of [...***...] to [...***...] studies to determine scaling between [...***...] and [...***...]
using [...***...] as well as comparisons of levels of [...***...] in the [...***...].

		3.3.4	[...***...] in the [...***...]. This study will determine the [...***...] in [...***...] and the
concentration of [...***...] in [...***...] when [...***...] are treated with [...***...] at the effective
dose and regimen

		3.3.5	[...***...]- (Final Report from Sections 2.3.2.). The initial study ([...***...]) will compare different regimens
of [...***...] administered after the [...***...]. The studies will include [...***...] and [...***...],
as well as [...***...] including [...***...].

 

		3.4	Clinical

		3.4.1	Conduct [...***...] study in [...***...] will be conducted as part of the scope of work to determine whether
CMX00l has a [...***...], as detected by [...***...].

 

		3.5	Regulatory

		3.5.1	Engaging the FDA on a path to support the treatment of smallpox indication with CMX-001

 

		3.5.2	Preparing materials for and requesting, scheduling and participating in all meetings with the FDA, including meetings to review
EUA and/or all other data packages;

 

***Confidential Treatment
Requested

    	8

    	 

    

 

		3.5.3	Providing BARDA with (i) the initial draft minutes and final draft minutes of any formal meeting with the FDA; (ii) final draft
minutes of any informal meeting with the FDA;

 

		3.6	CMC

		3.6.1	N/A (NO SCOPE)

 

		4.	PHASE III: [...***...]

 

Research and development of CMX-001 for the treatment
of smallpox and dsDNA viruses to include the following activities: [...***...]. 

The contractor shall carry out the following tasks
and subtasks and in accordance with agreed upon Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9)
which shall further detail the conduct of the specific tasks and sub tasks.

 

		4.1	Program Management (Consistent with section 2.1)

		4.1.1	Program management scope in BASE year is consistent with program management scope in each option year.

 

		4.2	Non-toxicology

		4.2.1	N/ A (no scope)

 

		4.3	Non-Clinical

		4.3.1	[...***...] studies: [...***...] will be conducted with the [...***...] of CMX001 identified in the [...***...]
studies. [...***...] will be [...***...] to receive [...***...] beginning at the [...***...]. These
studies will include [...***...] and [...***...] as well as [...***...] including [...***...] in [...***...].
The primary endpoint will be [...***...]

		4.3.2	[...***...] studies: This study will determine the [...***...] at the [...***...]. [...***...]
and [...***...] at the [...***...]. The primary endpoint will be [...***...]

		4.3.3	Initiate [...***...]: Conduct [...***...] studies for [...***...]. This study will determine the [...***...]
at doses selected based on [...***...]. [...***...] and [...***...].

 

***Confidential Treatment
Requested

    	9

    	 

    

 

		4.4	Clinical

		4.4.1	Phases I [...***...] study, If acceptable to FDA, the [...***...] database will be supplemented by a study in
[...***...]. The size of this study will be determined to ensure an adequate [...***...] database is available at
the time of [...***...]

		4.4.2	[...***...] study. This study will [...***...] doses of CMX001 to [...***...] to determine if the [...***...]
of CMX001 are comparable to those observed for [...***...], and to determine if any dose adjustment is necessary in [...***...].

 

		4.5	Regulatory

		4.5.1	Generating all necessary data and preparing documentation for [...***...] submissions to regulatory agencies;

		4.5.2	Preparing materials for and requesting, scheduling and participating in all meetings with the FDA, including meetings to review
[...***...], EUA and/or all other data packages;

		4.5.3	Providing BARDA with (i) the initial draft minutes and final draft minutes of any formal meeting with the FDA; (ii) final draft
minutes of any informal meeting with the FDA;

		4.5.4	Filing of [...***...]

 

		4.6	CMC

		4.6.1	Manufacture of [...***...] in sufficient quantities for use in non-clinical and late phase clinical studies. Develop
[...***...].

 

		5.	PHASE IV: [...***...]

 

Research and development of
CMX-001 for the treatment of smallpox to include the following activities: [...***...]. [...***...] studies and phase
I [...***...] study. The contractor shall carry out the following tasks and subtasks and in accordance with agreed upon
Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the
specific tasks and subtasks.

 

		5.1	Program Management (Consistent with section 2.1)

		5.1.1	Program management scope in BASE year is consistent with program management scope in each option year.

 

		5.2	Non-toxicology

		5.2.1	N/A (no scope)

 

***Confidential Treatment Requested

    	10

    	 

    

 

		5.3	Non-Clinical

		5.3.1	[...***...] studies. [...***...] will be randomized to receive [...***...] beginning at the [...***...].
These studies will include [...***...] and [...***...] as well as [...***...] including [...***...].
The primary endpoint will be [...***...]

		5.3.2	[...***...] Studies. This study will determine the [...***...] at the [...***...]. [...***...]
and [...***...] at the [...***...]. The primary endpoint will be [...***...]. If FDA requires a [...***...]
in the [...***...] studies, the [...***...] study may not be needed.

		5.3.3	Conduct [...***...] Studies. This study will determine the [...***...] at the [...***...]. [...***...]
and [...***...] at the [...***...].

 

		5.4	Clinical

		5.4.1	Phase 3 development including [...***...] study, [...***...] study, phases II [...***...] study. A [...***...]
study will be conducted to compare the [...***...] of CMX001 in [...***...] to [...***...]. A [...***...]
study will be conducted to compare the [...***...] of CMX001 when [...***...]. A [...***...] study will be
conducted to [...***...] to support an NDA.

 

		5.5	Regulatory

		5.5.1	Generating all necessary data and preparing documentation for NDA submissions to regulatory agencies;

		5.5.2	Preparing materials for and requesting, scheduling and participating in all meetings with the FDA, including meetings to review
IND, EUA and/or all other data packages;

		5.5.3	Providing BARDA with (i) the initial draft minutes and final draft minutes of any formal meeting with the FDA; (ii) final draft
minutes of any informal meeting with the FDA;

 

		5.6	CMC

		5.6.1	[...***...]. [...***...] of the process to demonstrate the [...***...] of a [...***...] will be
performed.

 

6. PHASE V: [...***...]

 

***Confidential Treatment Requested

    	11

    	 

    

 

Research and development of CMX-001 for the treatment
of smallpox to include the following activities: [...***...]. The contractor shall carry out the following tasks and subtasks
and in accordance with an agreed upon Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which
shall further detail the conduct of the specific tasks and subtasks.

 

		6.1	Program Management (Consistent with section 2.1)

		6.1.1	Program management scope in BASE year is consistent with program management scope in each option year.

 

		6.2	Non-toxicology

		6.2.1	N/A (no scope)

 

		6.3	Non-Clinical

		6.3.1	[...***...] Studies. This study replicates [...***...] if a [...***...] is necessary to achieve a [...***...]
result.

 

		6.4	Clinical

		6.4.1	Compile [...***...]. A database of [...***...] data collected from all CMX001 clinical studies, irrespective
of [...***...], will be populated and analyzed in order to support an [...***...] for smallpox.

 

		6.5	Regulatory

		6.5.1	Generating all necessary data and preparing documentation for NDA submissions to regulatory agencies;

		6.5.2	Submitting NDA documentation to the FDA in a timely manner, consistent with timelines set out in the contract and by the FDA.

		6.5.3	Preparing materials for and requesting, scheduling and participating in all meetings with the FDA, including meetings to review
IND, EUA and/or all other data packages;

		6.5.4	Providing BARDA with (i) the initial draft minutes and final draft minutes of any formal meeting with the FDA; (ii) final draft
minutes of any informal meeting with the FDA;

 

		6.6	CMC

		6.6.1	[...***...]. [...***...] of the process to demonstrate the [...***...] of a [...***...] will be
performed.

 

		7.	Other Items

 

	7.1	Facilities, Equipment and Other Resources. (Contract:
Section J)
	 	The Contractor shall provide equipment;
facilities and other resources required for implementation of the SOW dated January 11, 2011 to comply with all Federal

 

***Confidential Treatment
Requested

    	12

    	 

    

 

 and HHS regulations in:

 

		7.1.1	The [...***...] and use of [...***...];

		7.1.2	The acquisition, handling, storage and shipment of [...***...], including [...***...] required for working with
the [...***...];

		7.1.3	The [...***...] of [...***...] under cGMP;

		7.1.3.1	The design and conduct of [...***...]; and

		7.1.3.2	The conduct of [...***...] studies to determine [...***...] of [...***...]

		7.1.4	Design and conduct of [...***...] under GCP.

  

 

***Confidential Treatment Requested

 

    	13

    	 

    

 

	NEW BASE CONSIDERATION ACTIVITY TO BE ADDED TO ARTICLE F.2 DELIVERABLES
	Current 

Milestone #	Milestone Definition	Go Criteria	No-Go Criteria	Deliverable	WBS/SOW #	Date
	NEW 

MILESTONE	[...***...]	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...]
	OPTION 1 WORK SEGMENT ACTIVITIES MOVED TO BASE SEGMENT
	6.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...]
	15.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...]
	25.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...][...***...]	[...***...]

 

 

***Confidential Treatment Requested

 

    	 

    	 

    

  

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	1

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0009	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	Bilateral:
                                                                                                 Mutual Agreement of the Parties.

	 	 

	E.
    IMPORTANT:         Contractor       x
    is not.          o is
    required to sign this document and return                  
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this no cost unilateral administrative modification is to make the following administrative
correction under Contract Number HHSO100201100013C:

         

        1.    Under Article F.2. DELIVERABLES,
        under the NEW MILESTONE, under the column titled WBS/SOW#, the reference to WBS Number 1.3 is hereby deleted and replaced
        by WBS Number 1.8.

         

        B.    This
        is a no cost unilateral modification. All other terms and conditions of the contract remain unchanged.

 

        Period of Performance:
        02/16/2011 to 03/31/2013

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF
                                                             CONTRACTING OFFICER

	 	 
	 	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		7/25/12

	 	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

    	 

    	 

    

   

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ. NO.	5.
    PROECT NO. (if applicable)
	0010	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        D.C. 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
	x	B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 	Bilateral: Mutual Agreement of the Parties.

	 	 

	E.
    IMPORTANT:         Contractor        ̈
    is not.          x is
    required to sign this document and return           1       
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is to incorporate the following changes into contract number HHSO100201100013C:

         

        1.    The
        period of performance for the Option 1 performance segment CLIN 0002 of contract number HHSO100201100013C is hereby changed
        from 1 November 2012 through 31 October 2013 to 1 April 2013 through 31 March 2014, at no additional cost to the Government.
        If exercised by a contract modification,· the option exercise date for the Option 1 performance segment CLIN 0002
        will be 1 April 2013.

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF
                                                             CONTRACTING OFFICER

	 	 
	KENNETH
                                                                                    I. MOCH, PRESIDENT AND CEO

	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		10/17/12

	 /s/ Kenneth I. Moch	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

    	 

    	 

    

 

 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE      OF     PAGES
	 	HHSO100201100013C/005	2	2

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
        B. This is a no cost modification . The total amount
        and all other terms and conditions of contract number HHSO100201100013C remain unchanged.

        Period of Performance: 02/16/2011 to 03/31/2013

         
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

 

    	 

    	 

    

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	3

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0011	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)                          Net
Increase:                          $1,497,322.00

        See Schedule

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral: Mutual Agreement of the Parties.
	 	 

	E.
IMPORTANT:         Contractor       £
is not.          S is required
to sign this document and return           1       
copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is to add funding in the amount of $1,497,322.00 for the purpose of funding
a cost growth due to increases in indirect rates into the base segment ONLY of Contract Number HHSO100201100013C.

         

        1.     The
        addition of this cost growth to the base segment of Contract Number HHSO100201100013C results in Contract Line Item Number
        (CLIN) 0001 being changed as follows:

         

        

Total Estimated Cost: From $27,531,047.00
By $1,497,322.00 To $29,028,369.00

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF
                                                             CONTRACTING OFFICER

	 	 
	 KENNETH I. MOCH, PRESIDENT AND CEO	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		11/8/12

	/s/
                                                                                                  Kenneth I. Moch

	 11/7/12	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

  

    	 

    	 

    
 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE      OF      PAGES
	 	HHSO100201100013C/005	2	3

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	
         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

        
	
        No change to the Total Fixed Fee Amount of $1,927,173.00

         

        Total Estimated Cost Plus fixed Fee: From $29,458,220.00
        By $1,497,322.00 To $30,955,542.00

         

        2. This modification hereby results in an increase
        in the total amount of the contract from $29,458,220.00 by $1,497,322.00 to $30,955,542.00.

         

        3. Block 15G of the SF 26, the amount of $29,458,220.00
        shall be changed to $30,955,542.00. Also in Block 14 of the SF 26, the following CAN Number is added as follows:

         

        Appropriation Year: 2013; Object Class: 25329; CAN
        1992002 $1,497,322.00

         

        4. The period of performance for the base segment
        CLIN 0001 of Contract Number HHSO100201100013C remains unchanged at 16 February 2011 through 31 March 2013. The Statement of Work
        also remains unchanged. This bilateral modification does not authorize the performance of any Option segments under the contract.

         

        5. The second sentence in Article G.7. INDIRECT COST
        RATES of the contract is replaced with the following:

         

        FY 11 (Retroactive Adjustment ONLY) - Fringe Benefits
        at [...***...]% and Indirect at [...***...]%.

         

        FY 12 and FY 13 (Retroactive Adjustment and Billing)
        - Fringe Benefits at [...***...]% and Indirect at [...***...]%.

         

        6. Under Article F.2., DELIVERABLES, under the NEW
        MILESTONE, under the column titled WBS/SOW#, the reference to WBS Number 1.8 is hereby deleted and replaced with 11.0 (Base Consideration
        Activities).

         

        B. All other terms and conditions of the contract
        remain unchanged.

        Delivery: 03/31/2013

        FOB: Destination

        Period of Performance: 02/16/2011 to 03/31/2013

         

        Change Item 1 to read as follows(amount shown
is the obligated amount):
	 	 	 	
         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

        

	1	Research and development of CMX001 for the Treatment of Smallpox to include [...***...].

                                                                            

                                                                           Reports
and Other Data Deliverables.

                                                                            

                                                                           Obligated
Amount: $1,497,322.00

                                                                            

                                                                           Delivery
Location Code: OS-BARDA-SWITZER

                                                                           OS-BARDA-SWITZER

 

	 	 	 	1,497,322.00
	 	Continued ... 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

 

	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED	PAGE     OF   PAGES
	 	HHSO100201100013C/005	3	3

	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	
        330 Independence Ave, SW, Rm G644

        Washington DC 20201 US

        Amount: $24,819, 527.00

        Accounting Info:

        2011.1992002.25329 Appr. Yr. : 2011 CAN: 1992002 Object
        Class: 25329

        Funded: $0.00

         

        Delivery Location Code: OS-BARDA-SWITZER

        OS-BARDA-SWITZER

        330 Independence Ave, SW, Rm G644

        Washington DC 20201 US

        Amount: $4,638,693.00

        Accounting Info:

        2012.1992002.25329 Appr. Yr. : 2012 CAN: 1992002 Object
        Class: 25329

        Funded: $0.00

         

        Delivery Location Code: HHS

        HHS

        200 Independence Avenue, SW

        Washington DC 20201 US

        Amount: $1,497,322.00

        Accounting Info:

        2013.1992002.25329 Appr. Yr. : 2013 CAN: 1992002 Object
        Class: 25329

        Funded: $1,497,322.00

         
	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

 

    	 

    	 

    
 

 

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ NO.	5.
    PROECT NO. (if applicable)
	0012	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington,
        D.C. 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W. Rm G640

        Washington,
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No. street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN	 	 
	2505 MERIDIAN PARKWAY, SUITE 340	x	10A MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM, NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitatIon is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	 
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral:
    Mutual Agreement of the Parties.
	 	 

	E.
    IMPORTANT:         Contractor       £
    is not.          S is
    required to sign this document and return          1        
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is to incorporate the following changes into contract number HHSO100201100013C:

         

        1.     Under
        Attachment 1, Statement of Work dated 19 June 2012, under PART III, LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS,
        SECTION J - LIST OF ATTACHMENTS, under 2.5.4 the word "8 patients" is hereby deleted and replaced with the word
        "7 patients."

         

        2.     Under
        Article G. 3. KEY PERSONNEL under contract number HHSO100201100013C, [...***...] is hereby deleted and replaced by [...***...]

         

        Continued ...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME OF
                                                             CONTRACTING OFFICER

	 	 
	 KENNETH
    I. MOCH, PRESIDENT AND CEO	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		11/26/12

	 /s/ Kenneth I. Moch	 	/s/
        Ethan J. Mueller
	 
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

 

 

	CONTINUATION SHEET	
        REFERENCE NO. OF DOCUMENT BEING
        CONTINUED

        HHSO100201100013C/005
	PAGEOFPAGES
	2	2
	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	 	 	 	 	 
	 	
        and
        [...***...]
        is hereby deleted and replaced with [...***...].

         
	 	 	 	 
	 	 	 	 	 	 
	 	
        B. This is a no cost modification. The total amount and
        all other terms and conditions of contract number HHSO100201100013C remain unchanged.

         
	 	 	 	 
	 	 	 	 	 	 
	 	Period of Performance: 02/16/2011 to 03/31/2013	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 63.110

  

***Confidential Treatment Requested

 

    	 

    

 

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.
    CONTRACT ID CODE	PAGE     OF    PAGES
	 	 	1	2

	2.
    AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4.
    REQUISITION/PURCHASE REQ. NO.	5.
    PROJECT NO. (if applicable)
	0013	See
    Block 16C	N/A.	 

	6. ISSUED BY	CODE	ASPR-BARDA	7.
ADMINISTERED BY (If other than Item 6) 
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington
        DC 20201

         
	ASPR-BARDA

        330 Independence
        Ave, S.W., Rm G640

        Washington
        DC 20201

         

	8. NAME AND ADDRESS OF CONTRACTOR
    (No., street, county, State and ZIP Code)	x	9A. AMENDMENT
    OF SOLICITATION NO.
	 	 	 
	CHIMERIX, INC. 1377270	 	9B. DATED
    (SEE ITEM 11)
	CHIMERIX, INC.              2505
MERIDIAN P	 	 
	2505 MERIDIAN PKWY STE 340	x	10A. MODIFICATION
    OF CONTRACT/ORDER NO.
	DURHAM NC 277135246		HHSO100201100013C
	 	 	 
	 	 	10B. DATED (SEE ITEM 13)
	 	 	02/16/2011
	CODE
    	1377270	FACILITY
    CODE	 	 

	11.
    THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	oThe
                                                                          above numbered solicitation is amended as set forth
                                                                          in Item 14. The hour and date specified for receipt
                                                                          of Offers        o
                                                                          is extended.           o
                                                                          is not extended

        Offers must acknowledge
        receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following
        methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt
        of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference
        to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED
        FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of
        this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
        each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening
        hour and date specified.

	12.
                                     ACCOUNTING AND APPROPRIATION DATA (if required)

        N/A.

	13.
    THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK
    ONE	A.THIS
    CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER
    NO. IN ITEM 10A.
	 	  
		B.THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

 
	 	C.THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

 
	 	D.OTHER
    (Specify type of modification and authority)
	 S	Bilateral:
    Mutual Agreement of the Parties.
	 	 

	E.
    IMPORTANT:         Contractor       £
    is not.          S is
    required to sign this document and return          1        
    copies to the issuing office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION
    (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
	 
	Tax ID Number:            33-0903395

        DUNS Number:      121785997

        A.    The purpose of this modification is incorporate the following change into contract number HHSO100201100013C:

         

        

1.     The period of performance for the base performance segment
CLIN 0001 of contract number HHSO100201100013C is hereby changed from 16 February 2011 through 31 March 2013 to 16 February 2011
through 31 May 2013, at no additional cost to the Government.

 

2.     The period of performance for the Option 1 performance segment CLIN 0002 of contract number HHSO100201100013C
is hereby changed from 1 April 2013 through 31 March 2014 to 1

         

        Continued...

	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.

	15A.
    NAME AND TITLE OF SIGNER (Type or print)	16A. NAME AND
                                                             TITLE OF CONTRACTING OFFICER (Type or print)

	 	 
	 KENNETH
    I. MOCH, PRESIDENT AND CEO	ETHAN J. MUELLER
	 	 
	15B.
    CONTRACTOR/OFFEROR	15C.
    DATE SIGNED	16B.
        UNITED STATES OF AMERICA
	16C. DATE SIGNED
	 	 		 

	 /s/ Kenneth I. Moch	 2/20/13	/s/
        Ethan J. Mueller
	  2/21/13
	(Signature
    of person authorized to sign)	 	(Signature
        of Contracting Officer)
	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

    	 

    	 

    
 

	CONTINUATION SHEET	
        REFERENCE NO. OF DOCUMENT BEING
        CONTINUED

        HHSO100201100013C/0013
	PAGEOF
	2	2
	
        NAME OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	
        ITEM NO.

        (A)
	
        SUPPLIES/SERVICES

        (B)
	
        QUANTITY

        (C)
	
        UNIT

        (D)
	
        UNIT PRICE

        (E)
	
        AMOUNT

        (F)

	 	 	 	 	 	 
	 	
        June 2013 through 31 May 2014, at no additional cost to the Government. If exercised by a unilateral contract
modification, the option exercise date for the Option 1 performance segment CLIN 0002 will be 1 June 2013.

         
	 	 	 	 
	 	 	 	 	 	 
	 	
        B. This is a no cost modification. The total amount and
        all other terms and conditions of contract number HHSO100201100013C remain unchanged.

         
	 	 	 	 
	 	 	 	 	 	 
	 	Period of Performance: 02/16/2011 to 05/31/2013	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110Exhibit 10.21 

 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission.

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4)

and 230.406

 

 

 

LICENSE AGREEMENT

 

BETWEEN

 

CHIMERIX, INC

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE NO [...***...]

CASE NO [...***...]

CASE NO [...***...]

 

  ***Confidential
Treatment Requested

 

    	1

    	 

    

 

LICENSE AGREEMENT

 

This agreement (“Agreement”)
is made by and between Chimerix, Inc. a Delaware corporation having an address at 14024 Rue Saint Raphael, Del Mar, CA 92014 (“LICENSEE”)
and The Regents Of The University of California, a California corporation having its statewide administrative offices at 1111 Franklin
Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University
of California, San Diego, Technology Transfer & Intellectual Property Services, Mail-code 0910, 9500 Gilman Drive, La Jolla,
California 92093-0910 (“UCSD”). LICENSEE and UNIVERSITY may each be referred to herein as a “Party” or
collectively as the “Parties.”

 

This Agreement is effective on the date
of the last signature (“Effective Date”).

 

RECITALS

 

WHEREAS, the inventions disclosed in UCSD
Case Docket No. [...***...] and titled
“[...***...]” (“First Invention”), were made in the course of research at UCSD by [...***...] (hereinafter
and collectively, the “First Inventors”) and are covered by Patent Rights as defined below;

 

WHEREAS, the inventions disclosed in UCSD
Case Docket No. [...***...] and titled “[...***...]” (“Second Invention”), were made in the course of research
at UCSD by [...***...] (hereinafter and collectively, the “Second Inventors”) and are covered by Patent Rights as defined
below;

 

WHEREAS, the inventions disclosed in UCSD
Case Docket No. [...***...] and titled “[...***...]” (“Third Invention”), were made in the course of research
at UCSD by [...***...] (hereinafter and collectively, the “Third Inventors”) and at Dana Farber Cancer Institute (“DFCI”)
with a business address at 44 Binney Street, Boston, MA 02215 by [...***...] (“DFCI Inventor”) and are covered by Patent
Rights as defined below;

 

Whereas LICENSEE is aware that UNIVERSITY
is in negotiations with a Third Party for a license to the Second Invention for the field of osteoporosis and other metabolic bone
diseases;

 

WHEREAS, the research from which the First,
Second, and Third Inventions arose was sponsored in part by the Government of the United States of America and as a

  

***Confidential
Treatment Requested

  

    	2

    	 

    

 

consequence
this license is subject to overriding obligations to the Federal Government under 35 U.S.C. §§ 200-212 and applicable
regulations;

 

WHEREAS, the research from which the First
Invention arose was sponsored in part by a commercial entity, and the right granted to this entity under this agreement to negotiate
for a license to the First Invention has expired;

 

WHEREAS, the research from which the Second
Invention arose was sponsored in part by a commercial entity under a Materials Transfer Agreement, and the right granted to this
entity under this agreement to negotiate for a license to the Second Invention has expired;

 

WHEREAS, the First, Second, and Third Inventors
are employee of UCSD, and they are obligated to assign all of their right, title and interest in the Invention to UNIVERSITY;

 

WHEREAS, the DFCI Inventors are employees
of DFCI, and they are obligated to assign all of their right, title and interest in the Invention to DFCI;

 

WHEREAS, UNIVERSITY and DFCI have entered
an Inter-Institutional Agreement (“DFCI/UC Agreement”; UC control number [...***...]
with an effective date of October 16, 2001; Exhibit A) under which DFCI authorizes UNIVERSITY to have the exclusive right to prepare,
file, prosecute and maintain patent applications and patents covering Third Inventions in which both parties have an interest,
and the exclusive right to negotiate, execute and administer agreements for the commercialization of such inventions;

 

WHEREAS, [...***...] were also employees
of the Veterans Administration Medical Center at the time the Inventions were made, and, in accordance with the policy of the U.S.
Department of Veterans Affairs (“VA”), they have reported the Inventions to the VA for a determination of rights;

 

WHEREAS, the VA may decide that the U.S.
Government should retain its undivided right, title and interest in and to the First, and Third Inventions, and the First and Third
Inventors may be asked by the VA to assign all of their right, title and interest in and to the Inventions jointly to the U.S.
Government and UNIVERSITY;

 

WHEREAS the VA has relinquished its rights
to the Second Invention as stated in a letter to [...***...] (Exhibit B)

 

WHEREAS, the VA and UNIVERSITY entered
into a Cooperative Technology Administration Agreement (“VA/UC Agreement”; Exhibit C) under which the VA authorizes
UNIVERSITY to have the exclusive right to prepare, file, prosecute and maintain patent applications and patents covering the inventions
in which either or both

 

***Confidential
Treatment Requested

  

    	3

    	 

    

  

 parties have an interest and that arises from VA medical centers affiliated with UC campuses, and the exclusive
right to negotiate, execute and administer agreements for the commercialization of such inventions;

 

WHEREAS, LICENSEE entered into secrecy
agreements (UC Control No. [...***...]
effective March 15, 2001 and UC control number [...***...], effective April 3, 2001) with UNIVERSITY, (“Secrecy Agreement”),
for the purpose of evaluating the Invention;

 

WHEREAS, UNIVERSITY is desirous that the
Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public;

 

WHEREAS, LICENSEE is desirous of obtaining
certain rights from UNIVERSITY for commercial development, use, and sale of the Invention, and the UNIVERSITY is willing to grant
such rights; and

 

WHEREAS, LICENSEE understands that UNIVERSITY
may publish or otherwise disseminate information concerning the Invention at any time and that LICENSEE is paying consideration
thereunder for its early access to the Invention, not continued secrecy therein.

 

NOW, THEREFORE, the parties agree:

 

Article
1. DEFINITIONS

 

The terms, as defined herein, shall have
the same meanings in both their singular and plural forms.

 

		1.1	“Affiliate” means any corporation or other business entity in which LICENSEE owns or
controls, directly or indirectly greater than fifty percent (50%) of the outstanding stock or other voting rights entitled to elect
directors, or in which LICENSEE is owned or controlled directly or indirectly by greater than fifty percent (50%) of the outstanding
stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity
participation of greater than fifty percent (50%), then an “Affiliate” includes any company in which LICENSEE owns
or controls or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights
permitted by local law.

 

		1.2	“Sublicensee” means a Third Party to whom LICENSEE grants a sublicense of certain rights
granted to LICENSEE under this Agreement.

 

***Confidential
Treatment Requested

  

    	4

    	 

    

 

		1.3	“Field” means all human and veterinary uses with the exception that the Field specifically
excludes uses of the Second Invention for osteoporosis and other metabolic bone diseases.

 

		1.4	“Territory” means worldwide, but only in those countries where the Patent Rights exist
at any time during the term of this Agreement, subject to Paragraph 3.2

 

		1.5	“Term” means the period of time beginning on the Effective Date and ending on the later
of (i) the expiration date of the longest-lived Patent Rights; or (ii) the twenty-first (21st) anniversary of Effective Date.

 

		1.6	“First Patent Rights” means any of the following: the US patent application (serial
number [...***...]) disclosing and claiming
the First Invention, filed by First Inventors and assigned to UNIVERSITY; and continuing applications thereof including divisions,
substitutions, and continuations-in-part (but only to extent the claims thereof are enabled by disclosure of the parent application);
any patents issuing on said applications including reissues, reexaminations and extensions, First Patent Rights excludes corresponding
foreign applications and patents related to First Invention, for which the UNIVERSITY has not pursued patent rights outside the
United States.

 

		1.7	“Second Patent Rights” means any of the following; the international patent application
(serial number [...***...]) disclosing and claiming the Second Invention, filed by Second Inventors and assigned to UNIVERSITY;
and continuing applications thereof including divisions, substitutions, and continuations-in-part (but only to extent the claims
thereof are enabled by disclosure of the parent application); any patents issuing on said applications including reissues, reexaminations
and extensions; and any corresponding foreign applications or patents.

 

		1.8	“Third Patent Rights” means any of the following: the US patent application (serial
number [...***...]) disclosing and claiming the Third Invention, filed by Third Inventors and assigned to UNIVERSITY and DFCI;
and continuing applications thereof including divisions, substitutions, and continuations-in-part (but only to extent the claims
thereof are enabled by disclosure of the parent application); any patents issuing on said applications including reissues, reexaminations
and extensions; and any corresponding foreign applications or patents.

 

		1.9	“Patent Rights’’ means any and all or any combination of First, Second, Third
and Fourth Patent Rights.

 

***Confidential
Treatment Requested

  

    	5

    	 

    

 

		1.10	“Sponsor Rights” means all the applicable provisions of any license to the United States
Government executed by UNIVERSITY and the overriding obligations to the Federal Government under 35 U.S.C. §§ 200-212
and applicable governmental implementing regulations.

 

		1.11	“Licensed Method” means any method that is covered by the claims of Patent Rights the
use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement of any pending or
issued and unexpired claim within Patent Rights.

 

		1.12	“Licensed Product” means any services, composition or product that is covered by the
claims of Patent Rights, or that is produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation
of which would constitute, but for the license granted to LICENSEE by UNIVERSITY herein, an infringement of any pending or issued
and unexpired claim within the Patent Rights.

 

		1.13	“Net Sales” means the total of the gross invoice prices of Licensed Products sold by
LICENSEE, its Sublicensee or an Affiliate, or any combination thereof, less the sum of the following actual and customary deductions
where applicable and separately listed: [...***...]
(except for [...***...]. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate of Licensed Product
under this Agreement for (i) end use (but not resale) by the Sublicensee or Affiliate shall be treated as sales by LICENSEE at
list price of LICENSEE, or (ii) resale by a Sublicensee or an Affiliate shall be treated as sales at the list price of the Sublicensee
or Affiliate.

 

		1.14	“Patent Costs” means all out-of-pocket expenses for the preparation, filing, prosecution,
and maintenance of all United States and foreign patents and patent applications included in Patent Rights. Patent Costs shall
also include reasonable out-of-pocket expenses for patentability opinions, inventorship determination, preparation and prosecution
of patent application, re-examination, re-issue, interference, and opposition activities related to patents or applications in
Patent Rights.

 

		1.15	“VA” means the U.S. Department of Veterans Affairs.

 

		1.16	“VA/UC Agreement” means the Cooperative Technology Administration Agreement with an
effective date of May 19, 2000, which is attached hereto as Exhibit C and is incorporated herein by reference.

 

***Confidential
Treatment Requested

 

    	6

    	 

    

 

		1.17	“Combination Product” means any product which is a Licensed Product and contains other
product(s) or product component(s) that (i) does not use Invention, or Patent Rights; (ii) the sale, use or import by itself does
not contribute to or induce the infringement of Patent Rights; (iii) can be sold separately by LICENSEE, its Sublicensee or an
Affiliate; and (iv) enhances the market price of the final product(s) sold, used or imported by LICENSEE, its Sublicensee, or an
Affiliate.

 

		1.18	“Third Party” means any individual or entity other than LICENSEE or UNIVERSITY or an
Affiliate of LICENSEE or UNIVERSITY.

 

Article
2. GRANTS

 

		2.1	License.

 

Subject to the limitations set forth in
this Agreement, and the limitations set forth in the VA/UC Agreement, and Sponsor’s Rights, UNIVERSITY hereby grants to LICENSEE,
and LICENSEE hereby accepts, a license under Patent Rights to make, have made, use, sell, offer for sale, and import Licensed Products
and to practice Licensed Methods, in the Field within the Territory and during the Term.

 

The license granted herein is exclusive
for Patent Rights in the Field.

 

		2.2	Sublicense.

 

(a)          The
license granted in Paragraph 2.1 includes the right of LICENSEE to grant sublicenses to Third Parties during the Term of this Agreement
but only for as long as the license is exclusive.

 

(b)          With
respect to sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall;

 

(1)         not
receive, or agree to receive, anything of value in lieu of cash as considerations from a Third Party under a sublicense granted
pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY;

 

(2)         to
the extent applicable, include all of the rights of and obligations due to UNIVERSITY (and, if applicable, the Sponsor’s
Rights and the VA/UC Agreement) and contained in this Agreement;

 

(3)         promptly
provide UNIVERSITY with a copy of each sublicense issued; and

 

    	7

    	 

    

 

(4)         collect
and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver all
reports due, directly or indirectly, to UNIVERSITY from Sublicensees.

 

(c)          Upon
termination of this Agreement for any reason, UNIVERSITY, at its sole discretion, shall determine whether LICENSEE shall cancel
or assign to UNIVERSITY any and all sublicenses. However, if termination of this Agreement occurs due to the inability of LICENSEE
to pay Patent Costs to UNIVERSITY, Sublicensee, by assuming payment of Patent Costs, may request that UNIVERSITY continue their
Sublicense Agreement, wherein such request shall not be unreasonably denied.

 

		2.3	Reservation of Rights.

 

UNIVERSITY reserves the right to:

 

(a)          use
the Invention and Patent Rights for educational and research purposes;

 

(b)          publish
or otherwise disseminate any information about the Invention at any time; and

 

(c)          allow
other nonprofit institutions to use Invention and Patent Rights for educational and research purposes in their facilities.

 

DFCI reserves the right to:

 

(a)          use
the Third Invention and associated technology for educational and research purposes.

 

		2.4	Right to Expand Field of Use.

 

In the event that UNIVERSITY fails to execute
a license for the excluded field of use for the Second Invention (osteoporosis and other metabolic bone diseases) with the Third
Party currently negotiating with University, LICENSEE shall have the first right to negotiate a license to the excluded field of
use. UNIVERSITY shall have no longer than twenty-four (24) months to execute a license with the Third Party negotiating with the
University. LICENSEE shall have six (6) months from the date of notification by UNIVERSITY of availability of excluded field of
use rights to conclude a license agreement with UNIVERSITY.

 

    	8

    	 

    

 

Article
3. CONSIDERATIONS

 

3.1           Fees
and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement
are partial consideration for the licenses granted herein to LICENSEE under Patent Rights. LICENSEE shall pay UNIVERSITY:

 

(a)          in
recognition of LICENSEE being a startup business and in lieu of cash, a license issue fee in the form of one hundred and
five thousand (105,000) shares of Chimerix, Inc. Common Stock, from the Three Million Five-Hundred Thousand (3,500,000) shares
of Chimerix Common Stock authorized for issuance under LICENSEE’s Articles of Incorporation dated April 6, 2000 (Exhibit
D); and such stock shall be delivered to UNIVERSITY within sixty (60) days of notification of final approval by the UNIVERSITY
Office of the President in the name of “Shellwater & Co.”, a nominee of UNIVERSITY, provided however, that the
acceptance of LICENSEE’s common stock is subject to:

 

(i)          the
final approval of the Office of the President of UNIVERSITY. In the event that such approval is not granted, this Agreement shall
remain in effect and LICENSEE and UNIVERSITY shall renegotiate in good faith for a substitution of similar value for consideration.

 

(ii)         LICENSEE
and UNIVERSITY entering into a shareholder agreement outlining the rights of UNIVERSITY as a shareholder that is no less favorable
to the UNIVERSITY than to the common share-holding founders and is acceptable to the UNIVERSITY.

 

(b)          milestone
payments in the amounts payable according to the following schedule of events:

 

	Amount	 	Date or Event
	[...***...]	 	LICENSEE begins a Phase I clinical trial; payable for each of the first three Licensed Products to begin a Phase I clinical trial
	 	 	 
	[...***...]	 	LICENSEE begins a Phase III clinical trial; payable for each of the first three Licensed Products to begin a Phase III clinical trial

 

***Confidential
Treatment Requested

 

    	9

    	 

    

 

	[...***...]	 	LICENSEE receives the first US regulatory approval for the sale of the first Licensed Product for human therapeutic use
	 	 	 
	[...***...]	 	LICENSEE receives US regulatory approval for the sale of each subsequent Licensed Product(s) for human therapeutic use
	 	 	 
	[...***...]	 	LICENSEE receives regulatory approval for the sale of each Licensed Product in Europe
	 	 	 
	[...***...]	 	LICENSEE receives regulatory approval for the sale of each Licensed Product in Japan

 

 

(c)          an
earned royalty of [...***...] on Net Sales of Licensed Products by LICENSEE, or its Affiliate(s) (The “Royalty Rate”);
provided however that:

 

(i)          if
LICENSEE is required to license the intellectual property of a Third Party to make, have made, use, sell, offer to sell or import
Licensed Products, the earned royalty due hereunder shall be reduced in the proportion of [...***...] of royalty due to such Third
Party; and

 

(ii)         the
earned royalty due on Net Sales of Combination Product by LICENSEE and/or its Affiliate(s) shall be calculated as below: Earned
royalty due UNIVERSITY = A/(A+B+C . . .) x Royalty Rate on Net Sales of the Licensed Products, where: A is the separately
listed sale price of the Licensed Product or Licensed Product components; and B and C . . . are the separately listed
sale prices of the individual products or product components, respectively, that satisfied the requirements outlined in Paragraph
1.17. In the event that LICENSEE does not separately sell any of the B, C . . . products or product components used
in Combination Product, the purchase price paid by LICENSEE in the procurement of said products or product components shall be
used.

 

***Confidential
Treatment Requested

  

    	10

    	 

    

  

 in Combination Product, the
purchase price paid by LICENSEE in the procurement of said products or product components shall be used.

 

(iii)        under
no circumstances shall the royalty due to UNIVERSITY be less than [...***...]
of the amount due without the deductions allowable under 3.1 (c) (i) or (ii), therefore the royalties due to UNIVERSITY shall never
be less than [...***...] on Net Sales of Licensed Products by LICENSEE or its Affiliates.

 

(d)          a
percentage of sublicense fees, including, but not limited to option fees, license issue fees, license maintenance fees and
milestone payments for specified Licensed Products and excluding research and development contract payments for specific research
projects within the Field provided, however, that such research support shall not include executive and clerical salaries, legal
costs, or other costs not directly related to research.

 

(i)          The
percentage of sublicense fees payable to UNIVERSITY by LICENSEE will be determined according to the following schedule:

 

	Percentage to be paid	 	Date of Sublicensure
	 	 	 
	[...***...]	 	Prior to the first IND submission for a Licensed Product or prior to expenditure of [...***...] in research to identify, characterize or develop Licensed Products within the Field
	 	 	 
	[...***...]	 	Upon or after the expenditure of [...***...] in research to identify, characterize or develop Licensed Products within the Field; or on or after the first IND Submission for a Licensed Product, but prior to initiation of the first Phase III Clinical Study for a Licensed Product.
	 	 	 
	[...***...]	 	On or after initiation of the first Phase III Clinical Study for a Licensed Product

 

***Confidential
Treatment Requested

 

    	11

    	 

    

 

(e)          on
each and every sublicense royalty payment received by LICENSEE from its Sublicensees on sales of Licensed Product by Sublicensee,
either (i) royalties based on the royalty rate in Paragraph 3.1(c) as applied to Net Sales of Sublicensee, or (ii) [...***...]
of the royalties received by LICENSEE from Sublicensee; whichever amount is less.

 

(f)          beginning
in the first calendar year of commercial sales of the first Licensed Product by LICENSEE, its Sublicensee, or an Affiliate and
if the total earned royalties paid by LICENSEE, or its Affiliates under Paragraph 3.1(c) and (e) to UNIVERSITY in any such year
cumulatively amounts to less than [...***...] (“minimum annual royalty”), LICENSEE shall pay to UNIVERSITY a
minimum annual royalty on or before February 28 following the last quarter of such year the difference between [...***...] and
the sum of total, earned royalty paid by LICENSEE for such year under Paragraphs 3.1(c) and (e); provided, however, that for the
first year of commercial sales of the first Licensed Product, the amount of minimum annual royalty payable shall be pro-rated for
the number of months remaining in that calendar year.

 

(g)          All
fees and royalty payments specified in Paragraphs 3.1(b) through 3.1(f) shall be paid by LICENSEE pursuant to Paragraph 4.3 and
shall be delivered by LICENSEE to UNIVERSITY pursuant to Paragraph 10.1.

 

		3.2	Patent Costs.

 

LICENSEE shall reimburse UNIVERSITY all past (up to the Effective
Date) and future (on or after the Effective Date) Patent Costs plus a [...***...] patent service fee. Future Patent Costs will
be due within thirty (30) days following receipt by LICENSEE of an itemized invoice from UNIVERSITY. As of January 22, 2002, Past
Patent Costs are approximately [...***...] and are due according to the following schedule:

 

	Amount	 	Date or Event
	[...***...] of the past patent costs which is approximately [...***...]	 	The earlier of the one (1) year anniversary of the Effective Date or receipt of equity funding of $8,000,000 (Eight Million dollars).
	[...***...] of the past patent costs which is approximately [...***...]	 	The earlier of the two (2) year anniversary of the Effective Date or receipt of equity funding of $8,000,000 (Eight Million dollars).
	[...***...] of the past patent costs which is approximately [...***...]	 	The earlier of the three (3) year anniversary of the Effective Date or receipt of equity funding of $8,000,000 (Eight Million dollars).

 

***Confidential
Treatment Requested

 

    	12

    	 

    

 

	[...***...] of the past patent costs which is approximately [...***...]	 	The earlier of the four (4) year anniversary of the Effective Date or receipt of equity funding of $8,000,000 (Eight Million dollars).
	 	 	 	 

 

If UNIVERSITY licenses to Third Parties
uses of the Second Invention outside the Field, Patent costs for the Second Invention shall be prorated among LICENSEE and Third
Parties who have obtained from UNIVERSITY a license outside the Field.

 

		3.3	Due Diligence.

 

		(a)	LICENSEE, Affiliate or Sublicensee shall:

 

(1)         diligently
proceed with the development, manufacture and sale of Licensed Products; and

 

(2)         beginning
one year from the Effective Date of this Agreement, annually spend not less than One Hundred Thousand US Dollars (US$100,000)
for the development of Licensed Products during the next four (4) years of the Agreement. LICENSEE may, at its sole option,
fund the research of any one of the Inventors and credit the amount of such funding actually paid to UCSD against its
obligation under this paragraph.

 

(3)         on
or before the date ending five (5) years after the Effective Date, file an IND with the US FDA (or its equivalent in a foreign
country) for a Licensed Product; and

 

(4)         on
or before the date ending seven (7) years after the Effective Date, commence in the US a Phase II clinical trial (or its
equivalent in a foreign country) for first Licensed Product; and

 

(5)         on
or before the date ending nine (9) years after the Effective Date, commence a Phase III clinical trial (or its equivalent in
a foreign country) for first Licensed Product; and

 

(6)         on
or before the date ending twelve  (12) years after the Effective Date file with US FDA an NDA or PLA (or its equivalent in a
foreign country) for first Licensed Product; and

 

(7)         market
a Licensed Product in the US within six (6) months after receiving regulatory approval to market such Licensed Product;
and

 

***Confidential
Treatment Requested

 

    	13

    	 

    

 

(8)         fill
the market demand for Licensed Products following commencement of marketing at any time during the term of this Agreement; and

 

(9)         obtain
all necessary governmental approvals for the manufacture, use and sale of Licensed Products.

 

(b)          LICENSEE
may renegotiate the diligence criteria of Section 3.3(a) (the “Diligence Changes”) pursuant to significant changes
in the technological, regulatory or economic climate of the industry. LICENSEE must document these changes to UNIVERSITY. UNIVERSITY
reserves the right and option to either approve these Diligence Changes, such approval not being unreasonably denied, or to terminate
this Agreement or change LICENSEE’s exclusive license to a nonexclusive license under commercially reasonable terms.

 

		(c)	If LICENSEE, Affiliate or Sublicensee fails to perform the obligations specified in Paragraphs
33(a) (1)-(9) hereof, then UNIVERSITY shall have the right and option to either terminate this Agreement or change LICENSEE’s
exclusive license to a nonexclusive license. This right, if exercised by UNIVERSITY, supersedes the rights granted in Paragraph
2.1 hereof, and is subject to provisions of Paragraph 3.3 (d) hereof.

 

		(d)	If LICENSEE, Affiliate or Sublicensee fails to perform the obligations specified in Paragraphs
3.3(a)(3)-(7), but has otherwise fulfilled the obligations specified in Paragraphs 3.3(a)(1), (2), (8) and (9) for a Licensed Product
not to be used for human therapeutic use, LICENSEE will retain an exclusive license under this Agreement in a field and to the
extent necessary to reasonably protect proprietary commercial rights of the LICENSEE, Affiliate or Sublicensee for such Licensed
Product.

 

Article
4. REPORTS, RECORDS AND PAYMENTS

 

		4.1	Reports.

 

(a)           Progress Reports.

 

(1)         Beginning
January 1, 2003 and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall submit
to UNIVERSITY semi-annual progress reports covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities
to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such reports shall
include a summary of work completed; summary of work in progress; current schedule of anticipated events or milestones; market
plans for introduction of

 

 

    	14

    	 

    
 

Licensed Products; and summary
of resources (dollar value) spent in the reporting period.

 

(2)         LICENSEE
shall also report to UNIVERSITY, in its immediately subsequent royalty report, the date of first commercial sale of a Licensed
Product in each country.

 

(b)          Royalty
Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly
royalty reports on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report shall cover
LICENSEE’S (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall show:

 

(1)         the
gross sales, deductions as provided in paragraph 1.13, and Net Sales during the most recently completed calendar quarter and the
royalties, in US dollars, payable with respect thereto;

 

(2)         the
number of each type of Licensed Product sold;

 

(3)         sublicense
fees and royalties received during the most recently completed calendar quarter in US dollars and the portion payable to UNIVERSITY
with respect thereto;

 

(4)         the
method used to calculate the royalties and sublicense fees and the portion payable to UNIVERSITY thereto; and

 

(5)         the
exchange rates used.

 

(6)         If
no sales of Licensed Products have been made and no sublicense revenues have been received by LICENSEE during any reporting period,
LICENSEE shall so report.

 

		4.2	Records & Audits.

 

(a)          LICENSEE
shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured,
used, and sold, and sublicense fees received under this Agreement. Such records shall be retained by LICENSEE for at least five
(5) years following a given reporting period.

  

(b)          Upon
written request of UNIVERSITY, LICENSEE shall make such records available to UNIVERSITY as may be reasonably necessary to verify
the accuracy of the reports and payments hereunder. The specific requests shall be for records from any year ending not more than
five (5) years prior to the date

 

    	15

    	 

    

 

of such request. All records
shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit
Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement
for the sole purpose of verifying reports and payments or other compliance issues. Such inspector shall not disclose to UNIVERSITY
any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance
issues. In the event that any such inspection shows an under reporting and underpayment in excess of [...***...] for any twelve
(12) month period, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to
UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of [...***...] per year. Such interest shall
be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE.
For underpayment not in excess of [...***...] for any twelve (12) month period, LICENSEE shall pay the difference within thirty
(30) days without interest charge or inspection cost.

 

(c)          UNIVERSITY
may provide the VA with all financial information obtained from LICENSEE under Paragraph 4.1 hereof to the extent required under
VA/UC Agreement, and if such information is provided to the VA, UNIVERSITY will require that the VA not disclose it to third parties.

 

(d)          Notwithstanding
Paragraph 4.2(c) hereof, UNIVERSITY shall treat all financial information obtained from LICENSEE as confidential and shall cause
its accounting firm to retain all such financial information in confidence.

 

		4.3	Payments.

 

(a)          All
fees and royalties due UNIVERSITY shall be paid in United States dollars and all checks shall be made payable to “The Regents
of the University of California”, referencing UNIVERSITY taxpayer identification number, [...***...]. When Licensed Products
are sold in currencies other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the
country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the exchange
rate quoted in the Wall Street Journal on the last business day of the applicable reporting period.

 

(b)          Royalty Payments.

 

(1)         Royalties
shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered by LICENSEE or Affiliate to a Third Party,
or upon delivery to Affiliate if for end use by Affiliate.

 

***Confidential
Treatment Requested

 

    	16

    	 

    

 

(2)         LICENSEE
shall pay earned royalties quarterly on or before February 28, May 31, August 31 and November 30 of each calendar year, Each such
payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar quarter.

 

(3)         Royalties
earned on sales occurring or under sublicense granted pursuant to this Agreement in any country outside the United States shall
not be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country on the payment of royalty
income, except that all payments made by LICENSEE in fulfillment of UNIVERSITY’S tax liability in any particular country
may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting
from the transfer of such royalty payments.

 

(4)         If
at any time legal restrictions prevent the prompt remittance of part or all royalties by LICENSEE with respect to any country where
a Licensed Product is sold or a sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY
into US currency and shall pay UNIVERSITY directly from its US sources of funds for as long as the legal restrictions apply. If
the royalty rate specified in this Agreement should exceed the permissible rate established in any country, the royalty rate for
sales in such country shall be adjusted to the highest legally permissible or government-approved rate.

 

(5)         LICENSEE
shall not collect royalties otherwise due to UNIVERSITY, nor cause royalties to be paid to UNIVERSITY on Licensed Products sold
to the account of the US Government or any agency thereof as provided for in the license to the US Government.

 

(6)         In
the event that any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from which
no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and
from which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably
indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any
royalties that accrued before the date of such final decision, that are based on another patent or claim not involved in such final
decision.

  

(c)          Late
Payments, In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay
to

 

    	17

    	 

    

  

UNIVERSITY interest charges
at a rate of [...***...] or the maximum allowed by law, whichever is less. Such interest shall be calculated from the date payment
was due until actually received by UNIVERSITY.

 

Article
5. PATENT MATTERS

 

		5.1	Patent Prosecution and Maintenance.

 

(a)          Provided
that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.2, UNIVERSITY shall diligently prosecute and maintain
the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice. UNIVERSITY
shall promptly provide LICENSEE with copies of all relevant documentation relating to such prosecution and LICENSEE shall keep
this documentation confidential. The counsel shall take instructions only from UNIVERSITY, and all patents and patent applications
in Patent Rights shall be assigned solely to UNIVERSITY.

 

(b)          UNIVERSITY
shall consider amending any patent application in Patent Rights to include claims reasonably requested by LICENSEE to protect the
products contemplated to be sold by LICENSEE under this Agreement.

 

(c)          UNIVERSITY
shall apply for an extension of the term of any patent in Patent Rights if appropriate under the Drug Price Competition and Patent
Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this law. LICENSEE shall prepare all documents
and pay costs incurred for such application, and UNIVERSITY shall execute such documents and take any other additional action as
LICENSEE reasonably requests in connection therewith.

 

(d)          LICENSEE
may elect to terminate its reimbursement obligations with respect to any patent application or patent in Patent Rights upon three
(3) months’ written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such
application or patent when such notice of termination is received from LICENSEE. UNIVERSITY, in its sole discretion and at its
sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall then have no further license
nor any obligations under this Agreement with respect thereto. UNIVERSITY shall give written notice of any non-payment of any portion
of Patent Costs with respect to any application or patent to LICENSEE. If LICENSEE fails to cure the non-payment within sixty (60)
days, UNIVERSITY may provide a second written notice (“Notice of Termination”) to LICENSEE, indicating the specifics
of the termination of the license for such application or patent. The University is not obligated to file, prosecute, or maintain
Patent Rights outside of the

 

***Confidential
Treatment Requested

 

    	18

    	 

    

  

territory at any time or to
file, prosecute, or maintain Patent Rights to which Licensee has terminated its license hereunder.

 

		5.2	Patent Infringement.

 

(a)          If
LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with
reasonable evidence of the infringement. Neither UNIVERSITY nor LICENSEE shall notify a Third Party of the infringement of Patent
Rights without the consent of the other. Both UNIVERSITY and LICENSEE shall use reasonable efforts and cooperation to terminate
infringement without litigation.

 

(b)          LICENSEE
may request UNIVERSITY to take legal action against such Third Party for the infringement of Patent Rights. Such request shall
be made in writing and shall include reasonable evidence of such infringement and damages to LICENSEE. If the infringing activity
has not abated ninety (90) days following LICENSEE’s request, UNIVERSITY shall have the right to commence suit on its own
account. UNIVERSITY shall give notice of its election to commence suit in writing to LICENSEE by the end of the one-hundredth (100th)
day after receiving notice of such request from LICENSEE. LICENSEE may elect to join in that suit at its own expense. Should UNIVERSITY
not commence suit on its own account, LICENSEE may thereafter bring suit for patent infringement at its own expense, if the infringement
occurred in a jurisdiction where LICENSEE has an exclusive license under this Agreement. If LICENSEE elects to bring suit, UNIVERSITY
may join that suit at its own expense.

 

(c)          Recoveries
from actions brought pursuant to Paragraph 5.2(b) shall belong to the party (UNIVERSITY or LICENSEE) bringing suit and bearing
the expenses of the litigation. Legal actions brought jointly by UNIVERSITY and LICENSEE and fully participated in by both shall
be at the joint expense of the parties and all recoveries shall be shared jointly by them in proportion to the share of expense
paid by each party.

 

(d)          UNIVERSITY
and LICENSEE shall cooperate with each other in litigation proceedings at the expense of the party bringing suit. Litigation shall
be controlled by the party bringing the suit, except that either party may be represented by counsel of its choice in any suit
brought by the other party.

 

		5.3	Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under the terms
of this Agreement, or their containers, in accordance with the applicable patent marking laws.

 

    	19

    	 

    

 

Article
6. GOVERNMENTAL MATTERS

 

6.1           Governmental
Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation to be either
approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify
UNIVERSITY if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement.
LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated
with such reporting or approval process.

 

6.2           Export
Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed
Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations
and the Export Administration Regulations.

 

6.3           Preference
for United States Industry. If LICENSEE sells a Licensed Product or Combination Product in the US, LICENSEE shall manufacture
said Licensed Product substantially in the US.

 

Article
7. TERMINATION OF THE AGREEMENT

 

7.1           Termination
by The Regents. If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice
of default (“Notice of Default”) to LICENSEE. The Notice of Default shall state the asserted failure to perform or
violation by LICENSEE. If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default, UNIVERSITY may terminate
this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE. If
a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice.
Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any
accrued right of UNIVERSITY. The VA shall also have termination rights specified in Article 7 of the VA/UC Agreement under this
Agreement.

 

		7.2	Termination by Licensee.

 

(a)          LICENSEE
shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written notice to UNIVERSITY.
Said notice shall state LICENSEE’s reason for terminating this Agreement.

 

(b)          Any
termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior
to termination, or rescind any payment made to UNIVERSITY or action by LICENSEE prior to

  

    	20

    	 

    

 

time termination becomes effective.
Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.

  

		7.3	Survival on Termination. The following Paragraphs and Articles shall survive the termination
of this Agreement:

 

		(a)	Article 4 (REPORTS, RECORDS AND PAYMENTS);

 

		(b)	Paragraph 7.3 (Survival on Termination);

 

		(c)	Paragraph 7.4 (Disposition of Licensed Products on Hand);

 

		(d)	Paragraph 8.2 (Indemnification);

 

		(e)	Article 9 (USE OF NAMES AND TRADEMARKS);

 

		(f)	Paragraph 10.2 (Secrecy); and

 

		(g)	Paragraph 10.5 (Failure to Perform).

 

7.4           Disposition
of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose or all previously made or partially
made Licensed Product within a period of one hundred and eighty (180) days of the effective date of such termination provided that
the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement,
including but not limited to the rendering of reports and payment of royalties required under this Agreement.

 

Article
8. LIMITED WARRANTY AND INDEMNIFICATION 

 

		8.1	Limited Warranty.

 

(a)          UNIVERSITY
warrants that it has the lawful right to grant this license.

 

(b)          The
license granted herein is provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE or any other warranty, express or implied. UNIVERSITY and VA makes no representation or warranty that the Licensed Product,
Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights

 

    	21

    	 

    

 

(c)          In
no event shall UNIVERSITY or VA be liable for any incidental, special or consequential damages resulting from exercise of the license
granted herein or the use of the Invention, Licensed Product, or Licensed Method.

 

(d)          Nothing
in this Agreement shall be construed as:

 

(1)         a
warranty or representation by UNIVERSITY or VA as to the validity or scope of any Patent Rights;

 

(2)         a
warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement
is or shall be free from infringement of patents of third parties;

 

(3)         an
obligation of UNVERSITY or the VA to bring or prosecute actions or suits against Third Parties for patent infringement except as
provided in Paragraph 5.2 hereof;

 

(4)         conferring
by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY or the U.S. Government or DFCI other
than Patent Rights as defined in this Agreement regardless of whether these patents are dominant or subordinate to Patent Rights;
or

 

(5)         an
obligation of UNIVERSITY or the VA to furnish any know-how not provided in Patent Rights.

 

		8.2	Indemnification.

 

(a)          LICENSEE
shall indemnify, hold harmless and defend UNIVERSITY and the US Government, their officers, employees, and agents; the sponsors
of the research that led to the Invention; and the Inventors of the patents and patent applications in Patent Rights and their
employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from or arising out of exercise
of this license or any sublicense. This indemnification shall include, but not be limited to, any product liability.

 

(b)          LICENSEE,
at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in
force and maintain insurance or an equivalent program of self insurance as follows:

 

(1)         comprehensive
or commercial general liability insurance (contractual liability included) with limits of at least: (i) each occurrence, $1,000,000;
(ii) products/completed operations aggregate, $5,000,000; (iii) personal and advertising injury, $1,000,000; and (iv) general aggregate
(commercial form only), $5,000,000; and

 

    	22

    	 

    

 

(2)         the
coverage and limits referred to above shall not in any way limit the liability of LICENSEE.

 

(c)          LICENSEE
shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates shall: (i)
provide for thirty (30) day advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has been endorsed
as an additional insured under the coverage referred to above; and (iii) include a provision that the coverage shall be primary
and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried
or maintained by UNIVERSITY.

 

(d)          UNIVERSITY
shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY or the US Government in respect of which UNIVERSITY
intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of
any claims under this Article.

 

(e)          With
respect to the Third Invention and Third Patent Rights, the following Paragraphs 8.2(e)(1) and 8.2(e)(2) shall also be in effect:

 

(1) (i) LICENSEE shall
indemnify, defend and hold harmless DFCI and its trustees officers, medical and professional staff, employees, and agents and their
respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including
reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the Indemnitees, or any one of them, in
connection with any claims, suits, actions, demands or judgments (a) arising out of the design, production, manufacture, sale,
use in commerce, lease, or promotion by LICENSEE or by a Sulicensee, Affiliate or agent of LICENSEE, or any product, process or
service relating to or developed pursuant to, this Agreement or (b) arising out of any other activities to be carried out pursuant
to this Agreement.

 

(ii) LICENSEE’S
indemnification under Section 8.2 (e) (1) (i) (a) applies to any liability, damage, loss or expense whether or not it is attributable
to the negligent activities of the Indemnitees. Licensee’s indemnification under 8.2 (e) (1) (i) (b) does not apply to any
liability, damage, loss or expense to the extent that it is attributable to (a) the negligent activities of the Indemnitees, or
(b) the intentional wrongdoing or intentional misconduct of the Indemnitees.

 

(iii)
LICENSEE shall, at its own expense, provide attorneys reasonably acceptable to DFCI to defend against any actions brought or
filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions
are rightfully brought.

 

    	23

    	 

    

 

(iv)
If any such action is commenced or claim made or threatened against DFCI or other Indemnitees as to which LICENSEE is obligated
to indemnify it (them) or hold it (them) harmless, DFCI or the other Indemnitees shall promptly notify LICENSEE of such event.
LICNESEE shall assume the defense of, and may settle, that part of any such claim or action commenced or made against DFCI (or
other Indemnitees) which relates to LICENSEE’s indemnification and LICENSEE may take such other steps as may be necessary
to protect it. LICENSEE will not be liable to DFCI or other Indemnitees on account of any settlement of any such claim or litigation
affected without LICENSEE’S consent. The right of LICENSEE to assume the defense of any action is limited to that part of
the action commenced against DFCI and/or Indemnitees that relates to LICENSEE’S obligation of indemnification and holding
harmless.

 

(v)
LICENSEE shall require any Affiliates or Sublicensee(s) to indemnify, hold harmless and defend DFCI under the same terms set
forth in Sections 8.2 (e) (1) (i) - (iv).

 

(2) (i) At such time
as any product, process or service relating to, or developed pursuant to, this Agreement is being commercially distributed or sold
(other than for the purpose of obtaining regulatory approvals) by LICENSEE or by a Sublicensee, Affiliate or agent of LICENSEE,
LICENSEE shall, at its sole cost and expense, procure and maintain policies of commercial general liability insurance in amounts
not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming the Indemnitees as additional insureds. Such commercial
general liability insurance must provide (a) product liability coverage and (b) contractual liability coverage for LICENSEE’S
indemnification under Sections 8.2 (e) (1) (i)-(iii) of this Agreement. If LICENSEE elects to self-insure all or part of the limits
described above (including deductibles or retentions which are in excess of $250,000 annual aggregate), such self-insurance program
must be acceptable to the DFCI and the DFCI’s associated Risk Management Foundation. The minimum amounts of insurance coverage
required under these provisions may not be construed to create a limit of LICENSEE’s liability with respect to its indemnification
obligation under Sections 8.2 (e) (1) (i)-(iii) of this Agreement.

 

(ii)
LICENSEE shall provide DFCI with written evidence of such insurance upon request of DFCI. LICENSEE shall provide DFCI with
written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if LICENSEE
does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, DFCI has the right to
terminate this Agreement effective at the end of such fifteen (15) day period without any notice or additional waiting periods.

 

    	24

    	 

    

 

(iii)
LICENSEE shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement
during (a) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold (other than for the purpose of obtaining regulatory approvals) by LICNESEE or by a Sublicensee, Affiliate or
agent of LICENSEE and (b) a reasonable period after the period referred to in 8.2 (e) (2) (iii) (a) above which in no event shall
be less than fifteen (15) years.

 

(iv)
LICENSEE shall require any Affiliates or Sublicensee(s) to maintain insurance in favor of DFCI and the Indemnitees under the
same terms set forth in Sections 8.2 (e) (2) (i)-(iii).

 

Article
9. USE OF NAMES AND TRADEMARKS

 

9.1           Nothing
contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade
name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing).
Unless required by law, the use by LICENSEE of the name, “The Regents Of The University Of California” or the name
of any campus of the University Of California or the VA or DFCI is prohibited, without the express written consent of UNIVERSITY.

 

9.2           UNIVERSITY
may disclose to the Inventors the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY
shall give notice of its confidential nature and require that the Inventors not disclose such terms and conditions to others.

 

9.3           UNIVERSITY
or the VA may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to Third Parties, but UNIVERSITY
shall not disclose the financial terms of this Agreement to Third Parties, except where UNIVERSITY or the VA is required by law
to do so, such as under the California Public Records Act.

 

Article
10. MISCELLANEOUS PROVISIONS

 

10.1         Correspondence.
Any notice or payment required to be given to either party under this Agreement shall be deemed to have been properly given and
effective:

 

(a)          on
the date of delivery if delivered in person, or

 

    	25

    	 

    

 

(b)          five
(5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to
such other address as is designated by written notice given to the other party.

 

If sent to LICENSEE:

 

Chimerix, Inc.

14024 Rue Saint Raphael

Del Mar, CA 92014

Phone: (858) 755-7503

Attention: President

 

If sent to UNIVERSITY:

 

University of California, San Diego

Technology Transfer & Intellectual Property Services

9500 Gilman Drive

La Jolla, CA 92093-0910

Phone: (858) 534-5815

Attention: Director

 

		10.2	Secrecy.

 

(a)          “Confidential
Information” shall mean information relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the term of
this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall
within thirty (30) days of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE:

 

		(b)	Licensee shall:

 

(1)         use
the Confidential Information for the sole purpose of performing under the terms of this Agreement;

 

(2)         safeguard
Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar
nature;

 

(3)         not
disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a like
obligation of confidentiality) without the express written permission of

 

    	26

    	 

    
 

UNIVERSITY, except that LICENSEE
shall not be prevented from using or disclosing any of the Confidential Information that:

 

(i)          LICENSEE
can demonstrate by written records was previously known to it;

 

(ii)         is
now, or becomes in the future, public knowledge other than through acts or omissions of LICENSEE; or

 

(iii)        is
lawfully obtained by LICENSEE from sources independent of UNIVERSITY.

 

(c)          The
secrecy obligations of LICENSEE with respect to Confidential Information shall continue for a period ending five (5) years after
disclosure of Confidential Information.

 

10.3         Assignability.
This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only with the written consent
of UNIVERSITY, which shall not be unreasonably withheld; provided, however, that LICENSEE may assign this Agreement and all rights
and obligations hereunder without the written consent of UNIVERSITY to any person or entity that acquires all or substantially
all of LICENSEE’S assets or line of business to which this Agreement relates, whether by sale, merger or otherwise.

 

10.4         No
Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement shall be
deemed a waiver as to any subsequent and/or similar breach or default.

 

10.5         Failure
to Perform. In the event of a failure of performance due under this Agreement and if it becomes necessary for either party
to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorney’s
fees in addition to costs and necessary disbursements.

 

10.6         Governing
Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, without regard
to the conflicts of law provisions thereof but the scope and validity of any patent or patent application shall be governed by
the applicable laws of the country of the patent or patent application.

 

10.7         Force
Majeure. UNIVERSITY or LICENSEE may be excused from any performance required herein if such performance is rendered impossible
or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot,
and Insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes;
and floods, fires,

  

    	27

    	 

    

  

explosions, or other natural disasters.
When such events have abated, the non-performing party’s obligations herein shall resume.

 

10.8         Headings.
The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement.

 

10.9         Entire
Agreement. This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations
or understandings, either oral or written, between the parties relating to the subject matter hereof.

 

10.10         Amendments.
No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf
of each party.

 

10.11         Severability.
In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect,
such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall
be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.

 

IN WITNESS WHEREOF, both UNIVERSITY and
LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and
year written.

 

	CHIMERIX, INC.:	 	THE REGENTS OF THE 
	 	 	UNIVERSITY OF CALIFORNIA:
	 	 	 
	By	/s/ Karl Y. Hostetler	 	By	/s/ Alan S. Paau
	 	(Signature)	 	 	(Signature)
	 	 	 
	Name: Karl Y. Hostetler	 	Name: Alan S. Paau
	 	 	 
	Title: President and CEO	 	Director, Technology Transfer &
	 	 	Intellectual Property Services
	 	 	 
	Date	May 13, 2002	 	Date	May 13, 2002

  

    	28

    	 

    

  

Exhibit A

 

Copy of the

 

DFCI/UC AGREEMENT:

 

Inter-Institutional Agreement

 

With an Effective Date of October 16,
2001

 

    	 

    	 

    

  

Inter-Institutional Agreement

 

Between

 

The Regents of the University of California

 

and

 

Dana Farber Cancer Institute

 

for

 

The Management Of

 

Improved Lipid Prodrugs of Phosphonaoacid-Nucleoside
Conjugates

([...***...])(DFCI [...***...])

 

***Confidential
Treatment Requested

 

    	 

    	 

    

  

AGREEMENT

 

THIS AGREEMENT is effective
on the date of the last signature of this Agreement by and between Dana Farber Cancer Institute (“DFCI”), a not-for-profit
research institute having an address for official business at 44 Binney Street, Boston, MA, 02215 and The Regents of the University
of California (“UNIVERSITY”), having a system-wide business address at 1111 Franklin St., Oakland, California 9007-5200,
and represented by its San Diego campus (“UCSD”) Technology Transfer & Intellectual Property Services (“TTIPS”),
having an address at 9500 Gilman Drive, La Jolla, California 92093-0910.

 

BACKGROUND

 

Certain research performed
at UCSD by [...***...] (collectively,
“UCSD Inventor”) and at DFCI by [...***...] (collectively “DFCI Inventor”) resulted in the development
of an invention titled “Improved Lipid Prodrugs of Phosphonaoacid-Nucleoside Conjugates” which is disclosed in UCSD
Docket No. [...***...] (“Invention”) and DFCI Disclosure [...***...].

 

The Invention is covered
by Patent Rights (as later defined in this Agreement).

 

It is the mutual desire
of UCSD and DFCI that, for the purposes of this Agreement, the Invention be administered and commercialized by UCSD on behalf of
UCSD and DFCI; and DFCI agrees to forbear granting to any third party (other than to UCSD) any right, title, or interest in and
to the Patent Rights.

 

UCSD and DFCI agree:

 

1. DEFINITIONS

 

		1.1	“Patent Rights” means all right, title and interest in, to and under the US Patent
Application [...***...] filed by UCSD Inventor and DFCI Inventor on 6/8/00 and claiming the Invention, and any other patent applications,
including divisions, continuations, or continuations-in-part (but only to the extent such continuations-in-part are adequately
supported in the parent application) thereof; any corresponding foreign applications thereof; and any US or joint foreign patents
issued thereon or reissues or extensions thereof, assigned by each inventor to his respective institution.

 

		1.2	“Net Revenues” means gross proceeds received by UCSD from the licensing of Patent Rights
to third parties less a [...***...] administrative fee and less all reasonable and actual, past and future, out-of-pocket patent
costs (exclusive of any salaries, administrative, or other indirect costs) incurred by UCSD and/or DFCI in the preparation, filing,
prosecution, and maintenance of Patent Rights.

 

***Confidential
Treatment Requested

 

    	Page 1

    	 

    

 

		1.3	“License Agreement” means any agreement, including but not limited to license agreement,
option agreement, partnership agreement, and letter-of-intent, that is entered into by UCSD under this Agreement and grants to
or reserves for a third party the right to make, have made, use, have used, sell, have sold, offer to sell, and/or import products
covered by Patent Rights.

 

		1.4	“Licensee” means any third party granted a License Agreement by UCSD.

 

2. PATENT PROSECUTION AND PROTECTION

 

		2.1	UCSD shall promptly prepare and file appropriate United States patent applications covering the
Invention and shall promptly provide to DFCI all serial numbers and filing dates, together with copies of all the applications,
including copies of all Patent Office Actions, responses and all other Patent Office communications.

 

		2.2	UCSD shall, after consulting with DFCI and within eight (8) months of any United States filing,
make an election whether, when, and in what countries, to file foreign patent applications if countries where statutory protection
is available. If any foreign patent applications are filed, UCSD shall promptly provide to DFCI all serial numbers and filing dates.
UCSD also shall provide to DFCI copies of foreign patent applications and patent office actions as DFCI may request in the course
of prosecution.

 

		2.3	UCSD shall promptly record Assignments of domestic Patent Rights in the United States Patent and
Trademark Office and shall provide DFCI with a photocopy of each recorded Assignment.

 

		2.4	Notwithstanding any other provision of this Agreement, UCSD shall not abandon the prosecution of
any patent application (except for purposes of provisional conversion, filing continuation or continuation-in-part applications)
or the maintenance of any Patent Rights without prior written notice to DFCI.

 

		2.5	UCSD shall promptly provide to DFCI copies of all patents issued under Patent Rights.

 

3. LICENSING

 

		3.1	During the term of this Agreement, DFCI shall forbear granting to any third party (other than to
UCSD) any right, title, or interest in, to or under the Patent Rights and grants to UCSD the sole responsibility for administering
and commercializing the Invention.

 

    	Page 2

    	 

    

 

		3.2	UCSD shall diligently seek a Licensee for the commercial development of the Inventions and shall
promptly provide to DFCI copies of all License Agreements issued on the Inventions.

 

		3.3	Any License Agreement will include, but not be limited to, the following terms: a license issue
fee, an earned royalty, payment of patent costs by the Licensee, minimum annual royalties, diligence terms, indemnification of
UNIVERSITY and DFCI by Licensee, a limited warranty on the part of UNIVERSITY and a prohibition against the use of the name of
The Regents of the University of California or any campus thereof and DFCI. The indemnification will include the language attached
as Appendix A. Any changes to the language in Appendix A must be approved by DFCI and its insurer, the Risk Management Foundation.
Any License Agreement will further stipulate that nothing in the License Agreement confers by estoppel implication or otherwise,
any license or rights under any patents of UNIVERSITY or DFCI other than Patent Rights as defined herein, regardless of whether
such patents are dominant or subordinate to the Patent Rights.

 

		3.4	UCSD shall not issue any paid-up licenses or assign Patent Rights to any third party, notwithstanding
any other provision of this Agreement, without the prior written consent of DFCI.

 

		3.5	Unless under a License agreement the Licensee is required to pay directly to DFCI its pro rata
share of any Net Revenues, UCSD shall distribute [...***...]
of Net Revenues to DFCI within thirty (30) days of 30 December and 30 June of each year for the six-month period ending of those
dates during the term of this Agreement.

 

		3.6	Each party is solely responsible for calculating and distributing to its respective inventors any
share of Net Revenues in accordance with its respective patent policy during the term of this Agreement. UCSD shall pay UCSD Inventor.
DFCI shall pay DFCI Inventor.

 

		3.7	UNIVERSITY and DFCI expressly reserve the right to use the Invention and associated technology
for educational and research purposes.

 

4. RECORDS AND REPORTS

 

		4.1	UCSD shall keep complete, true and accurate accounts of all expenses and of all proceeds received
by it from each Licensee and shall permit DFCI to allow its own agents or a certified public accounting firm which is reasonably
acceptable to UCSD (with regards to conflict of interest issues) to examine its books and records in order to verify the payments
due or owing under this Agreement. Examinations will (i) occur not more than once per calendar year: (ii) be under an agreement
of confidentiality; and (iii) be paid for by 

 

***Confidential
Treatment Requested

 

    	Page 3

    	 

    

  

			DFCI. In the event that any such examination shows an under reporting and underpayment
in excess of [...***...] for any twelve
(12) month period, then UCSD shall pay the cost of the examination as well as any additional sum that would have been payable to
DFCI had UCSD reported correctly, plus an interest charge at a rate of [...***...] per year. Such interest shall be calculated
from the date the correct payment was due to DFCI up to the date when such payment is actually made by UCSD. For underpayment not
in excess of [...***...] for any twelve (12) month period, UCSD shall pay the difference within thirty (30) days without interest
charge or examination costs.

 

		4.2	UCSD shall submit to DFCI an annual report, setting forth the status of all patent prosecution,
commercial development, and licensing activity relating to the Invention.

 

5. PATENT INFRINGEMENT

 

		5.1	In the event that patent administrators responsible for Patent Rights at DFCI or UCSD learn of
the substantial infringement of any patent covered by this agreement, the party who learned of the infringement shall call the
attention of the other party to the infringement and provide written evidence of infringement. UCSD shall, in cooperation with
DFCI, use its best efforts to terminate infringement without litigation.

 

		5.2	If, however, the efforts of the parties are not successful in abating the infringement within ninety
(90) days after the infringer has been notified of the infringement, then UCSD may:

 

		5.2.1	continence suit on its own account; or

		5.2.2	permit an exclusive licensee to commence suit on its own account, or with UCSD; or

		5.2.3	UCSD may request that DFCI join as a party plaintiff in a patent infringement litigation,

 

DFCI has 90 (ninety) days to
inform UCSD of its decision to join or not join in such litigation. In no event may DFCI be joined in such a suit without its prior
written consent. In the event that UCSD chooses not to commence suit, or to allow an exclusive Licensee to do so, DFCI may do so
at its own election.

 

		5.3	Legal action to terminate infringement or recover damages, as is decided upon under paragraph 5.2,
will be at the full expense of the party on account of whom suit is brought and all recoveries recovered thereby will belong to
such party, provided, however, that legal action brought jointly by the parties and fully participated in by such parties shall
be at the joint expense of the parties (in shares to be mutually agreed upon) and all recoveries shall be shared jointly by them
in direct proportion to the share of expense paid by each party.

 

***Confidential
Treatment Requested

 

    	Page 4

    	 

    

 

		5.4	Each party shall cooperate with the other in litigation proceedings instituted hereunder but at
the expense of the party on account of whom suit is brought. The litigation will be controlled by the party bringing the suit,
except that DFCI may be represented by counsel of its choice pursuant to DFCI’s determination in any suit brought by UCSD
or a Licensee.

 

6. GOVERNING LAW

 

THIS AGREEMENT IS GOVERNED
BY AND INTERPRETED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, EXCEPT THAT THE SCOPE AND VALIDITY OF ANY PATENT OR
PATENT APPLICATION IN PATENT RIGHTS ARE GOVERNED BY THE APPLICABLE LAWS OF THE COUNTRY OF THAT PATENT OR PATENT APPLICATION.

 

7. NOTICES

 

Any notice required
or permitted to be given to the parties hereto is properly given if delivered, in writing, in person, or mailed by first-class
certified mail to the following addresses, or to such other addresses as may be designated in writing by the parties from time
to time during the term of this Agreement:

 

	To DFCI:	 	Dana Farber Cancer Institute
	 	 	Attention: Director, Office of Technology Transfer
	 	 	44 Binney Street
	 	 	Boston, MA 02115
	 	 	 
	To UNIVERSITY:	 	Technology Transfer and Intellectual Property Services
	 	 	Attention: Alan S. Paau, Director (Case No. [...***...])
	 	 	University of California, San Diego
	 	 	9500 Gilman Drive, MC - 0910
	 	 	La Jolla, California 92093-0910
	 	 	 
	For Overnight Courier:	 	Technology Transfer and Intellectual Property Services
	 	 	Attn: Alan S. Paau, Director (Case No. [...***...])
	 	 	University of California, San Diego
	 	 	10300 Torrey Pines Road
	 	 	La Jolla, California 92093-0910

 

***Confidential
Treatment Requested

 

    	Page 5

    	 

    

 

8. NO WAIVER

 

No waiver by either
party hereto of any breach or default of any of the covenants or agreements herein set forth may be deemed a waiver as to any subsequent
and/or similar breach or default.

 

9. ASSIGNABILITY

 

This Agreement is binding
upon and inures to the benefit of the parties hereto, their successors or assigns, but this Agreement may not be assigned by either
party without the prior written consent of the other party.

 

10. LIFE OF AGREEMENT

 

This Agreement is in
full force and effect from the effective date recited on page one and remains in effect for the life of the last-to-expire patent
in Patent Rights, unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this
Agreement.

 

11. TERMINATION

 

Unless a License Agreement
is in effect or has been agreed upon as to all financial terms, either party hereto may terminate this Agreement for any reason
upon at least sixty (60) days’ written notice (“Notice of Termination”) to the remaining party, but in any event
not less than sixty (60) days prior to the date on which responses to any pending Patent Office actions need to be taken to preserve
Patent Rights. After effective termination, each party may separately license its interest in the Patent Rights according to the
licensing party’s policy provided that each party pays one-half of all costs incurred thereafter in the preparation, prosecution,
and maintenance of Patent Rights. Apart from the obligation to share patent costs and apart from obligations identified in Article
12 (Confidentiality) and specific obligations accrued prior to termination, the parties will have no further rights or obligations
under this Agreement after effective termination.

  

		12.1	Subject to The California Public Records Act and the right of each party to acknowledge the existence
of this Agreement, UCSD and DFCI respectively shall hold the other party’s proprietary business, patent prosecution, engineering,
process and technical information, and other proprietary information in confidence using at least the same degree of care as that
party uses to protect its own proprietary information of a like nature for a period from

 

    	Page 6

    	 

    

 

12. CONFIDENTIALITY

 

			 the date of disclosure until five (5)
years after the date of termination of this Agreement. The disclosing party shall label or mark confidential, or as otherwise appropriate,
all proprietary information. If proprietary information is orally disclosed, the disclosing party shall reduce the proprietary
information to writing or to some other physically tangible form and deliver it to the receiving party within 30 days of the oral
disclosure, marked and labeled as set forth above. Manuscripts published in scientific journals, papers, and presentations at public
meetings that relate to proprietary information are exempt from the provisions of this Article after their timely submission to
and subsequent timely approval of the other party within 30 days of their submission. Notwithstanding the foregoing:

 

		12.2	Nothing in this Agreement in any way restricts or impairs the right of DFCI or UCSD to use, disclose
or otherwise deal with any information or data documented:

 

		12.2.1	that recipient can demonstrate by written records was previously known to it;

		12.2.2	that is now, or becomes in the future, public knowledge other than through acts or omissions of
recipient;

		12.2.3	that is lawfully obtained without restrictions by recipient from sources independent of the disclosing
party; or

		12.2.4	that was made independently without the use of proprietary information received hereunder.

 

		12.3	The confidentiality obligations of the parties under these terms will remain in effect for five
(5) years from the termination date of this Agreement.

 

13. USE OF NAMES AND TRADEMARKS

 

Except for acknowledging
the existence of this Agreement, nothing in this Agreement confers any right to use any name, trade name, trademark, or other designation
of either party to this Agreement (including contraction, abbreviation or simulation of any of the foregoing) in advertising, publicity,
or other promotional activities. Unless required by law, the use of the name, “The Dana-Farber Cancer Institute,” “The
Regents of the University of California,” or the name of any campus of the University of California is expressly prohibited.

 

14. NO IMPLIED LICENSE

 

This Agreement does
not confer by implication, estoppel, or otherwise any license or rights under any patents of either party other than the specific
Patent Rights, regardless of whether such patents are dominant or subordinate to Patent Rights.

 

    	Page 7

    	 

    

 

15. COMPLETE AGREEMENT

 

This Agreement constitutes
the entire agreement, both written and oral, between the parties, and all prior agreements respecting the subject matter hereof,
either written or oral, expressed or implied, are canceled.

 

IN WITNESS WHEREOF; both UNIVERSITY
and DFCI have executed this Agreement, by facsimile and/or in two (2) in duplicate originals, each of which shall be deemed an
original and all of which together shall constitute but one and the same instrument, by their respective and duly authorized officers
on the day and year written.

 

	The Dana-Farber Cancer Institute:	 	
        The Regents of the

        University of California:

	 	 	 
	By:	/s/ Ruth Emyanitoff, Ph.D.	 	By:	/s/ Dr. Alan Paau
	 	 	 
	Name: Ruth Emyanitoff, Ph.D.	 	Name: Dr. Alan Paau
	 	 	 
	Title:Director, Officer of Technology Transfer	 	Title: Director, TTIPS
	 	 	 
	Date:	October 11, 2001	 	Date:	10/16/2001

 

    	Page 8

    	 

    

 

Appendix A

 

Indemnification and Insurance

 

		1.	Licensee shall indemnify, defend and hold harmless DFCI and its trustees officers, medical and professional staff, employees,
and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss
or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the Indemnitees,
or any one of them, in connection with any claims, suits, actions, demands or judgments (a) arising out of the design, production,
manufacture, sale, use in commerce, lease, or promotion by Licensee or by a Sublicensee, Affiliate or agent of Licensee, or any
product, process or service relating to, or developed pursuant to, this Agreement or (b) arising out of any other activities to
be carried out pursuant to this Agreement.

 

		2.	Licensee’s indemnification under Section 9.1 (a) applies to any liability, damage, loss or expense whether or not it
is attributable to the negligent activities of the Indemnitees. Licensee’s indemnification under 9.1(b) does not apply to
any liability, damage, loss or expense to the extent that it is attributable to (a) the negligent activities of the Indemnitees,
or (b) the intentional wrongdoing or intentional misconduct of the Indemnitees.

 

		3.	Licensee shall, at its own expense, provide attorneys reasonably acceptable to DFCI to defend against any actions brought or
filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions
are rightfully brought.

 

		4.	If any such action is commenced or claim made or threatened against DFCI or other Indemnitees as to which Licensee is obligated
to indemnify it (them) or hold it (them) harmless, DFCI or the other Indemnitees shall promptly notify Licensee of such event.
Licensee shall assume the defense of, and may settle, that part of any such claim or action commenced or made against DFCI (or
other Indemnitees) which relates to Licensee’s indemnification and Licensee may take such other steps as may be necessary
to protect it. Licensee will not be liable to DFCI or other Indemnitees on account of any settlement of any such claim or litigation
affected without Licensee’s consent. The right of Licensee to assume the defense of any action is limited to that part of
the action commenced against DFCI and/or Indemnitees that relates to Licensee’s obligation of indemnification and holding
harmless.

 

		5.	Licensee shall require any Affiliates or Sublicensee(s) to indemnify, hold harmless and defend DFCI under the same terms set
forth in Sections 9.1 – 9.4.

 

Insurance.

 

		6.	At such time as any product, process or service relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, Affiliate or
agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain policies of commercial general liability
insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming the Indemnitees as additional
insureds. Such commercial general liability insurance must provide (a) product liability coverage and (b) contractual liability
coverage for Licensee’s indemnification under Sections 9.1 through 9.3 of this Agreement. If Licensee elects to self-insure
all or part of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate),
such self-insurance program must be acceptable to the DFCI and the DFCI’s associated Risk Management Foundation. The minimum
amounts of insurance coverage required under these provisions may not be construed to create a limit of Licensee’s liability
with respect to its indemnification obligation under Sections 9.1 through 9.3 of this Agreement.

  

		7.	Licensee shall provide DFCI with written evidence of such insurance
upon request of DFCI. Licensee shall provide DFCI with written notice at least fifteen (15) days prior to the cancellation,

 

    	 

    	 

    

  

			non-renewal or material change in such insurance; If Licensee
does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, DFCI has the right
to terminate this Agreement effective at the end of such fifteen (15) day period without any notice or additional waiting periods.

 

		8.	Licensee shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement
during (a) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, Affiliate or
agent of Licensee and (b) a reasonable period after the period referred to in 9.8 (a) above which in no event shall be less than
fifteen (15) years.

 

		9.	Licensee shall require any Affiliates or Sublicensee(s) to maintain insurance in favor of DFCI and the Indemnitees under the
same terms set forth in Sections 9.6 – 9.8.

  

    	 

    	 

    

 

Exhibit B

 

Copy of the

 

Letter from the Department of Veteran
Affairs

 

To

 

[...***...]

 

RE: Phosphonate Compounds

 

***Confidential Treatment Requested

 

    	1.

    	 

    

  

  

[...***...]

Director (664/00)

VA Medical Center

3350 La Jolla Village Drive

San Diego, CA 92161

 

Re: Phosphonate Compounds

 

Dear [...***...]:

 

This refers to your report concerning the
above-referenced invention which you submitted to this office pursuant to the provisions of 38 C.P.R, § 1.656. These regulations
provide that it is the duty of the General Counsel to determine the respective ownership rights, as between the Government
and the employee, in an employee invention. This letter constitutes such a determination within the meaning of these regulations.

 

With your Report, you provided a Summary
of the invention. The invention provides analogs of certain phosphonate compounds which are antiviral or antiproliferative.

 

Concerning the circumstances surrounding
the development of the invention, [...***...], you have indicated that you were employed as a staff physician at the VA Medical
Center in San Diego, California. You certified that the invention was made with a contribution by the VA of facilities and equipment.

 

According to 37 C.F.R. § 501.6(a)(1),
the Government is entitled to the entire right, title, and interest in and to any invention made by a Government employee
(i) during working hours, or (ii) with a contribution of the Government of facilities, equipment, materials, funds or information, or of the time
or services of other Government employees on official duty, or (iii) which bears a direct relation to or is made in consequence
of the official duties of the inventor. However, subsection (a)(3) provides that the facts and circumstances surrounding the making
of an invention do not preclude a determination that the Government may leave the entire right,

  

***Confidential Treatment Requested

 

    	 

    	 

    

  

 

2.

 

[...***...]

 

 title and interest in an invention
to the Government employee subject to law, (i.e., without reservation to the Government of a nonexclusive, irrevocable,
royalty-free license).

  

Based on the review and recommendation by
officials in VHA and the Office of General Counsel, I find that the facts and circumstances surrounding development of the invention
do not justify retention of any rights or license by the Government.

 

Consequently, I find that you are entitled
to the entire right, title and interest in and to the invention, subject to law. 37 C.F.R. § 501.6(a)(4).

 

I am enclosing a copy of this determination
which I request you sign (to acknowledge receipt) and return to this office.

 

I wish you the best of luck with your invention.

 

	 	Sincerely yours,
	 	 
	 	John W. Klein
	 	Assistant General Counsel

 

Enclosures

 

cc: Dr. Mindy Aisen (122)

University of California

 

	Acknowledgment of Receipt:	 	 	 	Date:	 	 
	 	 	[...***...]	 	 	 	 

  

***Confidential Treatment Requested

 

    	 

    	 

    

  

Exhibit C

 

Copy of the

 

VA/UC AGREEMENT:

 

Cooperative Technology Administration
Agreement

 

with an Effective Date of May 19, 2000

 

    	 

    	 

    

  

U.S. DEPARTMENT OF VETERANS AFFAIRS

 

AND THE UNIVERSITY OF CALIFORNIA

 

COOPERATIVE TECHNOLOGY ADMINISTRATION AGREEMENT

 

This Cooperative Technology Administration
Agreement (“Agreement”) is made as of this 19th day of May, 2000, by and between the United States Department of Veterans
Affairs (hereinafter referred to as “VA”), as represented by the Technology Transfer Program, Office of Research and
Development, having an address at 810 Vermont Avenue N.W., Washington, D.C. 20420, and The Regents of the University of California,
as represented by the Office of Technology Transfer, having an address at 1111 Franklin Street, 5th Floor, Oakland,
California 94607-5200 (“University”).

 

RECITALS

 

Whereas, VA and University through their employment relationship
with certain faculty and staff, through 37 CFR Part 501, and/or through 35 U.S.C. 200-212, as well as state law and implementing
policies, have an interest in inventions made by their employees;

 

Whereas, VA and University policies promote disclosure of research
results for the public’s use and benefit, as well as to define and protect the rights of inventors, provide for an equitable
distribution of the rewards and responsibilities associated with the invention(s), and provide that income from such invention(s)
be used for the purpose of promoting research and education;

 

Whereas, pursuant to their shared objectives, it is the mutual
desire of VA and University that their respective interests in such inventions be administered and managed exclusively by University
on behalf of both parties in a manner to ensure the timely commercialization of such inventions and to make their benefits widely
available for society’s use and benefit;

 

Whereas, VA is authorized to transfer to and to undertake all
suitable steps to administer its rights in any such existing or future invention through contract with a nonprofit organization
(including a university) under 35 U.S.C. 202(e) (to the maximum extent permitted by law), 35 U.S.C. 207(a)(3), or 35 U.S.C. 3710a;

 

Now, therefore, the parties hereto agree as follows:

 

		1.	DEFINITIONS

 

		1.1	“Dual Appointment Personnel (DAP)” means any person who is employed by and has entered into and signed an employment
or patent agreement with both VA and University.

  

		1.2	“Patent Rights” means all United States patent applications and patents and corresponding patent applications and
patents filed in countries other than the

 

    	 

    	 

    

 

			United States that are assigned to VA and University, including any reissues, extensions,
substitutions, divisions, continuations, and continuation-in-part applications (only to the extent, however, that claims in the
continuations-in-part applications are entitled to the priority filing date of the parent patent application) based on the subject
matter claimed in or covered by a Subject Invention.

 

		1.3	“Property Rights” means all personal property rights covering the tangible personal property in biological materials
directly associated with any Subject Invention.

 

		1.4	“Made” in relation to any Subject Invention means the conception or first actual reduction to practice of such
Subject Invention.

 

		1.5	“Subject Invention” means Patent Rights and/or related Property Rights covering any existing or future disclosed
invention in which both parties have an interest under their various policies, that is made either by a DAP or at least one inventor
from each party, and that is not a Disclaimed Invention.

 

		1.6	“Disclaimed Invention” means any Subject Invention for which University declines to pursue patenting, license or
commercialization activities under Section 2.2 of this Agreement.

 

		1.7	“License Agreement” means any executed agreement entered into by University under this Agreement that grants Licensee
the right to make, use, sell, offer for sale, or import products covered by or claimed by the Subject Invention being licensed
under such agreement or otherwise deals with administration of the Subject Invention, such as option or secrecy agreements.

 

		1.8	“Licensee” means any party, not including the United States Government, that enters into a License Agreement with
University.

 

		1.9	“Government” means the Government of the United States of America.

 

		1.10	“Fiscal Year” means July 1 through June 30.

 

		1.11	“Gross Revenues” means consideration received by University from the licensing of any Subject Invention, but not
including consideration in the form of research funding or other research support.

 

		1.12	“Net Revenues” means Gross Revenues, less any prior contractual obligations to third party research supporters
or joint owners, then less Administrative Fee, Expenses, Inventors Share, and Research Share for each Subject Invention.

 

		1.13	“Inventors Share” means those revenues due under the applicable University of California policy to named inventors
for each Subject Invention.

  

    	2

    	 

    

		1.14	“Research Share” means those revenues to be allocated directly for research purposes, if any, under the applicable
University of California Patent Policy for each Subject Invention.

 

		1.15	“Expenses” means legal and other direct expenses incurred by University (that are not otherwise reimbursed from
a third party) for patenting, protecting and preserving U.S. and foreign patent, copyright and related property rights, maintaining
patents and such other costs, taxes, or reimbursements as may be necessary or required by law for each Subject Invention.

 

		1.16	“Administrative Fee” means [...***...]
fee of Gross Revenues retained by University in consideration of University’s commercialization efforts for each for each
Subject Invention.

 

		1.17	“UC Site” means the campus or U.S. Department of Energy Laboratory managed by University at which a Subject Invention
is made.

 

		1.18	“Pooled Amount” means Net Revenues aggregated by UC site cumulatively over time beginning the effective date of
this Agreement for all of that UC Site’s Subject Inventions.

 

		2.	PATENT PROSECUTION AND PROTECTION

 

		2.1	Disclosure. The parties agree to promptly and in confidence report to the other party each Subject Invention. VA agrees to
provide to University a copy of its Determination of Rights letter to inventors regarding any Potential Subject Invention.

 

		2.2	Disclaimed Inventions. University shall notify VA in writing of any Individual Subject Invention for which the University declines
to pursue patenting, licensing or commercialization activities, and as of the date of such notice, that invention shall no longer
be considered a Subject Invention under this Agreement.

 

		2.3	VA authorizes University to have the exclusive right to prepare, file, prosecute, and maintain patent application(s) and patents
covering any Subject Invention. University shall promptly provide to VA, upon request, all serial numbers and filing dates, together
with copies of all such applications, including, on request copies of all Patent Office Actions, responses, and all other Patent
Office communications. In addition, University shall be granted Power of Attorney for all such patent applications.

 

		2.4	University shall make an election with respect to foreign filing including in which countries foreign filing will be done prior
to the election, within ten (10) months of any United States filing. If any foreign patent applications are filed, University shall
promptly, upon request, provide to VA all serial numbers and filing dates

 

***Confidential Treatment Requested

 

    	3

    	 

    

  

			together with copies of all such foreign patent applications,
including on request, copies of all Patent Office Actions.

 

		2.5	University shall promptly record assignments of domestic patent rights covering a Subject Invention in the United States Patent
and Trademark Office and shall promptly provide VA with a copy of each recorded assignment with respect to VA.

 

		2.6	Notwithstanding any other provision of this Agreement, University shall not abandon the prosecution of any patent application
including provisional patent applications (except for purposes of filing continuation application(s)) or the maintenance of any
patent for a Subject Invention without prior written notice to VA. Upon receiving such written notice, VA may, at its sole option
and expense, take over the prosecution of any such patent application, or the maintenance of any such patent, and such invention
shall no longer be considered a Subject Invention under this Agreement.

 

		2.7	University may decide to bail Property Rights as a more efficient commercialization method than patenting. If University so
decides, then University will follow the guidelines issued by the U.S. National Institutes of Health on such commercialization
approach.

 

		3.	LICENSING

 

		3.1	VA authorizes University to have the exclusive right to negotiate, execute, and administer any License Agreement. VA shall
not license to any third parties any Subject Invention unless this Agreement is terminated in accordance with Article 7 (Termination)
and there are no License Agreements in effect or under negotiation. VA also agrees to not pre-commit any Subject Inventions or
future inventions that would be Subject Inventions under this Agreement to a commercial research sponsor or other entity through
prior agreements made by VA foundations or others.

 

		3.2	VA authorizes University to have the sole right to diligently seek a Licensee and negotiate and enter into License Agreements
for the commercial development of any Subject Invention and to administer all such License Agreements for the mutual benefit of
the parties and in the public interest.

 

		3.3	University shall have the final authority to enter into negotiations and execute License Agreements. In accordance with Section
5.2, University shall provide VA with a copy of all executed License Agreements. VA shall keep these documents and related documentation
confidential, unless such disclosure is required by law, except that VA may disclose the existence of any License Agreement, but
only to the extent of the granting clause. VA will not disclose the names of the Licensee or any other terms contained in the Licensee
Agreement unless such disclosure is required under law.

  

    	4

    	 

    

 

		3.4	University agrees to not enter into a License Agreement for commercial development of Subject Invention with a company who
is identified on the current list of companies debarred from covered transactions as provided, and updated from time to time, by
the VA.

 

		3.5	Any respective License Agreement will include provisions that address the following:

 

		3.5.1	The License Agreement will be subject to the overriding obligations to the U.S. Government, including those set forth in 35
U.S.C. §200-212 or 15 U.S.C. 3710a, and applicable governmental implementing regulations, whichever may be appropriate.

 

		3.5.2	For a License Agreement granting an exclusive right to use or sell the Subject Invention in the United States, Licensee knowledges
that any patent products embodying the Subject Invention or produced through the use thereof will be manufactured substantially
in the United States.

 

		3.5.3	The Government shall have the nonexclusive, nontransferable, irrevocable, royalty-free, paid-up right to practice or have practiced
the Subject Invention throughout the world by or on behalf of the Government and on behalf of any foreign government or international
organization pursuant to any existing or future treaty or agreement to which the Government is a signatory.

 

		3.5.4	The Government sha1l retain the right to require University to grant to a responsible applicant a nonexclusive, partially exclusive,
or exclusive license to use the invention in the applicant’s licensed field of use on terms that are reasonable under the
circumstances; or, if University fails to grant such a license, to grant the license itself. The Government may exercise its rights
retained herein only in exceptional circumstances and only if the Government determines that (i) the action is necessary to meet
health or safety needs that are not reasonably satisfied by University; (ii) the action is necessary to meet requirements for public
use specified by Federal regulations, and such requirements are not reasonably satisfied by University; or (iii) University has
failed to comply with an agreement containing provisions described in 35 U.S.C. 204 or 15 U.S.C. 3710a(c)(4)(B), whichever is appropriate.

 

		4.	REVENUES

 

		4.1	Inventor Share. University shall be solely responsible for calculating and distributing Inventor Share pursuant to University
of California policy. Inventor Share will be distributed equally among the named inventors unless mutually agreed in writing by
all inventors.

  

    	5

    	 

    

 

		4.2	Research Share. University shall be solely responsible for calculating and distributing Research Share. The Research Share
will be pro-rated in proportion to the number of sole University, sole VA and DAP employee inventors. For financial calculation
purposes under this section, any DAP will be considered to be [...***...]
VA and [...***...] University, regardless of actual employment percentages.

 

		Example:	[...***...]

 

		4.3	Net Revenues. University agrees to pay to VA an amount equivalent to [...***...] of the Pooled Amount for each UC Site less
payments made by University to VA for previous Fiscal Years. University’s obligation to make payments to VA shall commence
from the date that the Pooled Amount calculation is positive for a UC Site. Such payments are payable in annual installments and
are due no later than January 31 for Pooled Amount calculation made for the prior Fiscal Year.

 

		4.4	All payments to VA, required under this Agreement shall be in U.S. Dollars and shall be made by University by check or bank
draft drawn on United States banks and shall be payable, as appropriate, to the “Department of Veterans Affairs (royalty).”
All such payments shall be sent to the following address:

 

Department of Veterans Affairs

Technology Transfer Financial Management Office (12TT)

810 Vermont Avenue NW

Washington, D.C. 20420

 

The payment under Section 4.3 will be accompanied with
an itemized accounting of performance of each individual Subject Invention.

 

		5.	RECORDS AND REPORTS

 

		5.1	University shall keep complete, true, and accurate accounts of all Expenses and of all Gross Revenues received by it under
each License Agreement and shall permit VA, or VA’s designated agent to examine its books and records in order to verify
the payments due or owed under this Agreement.

 

		5.2	University shall submit to VA at the address identified in Article 8 a semi-annual report, not later than January 31 covering
the period through the prior June 30 and not later than April 30 covering the period through the prior December 31, setting forth
the status of all patent prosecution, commercial development, and licensing activity concerning Subject Invention(s), and upon
request of the VA, copies of patents issued and, in confidence, License Agreements executed during that period.

 

***Confidential Treatment Requested

 

    	6

    	 

    

  

		5.3	The report required under Section 5.2 shall also be made within sixty (60) days of the termination of this Agreement.

 

		6.	PATENT INFRINGEMENT

 

		6.1	If the administrators responsible for this Agreement at VA or University learns of the substantial infringement of any Subject
Invention, then the party who learns of the infringement will promptly call attention to the infringement in writing to the other
party and provide the other party with reasonable evidence of the infringement. Neither party will notify a third party of infringement
without first obtaining written consent of the other party, which consent will not be unreasonably withheld. University, in cooperation
with VA, will use its best efforts to terminate the infringement without litigation. If the efforts of the parties are not successful
in abating the infringement within 90 days after the infringement was formally brought to the attention of the parties, then either
party will have the right to elect to:

 

		6.1.1	commence suit on its own account;

 

		6.1.2	permit an exclusive Licensee to bring suit separately, but only if University or VA elects not bring to bring suit;

 

		6.1.3	join with the other party or an exclusive Licensee in the suit; or

 

		6.1.4	refuse to participate in the suit;

 

and each party will give written notice of its election
to the other party within 10 days after the 90-day period. University may permit an exclusive Licensee to bring suit on its own
amount, either by formal notice or by failure to act within the period, but only if University or VA elects not to commence suit
or join each other in any suit.

 

		6.2	Such legal action as is decided upon will be at the expense of the party on account of whom suit is brought and all recoveries
recovered thereby will belong to such party, provided, however, that legal action brought by VA, University, and/or an exclusive
Licensee, and participated in by the parties bringing suit will be at the expense of such parties, and all recoveries will be allocated
in the following order:

 

		6.2.1	to each party reimbursement in equal amounts of the attorney’s costs, fees, and other related expenses to the extent
each party paid for such costs, fees, and expenses until all such cuts, fees, and expenses are consumed for each party; and

 

		6.2.2	any remaining amount shared by them in proportion to the share of expenses paid by each party.

 

    	7

    	 

    

  

Each party will cooperate with
the other in litigation proceedings instituted under this Agreement but at the expense of the party on account of whom suit is
brought. This litigation (including settlement) will be controlled by the party bringing the suit, except that University will
control the suit if brought jointly. Either party may be represented at its sole expense by counsel of its choice in any suit brought
by the other party or an exclusive Licensee. VA’s agreement in this paragraph is subject to U.S. Department of Justice approval
on a case-by-case basis.

 

		7.	TERM AND TERMINATION

 

		7.1	Term. This Agreement is effective when signed by both parties and shall extend until the expiration of the last-to-expire of
the License Agreements or patents covering a Subject Invention included under this Agreement, whichever is later, unless otherwise
terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement.

 

		7.2	Termination by Mutual Consent. University and VA may elect to terminate this Agreement, or portions thereof, at any time by
mutual consent in writing. In such event, any outstanding commitments to third parties through License Agreements, options thereto,
or research agreements concerning any Subject Invention(s) or future inventions that would be Subject Inventions under this Agreement
that were entered into by University or were reliant on this Agreement prior to the effective termination date shall survive this
Agreement.

 

		7.3	Termination by Unilateral Action.

 

		7.3.1	Written Notice. Either Party may unilaterally terminate this entire Agreement at any time by giving the other Party prior written
notice, but not less than six (6) months prior to the desired termination date.

 

		7.3.2	Commitments. In such event, any outstanding commitments to third parties through License Agreements, options thereto, or research
agreements concerning any Subject Invention(s) or future inventions that would be Subject Inventions under this Agreement that
were entered into by University or were reliant on this Agreement prior to the effective termination date shall survive this Agreement.
All uncancelable obligations shall be included within Expenses.

 

		7.4	Termination of License Agreement by VA. The VA may terminate a License Agreement if it is determined by VA that:

 

		7.4.1	University or any of its Licensees substantially fail to meet the material obligations set forth in the License Agreement;
or

 

		7.4.2	The VA determines that such action is necessary to meet requirements for public use specified by federal regulations issued
after the date of this Agreement and such requirements are not reasonably satisfied by University or any Licensees; or

  

    	8

    	 

    

  

		7.4.3	University or any Licensees have willfully made a material false statement of, or willfully omitted, a material fact in any
report required by this Agreement; or

 

		7.4.4	University or any Licensees commit a substantial breach of covenant or agreement contained in the License Agreement; or

 

		7.4.5	University or any Licensees materially defaults in making any payment or report required by this Agreement or a License Agreement;
or

 

		7.4.6	University or any Licensees is adjudged as bankrupt or has its assets placed in the hands of the receiver or makes any assignment
or other accommodation for the benefit of creditors; or

 

		7.4.7	University is held by a court of competent jurisdiction, without taking a further appeal, to have misused any patent rights
covering a Subject Invention.

 

		7.5	Prior to any termination of the License Agreement, VA shall furnish University and any Licensee of record a written notice
of intention to terminate, and University and any notified Licensee shall be allowed 30 days after the date of such notice to remedy
any breach or default of any covenant or agreement of the License Agreement or to show cause why the License Agreement should not
be terminated.

 

		7.6	The word termination’ and cognate words, such as ‘term’ and ‘terminate,’ used in this Article
7 and elsewhere in this Agreement are to be read, except where the contrary is specifically indicated, as omitting from their effect
the following rights and obligations all of which survive any termination to the degree necessary to permit their complete fulfillment
or discharge;

 

		7.6.1	University’s obligation to supply a terminal report as specified in Section 5.3 of this Agreement.

 

		7.6.2	VA’s right to receive or recover and University’s obligation to share Net Revenues or accruable for payment at
the time of any termination as specified in Article 4 of this Agreement.

 

		7.6.3	University’s obligation to maintain records and VA’s right to conduct a final audit pursuant to Section 5.1 of
this Agreement.

 

		7.6.4	Sublicenses, releases, and agreements of non-assertion running in favor of Licensees prior to any termination and on which
royalties shall have been paid.

  

    	9

    	 

    

		7.6.5	Any cause of action or claim VA accrued or to accrue, because of any breach or default by University.

 

		7.7	In the event the termination of this Agreement or conversion of this Agreement, any Licensee of record granted pursuant to
this Agreement may, at Licensee’s option, be converted to a license directly between Licensee and VA.

 

		7.8	After effective termination, each party may separately license its interests in Subject Inventions according to its own policy.
Apart from specific obligations of the parties under this Agreement accrued prior to termination, the parties will have no further
rights or obligations under this Agreement after such termination.

 

		8.	NOTICES

 

All notices required or permitted by this Agreement
to be given to the parties thereto shall be deemed to have been properly given if delivered in writing, in person or mailed by
prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier,
properly addressed to the other Party. Notices shall be considered timely if such notices are received on or before the established
deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial
carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier
or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.

 

Notices shall be sent to the mailing address below,
or alternative address(es) for individual Subject Inventions as identified in writing by the VA Director, Technology Transfer Program
or by the University Executive Director, Research Administration and Technology Transfer.

 

	To VA:	 	Director (122)
	 	 	Technology Transfer Program
	 	 	Office of Research and Development
	 	 	U.S. Department of Veterans Affairs
	 	 	810 Vermont Avenue N.W.
	 	 	Washington, D.C. 20420
	 	 	 
	To University:	 	The Regents of the University of California
	 	 	Office of the President
	 	 	Office of Technology Transfer (OTT)
	 	 	1111 Franklin Street, 5th Floor
	 	 	Oakland, California 94607-5200
	 	 	Attention: Executive Director,
	 	 	Research Administration and Technology Transfer

    	10

    	 

    

 

		9.	GOVERNING LAWS, SETTLING DISPUTES

 

		9.1	This Agreement shall be construed in accordance with U.S. Federal law and the laws of the State of California when not in conflict
with U.S. Federal law. Federal law and regulations will preempt any conflicting or inconsistent provisions in this Agreement. University
shall have all defenses available to it under California law.

 

		9.2	Any controversy or any disputed claim by either party against the other arising under or related to this Agreement shall be
submitted jointly to University, Executive Director of Research Administration and Technology Transfer, and to the VA, Director,
Technology Transfer Program, Office of Research and Development. University and VA will be free after written decisions are issued
by those officials to pursue any and all administrative and/or judicial remedies that may be available.

 

		10.	MISCELLANEOUS

 

		10.1	The Agreement or anything related thereto shall not be construed to confer on any person any immunity from or defenses under
the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to this Agreement shall not
be immunized from the operation of state or Federal law by reason of the source of the grant.

 

		10.2	It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set
forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

		10.3	This Agreement is binding upon and shall inure to the benefit of the parties hereto, their successors or assigns, but this
Agreement may not be assigned by either party without the prior written consent of the other party.

 

		10.4	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents
of University or VA other than Subject Inventions regardless of whether such patents are dominant or subordinate to Subject Inventions.

 

		10.5	Any modification to this Agreement must be in writing and agreed to by both parties.

 

		10.6	It is understood and agreed by University and VA that this Agreement constitutes the entire agreement, both written and oral,
between the parties, and that all prior agreements respecting the subject matter hereof, either written or oral, express or implied,
shall be abrogated, canceled, and are null and void and of no effect.

 

    	11

    	 

    

 

		10.7	Use of Name. Neither party may use the name of the other party in any way for advertising or publicity without the express
written consent of the other party, provided, however, that while University may not allow a Licensee to use the name of VA for
advertising or publicity, it does have the right to use the name of VA in connection with negotiating a License Agreement or sublicense
agreement and where required by law.

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to
be executed by their duly authorized representatives as follows:

 

	U.S. DEPARTMENT OF VETERANS	 	THE REGENTS OF THE UNIVERSITY OF
	AFFAIRS	 	CALIFORNIA
	 	 	 
	By:	/s/ John R. Feussner, M.D.	 	By:	/s/ Alan B. Bennett
	 	 	 
	Name: John R. Feussner, M.D.	 	Name: Alan B. Bennett
	 	 	 
	Title: Chief Research and Development Officer	 	Title: Executive Director,
	 	 	Research Administration and Technology Transfer
	 	 	 
	Date:	5/19/00	 	Date:	5/18/00

 

    	12

    	 

    

 

Exhibit D

 

Copy of the Articles of Incorporation
of Chimerix, Inc.

 

With an effective date of April 6, 2000

  

    	 

    	 

    

 

State of Delaware

 

Office of the Secretary of State

________________________

 

I, EDWARD J. FREEL, SECRETARY OF STATE OF
THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “CHIMERIX,
INC.”, FILED IN THIS OFFICE ON THE SEVENTH DAY OF APRIL, A.D. 2000, AT 3:30 O’CLOCK P.M.

 

A FILED COPY OF THIS CERTIFICATE HAS BEEN
FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

 

 

    	 

    	 

    

 

CERTIFICATE OF INCORPORATION

 

OF

 

CHIMERIX, INC.

 

ARTICLE I

 

The name of the corporation is Chimerix,
Inc.

 

ARTICLE II

 

The address of its registered office in
the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware
19801. The name of its registered agent at such address is The Corporation Trust Company.

 

ARTICLE III

 

The nature of the business or purposes to
be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation
Law of Delaware.

 

ARTICLE IV

 

A.           Classes
of Stock. The total number of shares of all classes of capital stock which this corporation shall have authority to issue is
Five Million (5,000,000) of which Three Million Five Hundred Thousand (3,500,000) shares of the par value of One-Tenth of One Cent
($.001) each shall be Common Stock (the “Common Stock”) and One Million Five Hundred Thousand (1,500,000) shares of
the par value of One-Tenth of One Cent ($.001) each shall be Preferred Stock (the “Preferred Stock”).

 

The Preferred Stock may be issued from time
to time in one or more series. Except for the Series A Preferred Stock, the Board of Directors is authorized to fix the number
of shares of any series of Preferred Stock and to determine the designation of any such shares. Subject to compliance with applicable
protective and voting rights provisions that have been granted to outstanding series of Preferred Stock in a Certificate of Designation
or this Certificate of Incorporation, the Board of Directors is also authorized to determine or alter the rights, preferences,
privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock and, within the limits and
restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting
any series, to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of
any such series subsequent to the issue of shares of that series unless a vote of the holders of such series is required pursuant
to the certificate or certificates establishing the series of Preferred Stock.

 

    	 

    	 

    

 

B.           Rights
Preferences and Restrictions of the Preferred Stock. The Series A Preferred Stock shall consist of 1,500,000 shares. The Series
A Preferred Stock shall have the voting power, preferences and relative, participating, optional or other special rights, and the
qualifications, limitations or restrictions thereof, as follows:

 

1.          Dividend
Provisions. The holders of shares of Series A Preferred Stock shall be entitled to receive dividends, out of any assets legally
available therefor, prior and in preference to any declaration or payment of any dividend (payable other than in Common Stock of
this corporation) on the Common Stock or any other junior equity security of this corporation, at the rate of $.08 per share of
Series A Preferred Stock (as adjusted for any stock splits, stock dividends, recapitalizations and the like) per annum, or if greater
the rate paid on the Common Stock, payable quarterly when, as and if declared by the Board of Directors. Dividends shall not be
cumulative. Dividends, if declared, must be declared and paid with respect to all series of Preferred Stock contemporaneously,
and if less than full dividends are declared, the same percentage of the dividend rate will be payable to each series of Preferred
Stock.

 

2.          Liquidation
Preference.

 

(a)          In
the event of any liquidation, dissolution or winding up of this corporation, either voluntary or involuntary, the holders of Series
A Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of this corporation
to the holders of Common Stock or other junior equity security by reason of their ownership thereof, an amount per share equal
to the sum of (i) $1.00 for each outstanding share of Series A Preferred Stock (the “Original Series A Issue Price”)
and (ii) an amount equal to all declared but unpaid dividends on each such share. If upon the occurrence of such event, the assets
and funds thus distributed among the holders of such series of Preferred Stock shall be insufficient to permit the payment to such
holders of the full aforesaid preferential amounts, then the entire assets and funds of this corporation legally available for
distribution shall be distributed ratably among the holders of Series A Preferred Stock in proportion to the product of the liquidation
preference of each such share, and the number of shares held by each such holder.

 

(b)          After
the distributions described in subsection (a) above have been paid, the remaining assets of this corporation available for distribution
to stockholders shall be distributed among the holders of Common Stock and Series A Preferred Stock pro rata based on the number
of shares of Common Stock held by each (assuming the full conversion of the outstanding Series A Preferred Stock).

 

(c)          A
liquidation, dissolution or winding up of this corporation shall be deemed to be occasioned by, or to include (unless the holders
of a majority of the Series A Preferred Stock then outstanding shall determine otherwise), (A) the acquisition of this corporation
by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization,
merger or consolidation) that results in the transfer of fifty percent (50%) or more of that outstanding voting power of this corporation,
or (B) a sale of all or substantially all of the assets of this corporation (any such event described in clause (A) or (B), a “Reorganization
Event”).

 

    	 

    	 

    

 

(d)          Any
securities to be delivered to the holders of Preferred Stock and Common Stock pursuant to this Section 2 shall be valued as follows:

 

(i)          Securities
not subject to investment letter or other similar restrictions on free marketability:

 

(A)         If
traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the securities on such exchange
over the 30-dry period ending three days prior to the closing;

 

(B)         If
actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices over the 30-day period
ending three days prior to the closing; and

 

(C)         If
there is no active public market, the value shall be the fair market value thereof, as mutually determined in good faith by the
Board of Directors of this corporation.

 

(ii)         The
method of valuation of securities subject to investment letter or other restrictions on free marketability shall be to make an
appropriate discount from the market value determined as above in (i)(A), (B) or (C) to reflect the approximate fair market value
thereof, as mutually determined in good faith by the Board of Directors of this corporation.

 

(e)          In
the event the requirements of this Section 2 are not complied with, this corporation shall forthwith either:

 

(i)          cause
such closing to be postponed until such time as the requirements of this Section 2 have been complied with, or

 

(ii)         cancel
such transaction, in which event the rights, preferences and privileges of the holders of the Preferred Stock shall revert to and
be the same as such rights, preferences and privileges existing immediately prior to the date of the first notice referred to in
subsection 2(f) hereof.

 

(f)          This
corporation shall give each holder of record of Preferred Stock written notice of such impending transaction not later than 20
days prior to the stockholders’ meeting called to approve such transaction, or 20 days prior to the closing of such transaction,
whichever is earlier, and shall also notify such holders in writing of the final approval of such transaction. The first of such
notices shall describe the material terms and conditions of the impending transaction and the provisions of this Section 2, and
this corporation shall thereafter give such holders prompt notice of any material changes. The transaction shall in no event take
place earlier than 20 days after this corporation has given the first notice provided for herein or earlier than ten days after
this corporation has given notice of any material changes provided for herein; provided, however, that such periods may be shortened
upon the written consent of the holders of a majority of the shares of the Preferred Stock then outstanding.

 

    	 

    	 

    

 

3.          Conversion.
The holders of Series A Preferred Stock shall have conversion rights as follows (the “Conversion Rights”):

 

(a)          Right
to Convert.

 

(i)          Subject
to subsection (c) below, each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, at any
time after the date of issuance of such share and prior to the close of business on any Redemption Date as may have been fixed
in any Redemption Notice with respect to such share, at the office of this corporation or any transfer agent for such series of
Preferred Stock, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the Original
Series A Issue Price by the Conversion Price at the time in effect for such series. The initial Conversion Price per share for
shares of Series A Preferred Stock shall be the Original Series A Issue Price; provided, however, that the Conversion Price for
shares of such series of Preferred Stock shall be subject to adjustment as set forth in subsection (c) below.

 

(ii)         Each
share of Series A Preferred Stock shall automatically be converted into shares of Common Stock at the Conversion Price at the time
in effect for such series immediately upon

 

(x)          the
consummation of this corporation’s sale of its Common Stock in a bona fide firm commitment underwriting pursuant to a registration
statement on Form S-1 (or successor form) under the Securities Act of 1933, as amended, which results in gross offering proceeds
to this corporation of at least $5,000,000, the public offering price of which was not less than $3.00 per share (adjusted to reflect
subsequent stock dividends, stock splits or recapitalizations); or

 

(y)          the
approval of holders of at least a majority of the outstanding shares of Series A Preferred Stock, voting together in accordance
with Section 4 hereof.

 

(b)          Mechanics
of Conversion. Before any holder of shares of a series of Preferred Stock shall be entitled to convert the same into shares
of Common Stock, such holder shall surrender the certificate or certificates therefor, duly endorsed, at the office of this corporation
or of any transfer agent for such series of Preferred Stock, and shall give written notice by mail, postage prepaid, to this corporation
at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate
or certificates for shares of Common Stock are to be issued. This corporation shall, as soon as practicable thereafter, issue and
deliver at such office to such holder of such series of Preferred Stock, or to the nominee or nominees of such holder, a certificate
or certificates for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall
be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of such series
of Preferred Stock to be converted and the person or

  

    	 

    	 

    

  

persons entitled to receive the shares
of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares
of Common Stock as of such date. If the conversion is in connection with an underwritten offer of securities registered pursuant
to the Securities Act of 1933, as amended, the conversion may, at the option of any holder tendering shares of such series of
Preferred Stock for conversion, be conditioned upon the closing with the underwriter of the sale or securities pursuant to such
offering, in which event the person(s) entitled to receive the Common Stock issuable upon such conversion of shares of such series
of Preferred Stock shall not be deemed to have converted such shares of such series of Preferred Stock until immediately prior
to the closing of such sale of securities.

 

(c)          Conversion
Price Adjustments of the Series A Preferred Stock. The Conversion Price of the Series A Preferred Stock shall be subject to
adjustment from time to time as follows:

 

(i) (A)         If
this corporation shall issue any Additional Stock (as defined below) without consideration or for a consideration per share less
than the Conversion Price for the Series A Preferred Stock, as the case may be, in effect immediately prior to the issuance of
such Additional Stock, the new Conversion Price shall be determined by multiplying the Conversion Price for such series of Preferred
Stock in effect immediately prior to the issuance of Additional Stock by a fraction:

 

(x)          the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (for purposes of
this calculation only, including the number of shares of Common Stock then issuable upon the conversion of all outstanding shares
of Preferred Stock at the Conversion Price for such shares in effect immediately prior to such issuance of Additional Stock and
excluding the number of Shares of Common Stock then issuable upon conversion or exercise of outstanding warrants, options or other
rights to purchase shares) plus the number of shares of Common Stock equivalents which the aggregate consideration received by
this corporation for the shares of such Additional Stock so issued would purchase at the Conversion Price for the shares of the
series of Preferred Stock with respect to which the adjustment is being made; and

 

(y)          the
denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (for purposes
of this calculation only, including the number of shares of Common Stock then issuable upon the conversion of all outstanding shares
of Preferred Stock at the Conversion Prices for such shares in effect immediately prior to

  

    	 

    	 

    

 

such issuance of Additional Stock and
excluding the number of Shares of Common Stock then issuable upon conversion or exercise of outstanding warrants, options or other
rights to purchase shares) plus the number of such shares of Additional Stock so issued.

 

Any series of issuances of Additional
Stock consisting of Common Stock or the same series of Preferred Stock, issued at the same price and occurring within a three-month
period, shall be treated as one issuance of Additional Stock for the purposes of this calculation.

 

(B)         No
adjustment of the Conversion Price for such series of Preferred Stock shall be made in an amount less than one cent per share,
provided that any adjustments which are not required to be made by reason of this sentence shall be carried forward and shall be
either taken into account in any subsequent adjustment made prior to three years from the date of the event giving rise to the
adjustment being carried forward, or shall be made at the end of three years from the date of the event giving rise to the adjustment
being carried forward. Except to the limited extent provided for in subsections (E)(3) and (E)(4), no adjustment of such Conversion
Price for such series of Preferred Stock pursuant to this subsection 3(c)(i) shall have the effect of increasing the Conversion
Price for such series of Preferred Stock above the Conversion Price for such series in effect immediately prior to such adjustment.

 

(C)         In
the case of the issuance of Common Stock for cash, the consideration shall be deemed to be the amount of cash paid therefor before
deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by this corporation for any underwriting
or otherwise in connection with the issuance and sale thereof.

 

(D)         In
the case of the issuance of the Common Stock for a consideration in whole or in part other than cash, the consideration other than
cash shall be deemed to be the fair value thereof as determined by the Board of Directors irrespective of any accounting treatment.

 

(E)         In
the case of the issuance of options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock or options to purchase or rights to subscribe for such convertible or exchangeable securities
(which are not excluded from the definition of Additional Stock), the following provisions shall apply:

 

    	 

    	 

    

 

(1)         The
aggregate maximum number of shares of Common Stock deliverable upon exercise of such options to purchase or rights to subscribe
for Common Stock shall be deemed to have been issued at the time such options or rights were issued and for a consideration equal
to the consideration (determined in the manner provided in subsections 3(c)(i)(C) and (c)(i)(D)), if any, received by this corporation
upon the issuance of such options or rights plus the minimum purchase price provided in such options or rights for the Common Stock
covered thereby.

 

(2)         The
aggregate maximum number of shares of Common Stock deliverable upon conversion of or in exchange for any such convertible or exchangeable
securities or upon the exercise of options to purchase or rights to subscribe for such convertible or exchangeable securities and
subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options
or rights were issued and for a consideration equal to the consideration, if any, received by this corporation for any such securities
and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the additional
consideration, if any, to be received by this corporation upon the conversion or exchange of such securities or the exercise of
any related options or rights (the consideration in each case to be determined in the manner provided in subsections 3(c)(i)(C)
and (c)(i)(D)).

 

(3)         In
the event of any change in the number of shares of Common Stock deliverable or any increase in the consideration payable to this
corporation upon exercise of such options or rights or upon conversion of or in exchange for such convertible or exchangeable securities,
including, but not limited to, a change resulting from the anti-dilution provisions thereof, the Conversion Price of the Series
A Preferred Stock obtained with respect to the adjustment which was made upon the issuance of such options, rights or securities,
and any subsequent adjustments based thereon, shall be recomputed to reflect such change, but no further adjustment shall be made
for the actual issuance of Common Stock or any payment of such consideration upon the exercise of any such options or rights or
the conversion or exchange of such securities; provided, however, that this section shall not have any effect on any conversion
of such series of Preferred Stock prior to such change or increase.

 

    	 

    	 

    

 

(4)         Upon
the expiration of any such options or rights, the termination of any such rights to convert or exchange or the expiration of any
options or rights related to such convertible or exchangeable securities, the Conversion Price of the Series A Preferred Stock
obtained with respect to the adjustment which was made upon the issuance of such options, rights or securities or options or rights
related to such securities, and any subsequent adjustments based thereon, shall be recomputed to reflect the issuance of only the
number of shares of Common Stock actually issued upon the exercise of such options or rights upon the conversion or exchange of
such securities or upon the exercise of the options or rights related to such securities; provided, however, that this section
shall not have any effect on any conversion of such series of Preferred Stock prior to such expiration or termination.

 

(ii)         “Additional
Stock” shall mean any shares of Common Stock issued (or deemed to have been issued pursuant to subsection 3(c)(i)(E)) by
this corporation after the date of the issuance of the Series A Preferred Stock, other than

 

(A)         Common
Stock issued pursuant to a transaction described in Subsection 3(c)(iii) hereof,

 

(B)         shares
of Common Stock issued or issuable to employees, directors, consultants or advisors under stock option and restricted stock purchase
agreements approved by the directors of this corporation, or

 

(C)         Common
Stock issued or issuable upon conversion of the Preferred Stock.

 

(iii)        In
the event this corporation should at any time or from time to time after the date of the initial issuance of the Series A Preferred
Stock fix a record date for the effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination
of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or
other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares
of Common Stock (hereinafter referred to as “Common Stock Equivalents”) without payment of any consideration by such
holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock
issuable upon conversion or exercise thereof), then as of such record date (or the date of such dividend distribution split or
subdivision if no record date is fixed), the Conversion Price of the Series A Preferred Stock shall be appropriately decreased
so that the number of shares of Common Stock issuable on conversion

  

    	 

    	 

    

 

of each share of such series shall be increased in proportion
to such increase of outstanding shares determined in accordance with subsection 3(c)(i)(E).

 

(iv)         If
the number of shares of Common Stock outstanding at any time after the effective date hereof is decreased by a combination of the
outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price for the Series A
Preferred Stock shall be appropriately increased so that the number of shares of Common Stock issuable on conversion of each share
of such series shall be decreased in proportion to such decrease in outstanding shares.

 

(v)          Notwithstanding
anything herein to the contrary, the operation of, and any adjustment of the Conversion Prices pursuant to, the provisions of subsection
3(c)(i) may be waived with respect to any specific share or shares of Preferred Stock, either prospectively or retroactively and
either generally or in a particular instance by a writing executed by the registered holder of such share or shares. Any waiver
pursuant to this subsection 3(c)(v) shall bind all future holders of the shares of Preferred Stock for which rights have been waived.
In the event that a waiver of adjustment of Conversion Price under this subsection 3(c)(v) results in different Conversion Prices
for shares of a series of Preferred Stock, the Secretary of this corporation shall maintain a written ledger identifying the Conversion
Price for each share of such series of Preferred Stock. Such information shall be made available to any person upon request.

 

(d)          Other
Distributions. In the event this corporation shall declare a distribution payable in securities of other persons, evidences
of indebtedness issued by this corporation or other persons, assets (excluding cash dividends) or options or rights not referred
to in subsection 3(c)(iii), then, in each such case for the purpose of this subsection 3(d), the holders of Series A Preferred
Stock shall be entitled to a proportionate share of any such distribution as though they were the holders of the number of shares
of Common Stock of this corporation into which their shares of such series of Preferred Stock, as the case may be, are convertible
as of the record date fixed for the determination of the holders of Common Stock of this corporation entitled to receive such distribution.

 

(e)          Recapitalizations.
If at any time or from time to time there shall be a recapitalization of the Common Stock (other than a subdivision, combination
or merger or sale of assets transaction provided for elsewhere in this Section 3 or in Section 2 hereof) provision shall be made
so that the holders of Series A Preferred Stock shall thereafter be entitled to receive upon conversion of such series of Preferred
Stock the number or shares of stock or other securities or property of this Corporation or otherwise, to which a holder of Common
Stock deliverable upon conversion would have been entitled on such recapitalization. In any such case, appropriate adjustment shall
be made in the application of the provisions of this Section 3 with respect to the rights of the holders of such series of Preferred
Stock after the recapitalization to the end that the provisions of this Section 3 (including adjustment of the Conversion Price
then in effect and the number of shares purchasable upon conversion of such

  

    	 

    	 

    

  

series of Preferred Stock) shall be applicable
after that event as nearly equivalent as may be practicable.

 

(f)          No
Impairment. The corporation will not, by amendment of its Certificate of Incorporation or through any reorganization, recapitalization,
transfer of assets, consolidation, merger, dissolution issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms to be observed or performed hereunder by this corporation, but will
at all times in good faith assist in the carrying out of all the provisions of this Section 3 and in the taking of all such action
as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Series A Preferred Stock against
impairment.

 

(g)          Fractional
Shares and Certificate as to Adjustments.

 

(i)          No
fractional shares shall be issued upon conversion of shares of a series of Preferred Stock, and the number of shares of Common
Stock to be issued shall be rounded to the nearest whole share. Whether or not fractional shares are issuable upon such conversion
shall be determined on the basis of the total number of shares of such series of Preferred Stock the holder is at the time converting
into Common Stock and the number of shares of Common Stock issuable upon such aggregate conversion.

 

(ii)         Upon
the occurrence of each adjustment or readjustment of the Conversion Price of Series A Preferred Stock, pursuant to this Section
3, this corporation, at its expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof
and prepare and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment
and showing in detail the facts upon which such adjustment or readjustment is based. This corporation shall, upon the written request
at any time of any holder of such series of Preferred Stock furnish or cause to be furnished to such holder a like certificate
setting forth (A) such adjustment and readjustment, (B) the Conversion Price at the time in effect, and (C) the number of shares
of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of a share of
such series of Preferred Stock.

 

(h)          Notices
of Record Date. In the event of any taking by this corporation of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other distribution,
any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property,
or to receive any other right, this corporation shall mail to each holder of Series A Preferred Stock at least 10 days prior to
the date specified therein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend,
distribution or right, and the amount and character of such dividend, distribution or right.

 

    	 

    	 

    

 

(i)          Reservation
of Stock Issuable Upon Conversion. This corporation shall at all times reserve and keep available out of its authorized but
unissued shares of Common Stock solely for the purpose of effecting the conversion of the shares of Series A Preferred Stock such
number of its shares of Common Stock as shall from time to time be sufficient to affect the conversion of all outstanding shares
of such series of Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be
sufficient to effect the conversion of all then outstanding shares of such series of Preferred Stock, in addition to such other
remedies as shall be available to the holder of such series of Preferred Stock, this corporation will take such corporate action
as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number
or shares as shall be sufficient for such purposes.

 

(j)          Notices.
Any notice required by the provisions of this Section 3 to be given to the holders of shares of Series A Preferred Stock shall
be deemed given if deposited in the United States mail, first class postage prepaid, and addressed to each holder of record at
such holder’s address appeasing on the books of this corporation.

 

4.          Voting
Rights.

 

(a)          The
holder of each share of Series A Preferred Stock shall have the right to one vote for each share of Common Stock into which such
Preferred Stock could be converted on the record date for the vote or written consent of stockholders. In all cases any fractional
share, determined on an aggregate conversion basis, shall be rounded to the nearest whole share. With respect to such vote, such
holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall
be entitled, notwithstanding any provision hereof, to notice of any stockholders’ meeting in accordance with the bylaws of
this corporation, and shall be entitled to vote, together with holders of Common Stock, with respect to any question upon which
holders of Common Stock have the right to vote.

 

5.          Protective
Provisions. In addition to any approvals required by law, so long as fifty percent (50%) of the original issued shares of Series
A Preferred Stock are outstanding, this corporation shall not without first obtaining the approval (by vote or written consent,
as provided by law) of the holders of at least, a majority of the then outstanding shares of Series A Preferred Stock:

 

(a)          sell,
convey, or otherwise dispose of or encumber all or substantially all of its property or business or merge with or into or consolidate
with any other corporation (other than a wholly owned subsidiary corporation) or effect any transaction or series of related transactions
in which more than 50% of the voting power of this corporation is disposed of; or

 

(b)          alter
or change the rights, preferences or privileges of the Series A Preferred Stock; or

 

(c)          increase
or decrease (other than by conversion) the authorized number of shares of Preferred Stock or the designated number of shares of
Series A Preferred Stock; or

 

    	 

    	 

    

 

(d)          authorize
or issue, or obligate itself to authorize or issue (by reclassification or otherwise) any new class or series of stock (or other
equity security including any other security convertible into or exercisable for any equity security) having a preference over,
or being on a parity with, the Series A Preferred Stock with respect to voting, dividends or upon liquidation; or

 

(e)          amend
this corporation’s Certificate of Incorporation or bylaws that would adversely affect the rights, preferences or privileges
of the Series A Preferred Stock;

 

(f)          repurchase
or redeem shares of the Common Stock of the corporation, other than the repurchase of shares from en employee, consultant or advisor
of the corporation pursuant to a stock purchase or stock option agreement between such person and the corporation providing for
such repurchase upon termination of employment; or

 

(g)          declare
or pay any dividend or distribution with reaped to the Common Stock of the corporation.

 

6.          Status
of Converted Stock. In the event any shares of Series A Preferred Stock shall be converted pursuant to Section 3 hereof, the
shares so converted shall be canceled and shall not be issuable by this corporation; and the Certificate of Incorporation of this
corporation shall be appropriately amended to effect the corresponding reduction in this corporation’s authorized capital
stock.

 

C.           Common
Stock.

 

1.          Relative
Rights of Preferred Stock and Common Stock. All preferences, voting powers, relative, participating optional or other special
rights and privileges, and qualifications, limitations, or restrictions of the Common Stock are expressly made subject and subordinate
to those that may be fixed with respect to any shares of the Preferred Stock.

 

2.          Voting
Rights. Except as otherwise required by law or this Certificate of Incorporation, each holder of Common Stock shall have one
vote in respect of each share of stock held by such holder of record on the books of this corporation for the election of directors
and on all matters submitted to a vote of stockholders of this corporation.

 

3.          Dividends.
Subject to the preferential rights of the Preferred Stock, the holders of shares of Common Stock shall be entitled to receive,
when and if declared by the Board of Directors, out of the assets of this corporation which are by law available therefor, dividends
payable either in cash, in property or in shares of capital stock.

 

4.          Dissolution,
Liquidation or Winding Up. In the event of any dissolution, liquidation or winding up of the affairs of this corporation or
any Reorganization Event, after distribution in full of the preferential amounts, if any, to be distributed to the holders of shares
of the Preferred Stock, holders of Common Stock shall be entitled to participate in any distribution of the assets of this corporation
in accordance with Section 2 of Article IV, Division B hereof.

  

    	 

    	 

    

 

ARTICLE V

 

This corporation is to have perpetual existence.

 

ARTICLE VI

 

In furtherance and not in limitation of
the powers conferred by the laws of the State of Delaware:

 

A.           The
Board of Directors of this corporation is expressly authorized to adopt, amend or repeal the bylaws of this corporation; provided,
however, that the bylaws may only be amended in accordance with the provisions thereof.

 

B.           Elections
of directors need not be by written ballot unless the bylaws of this corporation shall so provide.

 

C.           The
books of this corporation may be kept at such place within or without the State of Delaware as the bylaws of this corporation may
provide or as may be designated from time to time by the Board of Directors of this corporation.

 

ARTICLE VII

 

To the fullest extent permitted by Delaware
General Corporation Law as it now exists or as it may hereafter be amended, a director of the corporation shall not be personally
liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability
(i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not
in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General
Corporation Law or (iv) for any transaction from which the director derived an improper personal benefit. If the Delaware General
Corporation Law is hereafter amended to authorize further eliminating or limiting the personal liability of directors, then, after
approval by the stockholders of this Article, the liability of a director of the Corporation, shall be eliminated or limited to
the fullest extent permitted by the Delaware General Corporation Law as so amended.

 

Any amendment, repeal or modification of
the foregoing provisions of this Article VII, or the adoption of any provision in an amended or Certificate of Incorporation inconsistent
with this Article VII, by the stockholders of the Corporation shall be prospective only, and shall not adversely affect any right
or protection of a director of the Corporation existing at the time of such amendment, repeal, modification or adoption.

  

ARTICLE VIII

 

To the fullest extent permitted by applicable
law, this corporation is authorized to provide indemnification of (and advancement of expenses to) such agents of this Corporation

 

    	 

    	 

    

 

(and any other persons to which Delaware
law permits this corporation to provide indemnification) through bylaw provisions, agreements with such agents or other persons,
vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted
by Section 145 of the Delaware General Corporation Law, subject only to limits created by applicable Delaware law (statutory or
nonstatutory), with respect to actions for breach of duty to this corporation, its stockholders and others.

 

Any amendment, repeal or modification of
the foregoing provisions of this Article VIII shall not adversely affect any right or protection of a director, officer, agent
or other person existing at the time of, or increase the liability of any director of this corporation with respect to any acts
or omissions of such director, officer or agent occurring prior to such amendment, repeal or modification.

 

ARTICLE IX

 

Subject to compliance with applicable protective
voting rights that have been or may be granted to the Preferred Stock or series thereof in a Certificate of Designation or this
Certificate of Incorporation, this corporation reserves the right to amend or repeal any provision contained in this Certificate
of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon a stockholder herein are
granted subject to this reservation.

 

ARTICLE X

 

The name and mailing address of the incorporator
is

 

Karl Y. Hostetler

[...***...]

 

I, THE UNDERSIGNED, being the sole incorporator
hereinabove named, for the purpose of forming a corporation pursuant to the General Corporation Law of the State of Delaware, do
make this certificate, hereby declaring and certifying that this is my act and deed and the facts herein stated are true, and accordingly
have hereunto set my hand this 6th day of April, 2000.

 

	 	/s/ Karl Y. Hostetler
	 	Karl Y. Hostetler
	 	Sole Incorporator

  

***Confidential Treatment Requested

  

    	 

    	 

    

  

TABLE OF CONTENTS

 

	RECITALS	2
	ARTICLE 1. DEFINITIONS	4
	ARTICLE 2. GRANTS	7
	ARTICLE 3. CONSIDERATIONS	9
	ARTICLE 4. REPORTS, RECORDS AND PAYMENTS	14
	ARTICLE 5. PATENT MATTERS	18
	ARTICLE 6. GOVERNMENTAL MATTERS	20
	ARTICLE 7. TERMINATION OF THE AGREEMENT	20
	ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION	21
	ARTICLE 9. USE OF NAMES AND TRADEMARKS	25
	ARTICLE 10. MISCELLANEOUS PROVISIONS	25
	Exhibit A	
	Exhibit B	
	Exhibit C	
	Exhibit D	

 

    	 

    	 

    

 

FIRST AMENDMENT TO THE LICENSE AGREEMENT

EFFECTIVE May 13, 2002

BETWEEN

CHIMERIX, INC.,

AND

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

FOR

DOCKET
NOs. [...***...],
[...***...] and [...***...]

 

This amendment to the
agreement (“Amendment”) is made by and between Chimerix, Inc, a Delaware corporation having an address at 4401 Eastgate
Mall, San Diego, CA 92121 (“Chimerix”) and The Regents Of The University Of California, a California corporation having
its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“University”), as
represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer & Intellectual
Property Services, Mail-code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).

 

Capitalized terms used
but not otherwise defined herein shall have the meanings given them in the License Agreement (“License Agreement”)
between Chimerix and the University effective May 13, 2002 (UC control No. [...***...]).

 

This Amendment is effective
on the date of the last signature (“Effective Date”).

 

Whereas, Chimerix
has entered into the License Agreement wherein Chimerix was granted certain rights;

 

Whereas, the
Field of the license granted to Chimerix under the License Agreement excludes uses of the Second Invention for osteoporosis
and other metabolic bone diseases; and

 

Whereas, Chimerix
and University wish to amend the License Agreement;

 

Now Therefore,
Chimerix and University agree to amend the License Agreement to include certain modifications. These changes are to be substituted
for those relevant portions in the License Agreement and are effective on the Effective Date. For these purposes, changes are made
to the License Agreement as detailed below:

 

RECITALS

 

The fourth recital is deleted in its entirety.

  

***Confidential Treatment Requested

  

    	 

    	 

    

 

ARTICLE 1. DEFINITIONS.

 

Paragraph 1.3 is amended and restated to
read in its entirety: “Field” means all human and veterinary uses” .

 

Paragraph 1.9 is amended and restated to
read in its entirety: “Patent Rights” means any and all or any combination of First, Second and Third Patent Rights.

 

 

ARTICLE 2. GRANTS.

 

Paragraph 2.4 is deleted in its entirety.

 

 

ARTICLE 3. CONSIDERATIONS.

 

The final sentence of Paragraph 3.2 is
deleted in its entirety.

  

As consideration for the amendment of the
Field provided in this Amendment, and in addition to the consideration paid or payable under Article 3 of the License Agreement,
Chimerix shall:

 

(i)          issue
to University twenty five thousand (25,000) shares of Chimerix’ Common Stock (the “Additional Shares”) pursuant
to a restricted common stock agreement between the parties in substantially the form of the Restricted Common Stock Agreement dated
June 18, 2002 between the parties. The Additional Shares shall be issued in the name of “Shellwater & Co.”, as
nominee for University, provided, however, that issuance of Additional Shares by Chimerix shall be subject to final approval
by the Chimerix Board of Directors and acceptance of Additional Shares by University shall be subject to final approval by the
Office of the President of the University. The Additional Shares shall be issued within forty-five (45) days of approval by the
Chimerix Board of Directors or the University Office of the President, whichever occurs later. In the event that approval is not
granted for issuance or acceptance of Additional Shares, this Agreement shall remain in effect and Chimerix and University shall
renegotiate in good faith for a substitution of similar value for consideration. In the event that the parties can not agree on
the substitution of similar value for consideration within sixty (60) days from the September 27th, 2002 meeting of the Chimerix
Board of Directors, this Amendment shall be null and void; and

 

(ii)         pay
to University license maintenance fees of [...***...]
US Dollars ($[...***...]) per year and payable on the first anniversary of the Effective Date and annually thereafter on each anniversary;
provided however, that Chimerix’ obligation to pay this fee shall end on the date when Chimerix is commercially selling a
Licensed Product.

  

***Confidential Treatment Requested

 

    	2.

    	 

    

  

Except as specifically amended by this
Amendment, all other terms and conditions in the License Agreement shall remain unchanged and in full force and effect. The parties
agree that this Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original and all of
which together shall constitute but one and the same instrument.

 

IN WITNESS WHEREOF, both University
and Chimerix have executed this Amendment, in duplicate originals, by their respective and duly authorized officers on the day
and year written.

 

	CHIMERIX, INC.:	 	THE REGENTS OF THE
	 	 	UNIVERSITY OF CALIFORNIA
	 	 	 
	By:	/s/ Kevin P. Anderson	 	By:	/s/ Alan S. Paau
	 	 	 	 
	Name: 	Kevin P. Anderson	 	Alan S. Paau 
	 	 	 	Assistant Vice Chancellor,
	Title: 	VP, Business Development	 	Technology Transfer &
	 	 	Intellectual Property Services
	 	 	 
	Date: 	September 11, 2002	 	Date:	September 9, 2002

   

    	3.

    	 

    

  

SECOND AMENDMENT TO THE LICENSE AGREEMENT
EFFECTIVE MAY 13, 2002

 

BETWEEN

 

CHIMERIX, INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE
NOS. [
...***...], [...***...] AND [...***...]

 

This second amendment to the agreement ("Second
Amendment") is made by and between Chimerix, Inc., a Delaware corporation having an address at 2505 Meridian Parkway, Suite
340, Durham, NC 27713 ("Chimerix"), and The Regents of the University of California, a California corporation having
its statewide administrative offices at 1111 Franklin Street, Oakland, CA 94607-5200 ("University") as represented by
its San Diego campus having an address at University of California San Diego, Technology Transfer Office, Mail Code 0910, 9500
Gilman Drive, La Jolla, CA 92093-0910 ("UCSD").

 

Capitalized terms used but not otherwise defined
herein shall have the meaning given them in the license agreement effective May 13, 2002 (UC Control No. [...***...]) and the previously
executed first amendment effective September 11, 2002 (UC Control No. [...***...]), (together, the "Agreement")

 

This Second Amendment is effective on the
date of last signature ("Second Amendment Effective Date").

 

Whereas Chimerix has entered into the
Agreement wherein Chimerix was granted certain rights;

 

Whereas, Chimerix has requested a renegotiation
of certain terms of the Agreement in order to secure additional capital investment and partnering opportunities in order to complete
development of Licensed Products as anticipated in the Agreement;

 

Whereas Chimerix and University wish
to amend the Agreement;

 

Now Therefore, Chimerix and University agree
to amend the Agreement. These changes will be substituted for or added to those relevant portions in the Agreement and are effective
on the Second Amendment Effective Date. For these purposes, changes are made to the Agreement as described below. Terms and conditions
not changed in this Second Amendment will remain as detailed in the Agreement.

  

ARTICLE 3, PARAGRAPH 3.1b - Milestone Payments.
Previous versions are hereby deleted and replaced with the following:

 

	Amount	 	Date or Event
	 	 	 
	[...***...]	 	LICENSEE begins a Phase I clinical trial; payable one time for each of the first three Licensed Products to begin a Phase I clinical 

trial

 

***Confidential Treatment Requested

 

    	1.

    	 

    

 

	Amount	 	Date or Event
	 	 	 
	[...***...]	 	LICENSEE begins a Phase III clinical trial; payable one time for each of the first three Licensed Products to begin a Phase III clinical trial
	 	 	 
	[...***...]	 	Six months after LICENSEE begins a Phase III clinical trial; payable one time for each of the first three Licensed Products to begin a Phase III clinical trial. For CMX001, this payment will be due on or before June 15, 2011.
	 	 	 
	[...***...]	 	[...***...] after LICENSEE begins a Phase III clinical trial; payable one time for each of the first three Licensed Products to begin a Phase III clinical trial
	 	 	 
	[...***...]	 	LICENSEE receives the first US regulatory approval for the sale of the first Licensed Product for human therapeutic use
	 	 	 
	[...***...]	 	LICENSEE receives the first US regulatory approval for the sale of each subsequent Licensed Product(s) for human therapeutic use
	 	 	 
	[...***...]	 	LICENSEE receives the first regulatory approval for the sale of each Licensed Product in Europe for human therapeutic use
	 	 	 
	[...***...]	 	LICENSEE receives the first regulatory approval for the sale of each Licensed Product in Japan for human therapeutic use
	 	 	 
	[...***...]*	 	This amount is owed to UNIVERSITY the [...***...] that Net Sales of a Licensed Product in the United States reach or exceed [...***...]. LICENSEE will pay one half of the amount due to UNIVERSITY within [...***...] of the end of [...***...] and the balance within [...***...] of the first payment.
	 	 	 
	[...***...]*	 	This amount is owed to UNIVERSITY the [...***...] that Net Sales of a Licensed Product in Europe reach or exceed [...***...]. LICENSEE will pay one half of the amount due to UNIVERSITY within [...***...] of the end of [...***...] and the balance within [...***...] of the first payment.
	 	 	 
	[...***...]*	 	This amount is owed to UNIVERSITY the [...***...] that Net Sales of a Licensed Product in the rest of the world reach or exceed [...***...]. LICENSEE will pay one half of the amount due to UNIVERSITY within [...***...] of the end of [...***...] and the balance within [...***...] of the first payment.

  

*      If
Net Sales of a Licensed Product in the applicable region (i.e., US, Europe, rest of world) reach the specified dollar level
during a calendar year at a time prior to the expiration of the Patent Rights, and subsequently during the same calendar
year, the Patent Rights expire, the applicable milestone event will be deemed to have occurred, and the milestone payment
shall become due in full, at the time such Net Sales first reached the applicable dollar level (i.e., prior to expiration

 

***Confidential
Treatment Requested

 

    	2.

    	 

    

 

      of
the Patent Rights), provided that LICENSEE shall have sixty (60) days after the end of such calendar year in which to make payment.

 

ARTICLE 3, PARAGRAPH 3.1d(i) - Sublicense
Fees. Previous versions are hereby deleted and replaced with the following:

 

		(1)	The percentage of sublicense fees payable to UNIVERSITY by LICENSEE will be determined according to
the following schedule:

 

	Percentage to be paid	 	Date of Sublicensure
	[...***...]	 	Prior to the first to occur of (i) the first IND submission for a Licensed Product or (ii) expenditure of [...***...] in research to identify, characterize or develop Licensed Products within the Field.
	 	 	 
	[...***...]	 	On or after the first to occur of the events specified above, but prior to initiation of the first Phase III Clinical Study for a Licensed Product.
	 	 	 
	[...***...]	 	On or after the initiation of the first Phase Ill Clinical Study for a Licensed Product.

 

ADDITIONAL CONSIDERATION TO UNIVERSITY

 

Within the later of thirty (30) days of the
Second Amendment Effective Date or receiving final approval of the Office of the President of UNIVERSITY, Chimerix shall issue
to Shellwater & Co. an additional One Hundred Thousand (100,000) shares of Chimerix Common Stock, authorized for issuance under
Chimerix's Amended and Restated Certificate of Incorporation.

 

Except as specified by this Second Amendment,
all other terms and conditions in the Agreement shall remain unchanged and in full force and effect. The parties agree that this
Second Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original and all of which together
shall constitute but one and the same instrument.

 

IN WITNESS WHEREOF both University and
Chimerix have executed this Amendment in duplicate originals, by their respective and duly authorized offices on the day and year
written.

 

	CHIMERIX, INC.:	 	THE REGENTS OF THE
	 	 	UNIVERSITY OF CALIFORNIA
	 	 	 
	By:	/s/ Kenneth I. Moch	 	By:	/s/ Jane C. Moores
	 	 	 	 	 
	Name:	Kenneth I. Moch	 	Jane C. Moores, Assistant Vice Chancellor
	 	 	 	 Technology Transfer Office
	Title:	President & CEO	 	
	 	 	 	 
	Date:	December 17, 2010	 	Date:	December 15, 2010

  

***Confidential Treatment Requested

 

    	3.

    	 

    

  

THIRD AMENDMENT TO THE LICENSE AGREEMENT
EFFECTIVE MAY 13, 2002

 

BETWEEN

 

CHIMERIX, INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE
NOS. [...***...],
[...***...] AND [...***...]

 

This third amendment to the agreement ("Third
Amendment") is made by and between Chimerix, Inc., a Delaware corporation having an address at 2505 Meridian Parkway, Suite
340, Durham, NC 27713 ("Chimerix"), and The Regents of the University of California, a California corporation having
its statewide administrative offices at 1111 Franklin Street, Oakland, CA 94607-5200 ("University") as represented by
its San Diego campus having an address at University of California San Diego, Technology Transfer Office, Mail Code 0910, 9500
Gilman Drive, La Jolla, CA 92093-0910 ("UCSD").

 

Capitalized terms used but not otherwise defined
herein shall have the meaning given them in the license agreement between Chimerix and University effective May 13, 2002, having
UC Control No. [...***...] ("Original Agreement"), as amended by the previously executed first amendment effective September
11, 2002, having UC Control No. [...***...] (the "First Amendment"), and second amendment effective December 17, 2010,
having UC Control No. [...***...] (the "Second Amendment"), and supplemented by those certain email notifications regarding
patent prosecution matters dated March 14, 2007, and October 9, 2009, and having UC Control Nos. [...***...] and [...***...], respectively
(collectively, the "Patent Notices"). The Original Agreement, together with, and as amended or supplemented by, the First
Amendment, the Second Amendment and the Patent Notices, are collectively referred to herein as the "Agreement".

 

This Amendment is effective on the date of
last signature ("Third Amendment Effective Date").

 

Whereas, Chimerix has entered into
the Agreement wherein Chimerix was granted certain

rights;

 

Whereas,
Chimerix wishes to amend the Agreement to include additional technology ("New Inventions") disclosed to University under
UCSD Case Nos. [...***...] entitled "[...***...]" and its corresponding patent applications entitled "[...***...]"
invented by [...***...], both of UCSD, and [...***...] entitled "[...***...]", and its corresponding patent applications
entitled

 

***Confidential Treatment Requested

 

    	1.

    	 

    

  

"[...***...]",
invented by [...***...] of UCSD and [...***...] of Chimerix;

 

Whereas University is willing to amend
the Agreement to include the additional technology;

 

Now Therefore, Chimerix and University agree
to amend the Agreement. These changes will be substituted for or added to those relevant portions in the Agreement and are effective
on the Third Amendment Effective Date. For these purposes, changes are made to the Agreement as described below. Terms and conditions
not changed in this Amendment will remain as detailed in the Agreement.

 

Article 1. DEFINITIONS.

 

Paragraphs 1.11 and 1.12 are amended and restated
to read in their entirety as follows:

 

1.11 "Licensed Method"
means any method that is covered by the claims of Patent Rights the use of which would constitute, but for (a) the license granted
to LICENSEE under this Agreement and/or (b) LICENSEE's joint ownership interest in Fifth Patent Rights, an infringement of any
pending or issued claim within Patent Rights.

 

1.12 "Licensed Product"
means any service, composition or product that is covered by the claims of Patent Rights, or that is produced by the Licensed Method,
or the manufacture, use, sale, offer for sale, or importation of which would constitute, but for (a) the license granted to LICENSEE
under this Agreement and/or (b) LICENSEE's joint ownership interest in Fifth Patent Rights, an infringement of any pending or issued
claim within the Patent Rights.

 

Paragraph 1.9 is amended and restated to read
in its entirety as follows:

 

"Patent Rights"
means any and all or any combination of First Patent Rights, Second Patent Rights and Third Patent Rights (collectively, "Original
Patent Rights") and Fourth Patent Rights and Fifth Patent Rights (collectively, "New Patent Rights").

 

The following new definitions are hereby added
after Paragraph 1.18:

 

		1.19	"Fourth Patent Rights" means any of the following: the US patent [...***...] issued
1/26/2010 and the US application [...***...] filed 12/10/2009; the PCT application no. [...***...] filed 2/4/2005, based on the
priority of the provisional application [...***...] filed 2/5/2004 disclosing and claiming the New Invention of UCSD Case No. [...***...],
assigned to University; and continuing applications thereof including divisional, substitutions and continuations-in-part (but
only to the extent the claims thereof are enabled by disclosure of the parent application); any patents issuing on said applications
including reissues, reexaminations and extensions; and any corresponding foreign applications or patents.

  

***Confidential Treatment Requested

 

    	2.

    	 

    

 

1.20
"Fifth Patent Rights" means the US patent [...***...] issued 7/6/2010 and the US application [...***...]
filed 6/9/2010; the PCT application no. [...***...] filed 4/18/2007, based on the priority of the provisional application [...***...]
(filed 5/3/2006) disclosing and claiming the New Invention of UCSD Case No. [...***...] assigned jointly to University and Licensee;
and continuing applications thereof including divisional, substitutions and continuations-in-part (but only to the extent the claims
thereof are enabled by disclosure of the parent application); any patents issuing on said applications including reissues, reexaminations
and extensions; and any corresponding foreign applications or patents.

 

Article 2. GRANTS.

 

Paragraph 2.2 is amended to include the following
new subparagraph (d):

 

(d) If LICENSEE grants a license
to a third party under its own joint ownership interest in the Fifth Patent Rights, LICENSEE shall also concurrently grant a Sublicense
under University's joint ownership interest in the Fifth Patent Rights to said third party.

 

Article 3. CONSIDERATIONS.

 

Subparagraph (ii) under the heading "ARTICLE
3. CONSIDERATIONS" in the First Amendment is amended and restated to read in its entirety as follows:

 

		(ii)	pay to University license maintenance fees of: (A) [...***...] US Dollars ($[...***...]) per year,
payable on each anniversary of the Effective Date prior to the Third Amendment Effective Date; and (B) [...***...] US Dollars ($[...***...])
per year, payable on each anniversary of the Effective Date after the Third Amendment Effective Date; provided however that Licensee's
obligation to pay this fee shall end on the date when Licensee is commercially selling a Licensed Product.

 

Paragraph 3.1b — Milestone Payments.
The following shall be added at the end of Paragraph 3.1b (as amended by the Second Amendment):

 

		(i)	For any Licensed Product that uses either: 1) the New Patent Rights or 2) the Original Patent Rights
(but not both in one Licensed Product): then the milestone payments above will apply.

 

		(ii)	For any Licensed Product that use both the Original Patent Rights and any New Patent Rights, the following
additional milestones will apply:

 

		(1)	[...***...] at IND filing, payable one time for each of the first three such Licensed Products for
which an IND is filed;

  

***Confidential Treatment Requested

 

    	3.

    	 

    

 

		(2)	[...***...]
at Initiation of Phase II clinical trial, payable one time for each of the first three such Licensed Products to begin a Phase
II clinical trial.

 

		(iii)	The new milestone payment obligations specified in the foregoing subparagraph (ii) shall not
apply to the Licensed Products CMX001 and CMX157, currently in development and already past initiation of Phase II clinical trials,
which utilize the Original Patent Rights; provided, however, that if (A) a new Licensed Product that incorporates CMX001
and/or CMX157 is developed, and (B) the manufacture, use, sale, offer for sale or import of such new Licensed Product would
constitute, but for the license granted under this Agreement, an infringement of any pending or issued and unexpired claim within
the New Patent Rights, then the new milestones will apply to the extent that the regulatory process for the new Licensed Product
includes the event described in the milestone. For example, if a new IND is required, the new milestone would apply. If the new
Licensed Product does not require a new IND, then the revised milestone would not apply.

 

Paragraph 3.2 — Patent Costs.
The following shall be added at the end of Paragraph 3.2:

 

Licensee will reimburse University
for all past (prior to the Third Amendment Effective Date) and future (on or after the Third Amendment Effective Date) Patent Costs
for Fourth Patent Rights as described in the Agreement; past patent costs for Fourth Patent Rights as of the Third Amendment Effective
Date are approximately [...***...]. The

parties acknowledge that Licensee has prosecuted and maintained Fifth Patent Rights, and borne all associated Patent Costs, up
to the Third Amendment Effective Date, and will continue to do so after the Third Amendment Effective Date. Accordingly, this Paragraph
3.2 shall not apply to Fifth Patent Rights unless and until such time (if ever) as University assumes responsibility for prosecuting
and maintaining Fifth Patent Rights in accordance with Paragraph 5.1.

  

Article 5. PATENT MATTERS

 

Paragraph 5.1 — Patent Prosecution
and Maintenance. The following shall be added at the end of Paragraph 5.1:

 

		(e)	Notwithstanding Paragraphs 5.1(a) through 5.1(d) to the contrary, Licensee shall be responsible for
diligently prosecuting and maintaining Fifth Patent Rights, at Licensee's expense, using counsel of Licensee's choice. Licensee
shall keep University reasonably informed of progress with regard to the prosecution and maintenance of Fifth Patent Rights, and
shall consult with, and consider in good faith the requests and suggestions of, University with respect to prosecution and maintenance
of Fifth Patent Rights. In the event that Licensee desires to abandon or cease prosecution or maintenance of any application or
patent

 

***Confidential Treatment Requested

  

    	4.

    	 

    

  

			within Fifth Patent Rights in any country, Licensee shall provide reasonable prior written notice to University of such
intention to abandon (which notice shall, to the extent possible, be given no later than 60 days prior to the next deadline for
any action that must be taken with respect to any such application or patent in the relevant patent office). In such case, at University's
sole discretion, upon written notice to Licensee, University may elect to continue prosecution and/or maintenance of any such application
or patent, at its sole cost and expense and by counsel of its own choice. If University elects to continue such prosecution and/or
maintenance, then Licensee's exclusive license under University's joint ownership interest in such application or patent shall
terminate, but Licensee shall retain its joint ownership interest in such application or patent.

 

Paragraph 5.2 — Patent Infringement.
The following shall be added at the end of

Paragraph 5.2:

 

		(e)	Notwithstanding
Paragraphs 5.2(b) and 5.2(c) to the contrary, but subject to Paragraphs 5.2(a) and 5.2(d), Licensee shall have the first right
to take legal action against a Third Party for infringement of Fifth Patent Rights, at Licensee's expense, using counsel of Licensee's
choice. If Licensee fails to bring any such action or proceeding within (i) 120 days following the notice of alleged infringement,
or (ii) 30 days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions,
whichever comes first, then University shall have the right to bring and control any such action, at its own expense and by counsel
of its own choice, and Licensee shall have the right, but not the obligation, at its own expense, to be represented in any such
action by counsel of its own choice. Recoveries from actions brought pursuant to this Paragraph 5.2(e) shall first be applied
to reimburse the litigation costs of the party (Licensee or University) bringing suit and bearing the expenses of the litigation,
and then to reimburse the litigation costs of the other party. Any remaining recovery after such reimbursement shall be shared
by the parties as follows: (1) [...***...]% to the party bringing suit; and (2) [...***...]% to the other party.

 

Article 7. TERMINATION OF THE AGREEMENT.
The following shall be added at the end of Article 7:

 

		7.5	Notwithstanding any termination of this Agreement, Licensee shall retain its joint ownership interest
in Fifth Patent Rights.

 

ADDITIONAL CONSIDERATION TO UNIVERSITY

A one-time amendment fee of Five Thousand
US Dollars ($5,000) payable within thirty (30) days of the Third Amendment Effective Date.

 

Except as specified by this Amendment, all
other terms and conditions in the Agreement shall remain unchanged and in full force and effect. The parties agree that this Amendment
may be

  

***Confidential Treatment Requested

 

    	5.

    	 

    

  

 executed in two (2) or more counterparts, each of which shall be deemed an original and all of which together shall constitute
but one and the same instrument.

 

 

 

IN WITNESS WHEREOF both University and
Chimerix have executed this Amendment in duplicate originals, by their respective and duly authorized offices on the day and year
written.

 

	CHIMERIX, INC.:	 	THE REGENTS OF THE
	 	 	UNIVERSITY OF CALIFORNIA
	 	 	 	 	 
	By:	/s/ Kenneth I. Moch	 	By:	/s/ Jane C. Moores
	 	 	 	 
	Name:	Kenneth I. Moch	 	Jane C. Moores, Assistant
Vice Chancellor
	 	 	 	 Technology Transfer Office
	 	 	 	 
	Title:	President & CEO	 	 
	 	 	 	 	 
	Date:	September 14, 2011	 	Date:	September 7, 2011

  

    	6.

    	 

    

  

FOURTH AMENDMENT TO THE LICENSE AGREEMENT
EFFECTIVE MAY 13, 2002

 

BETWEEN

 

CHIMERIX, INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE
NOS. [...***...],
[...***...] AND [...***...]

 

This fourth amendment to the agreement ("Fourth
Amendment") is made by and between Chimerix, Inc., a Delaware corporation having an address at 2505 Meridian Parkway, Suite
340, Durham, NC 27713 ("Chimerix"), and The Regents of the University of California, a California corporation having
its statewide administrative offices at 1111 Franklin Street, Oakland, CA 94607-5200 ("University") as represented by
its San Diego campus having an address at University of California San Diego, Technology Transfer Office, Mail Code 0910, 9500
Gilman Drive, La Jolla, CA 92093-0910 ("UCSD"),

 

Capitalized terms used but not otherwise defined
herein shall have the meaning given them in the license agreement between Chimerix and University effective May 13, 2002, having
UC Control No. [...***...] ("Original Agreement"), as amended by the previously executed first amendment effective September
11, 2002, having UC Control No. [...***...] (the "First Amendment"), and second amendment effective December 17, 2010,
having UC Control No. [...***...] (the "Second Amendment"), and third amendment effective September 14, 2011, having
UC Control No. [...***...] (the "Third Amendment"), and any other revisions regarding the Patent Rights previously made.
The Original Agreement, together with, and as amended by, those revisions, the First Amendment the Second Amendment, and the Third
Amendment are collectively referred to herein as the "Agreement".

 

This Amendment is effective on the date of
last signature ("Fourth Amendment Effective Date").

 

Whereas, Chimerix has entered into
the Agreement wherein Chimerix was granted certain rights;

 

Whereas, Chimerix and University wish
to amend the Agreement to make certain corrections with respect to the recitals and to alter the rights and responsibilities of
the parties in light of Chimerix's current business plans;

 

***Confidential Treatment Requested

  

    	1.

    	 

    

 

Now Therefore, Chimerix and University agree
to amend the Agreement. These changes will be substituted for or added to those relevant portions in the Agreement and are effective
on the Fourth Amendment Effective Date. For these purposes, changes are made to the Agreement as described below. Terms and conditions
not changed in this Amendment will remain as detailed in the Agreement.

  

RECITALS. 

 

The second recital is amended and restated
to read in its entirety as follows:

 

WHEREAS,
the inventions disclosed in UCSD Case Docket No. [...***...]
and titled "[...***...]" ("Original Second Invention") were made in the course of research at UCSD by [...***...]
(hereinafter and collectively, the "Second Inventors") and are covered by Patent Rights as defined below;

 

A new third recital is added to read in
its entirety as follows:

 

WHEREAS, the inventions originally
disclosed in UCSD Case Docket No. [...***...] and titled "[...***...]" ("Additional Second Invention") were
made in the course of research at UCSD by [...***...] and were later joined with the Original Second Invention (now collectively
the "Second Invention") and are covered by Patent Rights as defined below;

 

The thirteenth recital is amended and restated
to read in its entirety as follows:

 

WHEREAS, the VA has relinquished
its rights to the Additional Second Invention ("[...***...]") as stated in a letter to [...***...] (Exhibit B) and UNIVERSITY
retains sole right, title and interest in the Additional Second Invention (subject to the license granted to the US Government),
and the VA has retained its rights to the Original Second Invention ("[...***...]");

 

***Confidential Treatment Requested

 

    	2.

    	 

    

 

The following new recital is hereby added
to the end of the recitals:

 

WHEREAS, subject to the VA/UC Agreement,
and the VA's determination of their right in the Original Second Invention, the UNIVERSITY and the VA own certain rights, title
and interest with respect to the Patent Rights for the Second Invention.

  

ARTICLE 2. GRANTS

 

Paragraph 2.2(c) is amended and restated
to read in its entirety as follows;

 

Upon termination of this Agreement
for any reason, UNIVERSITY will allow LICENSEE to assign to UNIVERSITY any Sublicense provided that: i) the applicable Sublicensee
is in good standing under its sublicense agreement with LICENSEE upon termination of this Agreement; and ii) such Sublicensee is
not currently involved in litigation as an adverse party to the UNIVERSITY. In no case, however, will UNIVERSITY be bound by duties
and obligations contained in any Sublicense that extend beyond the duties and obligations

of the UNIVERSITY set forth in this Agreement. The Sublicensee will promptly agree in writing to be bound by the terms of this
Agreement, including, in lieu of the payment obligations under the applicable Sublicense agreement, but not necessarily limited
to, payment to the UNIVERSITY of fees, royalties and reimbursements required under Article 3.

  

ARTICLE 3, CONSIDERATIONS

 

Paragraph 3.3(a)(6) is amended and restated
to read in its entirety as follows:

 

On
or before the date ending sixteen (16) years after the Effective Date file with the US FDA an NDA or PLA (or Its equivalent
in a foreign country) for the first Licensed Product; and

  

ARTICLE 5. PATENT MATTER*

 

Paragraph 5.2 is amended and restated to
read in Its entirety as follows:

 

(a)          If
LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with
reasonable evidence of the infringement. Neither UNIVERSITY nor LICENSEE shall notify a Third Party (other than a SUBLICENSEE)
of the infringement of Patent Rights without the consent of the other. Both UNIVERSITY and LICENSEE shall use reasonable efforts
and cooperation to terminate infringement without litigation.

  

 

    	3.

    	 

    

 

(b)          Except
as provided for in Section 5.2(e) below, LICENSEE may request UNIVERSITY to take legal action against such Third Party for the
infringement of Patent Rights. Such request shall be made in writing and shall include reasonable evidence of such infringement
and damages to LICENSEE. If the infringing activity has not abated thirty (30) days following LICENSEE's request, UNIVERSITY shall
have the right to commence suit on its own account. UNIVERSITY shall give notice of its election to commence suit in writing to
LICENSEE by the end of the fourtieth (40th) day after receiving notice of such request from LICENSEE. LICENSEE may elect
to join in that suit at its own expense. Should UNIVERSITY not commence suit on its own account, LICENSEE may thereafter bring
suit for patent infringement at its own expense, if the infringement occurred in a jurisdiction where LICENSEE has an exclusive
license under this Agreement. If LICENSEE elects to bring suit, UNIVERSITY may join that suit at its own expense.

 

(c)          Recoveries
from actions brought pursuant to this Section 5.2 shall belong to the party (UNIVERSITY or LICENSEE) bringing suit and bearing
the expenses of the litigation. Legal actions brought Jointly by UNIVERSITY and LICENSEE and fully participated in by both shall
be at the joint expense of the parties and all recoveries shall be shared jointly by them in proportion to the share of expense
paid by each party.

 

(d)          UNIVERSITY
and LICENSEE shall cooperate with each other in litigation proceedings at the expense of the party bringing suit. Litigation shall
be controlled by the party bringing suit, except that either party may be represented by counsel of Its choice in any suit brought
by the other party.

 

(e)          A
Party receiving any certification regarding the Patent Rights pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or
21 U.S.C. §§355 (j)(2)(A)(vii)(IV), or its successor provisions, or any similar provisions in a country in the Territory,
shall provide the other Party with a copy of such certification within fourteen (14) business days of receipt. In the case of UNIVERSITY,
receipt of the certification shall mean when the UNIVERSITY's licensing representative has actual knowledge of the certification.
Any notices served under this paragraph should be sent only to the UCSD Technology Transfer Office, 9500 Gilman Drive, MC 0910,
La Jolla, CA 92093-0910; Attn: Asst, Vice Chancellor for Technology Transfer, in order to facilitate any action needed on the part
of UNIVERSITY. Notwithstanding the UNIVERSITY's right to initiate action as described in section 5,2(b) above, under this paragraph
5.2(e), LICENSEE (or exclusive SUBLICENSEE) shall have the first right to initiate and prosecute any action, and LICENSEE shall
inform UNIVERSITY of such decision within seven (7) days of receipt of the certification. If LICENSEE or exclusive SUBLICENSEE
elects not to bring a suit, UNIVERSITY shall have the right to initiate and prosecute such action. Regardless of which Party has
the right to initiate and prosecute such action, both Parties shall, as soon as practicable after receiving notice of such certification,
convene and consult with each other regarding the appropriate course of conduct for such action. In all cases, the non-initiating
Party shall have the

  

    	4.

    	 

    

  

right to be kept fully informed
and participate in decisions regarding the appropriate course of conduct for such action, and the right to join (at its own expense)
and participate in such action.

 

Except as specified by this Amendment,
all other terms and conditions in the Agreement shall remain unchanged and in full force and effect. The parties agree that this
Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original and all of which together
shall constitute but one and the same instrument.

  

IN WITNESS WHEREOF both University and
Chimerix have executed this Amendment in duplicate originals, by their respective and duly authorized offices on the day and year
written.

 

	CHIMERIX, INC.:	 	THE REGENTS OF THE
	 	 	UNIVERSITY OF CALIFORNIA
	 	 	 
	By: 	/s/ Kenneth I. Moch	 	By:	/s/ Jane C. Moores
	 	 	 
	Kenneth I. Moch	 	Jane C. Moores
	President & CEO	 	Assistant Vice Chancellor Technology Transfer
	 	 	 
	Date:	July 19, 2012	 	Date:	July 18, 2012

  

    	5.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]